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“What is a scientist after all?  
It is a curious man looking through a keyhole,  
the keyhole of nature, trying to know what's going on.” 
 
(Jacques Yves Cousteau, 1910-1997) 
 
 
„Alice looking behind the curtain”, original illustration by John Tenniel for Lewis Carroll´s “Alice in Wonderland”, 1866 
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Summary 
 
Lysosomes are specialized cellular organelles for the degradation of endocytosed and 
intracellular material and essential regulators of cell homeostasis. Inside them, a multitude of 
soluble hydrolases ensures proper digestion of macromolecules. The importance of such 
organelles is well illustrated by the increasing number of human diseases related to defects in 
lysosomal functioning, the so-called lysosomal storage disorders (LSDs). To fulfill their 
degradative function lysosomes must firstly receive specific proteins, which after being 
synthesized in the endoplasmic reticulum (ER) need to be directed to the trans-Golgi network 
(TGN) for further processing and lysosomal targeting. The major pathway for lysosomal 
enzyme delivery, the M6P-dependent pathway, through which most enzymes reaches the 
lysosome, requires the recognition of a specific mannose 6-phosphate signal (M6P marker) 
selectively added to lysosomal enzymes in the TGN. Nevertheless, increasing evidence 
indicates the existence of additional or alternative pathways, M6P-independent, from the 
TGN to lysosomes. Presently, two alternative receptors which mediate that transport have 
been described: the lysosomal integral membrane protein LIMP-2 and sortilin.  
In this work, we focused our attention on the genes that contribute for a proper sorting of 
lysosomal enzymes, by coding for proteins which are directly involved in the above-referred 
transport pathways. The work is divided in two parts, each having specific aims. The first part 
addresses the molecular genetics and diagnosis of disorders related with malfunction of M6P 
pathway and the second reports on the studies addressing the role of the M6P-independent 
trafficking pathways in LSDs. 
Impairments in the M6P pathway are long known to cause two well-defined LSDs: 
Mucolipidosis types II (MLII) and III (MLIII), which are caused by total or partial loss of GlcNAc-
phosphotransferase activity, respectively. This enzyme is responsible for the first catalytic 
step leading to the formation of the M6P recognition marker. Far from being a simple protein, 
GlcNAc-phosphotransferase is a hexameric transmembrane enzyme, composed by three 
different subunits, α2β2γ2, encoded by two independent genes: GNPTAB, which codes for the 
aminoacidic precursor of the α- and β-subunits and GNPTG, which codes for the γ-subunit. 
Depending on the gene which is affected in each patient, mucolipidoses may be classified as 
alpha/beta (mutations in the GNPTAB gene) or gamma (mutations in the GNPTG gene). Even 
though ML II and ML III share similar clinical features, including skeletal abnormalities, ML II is 
the more severe in terms of phenotype with early onset of symptoms and death occurring, 
usually, between 5 and 8 years of age. Mutations in GNPTAB may underlie either ML II 
alpha/beta or ML III alpha/beta while defects in the GNPTG gene are only causative of ML III 
gamma. 
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For this study, a set of 23 unrelated ML II and III cases from several origins was screened, 
leading to the identification of 18 different mutations: 16 in the GNPTAB gene and 2 in the 
GNPTG gene. Of those, 13 were novel: 11 in the GNPTAB gene and 2 in the GNPTG gene. All 
mutations identified were further analyzed, paying special attention to the novel alterations. 
Whenever RNA samples were available real time PCR studies were performed, whose results 
suggested the possible existence of feedback regulation mechanisms between the α/β- and 
the γ-subunits. 
From the analyzed series of patients, some had particularly unusual molecular lesions and/or 
phenotypes, which triggered additional analyses.  
One of those patients was shown to harbor a homozygous genomic lesion in GNPTAB leading 
to the entire loss of exon 19 and some of its surrounding intronic regions (c.3435-
386_3602+343del897). Analysis of the deletion breakpoints indicated that the mutation was 
generated by an unequal homologous recombination process between highly similar Alu 
elements located in two regions within the gene where such kind of sequences were 
demonstrated to be present. Subsequent cDNA analysis revealed the presence of three 
abnormal transcripts created by this gross deletion at mRNA level: one without exon 19 
(p.Lys1146_Trp1201del); another with an additional loss of exon 20 (p.Arg1145SerfsX2), and a 
third in which exon 19 was substituted by a pseudoexon inclusion consisting of a 62 bp 
fragment from intron 18 (p.Arg1145SerfsX16). No other large deletions have been reported in 
the GNPTAB gene so far. 
Another patient had a peculiar phenotype, with severe prenatal skeletal abnormalities that 
fitted prior descriptions of a rare phenotype known as Pacman dysplasia. Retrospective 
analysis of the parents, inferred him to be heterozygous for two pathogenic mutations in the 
GNPTAB gene: the well-known c.3503_3504delTC (p.L1168QfsX5) and a novel frameshift 
variant, c.1701delC (p.F566LfsX5), thus supporting previous assumptions that at least some 
cases of Pacman dysplasia phenotype are, in fact, severe prenatal forms of ML II alpha/beta. 
Whenever possible, genotype-phenotype correlations were established. For the majority of 
patients analysed, assessment of severity was rather straightforward, with a strong 
correlation between the observed clinical phenotype and the type of molecular lesion 
assessed through molecular analysis. Nevertheless, the identification of three patients, 
carrying homozygous missense mutations but presenting with early onset severe symptoms 
(two patients with p.W81L and one with p.R986C), defied previous assumptions that such 
mutations would underlie a mild phenotype, while only nonsense and frameshift mutations 
would give rise to the more severe ML II alpha/beta phenotype. To explore the causes 
underlying these unusual genotype/phenotype relationships further analyses were performed. 
A panel of GNPTAB mutations, including the atypically severe missense ones, was expressed in 
model cell lines and analyzed through Western blot and Immunofluorescence. In general, the 
combined analysis of the mutants’ expression levels and subcellular location appeared to 
explain the associated phenotypes: mutants harboring the severe deletions revealed to be 
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retained in the ER, presenting only the non-cleaved α/β-precursor form; mild missense 
mutations were correctly located in the Golgi apparatus but presented reduced levels of the 
mature α- and β-subunits, when compared to the wild-type and, finally, severe missense 
mutations were either retained in the ER on the non-cleaved and inactive precursor form 
(p.W81L) or not expressed at all (p.R986C). The particularly severe consequences 
demonstrated for the aminoacid substitutions p.W81L and p.R986C, additionally suggested 
that residues W81 and especially R986 may assume crucial roles on the function and/or stability 
of GlcNAc-phosphotransferase. 
The observation that the GNPTAB deletion c.3503_3504delTC, already reported in several 
populations worldwide, was the most common disease allele among the Portuguese patients, 
has instigated us to perform a haplotypic analysis to investigate its origin. A total of 44 
patients and 16 carriers of this deletion, from different geographic regions, was analyzed for 
3 intragenic polymorphisms and 2 microsatellite markers flanking the GNPTAB gene. A 
common haplotype was identified in all chromosomes bearing the deletion, providing 
evidence that c.3503_3504delTC was due to a unique founder molecular lesion. Additionally, 
the level of diversity observed at the most distant microssatelite indicated it to be a 
relatively ancient mutation, whilst its geographical distribution further suggested it to have 
arisen in a peri-Mediterranean region. 
Recently, impairments of the M6P-independent travelling route were also associated with 
disease. From the two alternative receptors that have been described to be involved in 
lysosomal transport (LIMP-2 and sortilin), only LIMP-2 has been associated with disease. LIMP-
2 is responsible for the delivery of β-glucocerebrosidase (GCase, the defective enzyme in 
patients with Gaucher disease) to the lysosomes. Mutations in SCARB2, the gene that codes 
for this receptor, have been reported to underlie a serious autosomal genetic disorder 
presently known as action myoclonus renal failure (AMRF). Regarding sortilin (encoded by 
SORT1), which has been suggested to mediate transport of the sphingolipid activator proteins 
(SAPs) prosaposin (PSAP) and GM2 activator protein (GM2AP); acid sphingomyelinase (ASM) 
and cathepsins D and H, no storage disorder caused by its loss of function has been reported 
yet.  
In the second part of this work, the contribution of defects in the genes that code for proteins 
involved in the M6P-independent trafficking pathways was addressed. A sample of patients 
with symptoms suggestive of LSD but without definitive diagnose after routine tests was 
analysed for genetic impairments in SCARB2 and SORT1 genes. Attention was focused in 
uncharacterised patients whose clinical manifestations overlapped those that could 
predictably be due to loss of function of GCase, saposins, GM2AP and/or ASM which, 
theoretically, could be resultant from failures in M6P-independent pathways through which 
those proteins reach the lysosome. 
In a set of 120 individuals with clinical suspicion of LSD but without definitive biochemical 
and/or molecular diagnosis, no novel mutations were detected either on the SCARB2 or on 
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the SORT1 genes. So far, no evidence came that SORT1 deficiencies may be associated to LSD 
phenotypes. Still, enlarged sample sizes are needed in order to draw more reliable 
conclusions on the topic. Most probably, final conclusions may only be drawn when individuals 
carrying gene variants which disrupt protein function are described and their phenotype 
evaluated.  
Finally, a complementary point was also addressed: the role of variations in SCARB2 on the 
broad phenotype spectrum observed for Gaucher disease (GD) patients. GD has a huge 
phenotypic range and, even though some specific genotype-phenotype correlations have been 
established for a few of its causing mutations, the pathological cascade leading to the great 
variety of phenotypes among GD patients remains elusive, being still unclear why patients 
carrying identical GBA genotypes present with disparate phenotypes. Being the most common 
LSD and the first to have available enzyme replacement therapy (ERT), GD has been 
extensively studied over the years but, still, little is known on the factors that modify its 
associated phenotypes. Recently, mutations in the LIMP-2 coding gene were also reported to 
affect the severity of GD phenotype. To evaluate the role of SCARB2 mutations on the GD 
phenotype, the whole cohort of Portuguese GD patients (which totalizes 91 individuals) was 
screened and 1 novel mutation in the SCARB2 gene identified, reinforcing previous evidence 
that mutations in the gene that codes for the GCase transporter can act as GD modifiers. In 
the particular case of the Portuguese patient in whom this variant was identified, even 
though the clinical phenotype could, theoretically, be explained solely by the GBA genotype, 
the child had biochemical evidences suggesting poor response to treatment, which may be 
justified by the additional GCase carrier deficiency. From the results obtained in this study, 
however, it became clear that mutations in SCARB2 are not frequent modifiers of the GD 
phenotype; other genetic, epigenetic and/or environmental factors must exist that influence 
GD phenotypic manifestations. 
In general, this study reinforces the biological importance of a proper targeting of lysosomal 
proteins to their final destination, by highlighting the severe consequences of impairments in 
proteins involved in that process. 
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Resumo* 
 
Os lisossomas são organelos celulares especializados na degradação de material intracelular 
ou endocitado, desempenhando também um papel essencial na regulação da homeostasia 
celular. No seu interior, encontra-se um grande número de hidrolases solúveis que assegura 
uma eficiente digestão de todos os tipos de macromoléculas. A importância destes organelos 
é demonstrada pelo número crescente de doenças genéticas relacionadas com o deficiente 
funcionamento lisossomal, as denominadas doenças lisossomais de sobrecarga (DLS). De forma 
a cumprir as suas funções degradativas, os lisossomas têm de receber enzimas específicas 
que, após serem sintetizadas no retículo endoplasmático (RE), precisam de ser dirigidas até à 
face trans do complexo de Golgi para posterior processamento e transporte para o lisossoma. 
A principal via de transporte das enzimas lisossomais, a via dependente da manose 6-fosfato 
(M6P), por meio da qual a maioria das enzimas atinge o lisossoma, requer o reconhecimento 
de um sinal específico de manose-6-fosfato (marcador de M6P), que é selectivamente 
adicionado às enzimas lisossomais na face trans do Golgi. Recentemente, surgiram estudos 
revelando a existência de vias adicionais ou alternativas, independentes da M6P, de 
transporte para os lisossomas. Até ao momento, conhecem-se já dois receptores alternativos 
capazes de mediar esse transporte: a proteína integral da membrana lisossomal LIMP-2 e a 
sortilina. 
Este trabalho teve como principal alvo de estudo os genes que contribuem para o correcto 
transporte das enzimas lisossomais, isto é, aqueles que codificam proteínas diretamente 
envolvidas nas vias de transporte acima referidas. O trabalho foi estruturado em duas partes, 
cada uma apresentando objectivos específicos. A primeira aborda a genética molecular e o 
diagnóstico das doenças relacionadas com disfunção da via da M6P enquanto a segunda 
envolve estudos sobre o possível papel das vias independentes de M6P no desenvolvimento de 
DLS. 
Deficiências ao nível da via da M6P são há muito conhecidas, estando associadas a duas DLS 
bem definidas: as mucolipidoses tipo II (MLII) e III (MLIII) causadas, respectivamente, pela 
perda total ou parcial de actividade da enzima GlcNAc-fosfotransferase. Esta enzima é 
responsável pelo primeiro de dois passos catalíticos que resultam na formação do marcador 
de reconhecimento M6P. A GlcNAc-fosfotransferase é uma enzima transmembranar 
hexamérica, composta por três subunidades diferentes, α2β2γ2, codificadas por dois genes 
independentes: GNPTAB, codificador do precursor aminoacídico das subunidades α e β e 
GNPTG, que codifica a subunidade γ. Dependendo do gene que é afectado, as Mucolipidoses 
podem ser classificados como alfa/beta  (mutações no gene GNPTAB) ou gama (mutações no 
gene GNPTG). Embora ML II e ML III partilhem características clínicas semelhantes, incluindo 
anomalias esqueléticas, a ML II é mais grave em termos de fenótipo, sendo caracterizada pela 
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precocidade dos sintomas e morte prematura dos doentes, geralmente entre os 5 e os 8 anos 
de idade. Mutações no gene GNPTAB podem estar na base de ML II alfa/beta e ML III 
alfa/beta, enquanto que mutações no gene GNPTG apenas originam ML III gama. 
Entre os principais objectivos deste trabalho incluem-se a identificação dos defeitos 
moleculares causadores de ML II e III nos doentes referenciados da população Portuguesa, a 
avaliação dos efeitos de cada mutação ao nível da proteína/mRNA, e ainda o estudo da 
relação entre presença de uma dada mutação e a sintomatologia clínica.  
No decurso do trabalho, para além de todos os doentes portugueses conhecidos, foi ainda 
possível estudar vários doentes de outras origens, por terem sido referenciados ao nosso 
grupo para estudo molecular. No total, foi caracterizada uma amostra de 23 casos não 
aparentados de ML II e III, de várias origens, que conduziu à identificação de 18 mutações 
diferentes: 16 no gene GNPTAB e 2 no gene GNPTG. Dessas, 13 foram descritas pela primeira 
vez: 11 no gene GNPTAB e 2 no gene GNPTG. Todas as mutações identificadas, 
particularmente as novas, foram estudadas utilizando diversas abordagens. De referir, entre 
outras, a realização de estudos PCR em tempo real em amostras de RNA, disponíveis para a 
maior parte dos casos, cujos resultados sugeriram a possível existência de mecanismos de 
feedback na regulação da expressão das subunidades α/β e γ. 
Alguns dos doentes analisados apresentavam lesões moleculares e/ou fenótipos 
particularmente invulgares, o que desencadeou análises dirigidas. 
Num desses doentes, de origem palestiniana e com forma grave de MLII alfa/beta, a 
caracterização molecular levou à identificação em homozigotia de uma grande deleção, a 
única até agora conhecida no gene GNPTAB, que envolvia a perda de todo o exão 19 e 
algumas das suas regiões intrónicas adjacentes (c.3435-386_3602 + 343del897). A análise dos 
pontos de quebra da deleção permitiu deduzir o mecanismo explicativo subjacente ao seu 
aparecimento, podendo estar relacionado com um processo de recombinação homóloga 
desigual entre elementos Alu com elevado grau de homologia, localizados em duas das três 
regiões do gene onde se verificou estarem presentes este tipo de sequências. Posteriormente, 
uma análise do RNA do mesmo doente permitiu encontrar três transcritos anormais, 
resultantes, assim, da presença desta grande deleção: um, sem o exão 19 
(p.Lys1146_Trp1201del); outro, com uma perda adicional do exão 20 (p.Arg1145SerfsX2); e, 
um terceiro, no qual o exão 19 foi substituído pela inclusão de um pseudoexão que consistia 
num fragmento de 62 pb do intrão 18 (p.Arg1145SerfsX16).  
Outro doente, de origem indiana, também apresentava um fenótipo peculiar, muito grave 
(morte ao quarto dia de vida), envolvendo anomalias esqueléticas pré-natais severas 
compatíveis com descrições anteriores de um fenótipo raro conhecido como displasia de 
Pacman. A análise dos seus pais permitiu inferir retrospectivamente que o doente seria 
heterozigótico composto para duas mutações patogénicas no gene GNPTAB: a deleção 
c.3503_3504delTC (p.L1168QfsX5), já bem conhecida, e uma nova deleção, c.1701delC 
(p.F566LfsX5). Este resultado apoia hipóteses anteriores de que, pelo menos alguns casos de 
displasia de Pacman seriam, de facto, formas graves e pré-natais de ML II alfa/beta. 
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Sempre que possível, foram investigadas correlações genótipo-fenótipo. Para a maioria dos 
doentes, a avaliação do potencial patogénico de cada uma das mutações foi bastante 
coerente, tendo-se observado uma forte correlação entre o fenótipo clínico observado e o 
tipo de lesão molecular previamente identificada. No entanto, em três doentes, portadores 
de mutações missense em homozigotia, cujos sintomas, além de graves, surgiram muito 
precocemente (dois doentes p.W81L/p.W81L e um p.R986C/p.R986C), os seus fenótipos 
contrariavam pressupostos anteriores de que mutações do tipo das que apresentavam, 
missense, estariam associadas a fenótipos leves, enquanto apenas mutações nonsense e 
frameshift dariam origem aos fenótipos mais graves de ML II α/β. Para explorar as causas 
subjacentes a estas relações genótipo/fenótipo, expressou-se, em linhas celulares modelo 
(HEK e HeLa), um painel de mutações GNPTAB, incluindo as duas missense atipicamente 
graves, que posteriormente foram sujeitas a análise de Western Blot e Imunofluorescência. 
Como controlo, expressaram-se também duas deleções graves e três mutações missense 
associadas a fenótipos leves. No global, a análise combinada dos níveis de expressão e 
localização subcelular das proteínas mutantes, pareceu dar, de forma muito satisfatória, 
sentido aos fenótipos que lhes estavam associados: as deleções graves ficavam retidas no 
retículo endoplasmático (RE), apresentando apenas o precursor α/β não-clivado; as mutações 
missense leves ficavam correctamente localizadas no complexo de Golgi mas apresentavam 
níveis reduzidos das subunidades α e β maduras, quando comparados com o wildtype. 
Finalmente, as mutações missense graves, ou ficavam retidas no RE na forma precursora, não-
clivada e inactiva (p.W81L), ou não eram expressas de todo (p.R986C).  
Atendendo às consequências particularmente graves associadas às substituições aminoacídicas 
p.W81L e p.R986C, é de admitir que o resíduo W81 e, especialmente o resíduo R986, possam 
assumir papeis chave na função e/ou estabilidade da GlcNAc-fosfotransferase. 
A observação de que a deleção c.3503_3504delTC no gene GNPTAB, já descrita em várias 
populações a nível mundial, era o alelo mais comum entre os doentes portugueses, levou à 
realização de um estudo haplotípico com o objectivo de investigar a sua origem. Foi possível 
recrutar um total de 44 doentes e 16 portadores da deleção, provenientes de diferentes 
regiões geográficas, tendo sido analisados para três SNPs intragénicos e 2 microssatélites que 
flanqueiam o gene GNPTAB. A detecção de um haplótipo comum em todos os cromossomas 
portadores da deleção, constituiu forte indicação de que a mutação c.3503_3504delTC foi 
originada por uma lesão molecular fundadora única. Por outro lado, se o nível de diversidade 
associado a um dos microssatélites evidenciou tratar-se de uma mutação relativamente 
antiga, a sua distribuição geográfica apontou para a região peri-mediterrânica como sendo 
aquela onde provavelmente a mutação surgiu.  
Recentemente, deficiências ao nível da via de transporte independente da M6P foram 
também relacionadas com consequências patogénicas. No entanto, dos dois receptores 
alternativos já descritos (LIMP-2 e sortilina), apenas a perda de função da LIMP-2 foi 
inequivocamente associada a doença. A LIMP-2 é responsável pelo transporte da enzima β-
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glucocerebrosidase (cuja deficiência está associada a doença de Gaucher), para os lisossomas. 
Mutações em SCARB2, gene que codifica esta proteína, têm sido descritas como causais de 
uma doença genética autossómica grave, actualmente conhecida como epilepsia mioclónica 
com síndrome nefrótico (action myoclonus renal failure, AMRF). Relativamente à sortilina 
(codificada pelo gene SORT1), que se pensa mediar o transporte de proteínas activadoras de 
esfingolípidos (sphingolipid activator proteins, SAPs) prosaposina (PSAP) e proteína activadora 
de GM2 (GM2 activator protein, GM2AP); esfingomielinase ácida (acid sphingomyelinase, ASM) 
e das catepsinas D e H, nenhuma doença foi até agora conotada com a sua perda de função. 
Na segunda parte deste trabalho, abordámos a possível contribuição de alterações nos genes 
que codificam estes dois receptores alternativos para a génese das doenças lisossomais de 
sobrecarga. Foram pesquisadas mutações nos genes SCARB2 e SORT1 numa amostra 
constituída por doentes com sintomas sugestivos de DLS mas carecendo de diagnóstico 
definitivo após realização dos exames de rotina. Entre os doentes nesta situação, foram 
seleccionados aqueles cujas manifestações clínicas eram sobreponíveis às espectáveis por 
perda de função de β-glucocerebrosidase (GCase), saposinas, GM2AP e/ou ASM, partindo da 
hipótese de que os respectivos fenótipos poderiam, teoricamente, ser resultantes de falhas 
no transporte destas proteínas para o lisossoma. 
Porém, como num total de 120 doentes com suspeita clínica de DLS, mas sem diagnóstico 
bioquímico e/ou molecular definitivo, não foram detectadas mutações novas quer no gene 
SCARB2 quer no gene SORT1, até ao momento não se encontraram sinais de que alterações no 
gene SORT1 possam estar associadas a fenótipos de DLS. Sendo ainda necessário ampliar o 
tamanho da amostra, conclusões mais fiáveis provavelmente só poderão ser tiradas quando 
indivíduos portadores de variantes genéticas que perturbem a função da proteína forem 
encontrados e o seu fenótipo cuidadosamente avaliado. 
Finalmente, foi ainda abordado um ponto complementar: o papel de variantes no gene 
SCARB2 no espectro fenotípico da doença de Gaucher (Gaucher disease, GD). A GD apresenta 
uma enorme variabilidade fenotípica. Embora já tenham sido estabelecidas algumas 
correlações genótipo-fenótipo para certas mutações causais, a cascata patológica que leva à 
grande variabilidade de fenótipos entre doentes com GD não está completamente definida, 
estando por esclarecer a razão pela qual doentes com o mesmo genótipo GBA apresentam 
fenótipos distintos. Sendo a DLS mais comum e a primeira a ter terapia de substituição 
enzimática disponível (enzyme replacement therapy, ERT), a GD tem sido extensivamente 
estudada ao longo dos anos mas, ainda assim, pouco se sabe sobre os fatores que contribuem 
para a variabilidade observada ao nível dos fenótipos dos doentes. Recentemente, surgiram 
indícios de que mutações no gene que codifica LIMP-2 podem também afetar a gravidade do 
fenótipo de GD. Para avaliar o papel das mutações SCARB2 no fenótipo de GD, analisou-se a 
população de doentes portugueses com GD (91 indivíduos), tendo sido identificada uma nova 
mutação no gene SCARB2, reforçando assim evidências anteriores de que mutações no gene 
que codifica o transportador da GCase podem funcionar como modificadores de GD. No caso 
particular do doente português em que a alteração em SCARB2 foi encontrada, embora o 
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fenótipo clínico pudesse, aparentemente, ser explicado pelo respectivo genótipo GBA, a 
criança apresentava indícios bioquímicos sugestivos de fraca resposta ao tratamento, o que 
poderá ser justificado pela deficiência adicional ao nível do transportador. Este estudo deixa, 
no entanto, claro que mutações no gene SCARB2 não são modificadores frequentes do 
fenótipo de GD, devendo existir outros fatores genéticos, epigenéticos e/ou ambientais que 
influenciem mais as manifestações fenotípicas de GD. 
Em termos gerais, este trabalho reforça a importância biológica do correcto transporte das 
proteínas lisossomais até ao destino apropriado, ao destacar as graves consequências que 
advêm de deficiências em proteínas envolvidas nesse processo. 
 
 
Palavras Chave 
Transporte lisossomal; Mucolipidose tipo II (ML II); Mucolipidose tipo III (ML III); Epilepsia 
Mioclónica com Síndrome Nefrótico (AMRF); Doença de Gaucher (GD). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* O autor escreve de acordo com a antiga ortografia. 
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Abbreviation List 
 
α-gal   α-galactosidase  
β-gal   β-galactosidase 
β-gluc   β-glucocerebrosidase 
α-man   α-mannosidase  
ALS    amyotrophic lateral sclerosis 
AMRF   action myoclonus renal failure 
apo   apolipoprotein 
ASM   acid sphingomyelinase 
AV   autophagic vacuole  
BGT   biochemical genetic testing 
BMT   bone marrow transplantation 
CAD   coronary artery disease 
CD-MPR  cation-dependent mannose-6-phosphate receptor 
CESD   cholesteryl ester storage disease 
CI-MPR   cation-independent mannose-6-phosphate receptor 
CNS   central nervous system 
CO-IP   co-immunoprecipitation 
EE   early endosome  
ER   endoplasmic reticulum 
ERAD   endoplasmic reticulum-associated degradation  
ERT   enzyme replacement therapy 
ES   embryonic stem cells 
ESE   exon-splicing enhancer 
ESS   exon-splicing supressor 
FTLD   frontotemporal lobar degeneration 
GCase   β-glucocerebrosidase 
GD   Gaucher disease 
GM2AP   GM2 activator protein 
GWAS   genome wide association studies 
HDL   high density lipoprotein 
Hex A   β-hexosaminidase A 
HexT   hexosaminidase T 
hMSC   human mesenchymal stem cell 
IGF   insulin-like growth factor 
KO   knock-out 
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LDL   low density lipoprotein 
LDLR   low density lipoprotein receptor 
LE   late endosome 
LIMP-2   lysosomal integral membrane protein 2 
LINE    long interspersed elements 
LPL   lipoprotein lipase 
LSD   lysosomal storage diseases 
M6P   mannose-6-phosphate 
MGT   molecular genetic testing 
MI   myocardial infarction 
ML    Mucolipidosis 
MPR   mannose-6-phosphate receptor 
MPS   Mucopolysaccharidosis 
MRH   mannose-6-phosphate receptor homology domain 
NCL   Neuronal Ceroid Lipofuscinosis 
NGF   nerve growth factor 
NMD   nonsense mediated mRNA decay 
NPC   Niemann-Pick C 
ORF   open reading frame 
OTCD   ornithine transcarbamylase deficiency 
PD   Pacman dysplasia 
PGRN   progranulin 
PME   progressive myoclonus epilepsy 
PNGaseF  peptide N-glycosidase F 
PSAP   prosaposin 
PTC   premature termination codon 
qRT-PCR  quantitative real time polymerase chain reaction 
RAP   receptor-associated protein 
S1P   site-1-protease 
SAP   sphingolipid activator protein 
SINE   short interspersed element 
SNP   single nucleotide polymorphism 
TGN   trans-Golgi network 
UCE   uncovering enzyme 
VHL   Von Hippel-Lindau 
VLDL   very low density lipoprotein 
WT   wild type 
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1. LYSOSOME AND LYSOSOMAL STORAGE DISORDERS 
 
1.1. THE LYSOSOME 
Discovered in 1955 by Christian René de Duve as membrane-closed acidic compartments 
with acid phosphatase activity [De Duve et al., 1955], lysosomes (Figure 1.1) are key 
organelles in the regulation of cellular homeostasis, being responsible for the 
degradation of a multitude of proteins. Lysosomes contain more than 60 soluble 
hydrolases (e.g. proteases, phosphatases, glycosidases, lipases, nucleases, sulfatases) 
that are capable of degrading macromolecules and even membranes into their 
monomeric components [reviewed in Schröder et al., 2010].  
 
 
Figure 1.1: Purified lysosomes from rat liver, ×18,400.  
[de Duve, 2005¸ reproduced from The Journal of Cell Biology (26, 219–243; 1965)] 
 
Lysosomes receive their substrates through different internalization pathways: 
endocytosis, phagocytosis and autophagy (Figure 1.2) and are involved in a wide range of 
physiological functions from cell death and signaling to cholesterol homeostasis and 
plasma membrane repair [Saftig and Klumperman, 2009]. Lysosomal hydrolases are confined 
in the lumen of the lysosome and require an optimum pH (i.e., pH 4.5) to work. This 
acidic pH compared with the slightly alkaline pH of the cytosol (i.e., ~pH 7.2) is 
maintained by the activity of lysosomal integral membrane proteins (LIMPs, that 
represent the second class of lysosomal proteins), including the V-type proton (H+)-
ATPase [Williamson and Hiesinger, 2010] and the chloride ion channel CLC74 that pumps 
protons from the cytosol across the lysosomal membrane [Weiss, 2012; reviewed in Schröder et 
al., 2010]. 
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Figure 1.2: Intracellular pathways to the lysosome.  
[adapted from Pryor and Luzio, 2009] 
Endocytic cargo is internalised from the plasma membrane and delivered to early endosomes. 
Maturation of the early endosome gives rise to a late endosome/multi-vesicular body where the cargo 
destined for degradation has been sorted into intralumenal vesicles. The limiting membranes of late 
endosomes and lysosomes can fuse to form a hybrid organelle where degradation of endocytosed 
macromolecules commences. Lysosomes are reformed from the hybrid organelle by membrane retrieval 
and condensation reactions. Autophagic and phagocytic pathways both feed into the endocytic pathway 
with the lumenal contents of the autophagosome and phagosome eventually being delivered to the 
lysosome for degradation. (EE, early endosome; LE, late endosome) 
  
The biological relevance of lysosomes and of the repertoire of degradative enzymes they 
harbor is illustrated by the existence of over 50 different genetic disorders caused by a 
deficiency of a catabolic enzyme [Lübke et al., 2009] that as a whole are estimated to 
affect 1:4000-9000 live births [Michelakakis et al., 1995; Poorthius et al., 1999; Meikle et al., 
1999; Poupětová et al., 2010; Pinto et al., 2004]: the lysosomal storage diseases (LSDs). 
 
1.2. LYSOSOMAL STORAGE DISORDERS 
1.2.1. General description 
Most LSDs result from a deficiency of specific lysosomal enzymes. In a few cases, though, 
non-enzymatic lysosomal proteins or non-lysosomal proteins involved in lysosomal 
biogenesis are deficient [reviewed in Futerman and van Meer, 2004; Filocamo and Morrone, 2011]. 
Typically, LSDs are recessively inherited, monogenic and progressive diseases [reviewed in 
Futerman and van Meer, 2004; Filocamo and Morrone, 2011]. While the majority of LSDs is 
autosomal, a few also exist, such as MPS type II (Hunter syndrome) and Fabry disease, 
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which are X-linked recessive genetic disorders. 
The common biochemical hallmark of LSDs is the accumulation of un- or partially 
digested metabolites in the lysosome. This can arise through several mechanisms as a 
result of defects in any process underlying the lysosomal biology that hampers the 
catabolism of molecules in the lysosome, or the egress of naturally occurring molecules 
from the organelle: 1) defects in either glycosaminoglycan, lipid, or protein degradation; 
2) transport across the lysosomal membrane; or 3) endosome-lysosome trafficking. 
Actually, any disruption of lysosomal function can lead to the accumulation of 
undegraded substrate(s) in endosomes and lysosomes, eventually compromising cellular 
function [Parkinson-Lawrence et al., 2010]. Lysosomal accumulation activates a variety of 
pathogenetic cascades that result in complex clinical pictures characterized by multi-
systemic involvement [Wraith, 2002; Futerman and van Meer, 2004; Vellodi, 2005; Ballabio and 
Gieselmann, 2009; Vitner et al., 2010]. Presently, and even though some models have been 
suggested (Figure 1.3), we still lack a clear picture of the relevant events linking disease 
causing mutations to the symptoms of the disease which are determined by mechanisms 
operating not only at the cellular level, but also in tissues and organs. So, one of the 
greatest challenges is to understand how substrate storage impacts on function of cells, 
tissues and organs, causing disease pathogenesis. 
 
Figure 1.3: A proposed model for the pathogenesis of LSDs.  
[adapted from Ballabio and Gieselmann, 2009] 
Lysosomal storage leads to a reduction on the ability of lysosomes to fuse with autophagosomes. 
Consequently, there is a block (either total or partial) of autophagy maturation and defective 
degradation. As a result, it occurs an accumulation of authophagy substrates such as polyubiquitinated 
protein aggregates and dysfunctional mitochondria, promoting cell death, which is further triggered by 
the inflammatory response to cell damage. 
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Phenotypic expression is extremely variable both in terms of the clinical manifestations 
and of their severity, as it depends on the specific macromolecule which is accumulated, 
the site of production and degradation of the specific metabolites, the residual 
enzymatic activity and the general genetic background of the patient (See section 1.2.3). 
In general, over the last 25 years research on LSDs has been focused on the genetics of 
this group of disorders. During this period the majority of lysosomal enzymes-coding 
genes was cloned and a huge number of disease-causing mutations identified. Also our 
vision of the lysosome has changed tremendously. The lysosome is no longer viewed as 
just an end-point degradative compartment but rather as part of a very complex and 
interactive set of intracellular organelles that have a wide array of specialist functions. 
Lysosomes are integrally involved in phagocytosis, autophagy, exocytosis, receptor 
recycling and regulation, intracellular signaling, immunity, pigmentation, bone biology, 
and neurotransmission (Figure 1.4).  
This new view on the lysosome role brought the notion that defects in any one of the 
processes in which it is involved can be associated with lysosomal disease, leading then 
to the recognition that LSDs may be better viewed as conditions of molecular deprivation 
that result in specific pathogenic cascades [Walkley, 2009; Walkley and Vanier, 2009; Parkinson-
Lawrence et al., 2010].  
 
Figure 1.4: The lysosome as a central element of the cell.  
[adapted from Walkley and Vanier, 2009] 
Lysosomes link to the endocytic pathways, to the macroautophagy stream and its close allies, the 
ubiquitin-proteosomal system (UPS) and the chaperone-mediated autophagy (CMA) components. What 
flows into this system must also leave in some form, depicted here as the salvage pathway with delivery 
to the trans-Golgi network (TGN), mitochondria, and other sites in the cell. The complexity of the 
disease cascades in lysosomal disorders is conjectured to emanate in part from disruption of these 
interrelated components of the greater lysosomal system. (EE, early endosome; RE, recycling endosome; LE, late 
endosome; AV, autophagic vacuole; ER, endoplasmic reticulum). 
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Ultimately, a better comprehension of pathogenic pathways will likely afford clues to 
identify therapeutic targets which, in the future, can be used for the benefit of the 
patients [Ballabio and Gieselmann, 2009].  
To date, no worldwide epidemiological data are available on LSDs. There are, however, 
several studies in distinct populations focusing either LSDs as a group or some specific 
LSDs which are known to present a high prevalence in specific populations such as the 
Ashkenazi Jewish population, which is at high risk for Gaucher disease [Beuttler and 
Gradowsky, 2001], Tay–Sachs disease and Niemann–Pick disease [Vallance and Ford, 2003], or 
the Finnish population which is characterized by high incidence of aspartylglucosaminuria 
[Arvio et al., 1993] and infantile/juvenile NCLs [Santavuori, 1988]. Reports on LSDs as a whole 
are only available for a few countries: Greece (Michelakakis et al., 1995), The Netherlands 
(1:7,000; Poorthius et al., 1999), Australia (1:7700; Meikle et al., 1999), Czech Republic 
(1:8000; Poupětová et al., 2010) and Portugal (1:4000; Pinto et al., 2004) [reviewed in Filocamo 
and Morrone, 2011]. 
 
1.2.2. Classification: from the nature of the primary stored material to the type of 
molecular defect  
Classically, LSDs are classified on the basis of the nature of the accumulated substrate(s). 
From a clinical perspective, this classification is very useful and well accepted [Ballabio 
and Gieselmann, 2009]. Thus, disorders in which glycosaminoglycans (also called 
mucopolysaccharides) accumulation prevails are classified as Mucopolysaccharidoses*; 
those dominated by lipid storage are Lipidoses; the ones in which the accumulation of 
sphingolipids prevails are Sphingolipidoses; those mostly characterized by the storage of 
oligosaccharides are Oligosaccharidoses and so on [Schultz et al., 2011].  
This classification, even though highly intuitive and well-accepted both by clinicians and 
researchers, difficultly incorporates all the knowledge coming to light as the biochemical 
basis for LSDs started being unveiled. So, a novel classification is emerging, focused on 
the recent understanding of LSDs΄ molecular basis, that also includes groups of disorders 
due to: (i) non-enzymatic lysosomal protein defects; (ii) transmembrane protein defects 
(transporters and structural proteins); (iii) lysosomal enzyme protection defects; (iv) 
post-translational processing defects of lysosomal enzymes; (v) trafficking defects in 
lysosomal enzymes; and (vi) polypeptide degradation defects (Table 1.1). Finally, another 
group includes the NCLs, which are considered to be lysosomal disorders, despite with 
distinct characteristics [reviewed in Filocamo and Morrone, 2011]. 
 
 
* For an extensive review on MPSs see Appendix 1, review paper 1: Coutinho MF, Lacerda L, Alves S. Glycosaminoglycan storage 
disorders: a review. Biochem Res Int. 2012 [in press] 
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Table 1.1.: Lysosomal storage disorders. 
[adapted from Futerman and van Meer, 2004; Filocamo and Morrone, 2011 and Haltia and Gobel, 2012] 
 
Sphingolipidoses    
Fabry 
α-Galactosidase A 
Globotriasylceramide and blood-group-B 
substances 
Farber lipogranulomatosis Acid Ceramidase Ceramide 
Gaucher a -Glucosidase  
Saposin-C activator 
Glucosylceramide 
Glucosylceramide 
Niemann–Pick A and B Sphingomyelinase Sphingomyelin 
Sphingolipid-activator 
deficiency 
Sphingolipid activator Glycolipids 
GM1 gangliosidosis β-Galactosidase GM1 ganglioside 
GM2 gangliosidosis (Tay–
Sachs) 
β-Hexosaminidase A GM2 ganglioside and related glycolipids 
GM2 gangliosidosis 
(Sandhoff) 
β-Hexosaminidase A and B GM2 ganglioside and related glycolipids 
GM2 gangliosidosis (GM2-
activator deficiency)b 
GM2-activator protein GM2 ganglioside and related glycolipids 
Krabbe’s disease c Galactocerebrosidase β-galactosidase Galactosylceramide 
Metachromatic 
leucodystrophyd 
Arylsulfatase A/Saposin B activator 
Sulphated glycolipds/ Sulphated glycolipds 
and GM1 ganglioside 
Mucopolysaccharidoses (MPS) 
MPS I (Hurler, Scheie, 
Hurler/Scheie) 
α-Iduronidase Dermatan sulphate and heparan sulphate 
MPS II (Hunter) Iduronate-2-sulphatase Dermatan sulphate and heparan sulphate 
MPS IIIA (Sanfilippo A) Heparan N-sulphatase (sulphamidase) Heparan sulphate 
MPS IIIB (Sanfilippo B) N-Acetyl-α-glucosaminidase Heparan sulphate 
MPS IIIC (Sanfilippo C) Acetyl-CoA:α-glucosamide  
N-acetyltransferase 
Heparan sulphate 
MPS IIID (Sanfilippo D) N-Acetylglucosamine-6-sulphatase Heparan sulphate 
Morquio-A disease N-Acetylgalactosamine  
-6-sulphate-sulphatase 
Keratan sulphate, chondroitin-6-sulphate 
Morquio-B disease β-Galactosidase Keratan sulphate 
MPS VI (Maroteaux–Lamy) N-Acetylgalactosamine-4-sulphatase  
(arylsulphatase B) 
Dermatan sulphate 
MPS VII (Sly) β-Glucuronidase Heparan sulphate, dermatan sulphate, 
chondroitin-4- and -6-sulphates 
Oligosaccharidoses (glycoproteinoses) 
Pompe (glycogen-storage-
disease II) 
α-Glucosidase Glycogen 
Aspartylglucosaminuria Aspartylglucosaminidase  Aspartylglucosamine 
Fucosidosis α-Fucosidase Fucosides and glycolipids 
α-Mannosidosis α-Mannosidase Mannose-containing oligosaccharides 
β-Mannosidosis β-Mannosidase Man (β→4) GlcNAc 
Mucolipidosis I (Sialidosis) Sialidase (Neuraminidase) Sialyloligosaccharides and sialylglycopeptides 
Schindler disease 
α-N-Acetylgalactosaminidase 
Glyco-conjugates containing α-N-
acetylgalactosaminyl 
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Glycogenoses 
Glycogenosis II/ Pompe α-1,4- Glucosidase Glycogen 
Lipidoses   
Wolman/CESD Acid lipase Cholesterol esters 
Non-enzymatic lysosomal protein defects 
Gaucher a Saposin C Glucosylceramide 
GM2 gangliosidosis (GM2-
activator deficiency) b 
GM2-activator protein GM2 ganglioside and related glycolipids 
Krabbe c Saposin A Galactosylceramide 
Metachromatic 
leucodystrophy d 
Saposin B Sulphatides 
Integral membrane protein defects 
Transporters 
Cystinosis  Cystinosin Cystine 
Infantile sialic-acid-
storage disease and  
Salla disease 
Sialin Sialic acid 
Niemann–Pick C (NPC) NPC1 and NPC2 Cholesterol and sphingolipids 
Structural proteins   
Danon disease LAMP2 Cytoplasmic debris and glycogen 
Mucolipidosis (ML) IV Mucolipin-1 Lipids and acid mucopolysaccharides 
Lysosomal enzyme protection defects 
Galactosialidosis Cathepsin A Sialyloligosaccharides 
Post-transcriptional processing defects 
Multiple sulphatase 
deficiency 
Cα-formylglycine-generating enzyme Sulphatides 
Trafficking defects in lysosomal enzymes 
I Cell (ML II) 
 
UDP-N-acetylglucosamine:lysosomal  
enzyme N-acetylglucosaminyl-1- 
phosphotransferase – α/β subunits 
Oligosaccharides, mucopolysaccharides 
and lipids 
Pseudo-Hurler 
polydystrophy (ML III) 
UDP-N-acetylglucosamine:lysosomal  
enzyme N-acetylglucosaminyl-1- 
phosphotransferase –  α/β subunits  or  
γ subunit 
Oligosaccharides, mucopolysaccharides 
and lipids 
Polypeptide degradation defects  
Pycnodysostosis Cathepsin K Bone proteins 
Neuronal ceroid lipofuscinoses   
NCL 1  CLN1 (protein palmitoylthioesterase-1) Lipidated thioesters (saposins A and D) 
NCL 2  CLN2 (tripeptidyl amino peptidase-1) Subunit c of the mitochondrial ATP synthase 
NCL 3  Arginine transporter Subunit c of the mitochondrial ATP synthase 
NCL 5 CLN 5, soluble lysosomal protein Subunit c of the mitochondrial ATP synthase 
NCL 6 CLN 6, transmembrane protein of ER Subunit c of the mitochondrial ATP synthase 
NCL 7 CLN 7, lysosomal chloride channel Subunit c of the mitochondrial ATP synthase 
NCL 8 CLN 8, transmembrane protein of ER Subunit c of the mitochondrial ATP synthase 
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a,b,c,d GD caused by deficiencies in saposin C, GM2 gangliosidosis, Krabbe’s disease caused by deficiency of saposin A and Metachromatic  
Leucodystrophy were traditionally classified as sphingolipidoses but recent classifications based on the nature of the enzyme/protein 
defect, tend to skip them from the larger sphingolipidoses group and gather them in a more restrict group of LSDs due to non-
enzymatic lysosomal protein defects. e The human NCL category was recently expanded to incorporate four novel pathologies (NCL11-
14) but, even though the underlying genes have already been identified, these variants have not yet been recognized as independent 
clinical entities through OMIM annotation and data is still scare on their associated storage materials.  
 
1.2.3. Symptoms: from severe neuropathology to mild somatic disease  
Virtually all known LSDs are characterized by considerable phenotypic heterogeneity 
(Figure 1.5). Nevertheless, though, some common symptoms may be listed (Table 1.2).  
 
Figure 1.5: Schematic representation of the phenotypic continuum observed for LSDs. 
 
In general, a common characteristic of LSDs is the relentless development and 
progression of signs and symptoms. There is high morbidity which shortens, sometimes 
dramatically, the life span [Beck, 2001; Wraith, 2002]. The disease onset, however, may vary 
tremendously, not only between different diseases but even within the same disease. So, 
LSDs´phenotypes may range from extremely severe and early presentations with 
multisystemic and neuronal involvement, leading to death in the first years of life or 
even in the neo-natal period, to later onset milder disease with patients reported to 
survive until the 8th decade of life. 
Probably one of the most severe clinical presentations of LSDs is also the one with the 
earliest onset: hydrops fetalis, a condition in the fetus that is characterized by an 
accumulation of fluid in at least two fetal compartments. Recurrent non-immune hydrops 
fetalis is an uncommon but important presentation of LSDs. It has been already reported 
for several LSDs including Farber’s disease [Kattner et al., 1997], GM1-Gangliosidosis [Denis et 
al., 1996], Galactosialidosis [Haverkamp et al., 1996], Niemann–Pick disease type C [Meizner et 
al., 1990], infantile free sialic acid storage disease, Mucolipidosis II [Appelman et al., 1988], 
type 2 Gaucher disease [Reissner et al., 1998], MPSs IVA [Applegarth et al., 1987] and VII [Van 
NCL 10 Cathepsin D Saposins A and D 
NCL11 Progranulin  e 
NCL12 P type ATPase e 
NCL13 Cathepsin F e 
NCL14 Potassium channel tetramerisation 
domain –containing protein 7 
e 
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Dorpe et al., 1996] and Sialidosis [Ovali et al., 1998]. Since a series of conditions exist which 
may lead to non-immune hydrops fetalis while post-mortem analyses are frequently 
inconclusive, it is actually possible that cases due to lysosomal dysfunctions are 
underestimated. So, investigation of recurrent non-immune hydrops should include 
screening for LSDs [Piraud et al., 1996; reviewed in Vellodi, 2005]. In general, the disorders that 
can present with hydrops fetalis can also present in the newborn period with dysmorfism.  
Infants in the newborn period with a “Hurler-like” phenotype usually have Mucolipidosis 
II, infantile sialic acid storage disease or GM1-Gangliosidosis [reviewed in Wraith, 2002].  
The radiological abnormalities associated with LSDs are known as dysostosis multiplex. 
These are defects which are usually absent in the neonatal period but become 
progressively more evident during the first or second years of life. Different radiological 
abnormalities may be seen in different disorders, one of the most significant examples 
being the characteristic features seen in ML II patients who, in addition to a severe 
dysmorphism, have usually pronounced gingival hyperplasia [reviewed in Wraith, 2002].  
 
Table 1.2: General symptomatology of LSDs.  
[adapted from Wilcox, 2004] 
Obvious physical 
abnormalities 
Nonimmune hydrops fetalis; hepato/splenomegaly; macroglossia; 
coarse facies; skeletal disease, deformations, dysplasias with or 
without short stature, skeletal disproportion; hirsutism; macrocephaly; 
inguinal and umbilical hernias; skin lesions (angiokeratomas) 
 
Physical symptoms 
 
Joint stiffness; episodic crises of pain radiating from extremities, 
especially in children; acroparesthesias; heat and cold sensitivity; 
exercise intolerance; hoarse voice; recurrent otitis media, sinusitis, 
pneumonia 
 
Abnormal laboratory 
or imaging findings 
 
Unexplained proteinuria or isosthenuria; anemia; thrombocytopenia; 
vacuolated lymphocytes; white matter lesions; hydrocephalus on brain 
magnetic resonance imaging 
 
Neurologic 
 
Neurologic degeneration; peripheral neuropathy; progressive mental 
retardation; progressive dementia; behavioral abnormalities and 
psychosis; hyperactivity; excessive startle; seizures; hypotonia; 
weakness; spasticity; myoclonic jerks; ataxia; dystonia 
 
Ophthalmologic 
 
Corneal clouding; whorled corneal opacity; cataract; cherry red spot; 
macular degeneration; ophthalmoplegia, especially upward gaze palsy; 
optic atrophy; strabismus 
 
Cardiac 
 
Unexplained cardiomyopathy; valvular heart disease; arrhythmia 
 
Gastrointestinal 
 
Attacks of abdominal pain; diarrhea; constipation 
 
Renal 
 
Proteinuria; isosthenuria; tubular dysfunction 
 
Cutaneous 
 
Angiokeratomas (raised reddish-purple cutaneous vascular lesions); 
subcutaneous nodules; ichthyosis; hypohidrosis; coarse skin and hair 
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In synthesis: 1) within each disorder, there is usually a clinical spectrum that reflects the 
impact of different mutations on the function of the lysosomal compartment; 2) different 
disorders have remarkable similarities in clinical phenotype, especially when the stored 
substrates are similar (as is the case with some of the MPSs and the Sphingolipidoses), or 
when similar cells and tissues are involved (e.g., organomegally, bone pathology, and 
neuropathology); 3) there are some characteristic clinical symptoms that can be used to 
distinguish disorders from each other (e.g. gingival hyperplasia in ML II disease). Thus, 
despite the similarities in the clinical phenotype between different lysosomal storage 
disorders, no two disorders have identical pathophysiology [reviewed in Parkinson-Lawrence et 
al., 2010]. 
 
1.2.4. Diagnosis of LSDs 
LDSs are sometimes hard to recognize due to the wide spectrum of phenotypes that the 
patients may present (Figure 1.5). Indeed, the recognition of LSD clinical features 
requires clinical expertise, as most of them are not specific and can be caused by defects 
in other metabolic pathways (mitochondrial and peroxisomal), or by environmental 
factors [reviewed in Filocamo and Morrone, 2011]. Therefore, it is common to elapse a long 
period between the onset of the first symptoms and the definitive diagnosis. And even in 
the presence of typical clinical signs and symptoms, samples and diagnostic tests are 
different for each group of lysosomal disorders, being often specific of a given disease. 
This is one of the major reasons why definitive diagnosis of LSDs requires a close 
collaboration between laboratory specialists and clinicians, in order to reach a correct 
diagnose in the shortest time. 
Biochemical genetic testing (BGT), which includes the determination of the enzymatic 
activity of lysosomal hydrolases is feasible for most LSDs and essential for the diagnosis 
of primary lysosomal enzyme deficiency. Actually, the majority of patients is initially 
screened by enzyme assays and only after that the molecular studies are performed to 
determine the disease-causing mutation(s). In families with an already identified 
causative molecular defect, mutation analysis may be performed directly. Mutation 
analysis is done through molecular genetic testing (MGT), which can be performed either 
on DNA or RNA and comprises a range of different approaches for investigating the entire 
gene-coding regions and exon-intron boundaries, as well as the 5´and 3´untranslated 
regions (UTRs). It is not only useful but frequently necessary to confirm the enzymatic 
diagnosis of a LSD. For LSDs resulting from non-enzymatic lysosomal proteins, MGT is 
absolutely essencial for a proper diagnosis, the same happening for the analysis of post-
mortem samples [reviewed in Filocamo and Morrone, 2011]. 
Recently, another possibility is being discussed for the diagnosis of LSDs that foresees the 
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inclusion of some of them (e.g. Krabbe disease; Pompe disease; Fabry disease and several 
MPSs such as type I, IIIA, IIIB and VI) in neonatal screening programs [Giugliani, 2012; 
Simonaro et al., 2005] which would now be possible thanks to the significant advances that 
were made in last decade since dried blood spot technology was introduced for 
enzymatic assays and lysosomal protein profile was developed. The ongoing development 
of enzyme replacement therapy (ERT) and other treatments for several LSDs, combined 
with the growing evidence that early commencement of therapy improves outcomes, has 
increased the pressure for the introduction of newborn screening programs and a number 
of pilot studies are ongoing for LSDs [Simonaro et al., 2005; Spada et al., 2006; Lin et al., 2009; 
Chien et al., 2008; Hwu et al.2009; Duffner et al. 2009a; Duffner et al. 2009b; Fuller et al., 2011].  
 
1.2.5. Treatment: from bone marrow transplantation to gene therapy 
Currently, there is no cure available for any LSD, even though treatment strategies do 
exist for some of them.  In general, treatments for LSDs can be broadly divided into those 
that reduce the levels of biosynthesis of the accumulating substrate (substrate reduction 
therapy, SRT) and those aiming at directly addressing either the functional loss of the 
enzyme or its clinical effects (Figure 1.6).  
 
Figure 1.6: Therapies for lysosomal storage disorders. 
LSD treatments can be divided into those that reduce the levels of biosynthesis of the accumulating 
substrate (left side of the image) and those aiming at directly addressing either the functional loss of 
the enzyme or its clinical effects  (right side of the image). The later include (a) general treatments 
that deal mainly with the symptoms (ex.: bone marrow transplantation); (b) ERT and (c) potential new 
therapies such as the use of chemical chaperones, gene therapy or BBB-crossing therapies. Treatments 
marked with an * are in clinical use at present.  
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Of the treatments for symptoms, splenectomy used to be relatively common, at least for 
Gaucher-disease (GD) patients. Splenectomy can reduce the symptoms, such as 
thrombocytopenia (low platelet count) and anemia that accompany some LSDs, but does 
not cure the disease. Bone-marrow transplantation (BMT) is another option which 
sometimes is carried out. Umbilical cord blood transplantation is also being performed at 
specialized centers for a number of these diseases. The reason for such approaches lies 
on having found out that a small, but significant, fraction of lysosomal enzymes are 
secreted by the donor normal cells. So, transplanted bone marrow will eventually lead to 
the production of normal cells that secrete normal enzymes which may subsequently be 
internalized by the affected cells. Other approaches are also common to ameliorate 
symptoms of some particular LSDs. For example, chronic hemodialysis and/or renal 
transplantation are used in Fabry disease because renal insufficiency is a frequent 
complication. It should be stressed, however, that none of these treatment approaches 
are either specific or effective. Actually, no treatments are yet available targeting most 
of the rarer LSDs and overall the medical options are mostly directed towards disease 
management rather than therapy. 
Nevertheless, some rather specific and effective treatments are available for a restrict 
number of LSDs. Those are not the above referred general treatments for the symptoms, 
but instead, therapeutic approaches that deal directly with the cause of the disease, 
either by replacing the defective gene or enzyme or by directly targeting the systems 
that are affected by the accumulation of undegraded metabolites. Such approaches were 
only possible when remarkable progresses in genetic engineering allowed the production 
of recombinant proteins that could replace the missing enzyme providing specific 
treatment for a growing number of LSDs. This process started with intravenous ERT for 
GD in the 1990s, and was later extended to Fabry disease, Pompe disease and MPSs I, II 
and VI [Giugliani, 2012]. This therapy is likely to be extended to other LSDs in the near 
future and some clinical trials are already in course (e.g. MPS IVA). In general, ERT is 
more effective on later onset or milder variants of LSDs, as it has no impact on the 
neuropathology of the diseases, since the recombinant enzyme is unable to cross the 
blood brain barrier and so to reach the brain.  
The ineffectiveness of ERT and, in some cases BMT, to overcome neurological symptoms is 
one of the main reasons why additional therapeutic approaches are being investigated 
addressing the needs of the more severe types. SRT, for example, is currently being 
evaluated for some of these diseases (e.g. MPS I, II, IIIA and IIIB). Also chaperone therapy, 
which holds the potential to stabilize the defective enzymes produced by patients, or 
gene enhancement and gene therapy, techniques in which specific viral vectors may be 
used to directly transduce central nervous system (CNS) cells that would thus become an 
endogenous source of high levels of functional enzyme [Gritti, 2011], are also under 
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evaluation and are expected to provide a cure for many of these genetic diseases in the 
future [Beck, 2010].  
Despite the prospects of innovative therapeutic developments, without a detailed 
understanding of the precise mechanisms operating in each LSD, and without easy and 
early means of diagnosis, new and successful treatments will not become available 
[reviewed in Futerman and van Meer, 2004]. So, the major efforts at the moment should be 
focused both at unveiling the underlying pathological mechanisms that lead to LDSs 
phenotypes (See section 1.2.3) and at developing sensitive and early methods of 
diagnosis for such disorders (see Section 1.2.4).  
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2. TRAVELLING ROUTES TO THE LYSOSOME  
2.1. THE MANNOSE-6-PHOSPHATE PATHWAY* 
Like several other proteins, lysosomal hydrolases are synthesized in the endoplasmic 
reticulum (ER) and cotranslationally glycosylated on selected asparagine residues. 
Soluble lysosomal proteins are synthesized as pre-pro-proteins with an N-terminal signal 
sequence (20-25 aa), which translocates the precursor protein into the lumen of the ER 
[Hasilik et al., 2009]. The signal peptides are removed and initial protein glycosylation takes 
place. The signal motif for N-glycosylation is Asn-X-Ser/Thr (“X” being any amino acid 
except proline), which is a motif evolutionary highly conserved [Braulke and Bonifacino, 
2009]. The oligosaccharide branch Glc3Man9(GlcNAc)2 is attached to the amino group of 
the asparagine side chain amide, being then processed and modified in the ER and Golgi 
apparatus. Mature glycoproteins can contain three different types of N-glycans: high 
mannose, complex and hybrid sugars. Another post-translational modification taking 
place in the Golgi complex is O-glycosylation, where sugar residues can be transferred to 
the OH group of an amino acid side chain, mostly of serine or threonine. This type of 
glycosylation is a single monosaccharide transfer process initiated by specific GalNAc 
transferases (over 24 described). In contrast to N-glycosylation, O-glycosylation is not 
known to occur at a single consensus sequence. However, the various GalNAc transferases 
are highly specific and control the glycosylation process. Addition and modification of 
sugar residues also play an important role in protein folding, quality control and 
transport [Helenius and Aebi, 2001; Ruddock and Molinari, 2006]. When moving to the secretory 
pathway, these proteins are also selectively recognized by a phosphotransferase, UDP-N-
acetylglucosamine-1-phosphotransferase (GlcNAc-1-phosphotransferase), which initiates 
the two-step reaction that results in the generation of the M6P marker (Figure 2.1) on 
specific N-linked oligosaccharides.  
 
Figure 2.1: The Mannose-6-Phosphate recognition signal. 
 
 
* For an extensive review on the M6P travelling route see Appendix 1, review paper 2: Coutinho MF, Prata MJ, Alves S. The mannose-
6-phosphate pathway: Function and dysfunction. Mol Genet Metab. 2012; 105:542-50. 
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GlcNAc-1-phosphotransferase catalyses the transfer of a GlcNAc-1-phosphate residue 
from UDP-GlcNAc to C6 positions of selected mannoses in high-mannose type 
oligosaccharides of the hydrolases. The second step in the formation of the M6P marker 
involves the removal of the terminal GlcNAc by an N-acetylglucosamine-1-phosphodiester 
α-N-acetyl-glucosaminidase, also known as “uncovering enzyme” (UCE), exposing the M6P 
recognition signal. Next, the modified proteins are recognized by two independent 
receptors that bind the M6P residue of the newly synthesized lysosomal hydrolases in the 
TGN and finally, the ligand-receptor complex is packaged into clathrin-coated transport 
vesicles for delivery to endosomes and lysosomes (Figure 2.2) [Braulke and Bonifacino, 2009].  
 
Figure 2.2: Transport of newly synthesized lysosomal hydrolases to lysosomes. 
Lysosomal hydrolases are synthesized in the endoplasmic reticulum and move to the cis Golgi network, 
where they are covalently modified by the addition of mannose 6-phosphate (M6P) groups. The 
formation of this marker depends on the sequential effect of two lysosomal enzymes: UDP-N-
acetylglucosamine 1-phosphotransferase (GlcNAc-phosphotransferase) and N-acetylglucosamine-1-
phosphodiester α-N-acetyl-glucosaminidase (UCE). GlcNAc-phosphotransferase catalyses the transfer of 
a GlcNAc-1-phosphate residue from UDP-GlcNAc to C6 positions of selected mannoses in high-mannose 
type oligosaccharides of the hydrolases. Then, the uncovering enzyme removes the terminal GlcNAc, 
exposing the M6P recognition signal. At the trans-Golgi network, the M6P signal allows the segregation 
of lysosomal hydrolases from all other types of proteins through selective binding to the M6P receptors. 
The clathrin-coated vesicles produced bud off from the trans-Golgi network and fuse with late 
endosomes. At the low pH of the late endosome, the hydrolases dissociate from the M6P receptors and 
the empty receptors are recycled to the Golgi apparatus for further rounds of transport. 
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2.1.1. FUNCTIONAL COMPONENTS OF THE MANNOSE-6-PHOSPHATE PATHWAY 
2.1.1.1. GlcNAc-1-phosphotransferase* 
GlcNAc-phosphotransferase is a Golgi-resident 540-kDa hexameric transmembrane 
enzyme composed by three subunits, α2β2γ2 (Figure 2.3).  
 
Figure 2.3: Model of the GlcNAc-1-phosphotransferase complex. 
[adapted from Braulke et al., 2008 ; Encarnação et al., 2011] 
GlcNAc-1-phosphotransferase is a hexameric complex of three subunits (α2β2γ2). The α- and γ-subunits 
form disulfide-linked dimers. 
 
This enzyme is coded by two different genes: GNPTAB and GNPTG, encoding for the α/β- 
subunits and the γ-subunit, respectively. The GNPTAB gene contains 21 exons and spans 
85 kb on chromosome 12q23.3. It encodes a protein of 1256 amino acids with a predicted 
molecular mass of 144 kDa (α/β-precursor). Hydrophobicity analysis showed two 
transmembrane domains and 19 potential N-glycosylation sites (17 in the α-subunit and 3 
in the β-subunit) [Tiede et al., 2005].  
Proteolytic processing of the α/β-precursor between Lys928 and Asp929 generates the 
individual α- and β-subunits and is a prerequisite for the enzymatic activity of the 
GlcNAc-1-phosphotransferase complex [Tiede et al., 2005]. Recently Marschner et al. [2011] 
provided evidence that the α/β-subunit precursor of GlcNAc-1-phosphotransferase is 
cleaved by the site-1 protease (S1P; also known as subtilisin kexin isoenzyme–1, SKI-1). 
This enzyme is encoded by the MBTPS1 gene and is a membrane bound serine protease. 
The prototypical membrane-bound S1P substrates are the sterol regulatory element–
binding proteins SREBP1 and 2, which play a major role in lipid metabolism and 
cholesterol homeostasis  [referred in Marschner et al., 2011].  These  authors  verified  that  
S1P-deficient  
* For an extensive review on GlcNAc-1-phosphotransferase see Appendix 2, book chapter: Coutinho MF. N-acetylglucosamine-1-
phosphate transferase (GNPTAB, GNPTG) in Taniguchi N., Honke K., Fukuda M., Narimatsu H., Yamaguchi Y., Angata T. (Ed.) 
"Handbook of Glycosyltransferases and Related Genes". SpringerReference [in press] 
γ subunit 
α subunit 
β subunit 
Golgi 
lumen 
cytosol 
S - S 
S - S 
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cells failed to activate the α/β-subunit precursor and exhibited a mucolipidosis II–like 
phenotype. This implies a new focus for molecular diagnosis, since mutations in the gene 
that codes for this protease may be present in individuals with genetically undefined 
mucolipidosis II–like phenotypes. 
 
Figure 2.4: Modular structure of the human GlcNAc-1-phosphotransferase α/β-precursor. 
[adapted from Marschner et al., 2011] 
Schematic presentation of the modular structure of the α/β-precursor of the human GlcNAc-1-
phosphotransferase and its proteolytic processing to mature α- and β-subunits. 
 
The GNPTG gene, spanning 11 exons on chromosome 16p13.3, encodes the γ-subunit, 
which is a soluble glycoprotein of 305 amino acids, with a molecular weight of 97kDa 
capable to form disulfide-linked dimers [Raas-Rothschild et al., 2000]. The initial 305 
aminoacid polypeptide is processed into a mature form by proteolytic cleavage of a signal 
peptide with 24 amino acids; then the mature protein can form disulfide bonds [Tiede et 
al., 2004]. The γ-subunit contains two potential N-glycosylation sites at N88 and N115 
[Encarnação et al., 2011]. 
Functionally, the α/β-subunits constitute the catalytic portion of the enzyme and carry 
the substrate binding sites for UDP-GlcNAc and high mannose-type lysosomal enzymes 
[Kudo et al., 2005; Lee et al., 2007]. Whilst being in the α-subunit that are located the UDP-
GlcNAc binding site and homology region to the bacterial capsular polymerases [Tiede et 
al., 2004; Kudo et al., 2005; Bao et al., 1996], the β-subunit also appears to be necessary to the 
enzyme function, as demonstrated by the failure of transfection of the α-subunit alone to 
generate GlcNAc-1-phosphotransferase activity [Kudo et al., 2006a] plus the genetic 
evidence that truncation of the β-subunit results in GlcNAc-1-phosphotransferase 
deficiency [Tiede et al., 2004; Kudo et al., 2006a; Paik et al., 2005]. Moreover, the 
transmembrane domains on the α- and β-subunits are required for natural processing of 
the GlcNAc-1-phosphotransferase precursor [Kudo et al., 2006a].  
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Analysis of a library of cathepsin D/pepsinogen chimeric proteins along with mutant 
cathepsin L has shown that GlcNAc-1-phosphotransferase recognizes common 
conformation-dependent protein structures of lysosomal enzymes in which lysine residues 
are the major determinants [Baranski et al., 1990; Cantor et al., 1992; Cuozzo et al., 1995; Qian et 
al., 2010], as was also proven through antibody inhibition experiments with arylsulfatase A 
[Sommerlade et al., 1994]. In addition, the interaction of both subunits with the protein 
determinant of acid hydrolases stimulates the catalytic function of the transferase [Qian 
et al., 2010]. 
In 2007, Gelfman and colleagues generated a mouse model for GNPTAB deficiencies by 
microinjection of embryonic stem (ES) cell clones GNPTAB-/- into host blastocysts. 
Homozygous mice lacking α/β-subunits of GlcNAc-1-phosphotransferase presented with 
growth retardation, retinal degeneration and secretory cell lesions that do not exactly 
mimic the human disease. Nevertheless, the less severe phenotype of the GNPTAB-
knockout mouse enables studies designed to understand alternative molecular 
mechanisms involved in the trafficking of lysosomal enzymes to lysosomes and provides a 
valuable tool for assessing the role of proper lysosome function in the maintenance of the 
retina and the secretory cells of exocrine glands [Gelfman et al., 2007].  
The role of the γ-subunits of the GlcNAc-1-phosphotransferase remained elusive [Tiede et 
al., 2005; Kudo et al., 2006a] up to recently, when studies begun to appear demonstrating 
that the γ-chains are important to facilitate the proper folding of the full set of subunits 
in the GlcNAc-1-phosphotransferase and to maintain them in the right conformation, 
turning the enzyme competent for substrate recognition and binding. The γ-chains are 
also necessary to regulate the activity and expression of the α/β-subunits [Lee et al., 2007; 
Qian et al., 2010; Pohl et al., 2009; Pohl et al., 2010]. Pohl and colleagues [2009], after having 
identified, in a boy with MLIII gamma, a novel homozygous mutation in the GNPTG gene 
resulting in a truncated but stable γ-subunit protein, performed in vitro and in vivo 
experiments to characterize the mutation, obtained compelling support that the γ- 
subunit was involved in the regulation of the GlcNAc-1-phosphotransferase activity. 
Latter, the same group [Pohl et al., 2010] showed that in human macrophages the 
proteolytic cleavage of the γ-subunit of the GlcNAc-1-phosphotransferase leads to the 
formation of unique oligomers that fail to associate with the other GlcNAc-1-
phosphotransferase subunits in higher molecular mass complexes, which might explain 
why almost all proteins in human macrophages lack M6P residues. The limited proteolysis 
of the γ-subunits seems to be the regulator mechanism that controls the GlcNAc-1-
phosphotransferase activity and subsequent sorting efficiency of lysosomal enzymes. In 
mice lacking the γ-subunit, the extent of acid hydrolases phosphorylation relative to 
wild-type animals was investigated revealing that the γ-subunit increases the activity of 
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the α/β-subunits toward protein acceptors to variable extents [Qian et al., 2010]. The same 
study afforded evidence that the γ-subunit serves at least two roles. One is to interact 
with the high mannose oligosaccharides of the acceptor hydrolase, facilitating the 
addiction of the second GlcNAc-P to the molecule. This GlcNAc-P is transferred to a 
specific mannose residue on the 3’ arm of the high mannose unit, whereas the first 
GlcNAc-P almost always is added to a mannose on the 6’ arm of the glycan. The authors 
also postulate that a specific domain of the γ-subunit, the mannose 6-phosphate receptor 
homology (MRH) domain binds the high mannose oligosaccharide in such a way that the 
transfer of the second GlcNAc-P is enhanced, explaining the role of the γ-subunit in 
increasing the overall phosphorylation in a subset of the acid hydrolases [Qian et al., 2010]. 
This second role is in line with previous data from Lee et al. [Lee et al., 2007], who through 
the analysis of brain tissue of knock-out mice for the γ gene, observed that, for example, 
α-mannosidase and β-glucuronidase were similarly phosphorylated as in the wild-type 
brain, whereas β-hexosaminidase and β-galactosidase were not or were weakly 
phosphorylated [Lee et al., 2007]. 
 
2.1.1.2. The uncovering enzyme: N-acetylglucosamine-1-phosphodiester α-N-acetyl-
glucosaminidase 
N-acetylglucosamine-1-phosphodiester α-N-acetylglucosaminidase, also known as the 
uncovering enzyme (UCE) excises the covering GlcNAc from the GlcNAc-P-Man diesters, 
to form the M6P monoester recognition signal on lysosomal acid hydrolases (Figure 2.5). 
 
Figure 2.5: Schematic presentation of UCE action on the M6P recognition signal formation. 
 
UCE is a type I transmembrane glycoprotein of 515 amino acids which exists as a tetramer 
that cycles between the TGN and the plasma membrane [Varki and Kornfeld, 1981; Kornfeld et 
al., 1999; Lee et al., 2002]. This enzyme is coded by the NAGPA gene that contains 10 exons, 
being located on chromosome 16 [Kornfeld et al. 1999]. UCE presents six potential N-
glycosylation sites [Kornfeld et al. 1999], being synthesized as an inactive precursor that is 
activated upon proteolytic cleavage of a 24-aminoacid propiece by the endoprotease 
furin. As furin is localized in the TGN, newly synthesized UCE is inactive until reaching 
the terminal Golgi compartment [Do et al., 2002]. 
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To date no pathological conditions have been associated with the loss of UCE activity. 
Speculation on the existence or inexistence of such pathologies was maintained over 
years, with some authors arguing that an alternative mechanism of conversion of the M6P 
diesters to monoesters should exist, able to correct malformation of the recognition 
signal induced by UCE deficiency, while others argued that inactivating mutations in the 
UCE gene should be so rare events that could explain the non-observation of UCE related 
phenotypes. However, a few years ago, Chavez and collaborators [2007], shed some light 
on why UCE loss of function might not be associated with overt pathological condition, 
when demonstrating that the fifth repeat domain, of a total of 15 that constitute the 
cation-independent mannose-6-phosphate receptor (CI-MPR), is able to bind GlcNAc-P-
Man diesters. This binding occurred with much lower affinity than the binding to M6P 
monoesters, which take place in domains 1-3 and 9 of the same receptor [Chavez et al., 
2007]. The first evidence came from in vitro studies but next they were corroborated by 
in vivo experiments with mice lacking UCE, created through insertional mutagenesis in 
the gene that codes for UCE [Boonen et al., 2009]. Despite UCE-/- mice were viable, grew 
normally and lacked detectable histological abnormalities, the plasma levels of six 
monitored lysosomal hydrolases were 1.6 to 5.4-fold elevated over wild type levels. The 
secreted hydrolases contained GlcNAc-P-Man diesters, exhibited a decreased affinity for 
the CI-MPR receptor and no affinity at all to the cation-dependent mannose-6-phosphate 
receptor (CD-MPR). On the grounds of these results, Boonen and colleagues [2009] 
proposed that, in the absence of UCE, the weak binding of the lysosomal hydrolases to 
the CI-MPR allows enough sorting to lysosomes to prevent the tissue abnormalities seen in 
GlcNAc-1-phosphotransferase deficiency. The ability of the CI-MPR to recognize the 
product of GlcNAc-1-phosphotransferase implies that deficiencies in the UCE probably 
will not be lethal [Boonen et al., 2009]. Furthermore, it allows delivery to the lysosome of 
those acid hydrolases that may be poor substrates for the uncovering enzyme in 
quantities sufficient to prevent the severe phenotypes usually associated with LSDs [Olson 
et al., 2010]. 
 
2.1.1.3. Mannose-6-Phosphate receptors  
Once anchored in the N-linked oligosaccharides of newly synthesized hydrolases, the M6P 
recognition marker has to be recognized by specific receptors, so that the labeled 
hydrolases are correctly transported to the lysosome (Figure 2.2) [reviewed in Kornfeld and 
Mellman, 1989]. This role is carried out by the mannose-6-phosphate receptors (MPRs), 
which are type I transmembrane glycoproteins that bind their specific cargo proteins at 
pH 6,5-6,7, in the TGN and release them at pH 6, the typical pH inside late endosomes. 
Inside these compartments, lysosomal hydrolases dissociate from the MPRs, and when the 
pH drops further, during endosomal maturation, and reaches 5 - the typical acidic pH of 
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lysosomes which is maintained by a membrane ATP-driven H+ pump -, hydrolases begin to 
digest the endocytosed material delivered from early endosomes [reviewed in Alberts et al., 
2002].  
There are two different M6P receptors, both of them extensively characterized over the 
last decades [Kornfeld et al., 1992; Ludwig et al., 1995; reviewed in Ghosh et al., 2003]. The first is 
the cation-independent M6P receptor (CI-MPR or MPR300), a transmembrane glycoprotein 
of approximately 300-kDa that also binds with high affinity other ligands such as the 
insulin-like growth factor II (IGF II) that is involved in early growth and development. This 
is why the CI-MPR is also called the IGF II receptor. The extracytoplasmic domain of this 
receptor contains fifteen homologous repeating units of around 150 amino acids [Lobel et 
al., 1988; Oshima et al., 1988]. The third and the ninth of them provide two M6P binding 
sites, whereas the eleventh element provides a binding site to IGF II [Westlund et al., 1991; 
Dahms et al., 1993; Dahms et al., 1994]. Additionally, CI-MPR also contains one phosphodiester 
(Man6P-GlcNAc) binding site [Marron-Terada et al., 2000; Hancock et al., 2002]. The other 
receptor is the cation-dependent M6P receptor (CD-MPR or MPR46). The extracytoplasmic 
domain of this 46-kDa transmembrane glycoprotein is homologous to each of the 15 
repeats found in the extracytoplasmic domain of CI-MPR [Dahms et al., 1987] and contains 
one M6P binding site [Tong and Kornfeld, 1989]. The detergent-solubilized CD-MPR is a 
homodimer which may form tetramers in Golgi membranes [Dahms and Kornfeld, 1989; 
Waheed and von Figura, 1990]. 
Although related to one another, and even having similar domains, both MPRs are 
essential and non-synonymous components of the M6P-dependent targeting system. This 
was proven by gene disruption experiments in mice. Animals with disrupted CI-MPRs or 
CD-MPRs genes were partially impaired in intracellular lysosomal enzyme sorting [Köster et 
al., 1993; Ludwig et al., 1993]. Mutant mice lacking the CD-MPR are viable, while mice 
lacking the CI-MPR accumulate high levels of IGF-II and usually die perinatally, whereas 
mice that lack both IGF-II and CI-MPR are viable [Sohar et al., 1998]. A partial missorting of 
phosphorylated lysosomal enzymes was also observed in embryonic fibroblasts derived 
from mouse embryos lacking either the CI-MPR or the CD-MPR [Munier-Lehman et al., 1996]. 
Further experiments enlightened the fact that each mutant cell line secretes, in a large 
part, different phosphorylated ligands and that high levels of one MPR do not fully 
compensate for the absence of the other, demonstrating that the two MPRs have 
complementary targeting functions. One possible explanation is that each MPR recognizes 
different features of the lysosomal enzymes [Munier-Lehman et al., 1996]. Furthermore, 
primary fibroblasts from embryos lacking both MPRs are almost totally impaired in 
lysosomal enzyme sorting. As a consequence, cells accumulate undigested material in 
their endosomes/lysosomes [Ludwig et al., 1994] presenting a phenotype quite similar to 
the one characteristic of ML II fibroblasts, which have a lack of synthesis of the M6P 
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signal due to defects in GlcNAc-1-phosphotransferase. 
The idea that the MPRs are complementary in function was reinforced by studies of 
receptor deficient fibroblasts showing that three different subgroups of M6P containing 
proteins could be distinguished: (i) those which are preferentially secreted in the 
absence of the CD-MPR and, therefore, do not interact well with the remaining CI-MPR; 
(ii) those that are preferentially secreted in the absence of the CI-MPR and, therefore, do 
not interact well with CD-MPR and, finally, (iii) those which are only secreted in the 
absence of both MPRs, thus interacting equally well with either MPR [Munier-Lehmann et al., 
1996]. 
In terms of localization, the MPRs are distributed over several intracellular compartments 
including the TGN, the plasma membrane and the endosomes. At steady level, the 
majority of MPRs reside in the endosomes [Kornfeld and Mellman, 1989]. When located in the 
TGN, the MPRs divert the newly synthesized lysosomal hydrolases from the secretory 
pathway to the endocytic pathway, after which they unload their bound ligands. 
However, not all the hydrolases that are tagged for delivery to the endosome/lysosome 
compartment arrive to their proper destination. Actually, some escape binding to MPR in 
the TGN being directed, by default, to the cell surface, where they are secreted to the 
extracellular fluid. When this happens some MPRs can take a detour back to the plasma 
membrane, where they recapture the escaped lysosomal enzymes returning them to 
lysosomes by receptor-mediated endocytosis via early and late endosomes [in Alberts et al., 
2002]. The CI-MPR localized at the plasma membrane may also contribute to the partial 
rescue of those hydrolases [Marron-Terada et al., 2000; Dahms et al., 1987].  
 
 
2.1.2. IMPAIRMENTS IN THE MANNOSE-6-PHOSPHATE PATHWAY AND DISEASE 
2.1.2.1. Defective GlcNAc-1-phosphotransferase causing Mucolipidosis II and III 
Defective GlcNAc-1-phosphotransferase causes two distinct human lysosomal storage 
diseases, Mucolipidosis II (ML II) and Mucolipidosis III (ML III), which are among the few 
lysosomal storage disorders related to defects in non-lysosomal proteins. ML II, also 
known as I-cell disease, is characterized by a total loss of GlcNAc-1-phosphotransferase 
activity whether ML III, often referred to as pseudo-Hurler polydystrophy, manifests when 
enzymatic activity is reduced [Leroy and Spranger, 1970; Spranger and Wiedemann, 1970]. In both 
ML II and ML III patients, newly synthesized lysosomal enzymes fail to be correctly sorted 
to the endosome/lysosome compartment due to the absence or weak equipment in M6P 
residues. As a consequence, lysosomal dysfunction develops leading to accumulation of 
non-degraded material, the hallmark of this group of diseases. Unlike the majority of 
lysosomal storage disorders, which involve single enzymes acting in a catabolic pathway, 
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MLII and III results from impaired sorting of multiple enzymes to lysosomes that instead 
are over-secreted from cells. The excessive accumulation of non-degraded substrates 
results in the subsequent formation of large inclusion bodies.  
While ML II and ML III share similar clinical features, including skeletal abnormalities, ML 
II is the more severe in terms of phenotype [Leroy and Spranger, 1970]. In this pathology the 
skeletal system is severely affected, with abnormalities in both cartilage and bone. 
Linear growth decelerates during the first year of life almost stopping during the second 
year and death usually occurs between 5 and 8 years of age [Kornfeld and Sly in Scriver, 2001].  
ML III is a much milder disorder, being characterized by latter onset of clinical symptoms 
and slower progressive course, which may allow the survival into the eighth decade. 
Usual clinical findings in ML III patients include restricted joint mobility, short stature and 
mild Hurler-like dysmorphism, among other less severe features [Spranger and Wiedemann, 
1970; Umehara et al., 1997]. Only 50% of the patients present with mental retardation 
[Umehara et al., 1997]. 
Once GlcNAc-1-phosphotransferase is an hexameric complex whose protein subunits are 
encoded by two genes, depending on which of them harbors the causal mutation(s) and 
simultaneously on the severity/clinical course of the disease, the associated pathologies 
are classified as ML II alpha/beta (OMIM: 252500) and ML III alpha/beta (OMIM: 252600) if 
mutations are present in the GNPTAB gene, or ML III gamma (OMIM: 252605) if mutations 
occur in the GNPTG gene [Tiede et al., 2005; Raas-Rothschild et al., 2000]. 
To date, more than 100 different GNPTAB mutations have been reported, causing either 
ML II alpha/beta or ML III alpha/beta, including 30 missense, 20 nonsense, 32 small 
deletions, 25 small insertions, 2 small indels and 14 splice site mutations [HGMD and 
references therein; reviewed in Kollman et al., 2010]. Large genomic rearrangements appear to 
be rare (1,6%) although two gross insertions [Otomo et al., 2009; Tapino et al., 2008] have 
already been detected. Most of these mutations are private or rare. Uncommonly, 
however, the microdeletion c.3503_3504delTC, presents a remarkably wide geographical 
distribution, having been detected among Israeli and Palestinian Arab-Muslim, Turkish, 
Irish traveler [Bargal et al., 2006], Italian [Tapino et al., 2009] and U.S. patients [Kudo et al., 
2006b]. That deletion was found to be a frequent mutation in a French Canadian founder 
population [Plante et al., 2008]. 
Concerning the GNPTG gene, the mutations until now reported associated to 
Mucolipidosis type III gamma include 4 missense, 2 nonsense, 5 small deletions, 4 small 
insertions, 4 splice site mutations and 2 gross deletions [HGMD and references therein, 
reviewed in Kollman et al., 2010]. 
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Figure 2.6: Diagnostic strategy for MLII alpha/beta, ML III alpha/beta and ML III gamma. 
Even though direct assessment of GlcNAc-1-phosphotransferase is also possible, usually ML II and III 
biochemical confirmation is attained indirectly through detection of activities of standard lysosomal 
enzymes in plasma or in cultured fibroblasts. In general, a 10- to 20-fold increase in serum of lysosomal 
enzymes, together with decreased intralysosomal levels assessed in fibroblasts (or amniocytes in cases 
of prenatal diagnosis) is indicative of these disorders. Importantly, ML II cannot be distinguished from ML 
III on the basis of residual enzyme activity. Only subsequent molecular analysis and association with 
information on the clinical symptoms and age of onset allow definitive establishment of diagnosis. HexT – 
hexosaminidase T; Hex A – hexosaminidase A; α-man - α-mannosidase; α-gal - α-galactosidase; β-gal - β-galactosidase; β-gluc - β-
glucocerebrosidase 
 
 
2.1.2.2. Mutations in the lysosomal enzyme-targeting pathway causing stuttering 
Recently, it was disclosed an unexpected relation between mutations in the lysosomal 
enzyme-targeting pathway and persistent stuttering.  
Stuttering, is a disorder in which speech fluency can be severely compromised, but its 
primary causes, the high rates of spontaneous recovery and the etiological differences 
between persistent and resolved forms have resisted explanation. In the last years, 
genomewide scans provided signals of linkage at multiple chromosomal sites with 
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stuttering [Shugart et al., 2004; Riaz et al. 2005; Suresh et al., 2006; Wittke-Thompson et al., 2007], 
but the strongest evidence was with a locus on chromosome 12q, which was found in a 
study involving 46 consanguineous families from Pakistan [Riaz et al., 2005]. Afterwards, 
when Kang and colleagues [2010], focusing on the largest of those families, carried out a 
search for mutations across the chromosomal interval showing the strongest linkage, they 
ended up identifying a single nucleotide change in the GNPTAB gene (c.3598G>A). Then, 
the authors went on to sequence GNPTG, as well as NAGPA, in which mutations causing 
changes at highly conserved amino acid residues were also identified, as occurred in 
GNPTAB. A strong association was established between persistent stuttering and four 
mutations in the GNPTAB gene; three mutations in the GNPTG gene and three mutations 
in the NAGPA gene. This study unveiled an unsuspected culprit to explain stuttering in 
some cases, due to the nature of the implicated biologic pathway whose impairment had 
been essentially connected to lysosomal storage diseases. Yet, the affected subjects 
studied by Kang et al. [2010] stuttered but were otherwise normal, without presenting any 
of the typical symptoms of lysosomal malfunction, even being homozygous for some of 
the identified mutations on the GNPTAB and GNPTG genes. Eventually, this can be 
explained admitting that the efficiency of lysosomal targeting was only partially reduced 
in the presence of the detected mutations. Recently, Lee et al. [2011] performed a 
biochemical evaluation of the effect of the three NAGPA mutations which were 
associated with persistent stuttering and found that each mutation leads to lower 
cellular UCE activity [Lee et al., 2011].  
Additional studies in this area may contribute to a better understanding of the neural 
structures and functions within the brain that coordinate human speech, which are still 
poorly elucidated and to a better comprehension on the role of the M6P-dependent 
pathway for lysosomal enzyme routing in this area. 
 
 
2.2. THE MANNOSE-6-PHOSPHATE INDEPENDENT PATHWAY* 
Although M6P receptors play a major role in the intracellular transport of newly 
synthesized lysosomal enzymes in mammalian cells, there are, as previously referred 
several lines of evidence suggesting the existence of an alternative mechanism of 
lysosomal targeting [Ni et al., 2006], the first of which have come from analysis of cells of 
patients with I-cell disease, who despite lacking M6P-containing lysosomal enzymes, 
demonstrate normal lysosomal enzyme levels in several organs. 
 
 
* For an extensive review on the M6P travelling route see Appendix 1, review paper 3: Coutinho MF, Prata MJ, Alves S. A Shortcut to 
the Lysosome: The Mannose-6-Phosphate Independent Pathway. Mol Genet Metab. 2012; 107:257-66. 
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Other experimental approaches have also proven that there are soluble enzymes as well 
as non-enzymatic proteins that are transported to lysosomes in a M6P-independent 
manner, specifically by means of two alternative receptors: the lysosomal integral 
membrane protein (LIMP-2) and sortilin. LIMP-2 was implicated in the delivery of β-
glucocerebrosidase (GCase, the defective enzyme in patients with Gaucher disease) to 
the lysosomes [Reczek et al., 2007]. Sortilin, on the other hand, is a multifunctional 
receptor capable of binding different ligands, which has been suggested to mediate 
Golgi-to-lysosome transport of the sphingolipid activator proteins (SAPs) prosaposin 
(PSAP) and GM2 activator protein (GM2AP); acid sphingomyelinase (ASM); and cathepsins 
D and H [Canuel et al., 2008; Nielsen et al., 1999; Lefrancois et al., 2003; Canuel et al., 2008].  
 
2.2.1. LIMP-2 
2.2.1.1. A specific lysosomal receptor 
LIMP-2 was first described in 1995 [Calvo et al., 1995], but its role as a sorting receptor was 
only unveiled several years later when Reczek and colleagues [2007] unexpectedly 
realized it was responsible for the transport of GCase from the TGN to the 
endosomal/lysosomal compartment. LIMP-2 binds GCase in a pH-dependent fashion, 
enabling its association in the ER and transport to the lysosome, where the complex 
likely dissociates due to the acidic pH [Reczek et al., 2007]. In fact, during the passage 
through the various organelles of the secretory pathway, the receptor-ligand complex 
experiences a gradient of decreasing pH: the nearly neutral milieu of the ER allows 
GCase to associate with LIMP-2, whereas the low pH of the endosomes/lysosomes leads 
to the dissociation of GCase from LIMP-2 [Zachos et al., 2012]. Additional studies from Blanz 
et al. [Blanz et al., 2010] demonstrated that, through disruption of either the helical 
arrangement or the amphiphatic nature of the LIMP-2 coiled-coil domain (residues 152 to 
167), GCase binding was abolished. Furthermore, a synthetic peptide comprising the 
coiled-coil domain of LIMP-2 was shown to display pH-selective multimerization 
properties. All these data point out the importance of an intact coiled-coil structure for 
the interaction of LIMP-2 and GCase.  
Further analysis of the pH dependency of LIMP-2 and GCase binding by perturbing the 
intra-lysosomal pH in cultured cells revealed that lumenal acidification mediated by the 
vacuolar (H+)-ATPase triggers the dissociation of LIMP-2 and GCase in late 
endosomal/lysosomal compartments [Zachos et al., 2012]. Moreover, the same authors 
identified a single histidine residue in LIMP-2 (H171) that likely serves as the critical pH 
sensor. H171 is in close proximity to the previously described coiled-coil motif in the 
luminal domain of LIMP-2, which is necessary for GCase binding. Interestingly, that 
residue is not conserved in chicken or Xenopus, species that are also devoid of the 
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proposed coiled-coil domain, another important GCase binding factor. Thus, such species 
may be of great value to decipher additional roles of LIMP-2 other than transporting 
GCase to lysosomes [Zachos et al., 2012]. 
 
2.2.1.2. LIMP-2 and disease: action myoclonus-renal failure syndrome 
Mutations in the gene coding for this receptor prevent GCase from reaching the lysosome 
and from assuming its function inside the lysosome. Not surprisingly, SCARB2 mutations 
underlie a serious autosomal-recessive disorder presently known as action myoclonus-
renal failure syndrome (AMRF; OMIM#254900) [Berkovic et al., 2008; Balreira et al., 2008]. This 
disease combines progressive myoclonus epilepsy (PME), associated with storage material 
in the brain, and focal glomerulosclerosis, frequently with glomerular collapse.  
At the biochemical level, this condition was shown to be characterized by pathological 
levels of GCase activity in fibroblasts, normal or slightly reduced levels in leukocytes, 
increased levels in plasma and the absence of other markers of Gaucher disease (GD), 
such as elevated chitotriosidase activity [Dardis et al., 2009]. 
Recently, Hopfner and colleagues [Hopfner et al., 2011], by screening a German AMRF family 
with these features associated with renal failure, provided data indicating that 
demyelinating polineuropathy and dilated cardiomyopathy are part of the AMRF 
syndrome. The findings were confirmed almost simultaneously by Dibbens et al. [2011], 
who described a patient with PME and demyelinating peripheral neuropathy, also carrying 
a SCARB2 mutation that could explain the phenotype. This particular case had previously 
been published in the Archives of Neurology and presented with PME, preserved intellect 
and a nonprogressive generalized demyelination neuropathy [Costello et al., 2009]. By that 
time, failure to establish the cause of the phenotype, despite the extensive evaluation, 
led the authors to describe a novel PME syndrome, but due to the absence of renal 
failure, they withdrew the initial AMRF diagnosis.  
Currently, the presentation of PME without renal impairment [Dibbens et al., 2009] prompts 
additional screenings of the SCARB2 gene for PME causative mutations, as exemplified by 
the study of Rubboli et al. [2011], which reports on SCARB2 mutations in five non-related 
Italian patients who presented with PME of unknown origin of adolescent or adult onset.  
So far, no SCARB2 genotype-phenotype correlations have been established. From the 
inspection of the SCARB2 mutations found to date, no clear distinction emerges between 
the class (e.g., missense or nonsense) or position of the mutation and the patient 
phenotype. The phenotypic heterogeneity encompasses a wide range of tissues, but it is 
still unclear why some patients with SCARB2 mutations develop PME with or without renal 
failure, or why others develop mild hearing impairment or peripheral neuropathy [Rubboli 
et al., 2011].  
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Other symptoms may also occur, as suggested by the clinical manifestations observed in 
LIMP-2-deficient mice [Gamp et al., 2003], which presented increased postnatal mortality 
and uni- or bilateral hydronephrosis caused by an obstruction of the ureteropelvic 
junction. In addition, LIMP-2-deficient mice suffered from a peripheral demyelinating 
neuropathy [Gamp et al., 2003]. A subsequent study on that model revealed that the 
potassium channel KCNQ1 and its β-subunit KCNE1 were almost completely lost in the 
luminal part of marginal cells in the stria vascularis, affecting first higher and then lower 
frequency processing cochlear turns. The observation that LIMP-2 deficient mice 
displayed progressive hearing loss was particularly important because it suggested an 
important and previously unsuspected role for LIMP-2 in controlling the localization and 
the level of apically expressed membrane proteins such as KCNQ1, KCNE2 and megalin in 
the stria vascularis [Knipper et al., 2006]. Extrapolation of mouse studies to humans is still 
premature, but it is tempting to hypothesize that LIMP-2 may assume additional roles in 
the endocytic pathway. Nevertheless, because for the moment only a few clinical and 
neurophysiologic descriptions of AMRF syndrome have been reported [Berkovic et al., 2008; 
Balreira et al., 2008; Horoupian et al., 1977; Andermann et al., 1986; Rothdach et al., 2001; Badhwar et 
al., 2004; Vadlamudi et al., 2006], there is still much to learn about the clinical presentation 
and molecular basis of this disease. In the near future, more research exploring the 
function of SCARB2 gene and its role in cerebral and renal function is warranted [Rubboli 
et al., 2011] as well are new insights into its function in the endocytic pathway and its 
unidentified interacting partners [Knipper et al., 2006] are also needed.  
 
2.2.1.3. LIMP-2 and disease: SCARB2 mutations as modifiers of Gaucher disease 
Recently, SCARB2 mutations have also been demonstrated to act as modifiers in GD. 
Considering that LIMP-2 is the only known receptor for the enzyme that is deficient in 
Gaucher disease, Velayati and co-workers [2011] hypothesized that SCARB2 mutations 
could impact the Gaucher phenotype. In order to test that hypothesis, they re-evaluated 
a previously reported case of two siblings with GD with very disparate phenotypes [Eyal et 
al., 1991; Ron et al., 2008]. One sibling had been followed closely for over a decade with 
PME and dementia, while the second was subsequently diagnosed through family 
screenings, having only a few disease manifestations throughout his life, with no 
neurologic involvement. Both shared three GBA alterations: the maternally inherited 
c.535G>C (p.D140H) and c.10936G>A (p.E326K) and the paternally inherited c.586A>C 
(p.K157Q) [Eyal et al., 1991]. Extensive analyses, including studies of endoplasmic 
reticulum-associated degradation (ERAD), had previously been performed on fibroblasts 
from both siblings, demonstrating that the one with myoclonic epilepsy had increased 
ERAD of GCase and elevated intracellular cholesterol [Ron et al., 2008]. Velayati et al. 
[2011] screened this sib-pair for mutations in SCARB2 and found one novel, heterozygous, 
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maternally-inherited mutation, c.1412A>G (p.E471G), in the brother with GD and 
myoclonic epilepsy, which was absent in his sibling and controls. This finding 
demonstrated that LIMP-2 could serve as a modifier in GD. Although myoclonic epilepsy 
had previously been reported in heterozygotes with SCARB2 mutations [Reczek et al., 2007], 
only in this case was it possible to demonstrate that the SCARB2 mutation alone was not 
responsible for the development of such a phenotype, as it was also present in the sib's 
mother, who had a normal clinical phenotype [Velayati et al., 2011]. In the severely affected 
brother, however, the deficient GCase activity, accompanied by a mutation in the 
transporter, resulted in mistrafficking of the enzyme and contributed to the observed 
phenotype.  
 
2.2.2. SORTILIN 
2.2.2.1. Structural features: insights into sortilin function and evolution 
Sortilin is one of five members of a Vps10p domain receptor family, often found in the 
TGN and early endosomes: sortilin, SorLA, SorCS1, SorCS2 and SorCS3 [Willnow et al., 2008]. 
The Vps10 domain is a 10-bladed β-propeller consisting of three structural domains: the 
N-terminal domain (residues 45-576), followed by two smaller domains named 10CC-a 
(residues 577-633) and 10CC-b (residues 634-716) [Willnow et al., 2008]. Being the protein 
with the largest number of blades (10) at the Vps10 domain, sortilin has an increased 
potential to accommodate larger ligands when compared to similar proteins. With several 
highly conserved regions in the inner rim of the tunnel that correspond to different 
binding sites, sortilin has a unique structural organization that allows it to bind a series 
of different ligands. Furthermore, it is translated as an inactive propeptide, which is only 
activated after furine cleavage [Munck Petersen et al., 1999]. Its simple structural 
organization seems to be a key element of protein regulation because the sortilin 
propeptide blocks premature binding of any ligand, preventing simultaneous binding of 
ligands with conflicting functions [reviewed in Willnow et al., 2008]. Both sortilin and SorLA 
shuttle between the TGN and late endosomes through interactions between their 
cytoplasmic domains and various adaptors, including adaptor-protein-1 (AP1), Golgi-
localized, γ ear-containing, ARF-binding proteins (GGA1, GGA2 and GGA3) and the 
retromer complex [Nielsen et al., 2001; Nielsen et al., 2007]. Furthermore, the cytosolic tail of 
sortilin closely resembles the one of the MPRs, containing motifs known to be involved in 
trafficking from the Golgi to the endosome and vice versa. The retrograde recycling of 
sortilin involves an interaction with the retromer complex through a specific site in the 
cytosolic tail [reviewed in Canuel et al., 2009]. Finally, four particular amino acids in the 
cytoplasmic domain, which are shared by both sortilin and SorLA (the MVIA motif), seem 
to be crucial for binding to the cytosolic adaptors GGA1, 2 and 3 [Klinger et al., 2011]. 
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Table 2.1: Pleiotropic activities of sortilin in various biological pathways.  
[adapted from Dubé et al., 2011] 
Pathway Sortilin mediated role 
Lysosomal 
transport 
Mediates Golgi-to-lysosome transport of sphingolipid activator proteins 
(prosaposin and GM2 activator protein) [Lefrancois et al., 2003], acid 
sphingomyelinase [Ni et al., 2006] and of cathepsins D and H [Canuel et al., 
2008]. 
Neurotrophic 
signalling 
Binds proNGF forming an apoptotic signalling complex with p75NTR 
facilitating neuronal cell death [Nykjaer et al., 2004]; 
Transports TrkA, TrkB and TrkC to nerve synapse terminals enhancing 
their interaction with neurotrophins; 
Facilitates neuronal differentiation, survival and plasticity [Vaegter et al., 
2011]. 
Fronto-temporal 
lobar 
degeneration 
Modulates extracellular PGRN levels via binding and endocytosis; 
pathogenesis via decreased extracellular PGRN levels through 
haploinsufficiency [Hu et al., 2010]. 
Carbohydrate 
metabolism 
Binds and translocates Glut4 to the plasma membrane from Glut4 storage 
vesicles in response to insulin signalling [Shi et al., 2007]. 
Osteoblast 
differentiation 
Limits LPL-mediated suppression of mineralization activity in 
differentiating hMSC [Maeda et al., 2002]; 
Identified as a marker of late osteogenesis [Kulterer et al., 2007]. 
Lipoprotein 
metabolism 
  
Binds LDL RAP [Tauris et al., 1998]; 
Surface-expression mediates binding to LPL and subsequent degradation 
by endocytosis [Nielsen et al., 1999]; 
In vitro binding and endocytosis of apo A-V; facilitates lysosomal 
degradation of apo A-V [Nilsson et al., 2008]; 
Robust association between SORT1 variation (chromosome 1p13) and 
LDL-C concentrations [Samani et al., 2007]; 
Expression assays show regulatory effects on plasma LDL-C 
concentrations [Linsel-Nitschke et al., 2010; Musunuru et al., 2010; Kjolby et 
al., 2010]; 
Implicated in apo B-100 metabolism and VLDL secretion [Kjolby et al., 
2010]. 
 
There are some clues suggesting that the sortilin sorting pathway may represent an 
evolutionary mechanism for lysosomal transport older than the M6P pathway. Actually, 
even though the MPRs are usually described as analogous to the yeast Vps10p receptor, 
sortilin shares more similarities with Vps10p than the MPRs since it contains the Vps10 
domain, which is not present in the MPRs [Tauris et al., 1998]. Additionally, sortilin and 
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Vps10p interact with their ligands through proteinaceous interactions, while the MPRs 
recognize their ligands through an oligosaccharide side-chain, the M6P tag [Marcusson et 
al., 1994; Kornfeld and Kornfeld, 1985; Baldwin et al., 1993; reviewed in Canuel et al., 2009]. It 
appears, therefore, that the M6P pathway emerged as a very specific mechanism for 
sorting soluble lysosomal hydrolases. Nevertheless, it did not completely substitute the 
mechanism mediated by sortilin, which retained the ability to translocate different cargo 
proteins (see Section 3.4.3.). 
Albeit sortilin seems to be an ancient sorting receptor, during the evolutionary process it 
has developed additional functions [Table 2.1] that are gradually being discovered. In 
various pathways sortilin is revealing to play key roles, which can range from important 
functions in normal biological processes, such as glucose metabolism [Maeda et al., 2002; Shi 
and Kandror, 2005] and neuronal cell proliferation and death [Willnow et al., 2008; Nykjaer et 
al., 2004], to influencing pathological processes like those underlying Alzheimer’s disease 
[Mufson et al., 2010]. Sortilin is also acknowledged to play a part in lipoprotein metabolism 
by interacting with receptor associated protein (RAP) [Petersen et al., 1997] and binding 
lipoprotein lipase (LPL) [Nielsen et al., 1999] and apolipoprotein (apo) A-V [Nilsson et al., 
2008]. 
 
2.2.2.2. A multiligand lysosomal receptor? 
In 2003, the accumulated evidence of a possible role of sortilin as an alternative sorting 
receptor in the M6P-independent transport of newly synthesized hydrolases lead 
Lefrancois and colleagues [Lefrancois et al., 2003] to investigate whether sortilin could be 
involved in the sorting of SAPs. Earlier reports firmly demonstrated that SAPs (prosaposin 
and GM2AP) could reach the lysosomes in an M6P-independent manner. A few years 
earlier, a carbohydrate-independent pathway of native GM2AP had been characterized 
[Rigat et al., 1997]. Formerly, immunocytochemical analysis of tunicamycin-treated cells 
had shown that non-glycosylated prosaposin could be targeted more efficiently to 
lysosomes, whereas biochemical analysis revealed that prosaposin was associated with 
Golgi membrane fractions in an association not disrupted by free mannose 6-phosphate 
[Igdoura et al., 1996]. When Lefrancois et al. [2003] performed their first study on sortilin’s 
role as a lysosomal sorting receptor, they applied three approaches: a dominant-negative 
competition experiment, siRNA and co-immunoprecipitation (Co-IP) assays, which as a 
whole seemed to suggest that the SAPs (prosaposin and GM2AP) constituted a class of 
proteins whose lysosomal sorting and trafficking were mediated by sortilin. The 
dominant-negative construct was a truncated sortilin lacking the acidic cluster dileucine 
signal (∆cytosolic), which is implicated in the binding of GGAs [Nielsen et al., 2001]. That 
construct was retained in the Golgi apparatus and localized to the same compartment as 
Chapter I – Introduction                                                                                                                                          . 
32 
 
the Golgi marker. Full-length sortilin, in contrast, was not restricted to the perinuclear 
region but extended into punctuate structures. A C-terminal myc-tag was added to the 
construct, to discriminate between truncate and endogenous sortilin. The overexpression 
of such a construct abolished the punctuate staining seen in non-transfected COS-7 cells, 
suggesting that the truncated sortilin competed for the binding of prosaposin and 
abolished its transport to the lysosomal compartment. Through siRNA assays, the authors 
saw that ablation of sortilin increases the secretion of prosaposin into the culture media. 
Finally, Co-IP assays showed that sortilin interacts with both SAPs [Lefrancois et al., 2003].  
In 2006, with the same dominant-negative sortilin construct and using confocal 
microscopy, Co-IP and pulse-chase experiments, Ni and colleagues [Ni et al., 2006] 
suggested that sortilin was also involved in the lysosomal targeting of acid 
sphingomyelinase (ASM).  
Two years later, the same group also implicated sortilin in the lysosomal targeting of 
cathepsins D and H [Canuel et al., 2008]. Interestingly, when analyzing the cathepsins' 
interaction with the CI-MPR, the authors observed that, unlike cathepsin H, which bound 
exclusively to sortilin, cathepsin D was also able to bind to the CI-MPR. To better 
understand the role of sortilin and the M6P in the trafficking of cathepsins D and H, cells 
with both the sortilin and the M6P pathways blocked were examined, demonstrating that 
the transport of cathepsin D to the lysosomes occurs through both sorting pathways. In 
conclusion, sortilin appears to be the sole receptor necessary for lysosomal translocation 
of cathepsin H. Alternatively, the efficient transport of cathepsin D requires both the MPR 
and sortilin. 
Other soluble proteases that are known to be transported in a M6P-independent fashion 
exist, but this transport is not mediated by sortilin. This is the case of cathepsins K and 
L, where evidence of M6P-independent transport are well established. Nevertheless, 
when both cathepsins were studied using an approach similar to that applied to 
cathepsins D and H, it was observed that neither cathepsins K nor L interacted and 
immunoprecipitated with the MPR, nor did they interact with sortilin. Furthermore, their 
subcellular localization remained unaltered in cells transfected with truncated sortilin 
when compared to untransfected cells [Canuel et al., 2009].   
Yet, many aspects concerning sortilin’s function as an alternative receptor for lysosomal 
transport remain unclear and further studies are still needed to clarify sortilin’s 
subcellular location and interaction with its putative ligands. 
 
2.2.2.3. Sortilin and Disease: the cardiovascular risk association* 
Recently, genome-wide association studies (GWAS) brought into connection sortilin and 
cardiovascular risk.  
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GWAS have been reasonably successful in the identification of single nucleotide 
polymorphisms (SNPs) within or near genes associated with variations in plasma lipid and 
lipoprotein levels. More than 100 loci were reported to account for a significant part of 
the genetic variation in triglyceride, low-density lipoprotein (LDL) and high-density 
lipoprotein (HDL) cholesterol levels. In coronary artery disease or myocardial infarction 
(MI), GWAS have identified a smaller number of genetic loci, some of which are also 
associated with changes in traditional lipoprotein risk factors. Notably, within a widely 
replicated chromosome 1p13 locus associated with both myocardial infaction (MI) and 
LDL cholesterol levels [Kathiresan et al., 2008; Kathiresan et al., 2009; Musunuru et al., 2010; 
reviewed in Tall and Ai, 2011], the relevant SNPs were found to be located in a gene cluster 
containing four genes, one of them being SORT1.  
Subsequently, three independent teams [Linsel-Nitschke et al., 2010; Musunuru et al., 2010; 
Kjolby et al., 2010] tried to understand the biological mechanism relating SORT1 expression 
to LDL-cholesterol (LDL-C) levels and, ultimately, to risk of coronary artery disease 
(CAD). To this end, they used different approaches and, interestingly, they also came to 
different conclusions (Figure 2.7). The first study was developed by Linsel-Nitschke and 
colleagues [2010] who based on their findings, proposed that the overexpression of sortilin 
increases the internalization of LDL, with a consequent decrease of its plasma levels 
[Figure 2.7 (A) and (B)]. Soon after, through studies in human cohorts, hepatocytes and 
mice, Musunuru et al. [2010] reported an inverse relationship between sortilin expression 
and circulating LDL-C levels and further advanced with an explanatory mechanism 
through transcriptional regulation (liver-specific) of the SORT1 gene by the transcription 
factor C/EBPα [Figure 2.7 (C) and (D)]. Conversely, Kjolby and his team [2010] observed a 
direct relationship between the expression of Sort1 and the concentration of circulating 
LDL, suggesting it could result from increased VLDL secretion [Figure 2.7 (E) and (F)].  
Several explanations have been given to justify the discrepancy between these results 
but the answer seems to rely in sortilin itself, which appears to be a multifaceted protein 
that may assume different functions depending on the circumstances. Overall however, 
the three studies presented strong evidence demonstrating that SORT1 is a regulatory 
element of plasma LDL-C levels, adding a significant and previously unsuspected role to 
the sortilin-coding gene. 
 
 
 
 
* For an extensive review on sortilin and the cardiovascular risk association see Appendix 1, review paper 4: Coutinho MF, Prata MJ, 
Alves S. Sortilina e risco de doença cardiovascular (Portuguese/English version) [in press]. 
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Figure 2.7: Schematic representation of the three proposed models of sortilin function 
[adapted from Dubé et al., 2011] 
1. Linsel-Nitschke’s model: sortilin increases LDL metabolism. From their observations Linsel-Nitschke 
et al. [2010] proposed that the overexpression of sortilin increases the internalization of LDL, with a 
consequent decrease of its plasma levels. (A) Basal circulating LDL levels in human embryonal kidney 
cell line. (B) Transient expression of SORT1 in the same cell line was associated to increased 
internalization of extracellular labeled LDL particles. The authors proposed that increased interactions 
between sortilin and the LDLR with consequent increase of receptor-mediated endocytosis, were behind 
such observations. The upstream mechanistic basis for the upregulation of the LDLR was unclear, but 
could involve the LDLR directly, or related proteins like proprotein convertase subtilisin/kexin type 9. 
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The lowering of circulating LDL levels would be consistent with the expected clinical biochemical 
consequence of increased sortilin expression. 2. Musunuru’s model: sortilin decreases the production 
of LDL precursors. Musunuru et al. [2010] reported an inverse relationship between sortilin expression 
and circulating LDL-C levels and proposed an explanatory mechanism through transcriptional regulation 
(liver-specific) of the SORT1 gene by the transcription factor C/EBPα. (C) Basal circulating LDL levels in 
a humanized mouse model. (D) Increased SORT1 expression in the same cell line lowered LDL levels 
through a decrease in the production of very-low-density lipoprotein (VLDL), the precursor of LDL. While 
the upstream mechanistic basis of this decrease remain unclear, possibilities include disruption of 
lipidation of nascent lipoproteins (1) or shunting of nascent lipoproteins into intracellular degradation 
pathways (2). The lowering of circulating LDL precursors (3) would be consistent with the expected 
clinical and biochemical consequences of increased sortilin expression. 3. Kjolby’s model: sortilin 
facilitates VLDL secretion, increasing circulating LDL levels. (1) Apo B-100 is partially lipidated and 
transported to the TGN. (2) Binding of apo B-100 to sortilin facilitates maturation of pre-VLDL and 
secretion of VLDL from hepatocytes. Sort1 expression increases potential for a sortilin apo B-100 
complex, increases lipidation of nascent lipoproteins and VLDL formation. (3) Sortilin facilitates VLDL 
secretion from hepatocytes, with resulting increased circulating VLDL and ultimately LDL levels.  
 
2.2.2.4. Sortilin and Disease: molecular basis for familial amyotrophic lateral sclerosis? 
Recently, Belzil and co-workers [2012] hypothesized that, by reducing progranulin levels 
and promoting neurodegeneration (See Table 2.1), SORT1 mutations or SORT1 aberrant 
splicing could cause amyotrophic lateral sclerosis (ALS).  
That hypothesis was based on additional independent assumptions. First, causative 
mutations had just been reported in the TARDBP and FUS genes, encoding respectively for 
TAR DNA binding protein TDP-43 and RNA binding protein FUS (both involved in the 
regulation of transcription and RNA splicing) [Kabashi et al., 2008; Sreedharan et al., 2008; 
Kwiatkowski et al., 2009; Vance et al., 2009], in both ALS and frontotemporal lobar 
degeneration (FTLD) [Broustal et al., 2010; Huey et al., 2012]. Second, it had also been 
reported that depletion of TDP-43 in the mouse adult brain modifies the expression levels 
of FUS and GRN (gene encoding progranulin) and alters the splicing of SORT1 [Polymenidou 
et al., 2011]. Finally, sortilin had also recently been identified as a receptor that mediates 
progranulin uptake [Hu et al., 2010]. Thus, the authors speculated that TARDBP, GRN, and 
SORT1 act in a common pathological pathway and that mutations in any of those genes 
could result in a similar phenotype.  
To test this reasoning, they screened the SORT1 coding sequence for mutations in a 
cohort of 112 unrelated individuals with familial ALS and tested for aberrant splicing by 
RT-PCR using RNA samples from cell lines expressing six different ALS-associated TARDBP 
mutations [Belzil et al., 2012]. They identified one unique missense and two silent 
mutations; none of them were predicted to have functional effects. No aberrant SORT1 
splicing events were observed. From this study the authors concluded that SORT1 
mutations are not a common cause of familial ALS. 
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A proper knowledge of the different trafficking mechanisms responsible for the sorting of 
lysosomal proteins is essential to a better understanding of lysosomal function and may also 
unveil the molecular defects underlying LSD phenotypes. 
The major mechanism of transport of newly synthesized lysosomal enzymes to the 
endosomal/lysosomal compartment is mediated by the M6P recognition signal and its 
dysfunction results in the LSDs ML II and III. Alternative mechanisms of transport, M6P 
independent, were recently described but, for most cases it is still unclear how and if they 
might affect the function of the lysosome or the course of LSDs. 
The present work is focused in the study of genes involved in both M6P and M6P independent 
trafficking routes to the lysosome, relating them with the occurrence of LSDs. 
This thesis is divided in two major parts, each having specific aims. Part 1 addresses the 
molecular genetics, pathophysiology and diagnosis of disorders related with malfunction of 
M6P pathway and part 2 reports the study of the role of the M6P independent trafficking 
pathways in LSDs. 
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Part 1 
Molecular genetics, pathophysiology and diagnosis of disorders related with 
malfunction of the Man-6P pathway 
 
1. Regarding the study of M6P pathway, the main objectives were: 
 To perform the molecular characterization of the Portuguese patients with 
Mucolipidoses II and III for GNPTAB and GNPTG genes and to identify the molecular 
defects underlying these LSDs in Portugal, by so contributing to a better knowledge 
of their mutational spectrum and geographical distribution; 
 To enlarge our sample of ML II and ML III patients by contacting foreign 
institutions; 
 To develop effective molecular genetic testing techniques for ML II and ML III 
confirming and refining the enzymatic diagnosis by elucidating the sub-type of the 
disease (alpha/beta or gamma), according to the affected gene; 
 To carry out retrospective clinical analyses to assess the role of genetic 
variations on the clinical symptoms and outcome of ML II and III patients; 
 To establish, whenever possible, genotype-phenotype correlations that may be 
used for future genetic counseling by clinicians; 
 To study the impact of GNPTAB and GNPTG DNA mutations at mRNA and protein 
levels and obtain insights on their disease-causing mechanism. 
 
2. The observation that the GNPTAB deletion c.3503_3504delTC was the most common 
disease allele among the Portuguese patients, while also showing a worldwide broad 
distribution, led to pursuing two additional goals: 
 To investigate whether the worldwide spread of this mutation was due to a 
unique founder molecular lesion or if the deletion arose more than once through a 
recurrent mutational event;  
 To estimate the age of this deletion and its place of origin. 
 
3. Finally, the identification of two missense mutations (p.W81L and p.R986C) which 
were able to trigger a severe, early onset phenotype, contrarily to the usual phenotypes 
associated with missense mutations in the GNPTAB gene, prompted further analyses: 
 To study the impact of the two mutations at protein expression levels and at 
the subcellular distribution of GNPTAB mutant proteins in order to get insights on 
the atypical genotype-phenotype relations observed. 
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Part 2  
The role of Man-6P independent trafficking pathways in LSDs 
 
1. Regarding the M6P independent lysosomal trafficking the main objectives were:  
 To analyze molecularly SORT1 and SCARB2, the genes that encode sortilin and 
LIMP-2, respectively, in patients with clinical phenotypes suggestive of having a 
lysosomal storage disease but still without specific diagnosis; 
 To develop effective DNA-based methods for detection of mutations in the 
SCARB2 and SORT1 genes through both cDNA and gDNA analysis. 
 
2. Taking into account that LSDs are often the cause of hydropsis fetalis, a severe fetal 
condition, another investigation was also planned having as aim: 
 To analyze the SCARB2 gene in the available samples of non-explained cases of 
hydrops fetalis; 
 
3. The very recent evidence that a mutation in the gene that codes for LIMP-2 can act as 
a modifier in GD, led to address the issue through a study whose goal was: 
 To perform the molecular screening of the SCARB2 gene in GD patients in order 
to understand in what extent may SCARB2 variants influence the severity of GD 
phenotype. 
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Here we present a summary of the major results obtained in the studies focused on the 
molecular, biochemical and genotype-phenotype correlation analysis of patients 
suffering from impairments on the mannose 6-phosphate travelling pathway: ML II and 
ML III. For a more detailed description see papers 1 to 6.  
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1: Molecular Characterization of ML II and ML III patients 
We started by performing the molecular analysis of the GNPTAB and GNPTG genes in 13 
Mucolipidosis II and III patients (10 Portuguese, 1 Finnish, 1 Spanish of Arab origin and 1 
Indian), having identified 11 different mutations, 8 of which were novel: 6 in the GNPTAB 
gene (c.121delG, c.440delC, c.2249_50insA, p.W81L, p.I403T and p.E667X) and 2 in the 
GNPTG gene (c.610-1G>T and c.639delT). GNPTAB and GNPTG mRNA expression levels 
assessed through qRT-PCR analysis. The results suggested the possible existence of 
feedback regulation mechanisms between α/β- and the γ-subunits.  
In general, there was a strong correlation between the observed clinical phenotype and 
the genotype assessed through molecular analysis. Severely affected ML II alpha/beta 
patients, with progressive postnatal forms and death occurring before 10 years of age, 
presented with nonsense or frameshift mutations in homozigousity in the GNPTAB gene 
whereas the presence of at least one mild mutation in the GNPTAB gene or of mutations 
in the GNPTG gene was associated with the mildest pathologies ML III alpha/beta or ML III 
gamma, respectively. The only exception was one patient harboring the GNPTAB missense 
mutation c.242G>T (p.W81L) in homozygosity, who showed a more severe phenotype. 
(See paper 1: Encarnação et al., 2009).  
As a result from our initial study, molecular genetic testing for ML II and ML III became 
available in our Institute, allowing carrier detection and prenatal molecular diagnosis in 
several families and contributing to an effective improvement of genetic counseling. 
Being one of the first laboratories to provide molecular genetic testing for ML II and III, 
we received several samples from other countries, whose clinicians and/or centers 
requested molecular characterization of affected individuals. In total, we received 2 
patients from Denmark (1 of Palestinian origin), 3 Turkish patients and 2 of Indian origin. 
For all of them the molecular characterization was successful (Table 3.1), but the most 
interesting molecular defects were detected in the Palestinian and in the Indian patients, 
all suffering from ML II alpha/beta.  
The Palestinian patient, referred by a specialized Danish center, carried a homozygous 
deletion of exon 19 (c.3435-386_3602+343del897). This was the first case of a large 
homozygous intragenic GNPTAB gene deletion in a ML II patient. Long-range PCR and 
sequencing methodologies were used to refine the characterization of this 
rearrangement, leading to the identification of a 21 bp repetitive motif in introns 18 and 
19. Further analysis revealed that both the 5’and 3’breakpoints were located within 
highly homologous Alu elements suggesting that this deletion probably resulted from Alu–
Alu unequal homologous recombination (See paper 2: Coutinho et al., 2011a).  
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The first Indian ML II alpha/beta  patient harbored a novel homozygous mutation, 
p.R986C, in homozygousity. This was the second case in our lab in which a missense 
mutation was not associated, as usually, to a mild phenotype (ML III alpha/beta), but 
instead presented with severe phenotypes (ML II alpha/beta) (See paper 3: Coutinho et 
al., 2012a).  
The second Indian patient, who died on the fourth day of life after respiratory distress, 
had a peculiar phenotype with severe prenatal skeletal abnormalities that fitted prior 
descriptions of a rare phenotype known as Pacman dysplasia. Trough retrospective 
analysis of the parents, he was inferred to be heterozygous for two pathogenic mutations 
in the GNPTAB gene: the well-known c.3503_3504delTC (p.L1168QfsX5) and a novel 
frameshift variant, c.1701delC (p.F566LfsX5), thus supporting previous assumptions that 
at least some cases of Pacman dysplasia phenotype are, in fact, severe prenatal forms of 
ML II α/β (See paper 4: Coutinho et al., under preparation).  
Concerning the entire set of patients under study (Table 3.1), in general full 
characterization was possible applying the most conventional molecular approach, with 
the exception of two Portuguese subjects that were initially screened through cDNA 
sequencing but in whom only one of the mutant alleles was identified (See paper 1: 
patients P1 and P3). Latter, however, extensive gDNA and additional cDNA analyses were 
performed, eventually leading to a full characterization of the two individuals. Both were 
found to harbor NMD-triggering mutations: one nonsense mutation (p.E667X) and one 
small deletion (c.3503_3504delTC). These cases represent paradigmatic examples of 
tricky molecular diagnoses that could easily lead to a misclassification of the studied 
individuals, with tremendous consequences especially for prenatal diagnosis. Such cases 
highlight the importance of performing both biochemical and molecular genetic testing 
at both gDNA and cDNA levels whenever possible. 
 
 
2: Biochemical Studies of ML II-causing mutations 
The identification of three patients carrying homozygous missense mutations but 
presenting with early onset severe symptoms, defies previous assumptions that such 
mutations would usually underlie a mild phenotype, while only frameshift mutations 
would give rise to the more severe ML II alpha/beta phenotype. It became, then, 
mandatory to explore the causes underlying this unusual genotype/phenotype correlation 
in order to establish reliable genotype-phenotype predictions.  
The pathogenic mutations c.1581delC, c.3503_3504delTC, p.W81L, p.S399F, p.I403T, 
p.R986C and p.K1236M were inserted into a GNPTAB miniconstruct (αβ-mini 1-430+849-
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1256 in pcDNA3.1). Plasmids containing wild-type and mutant GNPTAB proteins were 
transfected into HEK and HeLa cells and analysed through Western Blot and 
Immunofluorescence, respectively. 
In general, the combined analysis of the mutants’ expression levels and subcellular 
location perfectly explains the phenotype: mutants harboring the severe deletions 
(c.1581delC and c.3503_4delTC) are retained in the ER, presenting only the non-cleaved 
α/β-precursor form; mild missense mutations (p.S399F, p.I403T and p.K1236M) are 
correctly located in the Golgi apparatus but present reduced levels of the mature α and β 
subunits, when compared to the wild-type and, finally, severe missense mutations were 
either retained in the ER on the non-cleaved and inactive precursor form (p.W81L) or not 
present at all (p.R986C) (See paper 5: Coutinho et al., under preparation).  
 
 
3: Haplotypic Analysis of the frequent ML II-causing mutation c.3503_3504delTC 
Another interesting result provided by the molecular study of ML II alpha/beta patients 
was the detection of a common mutation among our series of patients - the deletion 
c.3503_3504delTC. This mutation had already been detected in a series of populations 
and reports showed it to have a wide geographical distribution. To investigate whether its 
worldwide spread was due to a unique founder molecular lesion or if the deletion arose 
more than once through recurrent mutational event(s), we analysed 44 patients and 16 
carriers sharing this deletion but being from diverse geographic regions, for 3 intragenic 
polymorphisms and 2 microsatellite markers flanking the GNPTAB gene. We identified a 
common haplotype in all chromosomes bearing the c.3503_3504delTC implying a common 
origin of the mutation. In addition, while the level of diversity observed at the most 
distant microsatellite locus indicated that the mutation is relatively ancient (~2063 years 
old), its geographical distribution further suggested that it probably arose in a peri-
Mediterranean region (See paper 6: Coutinho et al., 2011b). 
 
 
  
 
 
As a complementary point to our study of patients suffering from diseases related to 
dysfunctional lysosomal traffic of M6P-tagged proteins we published: 
 A minireview on the M6P travelling route to the lysosome with special focus on its 
role in lysosomal function and dysfunction (Appendix 1, review paper 2: Coutinho 
et al., 2012). 
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Mucolipidosis 
classification 
Origin Gene 
Mutation 
(cDNA) 
Mutation 
(protein) 
Exon/ Intron 
affected 
Original 
reference 
P1 ML III α/β Portuguese GNPTAB c.1196C>T/c.3503_4delTCa p.S399F/p.L1168QfsX5a e7/e19 Bargal et al., 2006 Paper 1 
P2 ML III α/β Portuguese 
 
 
c.1196C>T/c.1999G>T a p.I403Tb/p.E667X a e10/ e10 This study Paper 1 
P3 ML III α/β Portuguese c.1196C>T/c.1196C>T p.S399F/p.S399F e7/e7 Bargal et al., 2006 Paper 1 
P4 ML III α/β Portuguese c.242G>T/c.242G>T p.W81L/p.W81L e3/e3 Kudo et al., 2006 Paper 1 
P5 ML II α/β Portuguese c.3503_4delTC/c.1999G>T p.L1168QfsX5/p.E667X e19/e13 Kudo et al., 2006/ 
This study 
Paper 1 
P6 ML II α/β Portuguese c.3503_4delTC/c.3503_4delTC p.L1168QfsX5/p.L1168QfsX5 e19/e19 Kudo et al., 2006 Paper 1 
P7 ML II α/β Portuguese c.3503_4delTC/c.3503_4delTC p.L1168QfsX5/p.L1168QfsX5 e19/e19 Kudo et al., 2006 Paper 1 
P8 ML II α/β Portuguese c.3503_4delTC/c.3503_4delTC p.L1168QfsX5/p.L1168QfsX5 e19/e19 Kudo et al., 2006 Paper 1 
P9 ML II α/β Indian c.440delC/c.440delC p.A147AfsX5/p.A147AfsX5 e5/e5 This study Paper 1 
P10 ML II α/β Portuguese c.3503_4delTC/c.3503_4delTC p.L1168QfsX5/p.L1168QfsX5 e19/e19 Kudo et al., 2006 Paper 1 
P11 ML II α/β Arab c.121delG/c.121delG p.V41FfsX42/p.V41FfsX42 e2/e2 This study Paper 1 
P12 ML II α/β Finish c.1581delC/c.2249_50insA p.S527SfsX20/p.N750KfsX8 e12/e13 Kudo et al., 2006/ 
This study 
Paper 1 
P13 ML II α/β Palestinian c.3435-386_3602+343del897/  
c.3435-386_3602+343del897 
3 abnormal transcripts i18/i18 This study Paper 2 
P14 ML II α/β Danish c.3503_4delTC/c.3503_4delTC p.L1168QfsX5/p.L1168QfsX5 e19/e19 Kudo et al., 2006 Not published 
P15 ML II α/β Turkish c.3503_4delTC/c.542C>G p.L1168QfsX5/p.S181X e19/e5 Kudo et al., 2006/ 
This study 
Not published 
P16 
b Turkish c.3503_4delTC/c.2822T>C p.L1168QfsX5/p. I941T e19/e14 
Kudo et al., 2006/ 
This study 
Not published 
P17 ML II α/β Turkish c.3503_4delTC/c.3503_4delTC p.L1168QfsX5/p.L1168QfsX5 e19/e19 Kudo et al., 2006 Not published 
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a When first published (Paper 1: Encarnação et al., 2009) only one of the mutations had been identified for both patients through cDNA analysis. Subsequent gDNA sequencing and NMD-
inactivation studies led to the identification of the second mutant allele on both patients. 
b No clinical data was available for this patient. 
c Pacman dysplasia phenotype. 
 
Note: Patients are divided into two groups according to the mutated gene and samples are numbered according to reference in the text. These numbers are not in accordance with the papers.   
 
 
P18 
b Turkish c.1124delG/c.1124delG p.R357QfsX2/ p.R357QfsX2 e10/e10 This study Not published 
P19 ML II α/β Indian c.2956C>T/c.2956C>T p.R986C/p.R986C e15/e15 This study Paper 3 
P20 ML II α/βc  Indian c.3503_4delTC/c.1701delC p.L1168QfsX5/p.F566LfsX5 e19/e13 Kudo et al., 2006/ 
This study 
Paper 4 
P21 ML II α/β Indian c.637-1G>A/c.637-1G>A 3 abnormal transcripts i6/i6 Cathey et al., 2010 Not published 
P22 ML II α/β Portuguese c.242G>T/c.242G>T p.W81L/p.W81L e3/e3 Kudo et al., 2006 Paper 5 
P23 ML III λ Portuguese GNPTG c.639delT/c.610-1G>T (IVS8-1G.T) p.F213LfsX7/3 transcripts e8/i8 This study Paper 1 
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Abstract 
Pacman dysplasia is a rare perinatal lethal skeletal dysplasia which has radiological 
findings overlapping with Mucolipidosis type II alpha/beta (MLII alpha/beta). There 
have been reports in literature proposing it as a severe prenatal phenotype of MLII 
alpha/beta. However, no conclusive evidence is available and some geneticists 
believe it to be a distinct entity. Here we report the identification of mutations in 
GNPTAB gene, which causes MLII alpha/beta, in an Indian family with Pacman 
dysplasia phenotype.  
 
 
Key Words:  Pacman dysplasia, Mucolipidosis type II alpha/beta (MLII alpha/beta), 
GNPTAB 
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Introduction 
Pacman dysplasia (PD) is a perinatal lethal skeletal dysplasia characterised clinically by 
presence of short, bowed limbs. Only a few cases of this condition have been reported in 
literature [Shohat et al., 1993; Wilcox et al., 1998; Miller et al., 2003; Saul et al., 2005]. The 
disorder is characterised radiologically by presence of periosteal cloaking, epiphyseal 
stippling and sagittal clefting of vertebra; and histological criteria, once chondro-osseus 
morphology reveals marrow fibrosis and large osteoclasts containing howship lacunae on 
their endosteal surface.  Mucolipidosis II alpha/beta  (ML II alpha/beta) is a lysosomal 
storage disorder caused by mutations in GNPTAB gene which leads to abnormal targeting 
of lysosomal enzymes to lysosomes [Tiede et al., 2005]. This can be detected biochemically 
on basis of marked elevation of plasma lysosomal enzymes [Kornfeld and Sly, 2001]. Another 
milder phenotype caused by mutations in GNPTAB gene is Mucolipidosis III alpha/beta (ML 
III alpha/beta), also known as Pseudo-Hurler dystrophy, which presents later in childhood 
like mucopolysacharidoses with predominant skeletal findings [Sanklecha et al., 1994; Paik et 
al., 2005; Kudo et al., 2006]. 
Clinically, neonates with ML II alpha/beta have coarse facies, joint contractures, 
deformed bones, developmental delay and inconsistently hepatomegaly. The radiological 
findings show dysostosis multiplex along with periosteal cloaking and epiphyseal stippling 
[Kornfeld and Sly, 2001; David-Vizcarra et al., 2010]. Recently, the question was raised of 
whether PD could not be actually a fetal/neonatal form of ML II alpha/beta presenting 
with secondary severe manifestations [Unger et al., 2005]. The hypothesis gained further 
sustainability  when Saul et al. [2005] confirmed the diagnosis of MLII alpha/beta  on basis 
of enzyme assay in the sib of a fetus previously reported to have Pacman dysplasia. 
However, Wilcox et al. [2005] disputed this by pointing out that these two conditions 
differed in their chondro-osseus morphology. They also documented normal lysosomal 
enzyme levels in cultured fibroblast from a patient with Pacman dysplasia [Wilcox et al., 
1998; Wilcox et al., 2005]. Therefore, the molecular basis of Pacman dysplasia still remains 
unconfirmed. 
Here we report on a neonate with PD phenotype deceased soon after birth, whose 
parents attended prenatal counselling for next pregnancy. Screening of the GNPTAB gene 
in the non-consanguineous couple allowed to detect that both members were carriers of 
pathogenic mutations, a finding that retrospectively gives grounds to a diagnosis of MLII 
alpha/beta in the proband. 
 
Case Report 
A non-consanguineous couple from North-eastern part of India attended for prenatal 
counselling in view of neonatal death in their previous male offspring. Review of the 
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antenatal records showed that the child was detected to have short bones in-utero since 
31 weeks of gestation. The ultrasound report at 37 weeks gestation showed that all long 
bones corresponded to 23-24 weeks. There was no evidence of hydrops. The child was 
born at term with a weight of 2.1kgs. He developed respiratory distress requiring assisted 
respiration and subsequently died on the fourth day. There were no physician records of 
the neonatal period. Photographs were brought by the parents, which showed presence 
of somewhat coarse facies, short limbs, large and dysplastic ears, flat nasal bridge and 
proptotic eyes. The left leg appeared to be deformed. The diagnostic clue was 
ascertained on the radiographs which showed short and broad long bones with wide 
diaphyses and massive periosteal cloaking, dense metaphyses and epiphyseal stippling 
(Figure 1). These findings led us to suspect a diagnosis of Pacman dysplasia/Mucolipidosis 
II alpha/beta. The plasma enzyme assays of the couple were non-contributary. No 
biological tissue from proband was available. DNA was extracted from peripheral blood of 
parents and the coding region of GNPTAB gene sequenced, together with its intronic 
flanking regions. 
 
Figure 1: Phenotypic presentation of the patient. 
Photographs showing a somewhat coarse facies, short limbs, large and dysplastic ears, flat nasal bridge 
and proptotic eyes and deformed left leg. X-rays showing short and broad long bones with wide 
diaphyses and massive periosteal cloaking, dense metaphyses and epiphyseal stippling. 
 
 
Results 
After GNPTAB sequencing, the consultant was found to be heterozygous for 
c.3503_3504delTC (p.L1168QfsX5) mutation in exon 19, which is a previously known 
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pathogenic mutation. The husband was heterozygous for a novel frameshift mutation 
c.1701delC (p.F566LfsX5) in exon 13.  
 
 
Discussion 
Pacman dysplasia was first described by Shohat et al. [1993] in a preterm female fetus of 
28 weeks gestation. They recognised it as a novel skeletal dysplasia with characteristic 
radiographic findings of epihyseal stippling and periosteal cloaking. The chondro-osseus 
morphology consisted of marrow fibrosis and expansion with numerous osteoclasts 
containing Howship lacunae on their endosteal surface, findings that were considered 
indicative of increased bone resorption. Subsequently, Wilcox et al. [1998] reported as PD 
both a male and female sibs terminated at 20 and 16 weeks pregnancy, respectively, on 
basis of ultrasound findings of short limb skeletal dysplasia. On post-mortem radiological 
and histopathological examination they also fitted the criteria for PD. Latter, Miller et al. 
[2003] reported a 20 week male fetus with Pacman dysplasia. This fetus had a subsequent 
female sibling who was clinically, radiographically and biochemically diagnosed to have 
ML II alpha/beta [Saul et al., 2005]. Consequently, Saul et al. recovered then the proposal, 
short before formulated by Unger et al. [2005], that Pacman dysplasia could be a 
prenatally manifesting severe phenotype of ML II alpha/beta. However, Wilcox et al. 
[2005] refuted this hypothesis by noticing that, even though the fetus originally reported 
by Miller et al. [2003] and re-assessed by Saul et al. [2005], could indeed be a case of ML II 
alpha/beta whose chondro-osseus preparation was inadequate to detect lysosomal 
inclusions (no material was available for electron microscopy or cultured fibroblasts for 
enzyme assays), the same was not possible for other cases. In fact, detailed revision of 
the first case reported by Shohat et al. [1993], did not demonstrate the presence of 
abnormal inclusions on the available formalin fixed material whereas atypical inclusions 
were quite evident in multiple cell types from a bone fide ML II alpha/beta  case 
identically prepared.  Furthermore, the enzyme assays from cultured fibroblasts of the 
sibs reported by Wilcox et al. were normal, ruling out the diagnosis of ML II 
alpha/beta [Wilcox et al., 2005]. Hence, they opined that Pacman dysplasia and ML II 
alpha/beta are distinct entities which can be distinguished by chondro-osseus morphology 
and presence of lysosomal storage, despite similarity in clinical and radiological features. 
ML II alpha/beta is a lysosomal storage disorder arising from mistrafficking of lysosomal 
enzymes from their synthesis site (ER) to the lysosomes, which is due to the absence of 
mannose-6-phosphate (M6P) recognition marker on the enzymes. This defect results from 
the deficiency of the enzyme UDP-N-acetylglucosamine-1-phosphotransferase (GlcNAc-
phosphotransferase), a heterohexameric complex whose α and β subunits are encoded by 
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the GNPTAB gene [reviewed in Braulke and Bonifacino, 2009; Coutinho et al., 2012]. Mutations in 
this gene lead to a phenotypic spectrum ranging from a neonatal/infantile presentation 
of ML II alpha/beta to a mild condition with childhood onset called ML III 
alpha/beta [Tiede et al., 2005; Paik et al., 2005; Kudo et al., 2006]. MLII alpha/beta is a 
progressive phenotype characterised by onset at birth, coarse facies, gum hypertrophy, 
developmental delay, short trunk short stature, joint contractures and radiologic findings 
of dysostosis multiplex [Kornfeld and Sly, 2001]. Patients with a very severe perinatal 
presentation can have bone deformities in form of bowed long bones, kyphosis, clubfeet 
etc., which overlap with PD.  The x-ray findings in these cases are of periosteal cloaking 
and epiphyseal stippling, which are also shared by patients with PD. Due to these clinical 
and radiological similarities, it is difficult to distinguish between PD and the prenatal 
phenotype of severe ML II alpha/beta, admitting that they actually are distinct entities, 
which for the moment, still lacks molecular support given the unknowledge of any 
genetic alterations underlying PD.   
In the case here reported, the fetus had clinical and radiographic findings suggestive of 
PD. Clinically, presentation with short bones prenatally at 31 weeks gestation has never 
been reported for a confirmed ML II alpha/beta case. Radiologically, the degree of limb 
shortening at term was severe, whereas the described cases of neonatal MLII 
alpha/beta  have low-normal limb lengths. In spite of both clinical and x-ray findings 
fitted better into a phenotype associated to PD, such findings are known to be quite 
similar in patients reported as PD and ML II alpha/beta presenting in neonatal period. 
Regarding the radiographic features, Miller et al. [2003] thought possible to differentiate 
between the two conditions through the presence of sagittal clefting and shorter 
metacarpals in cases with Pacman dysplasia, although very probably being gestation 
dependent radiological findings. Hence, clinically and radiologically our case represents 
the PD phenotype. Yet, the identification that the parents were both carriers of 
pathogenic mutations in the GNPTAB gene, strongly evinces that the proband was 
affected with ML II alpha/beta presenting with a PD phenotype. 
Genotype-phenotype correlations involving the GNPTAB gene suggest that frameshift or 
nonsense mutations lead to ML II alpha/beta presentation, while missense mutations 
usually cause the mildest ML III alpha/beta phenotype [Tiede et al., 2006]. In this work, the 
mutations detected in the non-consanguineous parents were both frameshift. The mother 
carried the mutation c.3503_3504delTC, which is the most common disease-causing 
variant in GNPTAB, already reported in several populations. When present in 
homozygousity or in combination with other frameshift or nonsense mutation, 
c.3503_3504delTC leads to a  severe MLII alpha/beta phenotype [Bargal et al., 2006; Kudo et 
al., 2006; Plante et al., 2008; Tappino et al., 2009; Encarnação et al., 2009]. The paternal 
mutation, c.1701delC, was a small deletion, detected here for the first time that also 
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creates a frameshift with consequent premature chain termination potentially leading to 
a truncated GlcNAc-phosphotransferase α/β-precursor lacking 686 amino acids. It is 
known that, in the Golgi apparatus, the α/β-precursor is cleaved between Lys928 and 
Asp929, giving rise to the mature α- and β-subunits which are both essential to the 
phosphotransferase’s enzymatic activity. The two identified mutant alleles are predicted 
to alter the normal open reading frame of the GNPTAB mRNA by introducing premature 
termination codons, which may either trigger the nonsense-mediated mRNA decay 
mechanism or give rise to the formation of highly truncated non-functional proteins. 
Hence, if simultaneously present in an individual, this should imply complete absence of 
GlcNAc-phosphotransferase activity, which most likely was the case of the proband under 
analysis, therefore explaining his severe phenotype.  
The message we sought to share from this study is that at least some cases of Pacman 
dysplasia phenotype, assessed in the absence of histological examination, are in fact 
severe prenatal forms of ML II alpha/beta. Nevertheless, we find it easy to admit that 
there may be casual heterogeneity in PD patients like in the siblings reported by Wilcox 
et al. [1998]. Possible sources may include, for instance, mutations in the gene coding for 
the site-1-protease (S1P) -the protease that cleaves the α/β-precursor of the GlcNAc-
phosphotransferase, as recently suggested by Marschner et al. [2011].  Apart from GNPTAB 
and S1P deficiencies, other genetic defects must also be envisioned, since failures on the 
activity of the phosphotransferase caused by mutations in any of these genes necessarily 
give rise to mistrafficking of lysosomal enzymes, which has already been shown not to 
occur in some patients with PD who have normal levels of lysosomal enzymes in plasma.  
Deficiencies of osteoclast inhibitor factor(s) have also been suggested to underlie PD 
phenotypes [Roodman, 1996; Wilcox et al., 1998], but until now they have never been 
documented. 
In conclusion, so far, only mutations in the GNPTAB gene allowed to explain two of the 
few reported cases presenting Pacman-like phenotypes. The question may be raised of 
whether those two patients were accurately diagnosed. It is possible that they escaped 
correct recognition as ML II alpha/beta due to the lack or unsatisfactory histological 
examination of their pathological material, which according Saul et al. might be critical 
to make a definitive diagnosis of PD. Still, when histological evaluation is not available, 
which is certainly a common situation, and the diagnostic must merely rely in clinical 
and/or radiological findings, ML II alpha/beta must be always considered as a possible 
cause of Pacman disease presentation. Eventually, only the discovery of the molecular 
basis of PD will enable the establishment of additional and more reliable features to 
distinguish between PD and ML II alpha/beta, further illuminating the reason of being, or 
not, two pathological entities. 
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Abstract 
Mucolipidoses type II and III (ML II and III) are genetic disorders respectively caused by 
completely absent or reduced activity of the enzyme GlcNAc-1-phosphotransferase, 
which participates in the synthesis of mannose 6-phosphate recognition marker. This 
heterohexameric enzyme (α2β2γ2) is a product of two distinct genes: GNPTAB and 
GNPTG. Mutations in GNPTAB result in ML II alpha/beta and ML III alpha/beta, while 
mutations in GNPTG are only associated with ML III gamma. It has been proposed that 
splicing and frameshift mutations are associated with more severe ML II  alpha/beta 
phenotype while missense mutations cause the mildest ML III  alpha/beta disease. 
Recent reports of ML II alpha/beta patients carrying homozygous missense mutations 
are defying this assumption. Here we have explored the expression levels and 
subcellular location of a panel of GlcNAc-1-phosphotransferase mutants and 
correlated the observed results with the severity of the phenotype presented by 
patients harboring them. 6 GNPTAB mutations were expressed in a wildtype α/β-
subunit miniconstruct: the missense mutations reported in severely affected patients 
(p.W81L and p.R986C), 2 severe deletions (c.1581delC and c.3503_3504delTC) and 2 
missense mutations reported in mildly affected individuals (p.S399F and p.K1236M). 
The overexpressed mutants were analysed by Western blot and immunofluorescence 
microscopy. In general, the combined analysis of the mutants’ expression levels and 
subcellular location not only explains but also allows for a prediction of the severity 
of the phenotype:  severe deletions are retained in the ER, in the non-cleaved 
inactive α/β-precursor form; mild missense mutations are correctly located in the 
Golgi apparatus but present reduced levels of the mature α- and β-subunits and, 
finally, severe missense mutations were either retained in the ER on the non-cleaved 
and inactive form (p.W81L) or not expressed at all (p.R986C). 
 
Key Words:  GlcNAc-1-phosphotransferase, ML II and III α/β, genotype-phenotype correlation. 
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Introduction  
Mucolipidosis type II (MLII; MIM# 252500) and type III (MLIII; MIM# 252600) are rare 
autosomal recessive disorders of lysosomal hydrolases trafficking which are, respectively, 
caused by completely absent or reduced activity of the enzyme GlcNAc-1-
phosphotransferase. This enzyme catalyzes the initial step of a two-step reaction that 
leads to the formation of the mannose 6-phosphate (M6P) recognition marker [Kornfeld and 
Sly, 2001). The mannose 6-phosphate marker is added exclusively to the N-linked 
oligosaccharides of lysosomal soluble hydrolases, as they pass through the cis-Golgi 
network and is responsible for their selective recognition by specific transmembrane 
receptors, present in the trans-Golgi (TGN): the cation-independent M6P receptor (CI-
MPR) and/or the cation-dependent M6P receptor (CD-MPR). The sequential action of 
these proteins, which is triggered upon arrival in the Golgi apparatus of soluble lysosomal 
enzymes allowing their subsequent transport to the endosomal/lysosomal compartment, 
constitutes the M6P-dependent targeting pathway [Storch and Braulke, 2005]. Any failure in 
this process may stop an entire repertoire of degradative enzymes from reaching the 
lysosomes and ensuring the normal cellular processes. This is the reason why mutations in 
GlcNAc-1-phosphotransferase may have a tremendous deleterious effect. 
GlcNAc-1-phosphotransferase is a heterohexameric enzyme composed of three subunits: 
α2β2γ2 [Bao et al., 1996]. This enzyme is a product of two distinct genes: GNPTAB and 
GNPTG [Kornfeld and Sly, 2001]. The GNPTAB gene codes for the enzymatically inactive α/β-
precursor [Tiede et al., 2005a] and the GNPTG gene codes for the γ-subunit [Raas-Rothschild et 
al., 2000]. The α/β-precursor contains the active site of the enzyme and consists of a 1256 
amino acid pro-peptide in a hairpin orientation that spans the membrane twice in such 
way that both its N and C termini are located in the cytosol [Kudo et al., 2005; Tiede et al., 
2005a]. This highly glycosylated precursor is latter cleaved into the individual α- and β-
subunits by the site-1-protease (S1P), thus becoming catalytically active [Marschner et al., 
2010]. The γ-subunit represents a soluble glycoprotein of 305 amino acids containing two 
in vivo N-glycosylation sites at positions 88 and 115. It forms disulfide-linked homodimers 
and localizes mainly in the cis-Golgi apparatus. The function of the γ-subunit remains 
elusive but evidence points that it may facilitate substrate recognition and assembly of 
entire complex [Raas-Rothschild et al., 2000; Pohl et al., 2010; Encarnação et al., 2011].   
Mutations in GNPTAB result in ML II alpha/beta and ML III alpha/beta  [Tiede et al., 2005; 
Paik et al., 2005; Kudo et al., 2006], while mutations in GNPTG are only associated with ML 
III gamma [Raas-Rothschild et al., 2000; Raas-Rothschild et al., 2004; Tiede et al., 2004]. ML II  
alpha/beta represents the most severe form of the disease with a fatal outcome usually 
between 5 and 8 years of age. Defects appear in early infancy or even prenatally, with 
patients typically presenting dwarfism, coarse facies, stiffness of the joints, several 
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skeletal abnormalities and severe mental retardation.  ML III  alpha/beta  and ML III 
gamma represent attenuated forms of the disease, with indistinguishable clinical 
symptoms. These forms of disease are characterized by a later onset, at the age of 2 to 4 
years, and a more slowly progressive course, permitting patient surviving into eighth 
decade, and mental retardation or learning disabilities affecting only 50 % of the patients 
[Dierks et al., 2009]. The variability in clinical symptoms observed in mucolipidoses is due 
to differences in residual activities of the GlcNAc-1-phosphotransferase, which result in a 
wide spectrum of severity ranging from prenatally lethal ML II alpha/beta to mild adult 
onset forms of ML III alpha/beta and ML III gamma [Dierks et al., 2009]. 
To date more than 100 different GNPTAB mutations have been described, causing either 
ML II  alpha/beta or ML III  alpha/beta [HGMD and references therein; Stenson et al., 2009]. 
Early reports suggested that, while splicing and frameshift mutations were usually 
associated with more severe phenotypes (ML II  alpha/beta ),  missense mutations were 
mainly associated with the milder ML III  alpha/beta  phenotype. Nevertheless, recent 
reports on ML II  alpha/beta patients harboring GNPTAB missense mutations in 
homozygous state challenge this initial assumption. Here we present a biochemical 
analysis of several disease-causing GNPTAB mutations previously reported in patients with 
well described phenotypes in order to get a first insight on the factors that account for 
the pathogenical effect of different mutations. GNPTAB mutations were inserted into a 
GNPTAB miniconstruct, transfected into HEK and HeLa cell lines and analysed through 
Western blot (WB) and Immunofluorescence (IF). In general, the combined analysis of the 
mutants’ expression levels and subcellular location perfectly explains the phenotype: 
mutants harboring the severe deletions are retained in the endoplasmic reticulum (ER), 
presenting only the non-cleaved α/β- and inactive precursor form; mild missense 
mutations are correctly located in the Golgi apparatus but present reduced levels of the 
mature α- and β-subunits, when compared to the wild-type and, finally, severe missense 
mutations were either retained in the ER on the non-cleaved and inactive precursor form  
or not expressed at all. 
 
 
Material and Methods  
Reagents  
Penicillin/streptomycin (P/S), bovine serum albumin (BSA), 4´,6´-diamidino-2-phenylindol (DAPI), 
cycloheximide, protease inhibitor cocktail, and other common laboratory reagents were obtained from 
Sigma-Aldrich. Fetal calf serum (FCS) was from PAA Laboratories. Dulbecco´s modified Eagle´s medium 
(DMEM) and GlutaMAX™ were from Invitrogen. Transfection reagent JetPEI® was purchased from Peqlab. 
Phusion® polymerase, GeneJET Plasmid Miniprep Kit, GeneJET PCR Purification Kit, dNTPs and 
prestained protein ladder Pageruler™ were from Thermo Scientific. Oligonucleotides used for sequencing 
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and mutagenesis were synthesized by MWG Biotech. Peptide N-glycosidase F was from Roche Applied 
Sciences. Media for cultivating Escherichia coli, Mowiol® and Roti®quant Protein Assay were from Roth.  
 
Antibodies 
An antiserum against the human, native α/β-precursor protein of the GlcNAc-1-phosphotransferase was 
produced by cDNA immunization. The expression mini constructs wildtype and non-cleavable mutant 
R925A [Marschner et al., 2010] were mixed and conjugated to 1-µm gold particles. Rats were immunized 
four times by ballistic DNA immunization. A serum sample was obtained 10 days after the last 
immunization [Koch-Nolte et al., 2005]. The complete serum was used for immunofluorescence 
microscopy stainings at a 1:250 dilution. 
Polyclonal rabbit antibodies against the human α- and β-subunit of the GlcNAc-1-phosphotransferase 
were described previously [Pohl et al., 2010; Kollmann et al., 2012]. Monoclonal antibodies against 
protein-disulfide isomerase (PDI) and Golgi marker protein (GM130) were obtained from Biomol and BD 
Biosciences, respectively. The monoclonal antibody against β-tubulin was purchased from the NICHD 
Developmental Studies Hybridoma Bank (University of Iowa). 
Secondary antibodies conjugated to horseradish peroxidase or Alexa Fluor® were purchased from 
Dianova and Invitrogen, respectively.  
 
Generation of mutant GNPTAB cDNA constructs 
The pathogenic GNPTAB mutations c.1196C>T, c.2956C>T, c.3707A>T, c.3503_3504delTC 
and c.242G>T (Figure 1) were inserted into the wildtype GNPTAB miniconstruct [Marschner 
et al., 2011] by site-directed mutagenesis using mutagenic primers and Phusion® 
polymerase. Mutagenic primers were designed individually according to the desired 
mutation using the web-based program PrimerX (www.bioinformatics.org/primerx). After 
PCR the methylated, nonmutated, parental DNAs were digested with Dpn I and 
transformed into E. coli. The plasmid DNAs were isolated and commercially sequenced to 
confirm proper introduction of the mutations (SeqLab). The generation of the GNPTAB 
c.345insC mutant was described recently [Kollmann et al., 2012]. 
 
Cell culture and transiently transfection 
Human embryonic kidney (HEK) and HeLa cells were maintained in DMEM supplemented 
with 10 % FCS, GlutaMAX™ and P/S at 37 °C and 5 % CO2. Cultured cells were plated on 6-
cm plates or on glass cover slips. The wildtype and each of the mutated cDNAs were 
transiently transfected independently in cells using JetPEI® reagent according to 
manufacturer instructions. 24 hours after transfection the cells were used for further 
analysis. 
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Western blot analysis 
Transfected HEK cells were lysed for 30 minutes at 4 °C in lysis buffer containing 0.2 % 
Triton X-100 and protease inhibitors in phosphate-buffered saline (PBS). The protein 
content of cell extracts was measured by Bradford Protein Assay. Aliquots of cell extracts 
(75 µg protein) were incubated in the presence or absence of 1 U PNGaseF for 1 hour at 
37 °C to remove N-glycans. Cell extracts were separated by SDS-PAGE (10 % 
polyacrylamide) and blotted onto nitrocellulose. After blocking with 5 % non-fat dry milk 
in PBS containg 0.1 % Tween-20, the membrane were incubated either with polyclonal 
antibodies anti α-subunit or anti β-subunit of the human GlcNAc-1-phosphotransferase. 
[Pohl et al., 2010; Kollmann et al., 2012]. β-Tubulin was used as loading control. The 
membrane was incubated with secondary HRP-conjugated goat anti-rabbit IgG antibody. 
The immunoreactive bands were visualized by enhanced chemoluminescence. 
Densitometric analyses were performed with the Image J software (http://rsbweb.nig.gov/ij) 
to quantify band intensities in Western blots.  
 
Immunofluorescence microscopic analysis 
Transfeted Hela cells were treated with 100 µg/ml cycloheximid for 40 min. Afterwards 
cells were fixed in 4 % paraformaldehyde for 20 minutes at room temperature and 
permeabilized with ice-cold 0.2 % Triton X-100 in PBS. Cells were incubated for 16 hours 
with primary antibodies and 1 hour with secondary antibodies conjugated to Alexa 
Fluor®546 and Alexa Fluor®488. After three washes the cells were embedded in Mowiol. 
Fluorescence was detected and images were obtained using a Leica DMIRE2 digital 
scanning confocal microscope and ADOBE PHOTOSHOP software, respectively. 
 
Figure 1: Schematic presentation 
of α/β-subunit constructs used in 
this study.  
The first scheme shows the wildtype full 
length α/β-subunit precursor and its 
domain structure. The following schemes 
refer to wild type and mutated GlcNAc-
1-phosphotransferase mini-constructs, as 
referenced in the image. 
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Results  
Expression analysis of α/β-subunit mutants of the GlcNAc-1-phosphotransferase 
The human α/β-subunit precursor of the GlcNAc-1-phosphotransferase is a highly N-
glycosylated type III membrane protein of 1265 amino acids. Cleavage by the site-1 
protease gives origin to the enzymatically active α- and β-subunits. For expression 
analysis of pathogenic mutations in the α- and β-subunits we inserted the mutations in a 
mini construct of the α/β-subunit precursor, that lacks amino acids 431 to 819 (Figure 1) 
but allow its efficient expression [Marschner et al., 2011]. Protein extracts of non-
transfected, wildtype and mutant α/β-subunit-overexpressing HEK cells were analysed by 
Western blotting using anti-serum against either the α-subunit (Figure 2 A) or the β-
subunit (Figure 2 B) of the human GlcNAc-1-phosphotransferase.  
In extracts of wildtype α/β-subunit-overexpressing cells, two immunoreactive forms of 
the protein were detected: the N-glycosylated ~120 kDa α/β-subunit precursor and the N-
glycosylated cleaved/mature α-subunit of ~75 kDa and β-subunit of ~45 kDa (Figure 2 A 
and B, lane 1 and 2) that was not detectable in non-transfected cells (Figure 2 A and B, 
lane 15 and 16). The treatment with PNGase F, hydrolyzing all N-linked oligosaccharides, 
resulted in a shift of the electrophoretic mobility  of the α/β-subunit precursor, cleaved 
α- and β-subunits to ~ 100 kDa, 55 kDa and 35 kDa, respectively (Figure 2 A and B, lane 
2).  
In protein extracts of cells overexpressing the missense mutations p.S399F the N-
glycosylated and non-glycosylated α/β-subunit precursor were observed, together with 
small amounts of the cleaved α- and β-subunits were observed (Figure 2 A and B, lane 3 
and 4). In extracts of cells overexpressing the p.R986C mutant, neither the α/β-subunit 
precursor nor the mature α-subunit could be detected. Same was registered when those 
cell extracts were incubated with PNGase F (Figure 2 A and B, lane 5 and 6). Protein 
extracts of cells overexpressing the missense mutation p.K1236M showed decreased 
levels of both α/β-subunit precursor α- and β-subunit (Figure 2 and B, lane 7) with the 
same molecular mass detected for cells overexpressing the wildtype α/β-subunit GlcNAc-
1-phosphotransferase. After PNGase F treatment a shift to the non-glycosylated forms 
were observed (Figure 2 A and B, lane 8). In protein extracts of cells overexpressing the 
frameshift mutation p.G1049RfsX16 or p.L1168fsX5 truncated N-glycosylated and non-
glycosylated α/β-subunit precursor were observed. No cleaved α- and β-subunits were 
detectable (Figure 2 A and B, lane 9 to 12). In protein extracts of cells overexpressing the 
missense mutations p.W81L only the N-glycosylated and non-glycosylated α/β-subunit 
precursor form but no cleaved α- and β-subunits were observed (Figure 2 A and B, lane 13 
and 14).   
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Figure 2: Western blot analysis of GlcNAc-1-phosphotransferase mutants in HEK cells. 
HEK cells were transfected with cDNA encoding the GNPTAB wildtype miniconstruct and the mutants 
p.W81L, p.S399F, p.L1168QfsX5, p.K1236M and p.G10489fsX16. The cells were incubated for 1 hour in 
the presence (+) or absence (-) of PNGase F. SDS-PAGE (10% polyacrylamide) was performed under 
reducing conditions followed by Western blot analysis against the human α-subunit (A) or β-subunit (B). 
β-Tubulin was used as a loading control. The positions of molecular mass marker proteins are indicated. 
 
Intracellular localization of α/β-subunit mutants of the GlcNAc-1-phosphotransferase 
The α/β-precursor of the GlcNAc-1-phosphotransferase is synthesized in the ER. The 
subsequent COPII-mediated vesicular transport from the ER to the Golgi apparatus 
requires a combinatorial sorting motif in the N- and C-terminal cytosolic domains [Franke 
et al., 2013]. In the Golgi apparatus the α/β-precursor is cleaved and activated by the site-
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1 protease [Marschner et al., 2011].  
To get an insight on the subcellular location of the different mutants here analysed, 
double immunofluorescence microscopy of HeLa cells overexpressing wildtype or mutant 
α/β-subunit of the GlcNAc-1-phosphotransferase was conducted with either marker 
proteins of the ER or the Golgi apparatus. For the staining of the GlcNAc-1-
phosphotransferase a novel monoclonal antibody generated in rats was used. In cells 
transfected with the wildtype miniconstruct [Marschner et al., 2011], complete co-
localization with the Golgi apparatus marker GM130 was observed, but not with the ER 
marker protein disulfide isomerase (PDI) (Figure 3). In cells overexpressing the mutant 
p.W81L, a co-localization, with the ER marker was observed. No mutant protein was 
present in the Golgi apparatus. 
Cells overexpressing the p.S399F mutant, the protein co-localized mainly with the ER but 
also partially with the Golgi apparatus indicating that small amounts of the mutant reach 
the Golgi apparatus.  
The mutant p.L1168QfsX5 co-localized with the ER marker PDI but not with the Golgi 
apparatus marker protein GM130.  
In cells overexpressing p.K1236M, on the other hand, a perfect co-localization with the 
Golgi apparatus was observed. No mutant protein was present in the ER.  
Finally, for cells overexpressing the frameshift mutation p.G1049AfsX16, a complete co-
localization with the ER marker PDI but not with the Golgi marker GM130 was observed. 
 
Figure 3: Analysis of subcellular location of GNPTAB mutant proteins in HeLa cell lines. 
HeLa cells were transfected with cDNA encoding the wild-type GNPTAB miniconstruct (αβ-mini 1-
430+849-1256 in pcDNA3.1), and the following mutants: p.W81L; p.S399F; p.L1168QfsX5, p.K1236M and 
p.G10489fsX16. Cells were costained for either the cis-Golgi apparatus marker protein GM130 (red; 
1:200 dilution) or the ER marker protein-disulfide isomerase, PDI (red; 1:400 dilution). Colocalization in 
merged images appears yellow.  
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Genotype-phenotype relation of analyzed α/β-subunit mutants of the GlcNAc-1-
phosphotransferase 
Table 1 – Summary classification of the known Mucolipidoses cases caused by the GNPTAB 
mutations under study according to zygosity and population of origin. 
 
GNPTAB mutation 
cDNA 
protein 
 
Clinical  
classification 
 
Zygosity  
 
Origin  
 
Reference 
 
c.1196C>T 
p.S399F  
  
 
MLIII alpha/beta 
  
  
 
homozygous 
 
Portuguese 
 
Encarnacao  et al., 2009 
 
 
heterozygous 
 
 
 
French 
 
Bargal et al., 2006 
 
Portuguese 
 
Encarnacao et al., 2009 
 
c.2956C>T 
p.R986C 
 
 
MLII alpha/beta 
 
homozygous 
 
Indian 
 
Coutinho et al., 2012 
 
c.3707A>T 
p.K1236M 
 
 
MLII alpha/beta 
(intermediate) 
 
homozygous 
 
German 
 
Tiede et al., 2006 
 
c.3145insC 
p.G1049RfsX16 
 
 
MLII alpha/beta 
 
homozygous 
 
? 
 
Tiede et al., 2005 
 
c.3503_3504delTC 
p.L1168fsX5 
  
 
MLII alpha/beta 
  
  
  
  
  
  
 
homozygous 
 
 
 
Portuguese 
 
Encarnacao et al., 2009 
 
? 
 
Kudo et al., 2006 
 
Arab-muslim, 
Turkish, Irish 
 
 
Bargal et al., 2008 
 
French-
Canadian 
 
 
Plante et al., 2008 
 
Italien, 
Argentinian, 
Bengalese 
 
 
Tappino et al., 2009 
 
heterozygous 
 
 
 
Portuguese 
 
Encarnacao et al., 2009 
 
Italien, 
Hungarian, 
Bulgarian, 
Argentinian 
 
 
Tappino et al., 2009 
 
MLIII alpha/beta 
(intermediate) 
  
  
 
heterozygous 
 
? 
 
Kudo et al., 2006 
 
French, Irish 
 
Bargal et al., 2008 
 
Argentinian 
 
Tappino et al., 2009 
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c.242G>T    
p.W81L 
 
 
MLII alpha/beta 
 
homozygous 
 
Portuguese 
 
Encarnacao et al., 2009 
 
Mutations in the GNPTAB gene result in a broad phenotypic spectrum that, ultimately, 
may be divided into two different diseases: one with an early onset severe phenotype (ML 
II  alpha/beta ) and other with a latter onset milder presentation (ML III  alpha/beta). 
Nevertheless, and as is described for most other lysosomal storage disorders, there is a 
phenotypic continuum. Consequently, clinical classification isn't always straightforward, 
with some cases being referenced/referred to as ML II/III intermediate. 
The mutations analysed in this study have already been reported in different populations 
and zygosities (Table 1) and some genotype-phenotype correlations suggested but no 
expression studies were ever presented to support/justify them. 
The missense mutation p.S399F was detected both in homozygosity and in heterozygosity 
and reported to cause the milder ML III alpha/beta disease. Patients harboring p.S399F 
were reported on the Portuguese [Encarnação et al., 2009] and French population [Bargal et 
al., 2006]. 
Mutation p.R986C, also missense, was detected in homozygous state in a patient of Indian 
origin with an early onset of symptoms and severe level of disability, therefore classified 
as ML II alpha/beta [Coutinho et al., 2012]. 
The missense mutation p.K1236M, on the other hand, was reported in a single German 
patient, classified as ML II/III intermediate whose age of onset was higher and degree of 
disability milder than usually reported for typical ML II alpha/beta patients [Tiede et al., 
2006]. 
The frameshift mutation p.G10489fsX16 was reported in homozygous state in a patient 
suffering from severe ML II alpha/beta. 
Finally, p.L1168fsX5, the most common disease-causing mutation reported in the GNPTAB 
gene, has been detected in virtually all studied populations, with the exception of the 
molecularly characterized patients from Japan. Its effect on the phenotype depends on 
zygozity: if present in homozygous state or in compound heterozygosity with another 
frameshift or nonsense mutation, underlies the more severe form of the disease (ML II 
alpha/beta) [Kudo et al., 2006; Bargal et al., 2008; Plante et al., 2008; Encarnação et al., 2009; 
Tappino et al., 2009]; when combined with missense mutations, however, it has already 
been reported to cause a milder form of the disease [Kudo et al., 2006; Bargal et al., 2008; 
Tappino et al., 2009]. 
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Discussion 
The first reports on the molecular characterization of large series of patients with 
mutations in the GNPTAB gene suggested that frameshift and nonsense mutations would 
be the ones causing the most severe ML II alpha/beta disease, while missense mutations 
either in homozygozity or in compound heterozygosity, would result in the milder 
phenotype, ML III  alpha/beta [Tiede et al., 2006]. Nevertheless, over the last few years, 
several studies have reported ML II  alpha/beta patients carrying missense mutations 
[Encarnação et al., 2009; Tappino et al., 2009; Otomo et al., 2009; Zarghooni and Dittakavi, 2009; 
Cathey et al., 2010], this leading to change the initial paradigm. It became, then, 
mandatory to explore the factors which could account for the severity of a particular 
GNPTAB mutation and, even though biochemical analysis have already been published for 
some mutations, many others have only been reported on a genetic and clinical basis 
[Encarnação et al., 2009; Guio et al., 2011; Heo et al., 2012]. In general, the phenotypic 
pathogenicity of missense mutations based strictly on genotype is difficult to predict, so 
expression of the mutant proteins is normally required to understand the effect of the 
amino acid change on folding, targeting, stability, and activity of the enzyme. So far, 
pathogenicity prediction of GNPTAB missense mutations has been mainly based on the 
nature of the affected amino acid, its evolutionary conservation, and position within the 
protein. Expression analyses were, then, required for a proper assessment of each 
mutant’s severity. 
In this work six pathogenic GNPTAB mutations were cloned and expressed into a GNPTAB 
miniconstruct (αβ-mini 1-430+849-1256 in pcDNA3.1): p.G1049AfsX16 (c.1581delC), 
p.L1168QfsX5 (c.3503_3504delTC), p.W81L, p.S399F, p.R986C and p.K1236M. Plasmids 
containing wild-type and mutant GlcNAc-1-phosphotransferase proteins were transfected 
into HEK and HeLa cells and analysed through WB and IF, respectively. Protein expression 
levels were evaluated through WB analysis (Figure 2). The subcellular distribution pattern 
observed was addressed by IF (Figure 3). 
In general, we observed a perfect correlation between the assessed features and the 
severity of the phenotype: mutants harboring the severe deletions are retained in the ER, 
presenting only the non-cleaved α/β- and inactive precursor form; mild missense 
mutations are correctly located in the Golgi apparatus but present reduced levels of the 
mature α- and β-subunits, when compared to the wild-type and, finally, severe missense 
mutations were either retained in the ER on the non-cleaved and inactive precursor form 
(p.W81L) or not expressed at all (p.R986C). 
The frameshift mutation c.3503_3504delTC (p.L1168QfsX5) is the most frequent ML II-
causing mutation having been reported in virtually all studied populations [Bargal et al., 
2006; Kudo et al., 2006; Plante et al., 2008; Tappino et al., 2009; Encarnação et al., 2009]. When 
present in homozygous form, or in combination with other frameshift or nonsense 
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mutation, c.3503_3504delTC leads to a severe MLII alpha/beta phenotype. Patients 
harboring this mutation in homozygosity have been reported to present a severe 
phenotype with dysmorphic facial features, gingival hyperplasia, radiographic skeletal 
changes psychomotor retardation, all of them with early onset of symptoms (usually 
during the first year of life). At least one prenatal diagnosis was also reported [Encarnação 
et al., 2009]. Previous reports had already demonstrated that the c.3503_3504delTC leads 
to a null or almost null GlcNAc-1-phosphotransferase activity. In fact, when a cDNA with 
this mutation was expressed, no activity could be demonstrated. Additionally, fibroblasts 
from a patient described in the original paper who was homozygous for this mutation, 
exhibited the very low value of <0.1% GlcNAc-1-phosphotransferase activity [Kudo et al., 
2006]. At protein level, such alteration was expected to result in a truncated protein 
(missing the last 84 amino acids) with a slightly lower molecular weight than the normal 
protein. In general, mutant transcripts harboring premature termination codons (PTC) 
such as this one trigger the nonsense mediated mRNA decay (NMD) mechanism, a cell 
quality control device which destroys abnormally small transcripts. Previous assessments 
of GNPTAB mRNA levels on fibroblasts harboring the c.3503_3504delTC in homozygosity 
showed a reduction of -4.7 relatively to control [Encarnação et al., 2009] suggesting that, 
even though the mutation may trigger NMD, this is not a fully efficient mechanism and 
some protein should still be produced.  In the present study, protein expression levels 
were evaluated through Western blot and results showed a clear reduction on the 
GlcNAc-1-phosphotransferase expression levels for this mutant. Furthermore, only the 
non-cleaved precursor form could be detected. This is highly significant since only after 
cleavage does the GlcNAc-1-phosphotransferase become active. So, any mutant which 
does not suffer S1P cleavage in the Golgi, will necessarily present null activity. From the 
Western blot results alone it is also possible to infer that the p.L1168QfsX5 
(c.3503_3504delTC) mutant is retained in the ER, never reaching the Golgi apparatus. 
This was further confirmed through costaining with ER and cis-Golgi markers (Figure 3). 
Similar WB and IF patterns were observed for the other severe deletion expressed on the 
GNPTAB miniconstruct, p.G10489fsX16 (c.1581delC): only the α/β-precursor could be 
detected and, from the IF images it was possible to verify it co-localized with the ER.  
These results are in perfect agreement to those which would be expected for a 
frameshift mutation and with the phenotype reported for patients carrying it. 
Concerning the missense mutations, different patterns were detected both through WB 
and IF. The two initial groups, composed one by the variants that were detected in 
patients suffering from a milder form of the disease (p.S399F and p.K1236M) and those 
identified in severely affected individuals (p.W81L and p.R986C), had completely 
different patterns, consistent with the observed phenotypes. 
The mild missense mutation p.K1236M was correctly located in the Golgi apparatus 
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(Figure 3).  
The mutant p.S399F, on the other hand, co-localized with the ER. Nevertheless, some of 
a slight co-localization with the Golgi apparatus was also observed (Figure 3). This is in 
accordance with the Western blot results for the same mutant that revealed major 
accumulation of the N-glycosylated ~120 kDa α/β-subunit precursor immunoreactive form 
together with minor bands which corresponded to the cleaved/mature α- and β-subunits 
of ~75 kDa and ~45 kDa, respectively (Figure 2). This implies that at least a small amount 
of the mutant α/β-precursor gets to be cleaved by S1P and correctly targeted to the 
Golgi. Clinical evidence seems to suggest that this small amount of mature α- and β-
subunits may provide residual GlcNAc-1-phosphotransferase activity minimizing the 
phenotypic effect of the pathogenic mutation. The only reported p.S399F homozygous 
individual has Portuguese origin and a mild ML III alpha/beta phenotype, without 
neurological impairment. Patient is now 28 years old and has higher education, which 
further demonstrates that this mutation is associated to a mild phenotype. 
The missense mutation c.242G>T (p.W81L) was retained in the ER on the non-cleaved and 
inactive precursor form, presenting a pattern similar to the one observed for frameshift 
mutations (Figure 2 and 3). This variant was first identified in homozygosity in a patient 
reported in 2009, who was diagnosed at the age of 4 months presenting clinical features 
of ML II alpha/beta such as gingival hypertrophy, hypertonia and delayed growth. Death 
occurred at 23 months of age by respiratory infection [Encarnação et al., 2009]. Latter, we 
characterized a second patient of Portuguese origin (not published) who was diagnosed at 
the age of 3 months with the exact same genotype and presented with typical ML II 
alpha/beta features (dysostosis multiplex, gingival hypertrophy, hypothyroidism, 
respiratory difficulties and delayed growth) and slight hepatosplenomegaly.  The fact that 
a second unrelated severely affected patient presented with the same genotype and a 
similar ML II  alpha/beta phenotype is particularly relevant since it reinforces the causal 
relationship between the p.W81L missense mutation and the severe form of the disease. 
No fibroblast cell lines were available for the second patient but, the index case had 
already been analysed through qtRT-PCR showing a significant decrease when compared 
with the median control values [Encarnação et al., 2009]. All computational predicted this 
mutation to be potentially damaging. Interspecific alignments of 54 homologous GlcNAc-
phosphotransferases revealed that it occurred at an evolutionarily conserved amino acid 
residue.  
Finally, we observed a complete absence of expression for the p.R986C mutant (Figure 
2). The p.R986C variant was identified in homozygosity in a severely affected patient 
[Coutinho et al., 2012]. The child, a boy of Indian origin, was only diagnosed at 5 years old, 
but first symptoms were reported one month after birth: coarse facies, depressed nasal 
bridge, epicanthic folds, severe gum hypertrophy, deformed chest, open mouth, widening 
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of wrists and contractures of fingers. The homozygous status of p.R986C was confirmed 
by sequencing genomic DNA from both parents. In silico predictions classified as 
potentially damaging and interspecific alignments revealed that it occurred at an 
evolutionarily conserved residue. Our present results support its association to a severe 
form of the disease, since no protein is present at all. Nevertheless, additional questions 
arise from the unusual pattern observed for this mutation. In theory, the absence of 
expression of the p.R986C GlcNAc-1-phosphotransferase mutant can be due to either 
mRNA instability or premature protein degradation but only additional analysis may bring 
some light on the effect of this variant in particular. 
 
 
Conclusion  
For the severe deletions c.440delC (p.G10489fsX16) and c.3503_3504delTC 
(p.L1168QfsX5), phenotype may be explained by abnormal cellular location. Mutant α/β-
precursor proteins are retained in the ER on their non-cleaved inactive form and 
accumulate on that compartment, never reaching the Golgi, where they should act.   
For the milder missense mutations (p.S399F and p.K1236M) were observed decreased 
protein levels which are consistent with reduced enzymatic activity. Nevertheless, and 
unlike the severe deletions where only the precursor is detected, these mutants give rise 
to both cleaved and non-cleaved forms of the α/β-subunits which reach the Golgi, 
presenting a normal (p.K1236M) or partially normal (p.S399F) subcellular distribution 
pattern, coincident with the cis-Golgi complex and similar to the control wild-type 
protein.  
For the atypically severe missense mutations (p.W81L and p.R986C), surprising 
observations were made: the p.W81L mutant is retained in the ER on the non-cleaved and 
inactive precursor form and the p.R986C does not seem to be expressed at all. The 
striking absence of expression observed for the p.R986C mutant raises the question of the 
role of residue R986 on the protein function and/or stability, prompting additional future 
studies on the topic. 
In conclusion, the combined analysis of the mutants’ expression levels and subcellular 
location perfectly explains the phenotype. Finally, being the identification of mutations 
in disease-affected genes the basis of genetic counseling, this study also highlights the 
need of a carefully and extensive analysis to provide a reliable genotype-phenotype 
correlation. 
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Here we present a summary of the major results obtained in the studies focused on the 
molecular and biochemical analyses of genes involved in the mannose 6-phosphate 
independent trafficking pathway. For a detailed description see papers 7 and 8.  
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1: Molecular analyses of undiagnosed LSD suspects 
In a set of 120 patients with clinical suspicion of LSD but without definitive biochemical 
and/or molecular diagnosis, no novel mutations were detected either on the SCARB2 or 
on the SORT1 gene. Patients were choosen on basis of their clinical manisfestations. 
Preference was given to individuals whose symptoms overlapped those already reported 
as associated to loss of function of GCase, saposins, GM2AP and/or ASM. In theory, such 
phenotypes, could result not only from defects of the specific enzyme(s) but also from 
failures in the M6P-independent pathways through which they reach the lysosome. 
Despite from our study no evidence came that SORT1 deficiencies may be associated to 
LSD phenotypes, enlarged sample sizes are needed to draw more reliable conclusions on 
the topic. 
In addition to the molecular screening, and even though no novel variants were detected, 
a careful in silico analysis of the previously known SORT1 coding variants was also 
performed. Assessement of these variants’ patogenical potential had never been reported 
and only carrier individuals have been referenced. Currently, all these variants are 
classified as polymorphisms but, from our computational analysis, some of them seem to 
harbor the potential to damage protein structure and/or function. Final conclusions may 
only be drawn after in vitro analysis or when individuals carrying such variants either in 
homozygosity or in compound heterozygosity are described and their phenotype 
evaluated.  
 
 
1: Molecular screening of the SCARB2 gene the Portuguese Gaucher Disease patients 
In a set of 91 unrelated Gaucher disease (GD) cases which constitute the whole 
population of Portuguese patients suffering from this disorder, one novel mutation 
affecting the SCARB2 gene was identified. As far as it was possible to evaluate, the 
clinical phenotype presented by the patient in whom this variant was identified was 
somehow in accordance to what has been described for the GBA genotype (p.L444P/ 
p.L444P). Nevertheless, the child has biochemical evidences suggestive of poor response 
to treatment, which may be justified by the additional GCase carrier partial deficiency.  
In general, though, results reinforce previous evidence that mutations in the gene that 
codes for the β-glucocerebrosidase (GCase) transporter can act as GD modifiers. 
However, it became also clear that, at least in the Portuguese population, genetic 
variability at SCARB2 does not account much to the GD phenotypic spectrum.   
The mutation detected, p.T398M is currently under evaluation for subsequent 
publication. Western blot and Immunofluorescence assays are being carried out in model 
                                                                                                                          Chapter III – Results and Discussion 
103 
 
cells lines transfected with a minigene carrying the mutation and on the patient’s 
fibroblasts to further investigate protein expression and subcellular localization of LIMP-2 
and GCase. 
 
 
  
 
 
As a theoretical complement to our study on genes/proteins involved in the M6P-
independent pathway, we published: 
 A minireview on the current knowledge on the discovery, study, structural 
features and cellular function of LIMP-2 and sortilin, with special attention to 
their role as alternative receptors to lysosomal trafficking  (Appendix 1, review 
paper 3: Coutinho et al., 2012); 
 A synthesis on the published works focusing a surprising association between 
SORT1 levels and risk of cardiovascular disease that has recently been unveiled 
(Appendix 1, review paper 4: Coutinho et al., in press). 
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Abstract 
Unlike most lysosomal proteins, beta-glucocerebrosidase (GCase) – the hydrolase 
defective in Gaucher disease (GD) – is specifically delivered to the lysosome through 
interaction with the lysosomal integral membrane protein type 2 (LIMP-2). Recently, 
mutations in the LIMP-2 coding gene, SCARB2, were reported to affect the severity of 
Gaucher phenotype. To understand the role of variations in SCARB2 in the broad 
phenotype spectrum observed for patients carrying similar GBA mutations, we have 
screened the gene in the Portuguese GD patients. We analyzed a total of 91 
individuals, having identified 3 different SCARB2 coding variants. Of those, 2 were 
known polymorphic variations, with high prevalence in the normal population 
(p.M159V and p.V396I) and the third was a novel coding variant, p.T398M, present in 
heterozygozity in one Gaucher patient. When analyzed both in silico and in vitro, 
this variation was predicted to be deleterious for protein function.  
In summary, this study demonstrates that at least in the Portuguese population 
genetic variability at SCARB2 does not account much to the GD phenotypic spectrum, 
even though reinforcing previous evidence that SCARB2 mutations can act as GD 
modifiers. 
 
 
Key Words: Gaucher disease, β-Glucocerebrosidase; LIMP-2, SCARB2. 
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Introduction 
Unlike most lysosomal proteins, beta-glucocerebrosidase (GCase) – the hydrolase 
defective in Gaucher disease (GD) – is specifically delivered to the lysosome through its 
interaction with the transmembrane protein LIMP-2 [Reczek et al., 2007; Griffiths, 2007]. Even 
though being an uncommon metabolic disorder, GD is the most prevalent lysosomal 
storage disorder with an estimated birth frequency of 1/50,000 in the Caucasian 
population [Meikle et al., 1999]. It is an autosomal recessive disorder caused by mutations in 
GBA - the gene encoding for GCase, with nearly 300 mutations having been described.  
GD is classically divided into three variants according to the absence or presence and 
progressivity of neuropathic disease. All variants have differing degrees of enlargement 
of liver and spleen, anemia, thrombocytopenia and skeletal disease. These can range 
from very severe to mild within each type, although the rate of progression generally is 
greater in younger patients. Also, the degrees of visceral organ involvement are not 
concordant in patients. For example, massive involvement of the liver and spleen is not 
necessarily accompanied by severe bone disease. The reverse is also true. In addition, 
this classification is not age dependent, but depends on the primary involvement of the 
CNS by GD in any age. Gaucher disease type 1 patients are free of primary CNS 
involvement. The variability of the phenotype of visceral manifestations ranges from 
severe fatal disease in the first two decades to essentially asymptomatic nonagenarians. 
Gaucher disease types 2 and 3 have primary CNS neuronopathic involvement. Types 2 and 
3 represent a continuum of disease phenotypes that differ, primarily in their rates of CNS 
and visceral disease progression. This continuum encompasses phenotypes leading to 
death in utero, or in the first few days of life, to rapidly progressive CNS and visceral 
diseases that are fatal in the first years, to more slowly progressive (yet severe) CNS 
(with mild to severe visceral disease) deterioration over a period of 2–3 years to decades 
[Frederickson and Sloan, 1978; Dreborg et al., 1980; Erikson et al., 1987; Sidransky et al., 1992; Lewis 
et al., 1994; reviewed in Zhao and Grabowski, 2002].  
Even though some specific genotype-phenotype correlations have been established for 
some of its causing mutations (i.e., p.N370S only encountered in patients with the 
attenuated type 1 GD; and p.L444P associated with type 3 GD patients with visceral 
manifestations), the pathological cascade leading to the great variety of phenotypes 
among GD patients remains elusive, being still unsolved why patients carrying identical 
GBA genotypes present with disparate phenotypes. Cases of twins, including monozygotic 
twins homozygous for the p.N370S mutation, who exhibit striking discordance in the 
clinical manifestations of GD [Cox and Schofield, 1997], illustrate some of the many reports 
available in the literature that highlight such variability. Clearly, restricting the molecular 
analysis to a single locus encoding an enzyme has failed to discern a great amount of the 
variability associated to GD phenotypes, giving reason for the current limited ability to 
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make prognostic predictions from genotypic data [Hruska et al., 2008]. In addition, variation 
in factors that influence GCase function in vivo, such as saposin C, solely does not seem 
enough to explain the divergent expression of disease [Tamargo et al., 2012]. Over the 
years, efforts were made to identify unknown genetic, epigenetic and/or environmental 
factors influencing GD phenotypic manifestations [reviewed in Cox, 2001 and Zhao and 
Grabowski, 2002], but despite that the steps taken forward were scarce. Recently, a 
mutation in the gene that codes for the GCase transporter, SCARB2, was described as one 
of those modifiers [Velayati et al., 2011].  
In order to understand if SCARB2 mutations are a common cause for the broad phenotype 
spectrum observed for patients carrying similar GBA mutations, we have screened the 
SCARB2 gene in the Portuguese GD patients. We screened 91 individuals and, apart from 
numerous recurrent intronic polymorphisms, only 3 SCARB2 coding variants were 
identified. Of those, 2 were known polymorphic variations, with high prevalence in the 
normal population (p.M159V and p.V396I) and the third was a novel coding variant, 
p.T398M. This alteration was present in heterozygozity in one Gaucher case. Its presence 
was screened in 50 control individuals and in none was it present. Bioinformatic tools 
(Polyphen and PANTHER) predict it to be deleterious for protein function.  
In general, this study reinforces previous evidence that SCARB2 mutations can act as 
modifiers of GD, even though highlighting that those are neither the only nor the most 
frequent cause of GD phenotype variability, at least in the Portuguese population. 
 
 
Material and Methods 
Patients 
A total of 91 GD patients was studied. No relationship could be detected between the 
different families. All GD diagnoses had previously been confirmed at clinical, 
biochemical and molecular levels. 
 
DNA sequencing  
Genomic DNA was isolated from cultured fibroblasts and/or peripheral blood according to 
standard procedures. PCR amplifications of all 12 exons of the SCARB2 gene and their 
corresponding intronic flanking regions were done with specific primers (primer 
sequences and PCR conditions available on request). Fragments were purified with 
ExoSap-IT (GE Healthcare, United Kingdom) according to the manufacturer’s instructions 
and sequenced using a BigDye Terminator Cycle Sequencing Kit (Applied Biosystems, 
Foster City, CA, USA) on an ABI PRISM 3130xl Genetic Analyser (Applied Biosystems, Foster 
City, CA, USA). Results were analysed with the sequence analysis software FINCH TV 
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(Geospiza, Seattle, WA, USA) version 1.3.1. 
 
Plasmids, Site-directed Mutagenesis and Transfection of wild-type and mutant SCARB2 
cDNA 
A pCMV6-Neo vector expressing wild-type (WT) LIMP-2 protein was purchased from 
Origene Inc. (Rockville, MD). Using QuikChange Site-directed Mutagenesis kit (Stratagene, 
USA), the missense mutation p.T398M, was introduced into the cloned wild-type SCARB2 
cDNA sequence according to the manufacturer’s protocol, and the presence of additional 
mutations, resulting from possible enzymatic misincorporation, was excluded by full 
sequencing of the construct. COS-7 cells were transfected with wild-type and mutant 
constructs using Lipofectamine 2000 Reagent (Invitrogen, USA) following Invitrogen 
guidelines. 
 
Western blot Analysis 
COS-7 cells were grown in 6-well plates and 24 h after transfection harvested and lysed 
for 1 hour at 4°C in 30 µL of RIPA buffer (50mM Tris-HCl pH 8.8, 0.1 % NP-40, 150mM 
NaCl, 2mM EDTA pH 7.5, 0.1 % SDS and 0.5 % Na-DOC). Proteins were quantified through a 
modified Lowry assay using Bio-Rad DC Protein Assay (Bio-Rad, USA), according to the 
manufacturer’s instructions. Protein samples (75 µg) were separated in 8% SDS-PAGE gel 
and electroblotted to Hybond-C Extra nitrocellulose membranes (Amersham Biosciences, 
UK). The membranes were then incubated with the following primary antibodies: anti-
LIMP-2 (1:3000, OriGen Inc., Rockville, MD) and mouse monoclonal anti-α-Tubulin 
antibody (1:10000, Sigma-Aldrich, USA). The secondary antibodies used were goat anti-
mouse IgG (H+L) HRP conjugate (1:3000, Invitrogen, USA) and rat anti-mouse monoclonal 
(1:12000, Sigma-Aldrich, USA). The signal was developed with the ECL Western blotting 
Analysis Systems (GE Healthcare, UK) and detected on ECL Hyperfilms (GE Healthcare, 
UK), using the Fujifilm system (Fujifilm, Japan). 
 
Bioinformatic Analysis 
To evaluate the potential effect of the reported SCARB2 coding variants, three 
bioinformatic tools were used: Sorting Intolerant From Tolerant (SIFT; 
http://blocks.fhcrc.org/sift/SIFT.html), PANTHER (http://www.pantherdb.org/), PolyPhen 
(http://coot.embl.de/PolyPhen/), and PROVEAN (http://provean.jcvi.org/index.php).  
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Results and Discussion 
From the total sample of 91 GD patients sequenced for the SCARB2 gene, only 3 SCARB2 
coding variants were detected, apart from numerous recurrent intronic polymorphisms. 
Of those, 2 were known polymorphic variations, with high prevalence in the normal 
population (p.M159V and p.V396I) and the third was a novel coding variant, p.T398M. 
This alteration was present in heterozygozity in one GD case. Its presence was screened 
in 50 control individuals and in none was it present. All bioinformatic tools used 
(Polyphen, PANTHER and PROVEAN) predict it to be deleterious for protein function.  
To check if the p.T398M could be acting as a GD modifier, we started by carefully 
reviewing the clinical history of the patient in which the SCARB2 variant was detected. 
Patient was the second child of young, healthy unrelated parents of Cape Verdean origin. 
The couple had two other children, both apparently healthy: a 6 year-old boy of and 1-
year-old girl. The boy was born of normal delivery at 40 weeks, after a monitored 
pregnancy with no registered complications. At seven months, the child developed a 
multi-symptomatic clinical presentation of abdominal distension, diarrhea, anorexia, 
feeding difficulties, rough coughing and progressive weight loss, remaining hospitalized 
for two months in Cape Verde. During that period progressive degradation of his general 
condition occurred, with repeated infections and significant weight loss. The boy 
developed severe anemia, thrombocytopenia, cardiomegaly and marked splenomegaly. 
His aggravated condition led to the child’s evacuation to Portugal for etiological 
clarification. He was received at the Hospital de Santa Maria (Lisbon) and reported mild 
hepatomegaly (3cm below the edge of the right ribs); exuberant splenomegaly (until the 
iliac crest); poor weight gain with cachexia; feeding difficulties and dysphagia; bilateral 
convergent strabismus; marked axial hypotonia; poor facial mimic; stridor; global 
psychomotor developmental delay; cardiomegaly with dilatation of the left cavities; 
interstitial lung disease with multiple recurrent infections including aspiration 
pneumonia. Three cardiac arrest events were also registered. Cerebral MRI showed 
supratentorial periventricular white matter alterations of tegmentum pontis and dentate 
nucleus, all aspects which are compatible with central nervous system (CNS) involvement 
in the context of GD. Initial investigations showed low β-glucocerebrosidase levels and 
the child was referenced for ERT, having started treatment. Nevertheless, subsequent 
therapeutic follow-up with assessment of chitotriosidase levels showed enzyme levels 
which were disparate from the ones expected for a GD patient under ERT treatment, 
suggesting lower response to treatment.  
Recombinant GCase uptake is known to be dependent from the receptor density 
(mannose-6-phosphate receptors and LIMP-2). That is, indeed, one the major reason for 
the variable organ response to ERT [Desnick and Schuchman, 2012]. Taking this into account, 
it would be expectable that any alteration causing either dysfunction or reduction of 
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LIMP-2 lead to a decrease in the efficacy of ERT in GD patients, as observed in our case. 
Preliminary results of Western blot assays in COS7 cells transfected with a minigene 
carrying the mutation show a decrease of LIMP-2 levels when compared to wild-type 
protein (data not shown). Nevertheless, additional experiments are still needed to 
further evaluate the effect of p. T398M on GCase transport. A tempting approach would 
be to carry on Western blot and Immunofluorescence microscopy analysis on the patient’s 
fibroblasts to investigate protein expression and subcellular localization of both LIMP-2 
and GCase. Additional assays to measure activity and extra-cellular secretion of GCase on 
the patient cell line are also predicted. 
 
 
Conclusion 
To the best of our knowledge this is the first time that a whole GD population is screened 
for mutations in this gene. From our results on the Portuguese population it was possible 
to conclude that SCARB2 mutations are neither the only nor the most frequent cause of 
GD phenotype variability. Nevertheless, with the identification of a novel mutation in one 
of the patients who present a severe GD phenotype and had a poor response to ERT 
standard treatment and its subsequent evaluation, our study reinforces previous evidence 
that SCARB2 mutations do act as modifiers of GD. 
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Abstract 
Lysosomes are essential regulators of cell homeostasis, since they harbour a vast 
repertory of specialized enzymes responsible for degrading endocytosed and 
intracellular material. The newly-synthesized lysosomal enzymes travel first to the 
trans-Golgi network (TGN) and then must be driven to the acidic organelle in order to 
exert their function. Whist the best-known pathway for TGN-to-endosome transport is 
the delivery of soluble lysosomal hydrolases by the MPRs, additional pathways from 
the TGN to lysosomes do exist, as recently demonstrated by the identification of two 
alternative receptors: LIMP-2, shown to be implicated in the delivery of β-
glucocerebrosidase to the lysosomes, and sortilin, proposed to be involved in the 
transport of several proteins including the sphingolipid activator proteins prosaposin 
and GM2AP, acid sphingomyelinase and cathepsins D and H.  
Disruption of the intracellular transport and delivery pathways to the lysosomes may 
result in lysosomal dysfunction, predictably leading to a range of clinical 
manifestations suggestive of lysosomal storage diseases (LSDs). However, for a great 
percentage of patients presenting such manifestations, no condition is successfully 
diagnosed because their metabolic profile does not fit any known LSD.  In order to 
analyse if, in this group of patients, the underlying causes of their phenotypes could 
be genetically determined by impairments in the two known M6P-independent 
receptors, we screened the genes SCARB2 and SORT1 that encode for, respectively, 
LIMP-2 and sortilin. No novel mutations were found on the SCARB2 gene and no 
pathogenic mutations were identified on the SORT1 gene. Other study approaches 
will be needed to clarify whether sortilin dysfunction may cause disease. 
 
 
Key Words:  M6P independent trafficking, LIMP-2, sortilin, lysosomal storage diseases 
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Introduction 
Lysosomes are responsible for the degradation of different substrates in the cell. This 
major function can only be fulfilled if a number of specific degradative enzymes, 
synthesized in the ER, is properly transported from the Golgi to the lumen of the acidic 
organelle. The majority of those soluble acid hydrolases is modified with mannose 6-
phosphate (M6P) residues that allow their recognition by specific M6P receptors in the 
Golgi complex, ensuring their transport to the endosomal/lysosomal system [Braukle and 
Bonifacino, 2008]. Even though M6P receptors play a major role in this intracellular 
transport, compelling evidence has emerged that alternative methods of lysosomal 
targeting do exist. Recently, two M6P alternative trafficking receptors were brought to 
light: lysosomal integral membrane protein LIMP-2 (encoded by the SCARB2 gene) and 
sortilin (encoded by the SORT1 gene). LIMP-2, a protein of the lysosomal membrane, was 
shown to be implicated in the delivery of β-glucocerebrosidase (GCase, the enzyme 
defective in patients with Gaucher disease) to the lysosomes [Reczek et al., 2007; Berkovic et 
al., 2008; Balreira et al., 2008]. Sortilin, is a multiligand receptor thought to be involved in 
the lysosomal trafficking of sphingolipid activator proteins (SAPs), prosaposin (PSAP) and 
GM2 activator protein (GM2AP), acid sphingomyelinase (ASM) and cathepsins D and H [Ni 
et al., 2006; Nielsen et al., 1999; Lefrancois et al., 2003; Canuel et al., 2008].  
Impairments of the M6P-dependent pathway are the basis of the rare genetic diseases 
Mucolipidosis II and III (ML II, OMIM# 252500 and ML III, OMIM# 252600), two conditions 
that currently are most of the times successfully diagnosed after routine screening tests. 
Similarly, impairments on the M6P-independent trafficking processes might also have 
hazardous effects to the organism, ultimately leading to overt disease. Actually, recent 
studies demonstrated that mutations in SCARB2 may underlie a serious autosomal-
recessive disorder presently known as action myoclonus-renal failure syndrome (AMRF) 
[Reczek et al., 2007; Berkovic et al., 2008; Balreira et al., 2008]. So, having in mind that 
mutations in the genes coding for LIMP-2 and sortilin could result in missorting or 
mistargeting of some the above-referred proteins, we sought to perform the molecular 
screening of these two genes targeting five specific groups of individuals presenting 
clinical manifestations frequently associated to lysosomal storage diseases (LSDs) but still 
with undiagnosed disorders. The loss of activity of specific lysosomal hydrolases or, more 
rarely, the defective function of non-enzymatic lysosomal proteins is the hallmark of 
LSDs, a large group of rare genetic diseases. LSDs have been recognised as one of the 
major groups of genetic disorders affecting children and adults, including over 50 
different disorders with a combined prevalence of around 1:4000-1:9000 live births.  LSDs 
represent a major public health problem aside from placing an enormous burden on the 
individuals and families affected [Meikle et al., 2006].  
Not rarely, however, in patients with clinical suspicion of LDS, the definitive diagnosis 
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cannot be achieved with enzymatic or molecular testing. We concentrated in the 
uncharacterised patients, recruiting for the present study those with phenotypes 
overlapping manifestations that could predictably be due to loss of activities of GCase, 
saposins, GM2AP and/or ASM, to find out whether those features could be resultant from 
failures in M6P-independent pathways through which those proteins reach the lysosome. 
Patients were sorted into five different groups according to their phenotypic picture: (1) 
local glomerulosclerosis myoclonus epilepsy; (2) metachromatic leukodystrophy/ 
Gaucher-like phenotype; (3) GM2 gangliosidosis-like phenotype; (4) Niemann-Pick types 
A/B-like and (5) hydropsis fetalis. In each group, the option to study sorting or trafficking 
of lysosomal proteins through M6P-independent pathways was made according to the 
suggestive clinical manifestations: groups (1) and (5) were screened for SCARB2, groups 
(3) and (4) for SORT1 and group (2) was screened for both genes. 
 
 
Material and Methods 
Patients 
We started by reviewing the clinical histories of patients with samples still available in 
our institution who had already undergone diagnostic testing for LSDs without having 
obtained any positive result. Patients were spitted in 5 groups based on their particular 
clinical features. Group (1) was constituted by patients presenting clinical manifestations 
characteristic of individuals which suffer from AMRF (glomerulosclerosis and/or with 
glomerular collapse). This group, together with group (2), was screened for the SCARB2 
gene. Groups (2), (3) and (4),  screened for the SORT1 gene, were classified according to 
the following characteristics:  (2) metachromatic leukodystrophy and/or Gaucher-like 
phenotype (acute neuronopathic form of the disorder with onset in infancy and 
premature death; additional features include hepatosplenomegaly, developmental 
regression, and growth arrest); (3) GM2 gangliosidosis-like phenotype (developmental 
retardation, followed by paralysis, dementia and blindness, with death in the first years 
of life; hallmark features include “cherry red spot”, balloon-shaped neurons in the 
central nervous system early and a persistent extension response to sound known as 
'startle reaction') and (4) Niemann-Pick types A/B-like phenotype (ranging from severe 
and premature neurologic degeneration resulting in early death to later-onset 
nonneurologic manifestations affecting the spleen, the liver, and the lungs). Finally, 
group (5), also screened for the SCARB2 gene, comprised all available samples of 
hydropsis fetalis cases. Whenever clinical descriptions were missing, we focused our 
attention on the initial physician requests referring the patients to our laboratory. So, in 
group (2) patients of unknown symptoms but whose initial physicians’ request asked for 
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Gaucher disease testing but whose final result was negative, were also included. 
Similarly, patients that had been tested for GM2 Gangliosidosis and Niemann-Pick disease 
but whose suspicions were not confirmed were additionally integrated in groups (3) and 
(4), respectively. The total sample comprehended 120 individuals. 
 
Molecular screening of the SCARB2 and SORT1 genes 
Genomic DNA was isolated from cultured fibroblasts and/or peripheral blood according to 
standard procedures. PCR amplifications of all 12 exons of the SCARB2 gene and 21 exons 
of the SORT1 gene and their corresponding intronic flanking regions were done with 
specific primers (primer sequences and PCR conditions available on request). Fragments 
were purified with ExoSap-IT (GE Healthcare, United Kingdom) according to the 
manufacturer’s instructions and sequenced using a BigDye Terminator Cycle Sequencing 
Kit (Applied Biosystems, Foster City, CA, USA) on an ABI PRISM 3130xl Genetic Analyser 
(Applied Biosystems, Foster City, CA, USA). Results were analysed with the sequence 
analysis software FINCH TV (Geospiza, Seattle, WA, USA) version 1.3.1. 
 
In silico analysis  
To evaluate the potential effect of the reported sortilin coding variants, three 
bioinformatic tools were used: Sorting Intolerant From Tolerant (SIFT; 
http://blocks.fhcrc.org/sift/SIFT.html), PANTHER (http://www.pantherdb.org/), PolyPhen 
(http://coot.embl.de/PolyPhen/), and PROVEAN (http://provean.jcvi.org/index.php).  
Modelling of sortilin tertiary structure was performed using the structure of the Vps10p 
domain in complex with neurotensin (Protein Data Bank file 3F6K.pdb) as template. 
Modelling was carried out by Swiss Model Server and in silico mutagenesis visualization 
was performed with PyMOL (http://pymol.sourceforge.net). For LIMP-2, no tertiary model 
could be designed since there are no known homologous proteins whose structure has 
already been crystallized. Predictions of the presence of exonic splice enhancer or 
silencer sequences were made using ESEfinder (http://rulai.cshl.edu/cgi-bin/tools/ESE3) 
[Cartegni et al., 2002] and SplicingRainbow (http://www.ebi.ac.uk/asd-srv/wb.cgi?method=8) 
[Stamm et al., 2006]. Rescue-ESE (http://genes.mit.edu/burgelab/rescue-ese/) [Fairbrother et al., 
2002] and PESXs-Search (http://cubweb.biology.columbia.edu/pesx/) [Zhang and Chasin, 2004] 
were used to analyze the binding of several splicing factors.  
 
 
Results  
In total, 67 individuals were screened for the SCARB2 gene. Among them, only non-
pathogenic and frequent variations were detected: eight were already registered in 
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Ensembl (rs3733259; rs894248; rs2289512; rs143655258; rs2289513; rs35369082; 
rs77814624; rs35583533) while three were not registered. Two of the identified 
polymorphisms affected the coding region of the SCARB2 gene: p.M159V (rs143655258) 
and p.V391I (rs77814624). Both were already registered in Ensembl as polymorphisms. In 
addition, all bioinformatic tools (PolyPhen, SIFT, PANTHER and PROVEAN) predicted them 
to be tolerated. These two variant alleles occurred at frequency of ≈2% and 3% in our 
patient sample and at 1% and 2% of our control sample (50 healthy Portuguese 
individuals), respectively. In the 1000 Genome project, frequencies of the two variations 
were 1% and 0%, respectively.  Out of the three not registered alterations, two were 
intronic and relatively common in our samples. The third was exonic, even though silent 
(c.567T>C; p.H189H), being present in heterozygosity in only one of the patients. To 
understand if it could have a deleterious effect by altering any exonic splicing enhancer 
(ESE) or exonic splicing suppressor (ESS), which consequently could interfere with 
splicing, we used four bioinformatic tools, ESEfinder, SplicingRainbow, Rescue-ESE and 
PESXs-Search, with all but PESXs-Search yielding identical predictions for the normal and 
the altered sequence. However, since according to PESXs-Search the substitution 568T>C 
would give rise to the loss of a PESS motif (“ATGTTTTC”), we screened the patient’s cDNA 
with specific primers but no differences were observed between control cDNAs and the 
patient’s sample (data not shown). As no other pathogenic mutation was found in that 
patient, such silent heterozygous variant can very likely be excluded as the cause of the 
phenotype.  
Concerning the SORT1 gene, we screened 53 individuals and identified seven different 
variations, all of them non-pathogenic: five already registered in Ensembl as 
polymorphisms (rs11181665; rs11142; rs72646560; rs2228604; rs74584797) and two that 
hadn’t yet been stored in the same database. Three of those variants occur in the coding 
region of the SORT1 gene (rs11142; rs72646560 and rs2228604) but none of them causes 
aminoacidic changes. They are also frequent both on the patient sample (≈11, 12 and 
17%, respectively) and on the general population (≈15, 6 and 30% of European alleles, 
respectively according to data from the 1000 Genome project on allele frequencies). 
 
 
 
Discussion 
LIMP-2 is a heavily N-glycoylated type III transmembrane protein [Fujita et al., 1991], 
representing the sorting receptor of GCase that is the enzyme defective in Gaucher 
Disease, the most common lysosomal storage disorder [Beutler, 1991].  Mutations in LIMP-2 
were recently reported to cause AMRF, a disease characterized by a remarkable 
combination of local glomerulosclerosis (frequently with glomerular collapse) and a series 
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of symptoms which are often associated to LSD, such as the presence of storage material 
in the brain [Berkovic et al., 2008; Balreira et al., 2008]. We admitted, therefore, that some of 
the patients presenting such symptoms but lacking positive results in previously 
performed diagnostic tests for LSDs, could carry mutations in SCARB2, the gene encoding 
LIMP-2. 
Sortilin’s role on disease, on the other hand, still remains elusive. To evaluate if some 
LSD-related symptoms could arise due to sortilin dysfunction, we focused attention on its 
putative targets, all of them lysosomal proteins of known biological relevance: SAPs 
(prosaposin and GM2 activator protein), ASM and cathepsins D and H [Ni et al., 2006; Nielsen 
et al., 1999; Lefrancois et al., 2003; Canuel et al., 2008].  Prosaposin (PSAP) is both a non-
enzymatic precursor of sphingolipid activator proteins (SAPs) and a secreted neurotrophic 
and myelotrophic factor [Jolivalt, 2008]. This molecule is a precursor protein common to 
four homologous glycoproteins: saposins A, B, C and D. Such glycoproteins are required 
for the in vivo degradation of sphingolipids with short carbohydrate chains and, even 
though presenting remarkable structural similarities, their functions are specific, with 
some overlaps for individual sphingolipid hydrolases. Total deficiency of all saposins 
(OMIM#611721) and specific deficiencies of saposin A (OMIM#611722), B (OMIM#249900) or 
C (OMIM# 610539) were already described in humans [Matsuda et al., 2001; Tamargo et al., 
2012].  Patients suffering from individual saposin deficiencies present atypical Krabbe 
disease, metachromatic leukodystrophy and Gaucher-like phenotypes, respectively 
[Christomanou et al., 1986; Stevens et al., 1981]. Combined saposin deficiency is a devastating 
disease with a complex multisystemic phenotype, demonstrating the essential role of the 
four saposins in vivo [Matsuda et al., 2001].  It seemed, though, quite tempting to explore 
whether a failure in the lysosomal targeting of prosaposin could have deleterious 
consequences if leading to the absence of some saposin activites. So, we screened the 
SORT1 and SCARB2 genes in patients presenting a phenotypic picture coinciding with that 
characteristic of Gaucher disease but without mutations in both the GBA gene (which 
codes for glucocerebrosidase) and in the PSAP (which codes for prosaposin). We also 
screened the SORT1 gene in unclassified patients with metachromatic leukodystrophy.  
GM2 ganglioside activator protein (GM2AP) is an essential cofactor for the lysosomal 
degradation of ganglioside GM2 by β-hexosaminidase A (hex A). Functional deficiencies in 
this protein result in a fatal neurological storage disorder, the AB variant of GM2 
gangliosidosis (OMIM #272750) [Wendeler et al., 2006]. Once again, it appeared reasonable 
to admit that mutations in SORT1 could cause a similar disease, by preventing the correct 
targeting of GM2AP to the lysosome and, consequently, its activator function.   
Two other lysosomal proteins had still to be considered if we wanted to address all 
possible metabolic dysfunctions that could result from an impaired lysosomal targeting 
mediated by sortilin: cathepsins D and H [Canuel et al., 2008]. Cathepsin D is a peptidase 
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belonging to the family of aspartic peptidases. Although it may assume some 
physiological effects such as hormone, antigen and mediator of neuropeptides 
processing, its major function is the digestion of proteins and peptides within the acidic 
compartment of the lysosome [Fusek et al., 2005]. Cathepsin H, on the other hand, is a 
lysosomal glycoprotein and a member of the cysteine proteinase family, which may be 
easily distinguished from other members of this family by its unique aminopeptidase 
activity [Rojnik et al., 2012]. Both cathepsin D and H seem to be cell biomarkers of specific 
cancers with distinct roles in pathological conditions [Mimae et al., 2012; Schweiger et al., 
2004]. It is also well established that the proper distribution of cathepsins, not only 
cathepsins D and H but several other members of the family, is essential for efficient 
lysosomal and cellular function [Urbanelli et al., 2008; Schweiger et al., 2004]. Nevertheless, 
none of these enzymes has ever been related to any type of storage disorder and so, 
there are no known effects of their failure or absence of any of them in the cell.  
In our patients sample, however, no genetic variants in SORT1 were detected that could 
explain the observed phenotypes. This does not deny, per se, the possibility that 
impairments on sortilin function may cause disease, especially if we take in account, on 
the one hand, the small size of the tested sample and the low prevalence of LSDs in 
general, and on the other, the fact that the establishment of a phenotypic criterion to 
screen for mutations in any gene involved in lysosomal function is far from being 
straightforward. Actually, even though some phenotypic effects of protein 
loss/malfunction may be easily predicted (such being the case of deficiencies or 
dysfunctions of saposins, which result in LSDs that mimic deficiencies of the enzymes 
activated by each particular Sap), others exist in which the correlation between the 
missing protein and its effect at clinical level is not so obvious (such being the case of 
LIMP-2 deficiencies, which result in a phenotype different from the one caused by the 
dysfunction of GCase, the enzyme it transports). 
In a complementary attempt to evaluate the possibility that SORT1 mutations cause 
disease, we performed in silico analysis of the 12 non-synonymous coding variants that 
have been described in the scope of the “1000GenomeProject” and were classified as 
polymorphisms, although none of them was ever detected in homozygouzity. In order to 
evaluate how genetic variants could affect protein function and, ultimately, cause 
disease we created a 3D-model for sortilin and performed in silico mutagenesis. Then, 10 
of the registered variants were tested on our 3D-model, cross-linking the results with 
PolyPhen and SIFT predictions, accounting for the size, cargo and structure of the altered 
residues. By doing so, we classified them into: (1) tolerated, (2) possibly and (3) probably 
damaging. The complete results of this in silico analysis are represented in Figure 1.  
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Figure 1: Complete results of the in silico analysis of SORT1 coding variants. 
A color code highlights the potential of each one to disrupt sortilin’s structure, impair its biological 
function and, ultimately, cause lysosomal storage and disease. Benign - green; possibly deleterious – 
orange; probably deleterious - red.  
 
Several parameters were taken in consideration: (a) conservation degree of the altered 
residue; (b) likelihood of the affected amino acid to change the secondary structure; (c) 
localization of the specific amino acid in the different protein domains, which together 
turned possible to predict which of the investigated 12 coding variants most likely affect 
the structure and, consequently, function of sortilin. Obviously, only additional in vitro 
and in vivo studies may confirm if the envisioned impairments will result indeed in 
disease.  
Given that two of the variants, p.S115F and p.I124V, are located in a tip region of the 
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molecule that could not be modelled, for them only the bioinformatic predictions and 
interspecific alignments were considered to establish the final classification of 
severity/pathogenicity. All other variants were modelled and analysed with all available 
tools. Variants p.I124V, p.N357S, p.E444Q, p.P478S and p.S746N were predicted to be 
tolerated/benign by all the bioinformatic tools (data not shown for PANTHER and 
PROVEAN). In general, these variants involve aminoacid changes that do not affect 
regions of the molecule which are highly conserved among species. Furthermore, there 
are no significant differences between the properties of the “normal” and the “mutated” 
residues (similar polarities, sizes and/or acidity).  
For p.S115F and p.V650M, discrepant results were yielded by PolyPhen and SIFT (and also 
PHANTER and PROVEAN) with half of them predicting them to be pathogenic and the 
other half to be tolerated. Concerning p.V650M, the similar properties of the involved 
aminoacids (See Figure 1, “normal” and “mutated” residues), could justify why a 
methionine in the position would be tolerated. Nevertheless, V650 is a highly conserved 
residue, indicating therefore that it may be crucial to guarantee protein functionality, 
even though no relevant sequence annotations were made for the loop region in the 
molecule where the residue is located. The situation is opposite for the missense 
alteration p.S115F, which despite implying a considerable alteration in aminoacid 
properties it changes S115 that is not particularly conserved among species. So, further 
approaches are still needed to illuminate the consequences of both variants on protein 
function. For the remaining variants, assessment of putative pathogenicity was less 
problematic, given the coincident or similar bioinformatic predictions. p.S316P, p.T371I, 
p.S389F and p.S424F, for example, are substitutions in which the properties of the 
involved aminoacids change drastically, not only in terms of polarity (polar → nonpolar) 
but also in size and chain properties. Whilst theoretically, any such substitutions is prone 
to disrupt protein structure and, consequently, its function, evidence that this might 
occur comes from the observation that the involved residue is evolutionary extremely 
conserved, as happens with p.S424F. The pathogenic nature of variants p.T371I, p.S389F 
and p.S424F can be further explained since they affect residues located on the 
surroundings of the neurotensin binding region, which is crucial for sortilin’s function on 
the CNS. In the case of variant p.D358Y, it was classified as possibly deleterious, even if 
not implying a dramatic change in aminoacids properties, because a tyrosine at the highly 
conserved position 358 is capable of establishing new polar contacts which tighten the 
structure near the neurotensin binding site, potentially affecting binding.  
A strong argument against the possibility that a lysosomal storage disorder could arise 
due to sortilin’s loss of function came from studies on a sortilin knockout (KO) mouse that 
did not display any clinically relevant phenotype [Zeng et al., 2009], although revealing a 
80% reduction of levels of intraendosomal/lysosomal prosaposin, which thereby clearly 
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supported the role of sortilin as an alternative receptor.  Actually, the results obtained 
for the sortilin KO mouse may be easily conciliated with the ones reported for mice 
deficient on the M6P receptors. In fact, when KO mice were created for the cation-
dependent M6P-receptor (CD-MRP) and for the cation-independent M6P receptor (CI-
MRP), none of them presented clinical phenotype, even though both had a partial 
missorting of phosphorylated lysosomal enzymes.  Only when a double KO was created 
did the mouse present pathological changes, indicating that, when one of the receptors is 
not functional, the other partially replaces it. So, presuming that other receptors besides 
sortilin do exist able to transport lysosomal hydrolases, it is possible that, when sortilin is 
not functional, such receptors assume a reinforced role to avoid mistargeting and cellular 
malfunction. Sortilin, as well as most of the members of the Vps10p family of sorting 
proteins, appears to be evolutionary much older than the MPR and taking into account, as 
experimental results suggest [Marcusson et al., 1994; Hampe et al., 2001; Petersen et al., 1997; 
Tauris et al., 1998], that MPRs have the capacity of replacing one another when any is 
deficient, it seems even more probable that sortilin and its related proteins that share 
the same domains already present on yeast, do perform vacuolar transport. On the 
frontline of the most probable alternative receptors stands SorLA, the unique other 
known Vps10p family member containing motifs shown to be involved in trafficking from 
the Golgi to the endosome and vice versa. Although no studies have yet been conducted 
to evaluate its function in the M6P-independent transport of lysosomal hydrolases, the 
observation that KO mice in which the gene for SorLA was inactivated did not exhibit 
abnormal phenotypes, also pinpoint to the existence of a complementary receptor [Zhu et 
al., 2004]. One final remark should also be made on animal models. There are differences 
in gene regulation between man and mouse respecting to sortilin, as demonstrated by 
the absence of a crucial C/EBP α binding site in mice [Musunuru et al., 2010; Russell and 
Proctor, 2006], which inevitably may hinder extrapolation of mouse studies to human when 
dealing  with sortilin.  
In summary, unlike from what happens concerning LIMP-2, the role that sortilin plays on 
disease is still far from being unveiled. In general, there is still much to learn not only on 
sortilin but also on other Vps10p family receptors and their role on the M6P-independent 
trafficking pathway. Some steps forward would be taken by the generation of a double 
knockout for sortilin and SorLA. In addition, important insights on sortilin’s role on 
disease, will probably come from finding out rare human patients harboring a large-
effect mutation in SORT1 (e.g., a loss of function mutation) and from a careful definition 
of their phenotype [Dubé et al., 2011]. 
 
 
                                                                                                                          Chapter III – Results and Discussion  
115 
 
Conclusion  
In this study we raised the question about whether some cases of patients suspected to 
have a LSD but remaining undiagnosed after routine tests could be due to genetic 
impairments in two recently discovered M6P-independent receptors LIMP-2 and sortilin. 
To address the issue we screened the encoding genes in subsamples of patients defined 
according to their phenotypic characteristics. No novel mutations were found on the 
SCARB2 gene and no pathogenic mutations were identified on the SORT1 gene. Other 
approaches will be needed to clarify whether sortilin dysfunction may cause disease. 
The relevance of alternative receptors is demonstrated by their involvement in disease. 
SCARB2 mutations were already shown to underlie the serious autosomal-recessive 
disorder AMRF [Berkovic et al., 2008]. Recently, SCARB2 mutations have also been 
demonstrated to act as modifiers in Gaucher disease (GD), contributing to a severe 
neuropathy even when present in heterozygous state [Velayati et al., 2011]. So, a better 
understanding on the M6P-independent routes to the lysosome will contribute to a more 
accurate understanding not only of crucial cellular processes, but also of the 
pathophysiological bases of severe and disabling diseases. Finally, knowledge of the 
different trafficking mechanisms responsible for the sorting of lysosomal proteins may be 
an enormous help for the building of new therapeutic strategies for LSDs.  
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Even though several questions were answered through our studies, many other novel and 
challenging questions have arisen.  
In this last section are summarised the main conclusions we were able to draw from our 
analysis on both M6P dependent and independent transport pathways of lysosomal enzymes 
and their involvement in disease, and in addition to it is presented an overview of the next 
steps of this study as well as a summary of the novel lines of research we intent to follow 
supported on these foundations.  
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Part 1 
 Molecular genetics, pathophysiology and diagnosis of disorders related with 
malfunction of M6P pathway 
 
 
In a set of 23 unrelated ML II and III cases, we have identified 18 different mutations: 16 
in the GNPTAB gene and 2 in the GNPTG gene. Of those, 13 were novel: 11 in the GNPTAB 
gene and 2 in the GNPTG gene (Table 3.1). 
 
All mutations identified were further analyzed with the most suitable approaches. 
Special attention was paid to the novel alterations: 
 Real time PCR studies were performed whenever cDNA samples were available, 
which pinpointed the existence of feedback regulation mechanisms between the  
α/β- and the γ-subunits; 
 Long-range PCR and extensive cDNA analysis were applied to characterize the 
novel deletion c.3435-386_3602+343del897, allowing the identification of the 
deletion breakpoints and the disentanglement of its effect at cDNA level that led 
to the creation of three abnormal transcripts;  
 Cycloheximid treatment of cultured patients’ cell lines was performed to inhibit 
mRNA degradation through NMD whenever nonsense and frameshift mutations 
detected through gDNA sequencing could not be confirmed by standard cDNA 
analysis, allowing their subsequent observation;   
 Transient expression of wild-type and mutant GNPTAB gene sequences in HEK and 
HeLa cells revealed to be crucial to further analyze the impact of several  
GNPTAB mutations; 
 Immunofluorescence and Western blot assays were used in a series of 7 GNPTAB 
mutants. Special attention was paid to the atypically severe missense mutations 
(p.W81L and p.R986C) whose results were cross-linked with the ones obtained for 
two severe deletions (c.1581delC and c.3503_4delTC) and three mild missense 
mutations (p.S399F, p.I403T and p.K1236M). From this study it became clear that 
the answer for the extreme pathogenicity of the two target mutations relied in 
ER-retention (abnormal subcellular location) of a non-cleaved precursor or in a 
total absence of the mutated protein, with consequent absence of 
phosphotransferase activity. 
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 Future Perspectives  
 
Presently, our future approaches concerning disorders related with malfunction of M6P 
pathway are mainly focused on specific causal mutations and may be divided into the 
following aspects: 
 Evaluation of the p.R986C GNPTAB mutation effects at mRNA and protein levels 
Given the unexpected results obtained for the GNPTAB mutation p.R986C, with a 
complete absence of GlcNAc-phosphotransferase expression on cells expressing it and 
with a extremely severe phenotype observed on the only known patient who harbours 
this variant in homozygosity, further analysis should be performed focusing residue R
986
 in 
particular. 
In order to unveil whether the absence of expression of the p.R986C Glc-NAc-
phosphotransferase mutant is due to mRNA instability or to premature protein 
degradation, different approaches may be followed. One of the possibilities is to perform 
quantitative real-time PCR to assess the GNPTAB mRNA levels of cells overexpressing 
p.R986C. Another tempting approach is to inhibit endoplasmic-reticulum-associated 
(ERAD) protein degradation with proteasome inhibitors and check whether the mutant 
protein can, then, be observed through standard Western blot assays. Also 
Immunofluorescence and co-immunofluorescence assays and pulse-chase experiments 
with 
35
S-labelled mutant protein may be performed to verify when and where, at a 
subcellular level, is the mutant targeted for degradation. 
Finally, knowledge of the phosphotransferase crystallographic structure could also 
provide a structural explanation for how distinct mutant residues affect the molecule 
function and/or stability including the assembly and interaction between the different 
subunits of this protein.  
 Biochemical studies of the novel p.I941T GNPTAB mutation 
Recent identification of the novel p.I941T GNPTAB mutation in a Turkish patient from 
whom no clinical data was available also prompts additional biochemical studies to 
disclosure possible effects of this alteration and predict its phenotypic effect. 
Expression of p.I941T mutation and assessment of its associated protein expression levels 
and subcellular location, in a similar way as described on the Results and Discussion 
section (Paper 5) is already planned.  
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Part 2  
The M6P independent trafficking pathways in LSDs 
 
 
In a set of 120 individuals with clinical suspect of LSD but without definitive biochemical 
and/or molecular diagnosis, no novel mutations were detected either on the SCARB2 or 
on the SORT1 gene. From our experience so far, no evidence came that SORT1 
deficiencies may be associated to LSD phenotypes. Still, enlarged sample sizes are 
needed in order to draw more reliable conclusions on the topic. 
 
In a set of 91 unrelated Gaucher disease (GD) cases, which altogether constitute the 
whole cohort of Portuguese patients suffering from this disorder, we have identified 1 
novel mutation in the SCARB2 gene, reinforcing previous indications that mutations in the 
gene that codes for the β-glucocerebrosidase transporter can act as GD modifier. From 
our study, however, it appears that genetic variability at SCARB2 does not account much 
to the GD phenotypic spectrum.   
 
 
 Future Perspectives  
 
In order to carry on the analysis on the contribution of genetic impairments of the M6P-
independent receptors to LSD phenotypes, it would be important, not only to continue 
screening the SORT1 and SCARB2 genes in LDS suspects’ and the study of the SCARB2 
mutation p.T398M as a GD modifier, but also to evaluate the potential of the Vps10p-
family member SorLA as an alternative receptor for Golgi-to-lysosome transport. In 
summary, future approaches may be divided into the following main lines: 
 Characterization of the M6P-independent pathway on patients with LSD-phenotype – 
molecular, in silico and in vitro studies 
SORT1 and SCARB2 molecular screenings should continue to be performed to obtain a 
better assessment of how both genes might contribute to LSD related phenotypes.  
Every time a novel variant is identified in any of the genes, its effect on protein function 
will be bioinformatically predicted. Whenever possible (available immortalized fibroblast 
cell line), cDNA analysis will also be performed to confirm the presence of each mutation 
and study their effect upon mRNA processing. If cDNA is not available, expression 
constructs containing wild-type or mutant minigenes will be developed. The effect of 
each mutation will be further evaluated in vitro through functional studies. Western Blot 
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and Immunofluorescence assays will be performed to evaluate the effect of each variant 
on protein expression and cellular distribution, respectively.  
 Biochemical studies of the novel p.T398M SCARB2 mutation 
The mutation detected, p.T398M is already under evaluation. Western Blot and 
Immunofluorescence assays are being carried out in COS7 cells transfected with a 
minigene carrying the mutation and on the patient’s fibroblasts to further investigate 
protein expression and subcellular localization of LIMP-2 and β-glucocerebrosidase. 
Additional assays of β-glucocerebrosidase activity and extra-cellular secretion on the 
patient cell line are also predicted. 
 Evaluation of the structural interaction between sortilin and its lysosomal ligands-  
silico studies 
Light should be shed on the molecular mechanism underlying the interaction between 
sortilin and its lysosomal ligands: PSAP, GM2AP, ASM and cathepsins D and H. A tempting 
computational approach would comprise extensive sequence analysis, through multiple 
alignments, secondary structure/disordered regions prediction, threading and homology 
modeling.  
 Evaluation of SorLA’s potential to be an alternative receptor - molecular, in silico and 
in vitro studies 
Taking into account that, apart from sortilin, SorLA is the only known Vps10p family 
member which contains Golgi-to-lysosome trafficking motifs, it’s potential to be an 
alternative receptor should also be addressed. An interesting approach would be to 
develop a dominant negative SorLA vector and use it for co-immunoprecipitation and 
immunofluorescence assays. We propose cathepsins K and L as SorLA’s possible ligands (i) 
for their long known ability to reach the lysosome in a M6P-independent fashion; (ii) for 
their structural and functional similarities to cathepsins D/H and (iii) for the already 
existing experimental evidences that sortilin isn't responsible for their Golgi-to-lysosome 
transport.  
If the role of SorLA as an alternative receptor for cathepsins K/L is confirmed, their 
interaction could be as well modulated through a computational approach. 
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 Additional Remarks  
 
Apart from the specific data collected on impairments of the lysosomal travelling routes, 
several important and general progresses were achieved with this study: 
 
 Importance of Molecular Genetic Testing (MGT) 
First of all, it was possible to implement MGT techniques for three different diseases: ML 
II, ML III and AMRF. The establishment of MGT for LSDs is essential for the definitive 
diagnosis of these diseases, by confirming the enzymatic diagnosis. In the particular case 
of AMRF, only MGT may allow definitive diagnose. Also, for Mucolipidosis type III, only 
through MGT is it possible to classify the subtype of the disease (III alpha/beta or III 
gamma) and identify the phosphotransferase subunit which is affected in each patient. It 
is also the only suitable approach in post-mortem diagnoses, where the only specimens 
available are DNA samples. Such diagnoses are of major importance to the follow-up of 
affected families. In fact, knowing the genotype of LSD patients allows carrier detection 
in their family’s members, which opens the possibility of offering them adequate genetic 
counseling. Once the molecular diagnosis of an LSD patient is ascertained, genetic 
counseling for at-risk couples includes prenatal testing on chorionic villi (at 11-12 weeks) 
or amniocytes (at 16 weeks). Finally, whenever genotype-phenotype correlations are 
reasonably strict, as was often observed in our study, prognosis of disease is much more 
reliable. Unfortunately, at present there are no available therapies for any of these 
diseases but still, in the future, the availability of MGT for MLII, MLIII and AMRF will be 
essential to support therapeutic choices that hopefully will diminish the burden of these 
devastating diseases. 
 
 Relevance of cDNA analysis and alternative MGT methods for a correct diagnose  
From the detection of a gross deletion involving the exon 19 of the GNPTAB gene, several 
important recommendations may be done for an accurate molecular diagnose of ML II 
disease. It is important to bear always in mind the possible existence of such large 
deletions when performing molecular screenings of the GNPTAB gene, being aware that 
when present in heterozygosity, they might easily escape detection through DNA genomic 
analyses. Without direct cDNA examination this kind of mutations may remain 
unidentified. Furthermore, our studies on two independent ML III cases in which only one 
of the mutant alleles could be detected through conventional cDNA screening due to the 
efficient action of the NMD mechanism, highlight the necessity of combining diverse 
analytical approaches on different samples to reach a precise diagnose. 
In addition to the biochemical testing, both gDNA and cDNA analyses must be carried out 
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whenever suitable biological material is available. Furthermore, ML II α/β and ML III α/β 
cases with only one mutant allele detected by direct sequencing should be further 
examined for the presence of large heterozygous deletions to strengthen the accuracy of 
genetic counselling and prenatal diagnosis in the families at risk. 
 
 Establishment and interpretation of genotype-phenotype correlations 
The establishment of genotype-phenotype correlations is a major goal in Clinical 
Genetics. However, dealing with predictions on the severity of a given mutation is a 
delicate matter due to the influence they may have on genetic counseling. 
From our molecular characterization of ML alpha/beta patients with subsequent 
identification of three cases in which homozygous missense mutations were underlying a 
severe phenotype, it became clear that, even when, for a certain gene, some genotype-
phenotype correlations are already known, and clues do exist on the association between 
a certain type of mutation and the level of severity of its associated phenotype, care 
should be taken when classifying a novel variant as “mild” or “severe” respecting the 
putative phenotypic impact. Only extensive biochemical studies may allow a deep 
analysis of a mutation’s effect. 
The study on GD patients brought to light other limitations of genotype-phenotype 
analyses. In fact, although often saw as a prototype for LSDs and being the most common 
of these diseases, GD early turned out to be a good example of complexity in a 
monogenic disorder, with the observation of patients carrying the same genotype at GBA 
while presenting quite disparate phenotypes. Studies on different populations of GD 
patients over the years have been quite instructive in this regard, demonstrating that 
single GD genotypes, expressed in relatively similar environments, give rise to a wide 
range of phenotypes, from severe infantile neuropathic and visceral disease to milder 
variants with neuropathic disease onset in the 4
th
 to 6
th
 decades. From such analysis, 
became well established that the major variation in phenotype must have significant 
genetic basis, i.e. modifier genes. Abnormalities of GCase’s transporter (LIMP-2) and 
activator (saposin C) proteins are examples of disease modifiers which explain why, 
frequently, the genotype and the phenotype do not seem to match. Nevertheless, other 
modifiers are thought to exist. Diseases like GD clearly illustrate that all manifestations 
encountered in a single gene disorder may not be thoroughly explained by the primary 
mutation in the gene of interest.  
In conclusion, we should emphasise that the identification of novel variants per se, do 
not allow an accurate prediction of the phenotype. Ideally, studies on genotype-
phenotype correlation should integrate the complexity of factors that underlie the range 
of phenotypic variability in a given disease, which is naturally critically hampered by the 
unsatisfactory knowledge on these factors and interaction between them. 
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Impaired degradation of glycosaminoglycans (GAGs) with consequent intralysosomal accumulation of undegraded products
causes a group of lysosomal storage disorders known asmucopolysaccharidoses (MPSs). Characteristically, MPSs are recognized by
increased excretion in urine of partially degraded GAGs which ultimately result in progressive cell, tissue, and organ dysfunction.
There are eleven diﬀerent enzymes involved in the stepwise degradation of GAGs. Deficiencies in each of those enzymes result
in seven diﬀerent MPSs, all sharing a series of clinical features, though in variable degrees. Usually MPS are characterized by a
chronic and progressive course, with diﬀerent degrees of severity. Typical symptoms include organomegaly, dysostosis multiplex,
and coarse facies. Central nervous system, hearing, vision, and cardiovascular function may also be aﬀected. Here, we provide
an overview of the molecular basis, enzymatic defects, clinical manifestations, and diagnosis of each MPS, focusing also on the
available animal models and describing potential perspectives of therapy for each one.
1. Introduction
Themucopolysaccharidoses (MPSs) are a group of lysosomal
storage disorders caused by deficiency of enzymes catalyzing
the stepwise degradation of glycosaminoglycans (GAGs) and
characterized by intralysosomal accumulation and increased
excretion in urine of partially degraded GAGs, which
ultimately results in cell, tissue, and organ dysfunction [1].
Glycosaminoglycans (previously called mucopolysaccha-
rides), with the exception of hyaluronic acid, are the degrada-
tion products of proteoglycans that exist in the extracellular
matrix and are proteolytic cleaved, giving origin to GAGs,
which enter the lysosome for intracellular digestion. There
are four diﬀerent pathways of lysosomal degradation of
GAGs, depending on the molecule to be degraded: dermatan
sulfate, heparan sulfate, keratan sulfate, and chondroitin
sulfate. The stepwise degradation of glycosaminoglycans
requires 10 diﬀerent enzymes: four glycosidases, five sulfa-
tases, and one nonhydrolytic transferase, whose structure,
biosynthesis, processing, and cDNA sequence have already
been extensively documented. Deficiencies of each one of
these enzymes have already been reported and result in
seven diﬀerent MPSs, all of them sharing a series of clinical
features, even though in variable degrees (summarized in
Table 1) [1, 2].
Usually, MPSs are characterized by a chronic and
progressive course, with diﬀerent velocities of progression
depending on the severity of each one. The typical symptoms
include organomegaly, dysostosis multiplex, and a charac-
teristic abnormal facies. Hearing, vision, and cardiovascular
function may also be aﬀected. Additionally, joint mobility
may also be compromised. The majority of symptoms may
be explained by abnormal accumulation of undegraded
substrates within the lysosomes. In fact, the continued
presentation of GAGs to cell for degradation results in
storage, which gives rise to an enlargement of lysosomes.
As substrates accumulate, the lysosomes swell and occupy
more and more of the cytoplasm. As a consequence of
this increased number and size of lysosomes, other cellular
organelles may be obscured, and the nuclear outline may
be deformed. As the process continues, the enlarged cells
lead to organomegally. Abnormalities observed in heart cells
and function may also be explained by GAGs accumulation.
The increase of storage material within the cells of the heart
valves causes an alteration of the cell’s outline, changing
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them from fusiform to round. As a consequence, the valve
leaflet and cordae tendinea become thickener and interfere
with normal cardiac function, producing valvular stenosis.
At corneal level, also, storage of undegraded GAGs results in
reflection and refraction of light, leading to the cloudiness
which is so typical of these pathologies. Also at the CNS
level, swollen neurons and lysosomes may produce lesions
that include the development of meganeurites and neurite
sprouting (reviewed in [3, 4]).
Traditionally, MPSs are recognized through analysis
of urinary GAGs. Several methods have been devised, to
precise qualitative identification and quantitative measure-
ments. These analyses of urinary GAGs allow discrimination
between broad classes of MPSs but cannot distinguish
subgroups. Definitive diagnosis is usually accessed through
enzymatic assays of the defective enzyme in cultured fibrob-
lasts, leukocytes, and serum or plasma (reviewed in [1]).
During the last decade; however, dried blood spot technology
was also introduced for enzymatic assays, allowing cheaper,
easier, feasible diagnosis and opening the possibility for large
population screenings (see Section 11 for more details).
In general, MPSs are transmitted in an autosomal
recessive fashion, except for MPS II, which is X-linked.
This paper provides an overview of the molecular basis,
enzymatic defects, clinical manifestations, and diagnosis
of each glycosaminoglycan storage disease, focusing also
on the respective animal models and describing potential
perspectives of therapy which are being tested as well as the
ones which are already available (summarized in Table 2).
2. Mucopolysaccharidosis I
Mucopolysaccharidosis I is caused by a deficiency of α-
L-iduronidase (IDUA; EC 3.2.1.76) and can result in a
wide range of phenotypic involvement with three major
recognized clinical entities: Hurler (MPS IH; MIM#607014),
Hurler-Scheie (MPS IH/S; MIM#607015), and Scheie (MPS
IS) syndromes. Hurler and Scheie syndromes represent
phenotypes at the severe and mild ends of the MPS I clinical
spectrum; respectively, and the Hurler-Scheie syndrome is
intermediate in phenotypic expression [20]. It is important
to stress that, although MPS I may be subdivided into these
three clinically diverse entities, the underlying enzymatic
defect is common to all of them, being all caused bymutation
in the gene encoding α-L-iduronidase (IDUA).
Functionally, α-L-iduronidase is essential to the correct
metabolism of both dermatan sulfate and of heparan sulfate,
hydrolyzing the terminal α-L-iduronic acid residues of the
above-referred glycosaminoglycans [1].
In 1992, Scott and colleagues [21] were able to clone and
purify the gene that encodes this enzyme, IDUA, demonstrat-
ing that it spans approximately 19 kb and contains 14 exons.
The first 2 exons are separated by an intron of 566 bp, a large
intron of approximately 13 kb follows, and the last 12 exons
are clustered within 4.5 kb. Previously, this gene was mapped
to 4p16.3, through unequivocal in situ hybridization and
southern blot analysis of mouse-human cell hybrids [22].
There are, presently, several animal models known for
MPS I.
In 1979, Haskins and colleagues [5] described α-L-
iduronidase deficiency in a cat, and, few years later, Shull et
al. [6] and Spellacy et al. [23] reported a similar deficiency
in the dog. Subsequent studies lead to cloning and charac-
terization of the canine IDUA gene as well as the mutation
causing the observed phenotype [24, 25] and proved it to
be a good model for study of human MPS I. So, in 1994,
Shull and collaborators [26] published the first results of
enzyme replacement therapy in the canine model. Through
intravenous administration of recombinant human α-L-
iduronidase, these authors managed to obtain a remarkable
resolution of lysosomal storage in both hepatocytes and
Kupﬀer’s cells. In the same year, Grosson et al. [27] mapped
the homologous IDUA locus in the mouse to chromosome 5.
That knowledge was later used to create a knock-out mouse
presenting the characteristic MPS I features [7, 28].
Currently, both hematopoietic stem cell transplantation
(HSCT) and enzyme replacement therapy (ERT) using
laronidase (recombinant human α-L-iduronidase, Aldu-
razyme) are available for MPS I. HSCT is the recommended
treatment for patients with severe MPS I, before 2 years
of age [29–32]. ERT is recommended for the other cases,
and it has been shown to be eﬀective in ameliorating
some of the clinical manifestations of MPS disease. Among
positive eﬀects are decreased hepatosplenomegaly, improved
respiratory and myocardial function and physical capacity
[33–35] as well as improvement in active movement followed
by enhanced self-care [36]. Recently, several reports have
been published trying to evaluate long-term eﬀect of ERT on
the natural history of treated patients. From those studies,
several conclusions have been reached. Concerning treated
patients’ growth pattern, it became clear that children with
MPS I grow considerably slower than healthy individu-
als, and diﬀerences between healthy and aﬀected children
increase with age [37]. Other relevant evidences show that
early treatment of attenuated MPS I may significantly delay
or prevent the onset of the major clinical signs, substantially
modifying the natural history of the disease [38]. Additional
investigation is needed to clarify the mechanisms by which
improvements are achieved in laronidase-treated patients.
Such knowledge may support the development of ERT
directly targeting the brain.
2.1. Hurler’s Syndrome (MPS IH). Hurler’s syndrome is the
most severe form of MPS I and has been, over the last
decades, the prototype description of MPS. Nevertheless,
this may be misleading, since not all MPSs share the same
features, and this pathology in particular is not representative
of all of them, but only of the most severe end of a
broad clinical spectrum (reviewed in [1]). Like all other
MPSs, the clinical course of this disease is progressive, with
multiple organ and tissue involvement. Hallmark clinical
features of Hurler syndrome include coarse facies, corneal
clouding, mental retardation, hernias, dysostosis multiplex,
and hepatosplenomegaly. Children with Hurler’s syndrome
appear normal at birth and develop the characteristic
appearance over the first years of life [39]. Length is often
normal until about 2 years of age when growth stops; by age
of 3 years, height is under the third percentile [40]. Cardiac
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Table 2: Available therapeutic approaches for mucopolysaccharidoses.
Pathology Subtype Available therapeutic approaches
MPS I
Hurler (H) HSCT (recommended before 2 years of age)
Hurler -Scheie (H/S) ERT with Aldurazyme (laronidase; recombinant human α-L-iduronidase)
Scheie (S) ERT with Aldurazyme (laronidase; recombinant human α-L-iduronidase)
MPS II Hunter ERT with Elaprase (idursulfase; recombinant human iduronate sulfatase)
MPS III
Sanfilippo A ∗Not available∗
Sanfilippo B ∗Not available∗
Sanfilippo C ∗Not available∗
Sanfilippo D ∗Not available∗
MPS IV
Morquio A ERT: ongoing clinical trial (with recombinant human GALNS)
Morquio B ∗Not available∗
MPS VI (Maroteaux-Lamy) ERT with Naglazyme (galsulfase; recombinant human arylsulfatase B)
MPS VII (Sly) ∗Not available∗
MPS IX ∗Not available∗
disease and respiratory complications are common. Acute
cardiomyopathy associated with endocardial fibroelastosis
has been a presenting condition in some infants with MPS
I less than 1 year of age [41]. Upper and lower respiratory
tract infections are also frequent [42]. Developmental delay
is often apparent by 12 to 24months of age, with a maximum
functional age of 2 to 4 years followed by progressive
deterioration. Most children develop limited language as a
consequence of developmental delay, chronic hearing loss,
and enlarged tongue [1]. Dermal melanocytosis may also be
found in Hurler patients [43], as well as in patients suﬀering
from other LSDs, such as GM1 gangliosidosis. Nevertheless,
Hurler’s syndrome is the most common lysosomal storage
disease associated with dermal melanocytosis, as revealed by
a literature analysis.
2.2. Hurler-Scheie’s Syndrome (MPS IH/S). MPS IH/S corre-
sponds to a clinical phenotype which is intermediate between
the Hurler and the Scheie syndromes. It is characterized by
progressive somatic involvement with dysostosis multiplex
but little or no mental retardation. First symptoms usually
occur between 3 and 8 years. Characteristic features of
Hurler’s syndrome, such as corneal clouding, joint stiﬀness,
deafness, and valvular heart disease, can also appear in MPS
IH/S patients. Nevertheless, the onset of these symptoms
occurs much later than that in the severe MPS I type, begin-
ning in the midteens and leading to significant impairment
and loss of function. Other clinical features, such as microg-
nathism, pachymeningitis cervicalis, and compression of the
cervical cord due to GAG accumulation in the dura, may also
occur. Cardiac and respiratory complications may explain
the high clinical mortality (reviewed in [1]).
2.3. Scheie’s Syndrome (MPS IS). Scheie’s syndrome was
earlier thought to be a separate entity designated MPS V,
instead of a phenotypical subtype of MPS I [44]. This
pathology is characterized by a mild phenotype in which
dysostosis multiplex can be present. Joint involvement is
marked in the hand with a claw-hand deformity. Patients
also have genu valgum, stiﬀ, painful feet, and pes cavus [1].
Cardiac and respiratory complications are much milder than
in the Hurler syndrome, with aortic and mitral valvular
disease being a common feature [45]. At a respiratory
level, Perks et al. [46] have reported two brothers with
Scheie’s syndrome suﬀering from sleep apnea, but no
other complications are known. Intelligence is normal [1].
Pachymeningitis cervicalis (compression of the cervical cord
secondary to glycosaminoglycan accumulation in the dura)
may also occur.
3. Mucopolysaccharidosis II
(Hunter’s Syndrome)
Mucopolysaccharidosis II is the sole MPS transmitted in an
X-linkedmanner and is caused by deficiency of the lysosomal
enzyme iduronate sulfatase, which is crucial to the correct
degradation of heparan and dermatan sulfate, by cleaving
their O-linked sulfate. As a result, there is a progressive
accumulation of glycosaminoglycans in nearly all cell types,
tissues, and organs. Patients with MPS II excrete excessive
amounts of dermatan sulfate and heparan sulfate in the urine
[20, 47]. Hunter syndrome is caused by mutation in the gene
encoding iduronate-2-sulfatase (IDS).
Although the disease is known since the early 1970s,
being the first MPS to be defined clinically in humans, it
was not until the 1990s that the IDS was cloned. In 1991,
Wilson et al. [48] localized the gene to Xq28. Two years later,
Flomen and coworkers [49] described the gene’s structure as
containing 9 exons and characterized the intron sequences
surrounding them. In the same year, Wilson et al. [50]
reported the complete sequence of the IDS gene, which spans
approximately 24 kb. The potential promoter for IDS lacks a
TATA box but contains GC box consensus sequences, which
are consistent with its role as a housekeeping gene.
Curiously, a second IDS gene (IDS2) was identified by
Bondeson et al. [51]. It is a pseudogene and is located within
90 kb telomeric region of the IDS gene and involved in a
recombination event with the primary IDS gene in about
13% of patients with the Hunter syndrome.
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Traditionally, the Hunter syndrome comprises 2 recog-
nized clinical entities, according to the severity of symptoms:
mild and severe. Although largely used, this nomenclature
does have its diﬃculties, since the mild and severe forms
represent the two ends of a wide and continuous spectrum of
clinical severity. Also, in terms of iduronate deficiency, these
forms cannot be distinguished since the enzyme’s activity is
equally deficient in both (reviewed in [1]). They are, though,
separated almost exclusively on clinical grounds, although
nowadays mutation analysis may help distinguish them.
This classification of MPS goes back to 1972, when
McKusick distinguished between the severe form (which he
called MPS IIA), with progressive mental retardation and
physical disability and death before age 15 years in most
cases, and the mild form (called MPS IIB) compatible with
survival to adulthood and in which intellect is impaired
minimally, if at all. He also pointed out the lack of corneal
clouding in the X-linked form of MPS as opposed to the
autosomal forms.
Presently, this classification has become obsolete since, in
2008,Wraith et al. [47] stated that MPS II should be regarded
as a continuum between the two extremes (severe and
attenuated). They noted that, although the clinical course for
the more severely aﬀected patients is relatively predictable,
there is considerable variability in the clinical phenotype and
progression of the more attenuated form of the disease and,
so, it would not be correct to consider the milder form as
a separate entity but, instead, look at Hunter’s disease as
a phenotypical continuum, with several possible degrees of
severity.
In 1998, Wilkerson et al. [8] described Hunter’s syn-
drome in a Labrador retriever, with the typical clinical
features observed in humans: coarse facies, macrodactyly,
corneal dystrophy, progressive CNS deterioration, and pos-
itive biochemical diagnosis for MPS through urine analysis.
After the successful results obtained in improving certain
disease manifestations in patients with MPS I, including
visceral manifestations and attenuation of neurologic disease
progression [29, 52], hematopoietic stem cells transplanta-
tion (HSCT) has also been performed in several patients
with MPS II. Unfortunately, although the transplantation of
hematopoietic stem cells provides some enzymatic recon-
struction in many target tissues with decreased excretion of
GAGs in urine, decreased liver and spleen volumes, dimin-
ished facial coarsening, and improved respiratory function
and joint mobility [53, 54], the results at neurological level
were disappointing (reviewed in [55]). The additional risk
of morbidity and mortality associated to this procedure
led investigators to focus their attention in ERT for this
pathology, with much better results, as discussed below.
A knock-out mouse model for MPS II was developed
by replacing exon 4 and a portion of exon 5 of IDS with
the neomycin-resistance gene [9, 56]. Aﬀected mice exhibit
a phenotype with notorious similarities to human disease,
both at the biochemical and the clinical levels [9]. Several
studies with this knock-out mouse model were done to
assess the eﬀect of ERT [56] as well as dose and various
dosing regimens of idursulfase in urine and tissue GAG levels
[57]. The results of these studies were quite promising, with
a marked decrease in urinary GAGs as well as decreased
GAG accumulation in several tissues [56] verified for several
idursulfase doses and several dosing frequencies [57]. These
studies have been used to support the first clinical trial
of recombinant IDS in Hunter’s syndrome patients. At the
moment, both phase I/II [58] and phase II/III [59] clinical
studies have proven not only the eﬃcacy but also the safety
of idursulfase replacement therapy. Consequently, ERT with
recombinant human iduronate sulfatase (Elaprase, idursul-
fase, Shire Human Genetic Therapies Inc.) was approved
in the US (July, 2006) and the European Union (January,
2007) for the treatment and the management of MPS II. The
recommended dose is 0.5mg/kg administered once weekly
as an intravenous infusion (reviewed in [55]). As time goes
by, additional evidence on the eﬃcacy of ERT for MPS
II patients is being published, as long-term treatments are
successful. This is the case of a recently published report on
the improvements observed in a 7 years and 10 months old
child who began a 36 months’ treatment with Elaprase at 4
years and 10 months. At the end of the treatment, the child
presented normal excretion of GAGs in urine, normal-sized
liver and spleen, and significant bone remodeling. Cardiac
and neurological development, however, still progressively
deteriorated [60]. This year, protective eﬀects of ERT in
MPS II patients were also reported for DNA damaging in
leukocytes [61] and oxidative stress [62].
4. Mucopolysaccharidosis III
(Sanfilippo’s Syndrome)
The Sanfilippo syndrome, or mucopolysaccharidosis III, is
caused by impaired degradation of heparan sulfate [1] and
includes 4 subtypes, each due to the deficiency of a diﬀerent
enzyme: heparan N-sulfatase (type A; MIM no. 252900),
α-N-acetylglucosaminidase (type B; MIM no. 252920),
acetyl CoA: α-glucosaminide acetyltransferase (type C; MIM
no. 252930), and N-acetylglucosamine-6-sulfatase (type D;
MIM#252940). At a clinical level, the four subtypes are quite
similar, with a characteristic severe central nervous system
degeneration associated with mild somatic disease. Onset of
clinical features usually occurs between 2 and 6 years, severe
neurologic degeneration occurs in most patients between 6
and 10 years of age, and death occurs typically during the
second or third decade of life. Type A has been reported to
be the most severe, with earlier onset and rapid progression
of symptoms and shorter survival [63].
4.1. Mucopolysaccharidosis IIIA (Sanfilippo A). General MPS
IIIA clinical features include severe mental retardation with
relatively mild somatic features (moderately severe claw hand
and visceromegaly, little or no corneal clouding, little or no
vertebral change). Usually, this pathology is characterized
by marked overactivity, destructive tendencies, and other
behavioral aberrations.
MPS IIIA phenotype is caused by mutations in the gene
encoding N-sulfoglucosamine sulfohydrolase, also named
heparan sulfate sulfatase (SGSH; 605270). This enzyme is
specific for sulfate groups linked to the amino group of
glucosamine.
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In 1995, the gene encoding N-sulfoglucosamine sul-
fohydrolase, SGSH, was isolated, sequenced, and cloned
[64]. Later, it was shown to contain 8 exons spanning
approximately 11 kb [65].
There are two animal models known for MPS IIIA.
The first to be discovered was the canine model when
Fischer et al. [10] identified sulfaminidase deficiency in
two adult wire-haired dachshund littermates. Subsequently,
Aronovich et al. [66] determined the normal sequence of the
canine heparan sulfate sulfatase gene and cDNA, through
PCR-based approaches. Another model was described in
2001, when Bhattacharyya and collaborators [11] found a
spontaneous mouse mutant of MPS IIIA resulting from a
missense mutation (D31N) in the murine sulfatase gene.
Aﬀected mice die at about 10 months of age, exhibiting
notorious visceromegaly, distended lysosomes and heparan
sulfate accumulation in urine. Hemsley and Hopwood
[67] found that these mice had severe brain involvement,
with impaired open field locomotor activity and behavioral
changes, suggesting axonal degeneration. Later, Settembre et
al. [68] observed increased autophagosomes resulting from
autophagosome-lysosome function in these mice. Similar
findings were observed in another mouse model of another
lysosomal storage disorder (multiple sulfatase deficiency;
MSD; MIM no. 272200), reinforcing the recent idea that
these diseases are disorders of autophagy, which may be
a common mechanism for neurodegenerative lysosomal
storage disorders.
MPS IIIA mice were recently tested for substrate depri-
vation therapy with both genistein and rhodamine B, two
chemicals that inhibit GAG synthesis ([4, 69], reviewed
in [70]). Encouraging results were obtained with both
compounds, and this therapeutic approach started to be
considered for severalMPSs (see Section 11 formore details).
Other interesting results were also obtained when siRNAs
were used to reduce GAG synthesis in MPS IIIA mice. Last
year, this approach was tested by Dziedzic et al. [71], who
managed to reduce mRNA levels of four genes, XYLT1,
XYLT2, GALTI, and GALTII, whose products are involved in
GAG synthesis. This decrease of levels of transcripts corre-
sponded to a decrease in levels of proteins encoded by them.
Moreover, eﬃciency of GAG production in these fibroblasts
was considerably reduced after treatment of the cells with
siRNA. Either way, substrate deprivation therapy seems to be
a promising approach for Sanfilippo’s syndrome type A.
Gene therapy approaches are also being tested in MPS
IIIA mice. Recently, promising results have been reported by
Fraldi et al. [72], who performed experiments with intrac-
erebral adeno-associated-virus- (AAV-) mediated delivery of
SGSH gene, together with SMUF1 gene, which exhibits an
enhancing eﬀect on sulfatase activity when coexpressed with
sulfatases. They observed a visible reduction in lysosomal
storage and inflammatory markers in transduced brain
regions, together with an improvement in both motor and
cognitive functions.
4.2. Mucopolysaccharidosis IIIB (Sanfilippo B). With a phe-
notype quite similar to MPS IIIA, the Sanfilippo syn-
drome B is characterized by deficiencies of α-N-acetyl-
glucosaminidase, caused by mutations in the NAGLU gene
that encodes this enzyme. α-N-Acetylglucosaminidase is
required for the removal of the N-acetylglucosamine residues
that exist in heparan sulfate or are generated during lysoso-
mal degradation of this polymer by the action of heparan
acetyl-CoA: α-glucosaminide N-acetyltransferase (reviewed
in [1]).
The NAGLU gene was cloned in 1995 by Zhao and
colleagues [73]. The deduced 743-amino acid protein has a
20- to 23-residue leader sequence, consistent with a signal
peptide, and 6 potential N-glycosylation sites. It contains 6
exons and spans 8.3 kb on chromosome 17q21 [74].
Similarly to the above-referred MPS III syndrome, there
is also a natural occurring mutant for Sanfilippo B. It
was described by Ellinwood and coworkers, in 2003, in
Schipperke’s dogs [12].
During the last decade, Li et al. [75] created a laboratorial
murine MPS IIIB was also constructed trough targeted
disruption of the NAGLU gene [76]. With a phenotype
quite similar to that of patients with MPS IIIB, this model
began immediately to be used for therapeutic approaches
as well as for pathogenesis studies. The first studies were
done to evaluate the potential of ERT for this pathology
[76]. The results, however, were quite disappointing since the
recombinant NAGLU produced in Chinese hamster ovary
(CHO) cells was not eﬃciently captured by MPS IIIB cells,
either in vitro [77, 78] or in vivo [76]. This diﬃculty has
turned the search for a treatment for MPS IIIB even more
challenging. Presently, several therapies are under evaluation
for this disease, including cell-mediated therapy, enzyme
enhancement therapy, substrate deprivation therapy, and
viral gene therapy (reviewed in [79]).
Promising results are being achieved through gene
therapy approaches inMPS IIIBmice, namely, through direct
microinjection into the brain of adeno-associated virus
(AAV) vectors coding for NAGLU [80–82] and intravenous
injections and intracranial gene delivery of lentiviral (LV)
vector of NAGLU [83–85].
4.3. Mucopolysaccharidosis IIIC (Sanfilippo C). Sanfilippo
syndrome C is, in general, characterized by the same clinical
features described to MPS IIIA. Nevertheless, the enzyme
deficiency in this pathology is diﬀerent from the one causing
the latter. Type C disease is caused by mutations in the
gene encoding heparan acetyl-CoA: α-glucosaminide N-
acetyltransferase (HGSNAT; 610453). This is the only known
lysosomal enzyme that is not a hydrolase. It catalyzes
the acetylation of the glucosamine amino groups that
have become exposed by the action of heparan-N-sulfatase
(reviewed in [1]).
TheHGSNAT gene was cloned in parallel by two diﬀerent
groups, during the last decade: Fan et al. [86] and Hrˇebı´cˇek
et al. [87]. The molecular defects underlying MPS IIIC
remained unknown for almost three decades due to the low
tissue content and the instability of HGSNAT [88].
To date, 54 HGSNAT sequence variants have been
identified including 13 splice-site mutations, 11 insertions
and deletions with consequent frameshifts and premature
termination of translation, 8 nonsense, and 18 missense
(reviewed in [89]).
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Recently, two independent studies from Feldhammer et
al. [88] and Fedele and Hopwood [90] have performed
exhaustive functional analysis of the majority of the missense
mutations already reported for the HGSNAT gene. Attention
was focused in this particular type of mutations since
there are several MPS IIIC patients carrying only missense
mutations, either homozygous or heterozygous, who present
an unexpected severe phenotype. In fact, although splicing
and frameshift mutations are usually associated to that type
of phenotype, since they give rise to premature termina-
tion codons and trigger nonsense-mediated mRNA decay
(NMD); missense mutations are traditionally associated to
milder disease. Nevertheless, this typical/general pattern is
not observed forMPS IIIC. That is why these alterations were
specifically cloned, expressed, and analyzed for their folding,
targeting, and enzymatic activities. As a result, Fedele and
Hopwood [90] have observed that the expression levels and
enzymatic activity of most mutants were extremely low or
even negligible. Feldhammer and colleagues [88], on the
other hand, have observed that those mutations cause a
misfolding of the enzyme, which is not correctly glycosylated.
As a consequence, HGSNAT is not targeted to the lysosome
but, instead, stays in the endoplasmic reticulum (ER). Thus,
enzyme folding defects due to missense mutations, together
with NMD seem to be the major molecular mechanisms
underlyingMPS IIIC. This makesMPS IIIC a good candidate
for enzyme enhancement therapy, where active site-specific
inhibitors are used as pharmacological chaperones to modify
the conformation of the mutant lysosomal enzymes usually
retained and degraded in the ER, in order to increase the
level of the residual activity to a point which is suﬃcient to
reverse the clinical phenotypes [88]. Together with inhibitors
of heparan sulphate synthesis, pharmacological chaperones
are currently being tested to reduce storage of this polymer
in the CNS to levels suﬃcient to stop neuronal death and
reverse inflammation.
4.4. Mucopolysaccharidosis IIID (Sanfilippo D). Like the
previousMPS III subtypes, Sanfilippo’s syndrome D presents
a phenotype similar to MPS IIIA, with a singular enzyme
deficiency underlying it: mutation in the gene encoding N-
acetylglucosamine-6-sulfatase (GNS; 607664). The enzyme
was originally described as specific for the 6-sulphated N-
acetylglucosamine residues of heparan sulphate. However,
the early data have been reinterpreted, and given that this
sulfatase is in fact able to desulphate the 6-sulphated N-
acetylglucosamine present in α- or in β-linkage or even as
a free monosaccharide (reviewed in [1]).
N-Acetylglucosamine-6-sulfatase (EC 3.1.6.14) was puri-
fied and characterized by Freeman et al. [91], who identified
4 diﬀerent forms of the enzyme in liver. Its catalytic proper-
ties were studied by Freeman andHopwood [92]. Afterwards,
Robertson et al. [93] assigned the glucosamine-6-sulfatase
gene, which they symbolized G6S, to chromosome 12q14 by
in situ hybridization of a tritium-labeled G6S cDNA probe.
The localization was confirmed by using the cDNA clone in
analyses of DNA from human/mouse hybrid cell lines. More
recently, that information was completed by the work ofMok
et al. [94], who amplified and sequenced the promoter and
14 exons of the GNS gene from a patient with MPS IIID.
By analyzing that patient, it was also possible to identify
a homozygous nonsense mutation in exon 9, predicted to
result in premature termination at codon 355, as well as
two common synonymous coding SNPs. At the same time,
another group identified a 1-bp deletion in the GNS gene in
another aﬀected individual [95].
A naturally occurring large animal model was described
by Thompson et al. [13], who reported type D Sanfilippo’s
syndrome in a Nubian goat. Later, caprine MPS IIID was
used to evaluate the eﬃcacy of ERT in this pathology.
Recombinant caprine N-acetylglucosamine-6-sulfatase was
administered intravenously to one MPS IIID goat at 2, 3,
and 4 weeks of age. As a result, a marked reduction of
lysosomal storage vacuoles was observed in hepatic cells, but
no amelioration was noticed concerning the CNS lesions.
No residual enzyme activity was observed either in brain
or liver. Taking this preliminary results into account, it was
considered that other treatment regimens will be necessary
for MPS IIID [96].
5. Mucopolysaccharidosis IV
Mucopolysaccharidosis IV, or Morquio’s syndrome, is caused
by impaired degradation of keratan sulphate. Presently,
there are two known enzyme deficiencies causing 2 dif-
ferent subtypes of Morquio’s syndrome: deficiency in N-
acetylglucosamine-6-sulfatase (causing Morquio’s disease
type A; MIM no. 253000) and deficiency in β-galactosidase
(causing Morquio’s disease type B; MIM no. 253010). Both
MPS IV subtypes present a wide spectrum of clinical
manifestations, but there are some characteristic com-
mon features: short trunk dwarfism, fine corneal deposits,
spondyloepiphyseal dysplasia. Actually, the predominant
clinical features of Morquio’s syndrome are the ones related
to the skeleton. Most of the times, this severe somatic disease
is accompanied by a normal intelligence [1]. Patients with the
severe phenotype do not normally survive past the second or
third decade of life [97].
5.1. Morquio’s Syndrome Type A. Morquio’s syndrome A is
caused by mutations in the gene encoding galactosamine-6-
sulphate sulfatase (GALNS), which plays a crucial role on
the degradation of both keratan sulphate and chondroitin
sulphate.
The gene coding for human galactosamine-6-sulphate
sulfatase (GALNS), was mapped to chromosome 16q24.3
trough fluorescence in situ hybridization assays [98]. Its
structure was described at the same time by independent
groups as comprising 14 exons and spanning approximately
40–50 kb [99, 100]. Curiously, the GALNS gene contains an
Alu repeat in intron 5 and a VNTR-like sequence in intron 6
[100].
No natural occurring model is known for either type A
or type B Morquio’s syndrome. Nevertheless, a laboratorial
murine model for type A syndrome was created from
an induced disruption in exon 2 of the GALNS gene.
Mutants presented no detectable enzyme activity and showed
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increased GAG levels in urine. GAGs accumulation was also
detected in several tissues including liver, kidney, spleen,
heart, brain, and bone marrow [14]. These mice were
later tested for enzyme replacement therapy and, after a
12-week long treatment with native GALNS or SUMF1-
modified GALNS, showed manifest clinical improvement,
demonstrated by a marked reduction of storage material in
visceral organs, bone marrow, heart valves, ligaments, and
connective tissue. The clearance of stored material in brain
was dose dependent, and the keratan sulphate blood levels
were reduced to normal [101].
Presently, there is no eﬀective therapy for MPS IVA
and care has been palliative, as in the majority of LSDs.
Enzyme replacement therapy (ERT) and hematopoietic stem
cells therapy (HSCT) have been considered as potential
therapeutic approaches for MPS IVA (reviewed in [102]),
ERT being, though, the most attractive candidate, since
aﬀected patients lack CNS involvement.
Recently, Rodrı´guez et al. [103] have produced a recom-
binant GALNS enzyme in Escherichia coli BL21. To produce
suﬃcient amounts of purified GALNS enzyme, high level
expression of GALNS in Chinese hamster ovary (CHO) cells
has been established as a source of selectively secreted human
recombinant enzyme. This recombinant enzyme has already
been tested in themurine knock-out model, with consequent
clearance of tissue and blood keratan sulphate [101]. These
results provided important preclinical data for the design of
GALNS ERT trials, which are now in course.
5.2. Morquio’s Syndrome Type B. Although presenting over-
lapping clinical features, Morquio’s syndrome B is genetically
distinct from Morquio’s syndrome A, being caused by
impairments in another enzyme involved in the stepwise
degradation of keratan sulphate: β-galactosidase, which is
coded by the GLB1 gene. Beta galactosidase hydrolases ter-
minal β-linked galactose residues found in GM1 ganglioside,
glycoproteins, and oligosaccharides, as well as in keratan
sulphate (reviewed in [1]).
The GLB1 gene spans 62.5 kb and contains 16 exons
[104, 105] and maps to chromosome 3p21.33 [106]. The
deduced 677-residue protein has a calculated molecular mass
of 75 kD and contains a putative 23-residue signal sequence
and 7 potential asparagine-linked glycosylation sites. It may
be interesting to refer that the GLB1 gene gives rise to 2
alternatively spliced mRNAs: a major 2.5-kb transcript that
encodes the classic lysosomal form of the enzyme of 677
amino acids, and a minor 2.0-kb transcript that encodes a β-
galactosidase-related protein (elastin-binding protein, EBP)
of 546 amino acids with no enzymatic activity and a diﬀerent
subcellular localization. Exons 3, 4, and 6 are absent in the
2.0-kb mRNA as a consequence of alternative splicing of the
pre-mRNA [107–109].
Presently, there are no known animal models for MPS
IVB, either natural or engineered.
6. Mucopolysaccharidosis V
The designation MPS V is no longer used. In fact, the
phenotype which was first classified as MPS V, was later
found to be the milder form of MPS I (Scheie’s syndrome),
caused by deficiencies in α-L-iduronidase, with the typical
stiﬀ joints, clouding of the cornea most dense peripherally,
survival to a late age with little if any impairment of intellect
and aortic regurgitation [44].
7. Mucopolysaccharidosis VI
(Maroteaux-Lamy Syndrome)
Mucopolysaccharidosis type VI is an autosomal recessive
lysosomal storage disorder resulting from a deficiency of
arylsulfatase B (N-acetylgalactosamine-4-sulfatase). Clini-
cal features and severity are variable but usually include
short stature, hepatosplenomegaly, dysostosis multiplex, stiﬀ
joints, corneal clouding, cardiac abnormalities, and facial
dysmorphism. Intelligence is usually normal [110].
Arylsulfatase B is a lysosomal enzyme that removes the
C4 sulphate ester group from the N-acetylgalactosamine
sugar residue at the nonreducing terminus of dermatan
sulphate and chondroitin sulphate, during lysosomal degra-
dation [111]. The gene that codes for this enzyme was first
mapped to chromosome 5q11-q13 [112] and is now known
to contain 8 exons and span about 206 kb [111].
In 2002, a 3-year-old Siamese/short-haired European cat
was referred for clinical disease characterized by dwarfism,
facial dysmorphia, paralysis, small and curled ears, corneal
clouding, and large areas of alopecia. X-ray examination
showed multiple bone dysplasias. These features lead to
suspect from a mucopolysaccharide storage disorder. Subse-
quent analysis proved it to be a natural occurring form of the
Maroteaux-Lamy syndrome [15].
This MPS VI model has been extensively used over
the last years to test ERT for this specific pathology.
In 2003, Auclair and colleagues [113] have evaluated the
cats’ response to infusions of recombinant human N-
acetylgalactosamine-4-sulfatase (rhASB) and observed an
overall improvement in the disease condition at physical,
neurological, and skeletal levels. Later, the same team has
demonstrated that a high rate of immunotolerance towards
rhASB can be achieved in MPS VI cats with a short-course
tolerisation regimen [114], which may help the implementa-
tion of such procedures. Another interesting approach was
designed, specifically to ameliorate joint disease in MPS
IVA, through long-term articular administration of rhASB,
leading to a notorious improvement in feline joint disease
[115]. These successful results lead to the development
of clinical trials in MPS VI patients, and three clinical
studies including 56 patients have evaluated the eﬃcacy and
safety. As a consequence, enzyme replacement therapy (ERT)
became available. The specific ERT for MPS VI, galsulfase
(Naglazyme, Biomarin Pharmaceutical) was approved in
2005 by FDA and in 2006 by EMA. Long-term follow-up data
with patients treated up to 5 years showed that ERT is well
tolerated and associated with sustained improvements in the
patients’ clinical condition [2, 116].
Even though presently there is ERT available for these
patients, other therapeutic approaches are being tested in
animal models for MPS VI. In 2009, the first attempt of
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successful gene therapy was performed through lentiviral-
mediated gene transfer to joint tissues of the rat, with
consequent correction of MPS VI cells [117]. This year,
another study, involving intravascular administration of
adeno-associated viral vectors inMPS VI cats, was published.
After gene transfer the authors observed clearance of GAG
storage, improvement of long bone length, reduction of heart
valve thickness, and improvement in spontaneous mobility
[118]. Either way, promising therapeutic strategies for MPS
VI patients may be arising.
8. Mucopolysaccharidosis VII
(Sly’s Syndrome)
MPS VII, also known as Sly’s syndrome, is characterized
by the impossibility to degrade glucuronic acid-containing
GAGs, due to impaired function of β-glucuronidase, which
removes the glucuronic acid residues present in dermatan
sulphate as well as in heparan and chonroitin sulphates
(reviewed in [1]). Clinical features are highly variable, with
phenotypes ranging from severe fetal hydrops to mild forms
allowing survival into adulthood. Typical features include
hepatomegaly, skeletal abnormalities, coarse facial features,
and variable degrees of mental impairment [119].
MPS VII was first reported by Sly and collabora-
tors in 1973, in a boy with skeletal changes consistent
with MPS, hepatosplenomegaly, and granular inclusions in
granulocytes. Additional features included hernias, unusual
facies, protruding sternum, thoracolumbar gibbus, vertebral
deformities, and mental deficiency. When β-glucuronidase
activity was measured in fibroblasts, obtained values were
less than 2% of control values. Both parents and several sibs
of the mother showed an intermediate level of the enzyme
[120].
In 1990, Miller et al. [121] reported that the gene
encoding β-glucuronidase (GUSB) is 21 kb long, contains 12
exons, and gives rise to two diﬀerent types of cDNAs, through
an alternate splicing mechanism. Speleman et al. [122] used
fluorescence in situ hybridization to map the GUSB gene to
7q11.21-q11.22. This map position was confirmed by dual-
color hybridization of β-glucuronidase and another gene
which had been mapped proximal to it: elastin (7q11.23).
Several pseudogenes, located on chromosomes 5, 6, 7, 20,
22, and Y, were also detected by Shipley et al. [123], when
amplifying exons 2–4, 3, 6-7, and 11.
In 2009, Tomatsu et al. [124] provided a review of
mutations in the GUSB gene that cause MPS type VII. Forty-
nine diﬀerent pathogenic mutations have been reported
in the literature, with approximately 90% of them being
missense mutations. Approximately 40% of the known
GUSB mutations occur at CpG sites within the gene. The
most common mutation is L176F, which has been found
in several populations: American (Caucasian), Brazilian,
British, Chilean, French, Mexican, Polish, Spanish, and Turk-
ish ([125–127], reviewed in [124]). Genotype/phenotype
analysis indicated that the most severe phenotype was
associated with truncating mutations and with mutations
aﬀecting either the hydrophobic core or the modification of
packing.
In 1984, mucopolysaccharidosis type VII (Sly syndrome)
was described in a mixed-breed dog [16]. Since then,
several other aﬀected dogs have been studied, in the animal
colony established at the University of Pennsylvania, the
School of Veterinary Medicine [128] and, later, in a 12-
week-old male German Shepherd dog studied in the same
school [129]. All dogs shared the same missense mutation
and developed similar phenotypes with skeletal deformities,
corneal cloudiness, cytoplasmic granules in the neutrophils
and lymphocytes of blood and CSF, and glycosaminoglycans
in urine [129]. Another animal model was described as
naturally occurring: the gusmps/mps mouse, which has a 1 bp
deletion in exon 10 resulting in a progressive degenerative
disease that reduces lifespan and causes facial dysmorphism,
growth retardation, deafness, and behavioral defects [17].
Nevertheless, opportunities for experimental therapies were
greatly expanded by the work of Tomatsu et al., in 2006
[18], who developed a new MPS VII mouse model, which
is tolerant to both human and murine GUS, without the
characteristic immune responses that complicated evalua-
tion of the long-term benefits of enzyme replacement or gene
therapy when the naturally occurring mice were used. Ever
since, several therapeutic approaches have been attempted in
MPS VII mice, and the results have been encouraging. That
is the case of the works by Bosch and collaborators, who have
been working on gene therapy for this pathology, in order to
correct brain lesions. They have used both adeno-associated
virus (AAV) [130] and lentivirus-mediated gene transfer
[131] and observed that there was a significant correction of
pathology in the brain of aﬀected mice.
Other therapeutic approaches had already been attempt-
ed, but their results were not as promising. In fact, in 1998,
allogenic bone marrow transplantation was reported in a
12-year-old Japanese girl with consequent improvement of
motor function and daily life activities, decrease of upper
respiratory and ear infections, but no improvement at all in
cognitive function [132].
9. Mucopolysaccharidosis VIII
The clinical entity once known as MPS VIII was described
in a single patient, in the late 1970s. The patient, a 5-year-
old child, presented short stature, coarse hair, hepatomegaly,
mild dysostosis multiplex, mental retardation, and no signs
of corneal clouding. Biochemical analysis of the urine
revealed increased excretion of keratan and heparan sulphate
[133, 134]. The biochemical findings described by this group
lead to suspect the existence of two hexosamine sulfatases
and propose the existence of this novel MPS, caused by
glucosamine-6-sulfatase [133].
Nevertheless, subsequent analysis on Diferrante’s labora-
tory brought this idea down, and the designation MPS VIII
was abandoned [135].
10. Mucopolysaccharidosis IX
Mucopolysaccharidosis IX, also known as hyaluronidase
deficiency, is caused by mutations in the HYAL1 gene.
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This disease was first discovered by Natowicz et al.
[136] in a 14-year-old girl with short stature and multi-
ple periarticular soft-tissue masses. Radiographic analysis
showed nodular synovia, acetabular erosions, and a popliteal
cyst. Lysosomal storage of hyaluronan (HA) was evident
within the macrophages and fibroblasts of biopsied soft-
tissue masses, and serum concentrations were elevated
38–90-fold. She was proven to have a storage disease of
hyaluronan (hyaluronic acid) due to a genetic deficiency of
hyaluronidase. The descriptions of hyaluronidase deficiency
in this family are consistent with autosomal recessive inheri-
tance.
In order to determine the molecular basis of MPS IX,
Triggs-Raine et al. [137] analyzed 2 diﬀerent candidate
genes tandemly distributed on chromosome 3p21.3, both
encoding proteins with homology to a sperm enzyme with
hyaluronidase activity. These genes, HYAL1 and HYAL2,
encode 2 distinct lysosomal hyaluronidases with diﬀerent
substrate specificities. When characterizing the patient with
hyaluronidase deficiency originally reported in [136], they
verified that he was a compound heterozygote for 2 muta-
tions in the HYAL1 gene: a missense mutation (c.1412G>A),
which introduced a nonconservative amino acid substitution
in a putative active site residue (p.Glu268Lys) and a complex
intragenic rearrangement, 1361del37ins14, which resulted in
a premature termination codon. Through this work, they
have also showed that these 2 hyaluronidase genes, together
with a third adjacent HYAL3 gene, had markedly diﬀerent
tissue expression patterns, consistent with diﬀering roles in
the metabolism of hyaluronan. These findings allowed this
team not only to explain the unexpectedly mild phenotype
of MPS IX but also to predict the existence of other
hyaluronidase-deficiency disorders.
Presently, three other hyaluronidase-related genes
(HYAL4, HYALP1, SPAM1) have been identified at 7q31.3
[138]. These genes are predicted to encode hyaluronidases,
endoglycosidases that initiate the degradation of HA, a large
negatively charged GAG found in the extracellular matrix
(ECM) of all vertebrate cells [19].
Since there is only one patient reported to date, the
development and characterization of a model of Hyal1
deficiency was the first logical step in understanding themain
phenotypic symptoms associated with MPS IX. During this
decade, a mouse model for MPS IX has become available and
was fully characterized [19]. Overall, it was observed that
the murine MPS IX model displays the key features of the
human disease. Nevertheless, during the same year, another
mutant mouse suﬀering from a hyaluronidase deficiency
was described, this one deficient in HYAL2 [139]. Skeletal
and hematological anomalies were described in this model,
raising the possibility that a similar defect, defining a new
MPS disorder, exists in humans [139].
11. Conclusion
The elucidation of enzyme deficiencies underlying mucopol-
ysaccharidoses was crucial to unveil the normal pathways
of glycosaminoglycan catabolism. In fact, only through the
consequences of their absence became the role of several
enzymes evident. The majority of these enzyme deficiencies
were discovered during the 1970s. Over the last decades
the enzyme deficiencies underlying each disease, and the
molecular defects causing them have been identified and
extensively analyzed and characterized. As a result, six
diﬀerent MPS are known, caused by deficiencies in one
of the ten diﬀerent enzymes necessary to intralysosomal
degradation of GAGs through one of the four diﬀerent
degradation pathways.
Each disease has its own hallmark features. Neverthe-
less, a common pattern arouses: MPS are usually chronic,
with a progressive course and diﬀerent severity degrees.
Organomegaly, dysostosis multiplex, and CNS involvement
are common but not necessary features.
Over the years, several MPS have been recognized in ani-
mals as naturally occurring diseases, and others were created
by knock-out technology. Most animal colonies have been
established from single related heterozygous animals, in such
a way that the aﬀected oﬀspring is homozygous for the same
mutant allele. All these models present disease pathology
similar to that seen in humans, making the animals extremely
valuable for both investigation of disease pathogenesis and
testing of therapies. Large animal homologues are similar to
humans in natural genetic diversity, approaches to therapy
and care, and possibility of evaluating long-term eﬀects of
treatment. Presently, therapeutic strategies for MPS include
enzyme replacement therapy, heterologous bone marrow
transplantation, and somatic cell gene transfer, all of which
have been tested in animals with some success. During the
80s, transplantation of hematopoietic stem cells was tested
for several MPSs. Theoretically, haematopoietic stem cells
taken from a normal compatible donor and transplanted
into an enzyme-deficient recipient can provide a safe,
permanent, and self-replicating source of bone marrow-
derived cells. By secreting active lysosomal enzymes, these
cells cross-connect nonbone marrow-derived cells. Several
animal models for GAGs storage diseases have already
been subjected to/undergone BMT. From those experiments,
along with human clinical trials already tried, it was possible
to verify that there are important variations in therapeutic
response among diﬀerent pathologies with some diseases
with CNS pathology which can be successfully treated by
BMT (the severe form of MPS I, being the example for
the GAG storage disorders; [140]) whereas others cannot
(MPS II and III in which BMT was tested with few success;
[3, 141]). These variations are usually attributed to the
diﬀerent capacities of secretion, stability, and uptake of
each specific enzyme. Nevertheless, important conclusions
could be drawn from the collective experience of postnatal
transplantation including the idea that the earlier the
transplants are performed, the better the clinical response. In
the 90s; however, a novel approach started to be tested: ERT.
Nowadays, it has been the most tested approach in animal
models of GAG storage disorders. Until now, the obtained
results have been highlighting the potential of administered
recombinant enzyme to reduce GAG accumulation. ERTs are
presently available for MPS I (since 2003), II (since 2005),
and VI (since 2006). Clinical trials are also in course for MPS
IVA treatment through ERT. Nevertheless, this approach is
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ineﬀective for the brain since recombinant enzymes are not
able to cross the blood-brain barrier (BBB). This is one of the
reasons why other therapies are being tested for MPS with
CNS involvement. ERT with direct administration of the
recombinant enzyme into the brain (intrathecal injections)
is also being considered in order to overcome that diﬃculty.
Presently, such approaches are being considered forMPS IIIA
and to overcome the cognitive deficit of MPS II and MPS I
(reviewed in [142]).
Somatic cell gene transfer is another possible approach,
but a long way needs yet to be travelled towards such a
therapy is applicable to patients.
Finally, substrate deprivation therapy (or substrate
reduction therapy) is also being considered for some MPSs.
This approach is being tested with both genistein and
rhodamine B (reviewed in [70]). Genistein, a chemical from
the group of isoflavones, has been shown to inhibit the
synthesis of GAGs in fibroblasts of patients with various
forms of MPSs, namely, types I, II, IIIA, and IIIB [4, 143].
Similar results were obtained with rhodamine B, an inhibitor
with an unknownmechanism of action. Remarkably, in MPS
IIIA mice treated with rhodamine B, GAG storage decreased
not only in somatic tissues, but also in brain, with improved
behaviours of the animals [144, 145]. These encouraging
results lead to the development of open-label pilot clinical
studies with children suﬀering from Sanfilippo’s syndrome
types A and B in which a genistein-rich isoflavone extract
(SE-2000, Biofarm, Poland) orally administered for 12
months. After one year of treatment, statistically significant
improvement in all tested parameters was demonstrated
(reviewed in [70]).
In order to better quantify and assess the eﬃcacy of
these therapeutic approaches, investigators have been trying
to indentify suitable biomarkers for MPS, which allow the
evaluation of short- and long-term treatment eﬀects. This is
also assuming particular importance since early detection of
MPS is an important factor in treatment success. Recently
discovered biomarkers include heparin cofactor II-thrombin
complex and dermatan sulphate:chondroitin sulphate ratio
[146]. Other biomarkers and/or therapeutic targets for MPS
joint and bone disease recently identified through animal
studies include several proinflammatory cytokines, nitric
oxide, and matrix metalloproteinases (MMPs; [147]).
Another hot topic which is recently being discussed refers
to the possibility of including someMPSs (particularly type I,
IIIA, IIIB, and VI) in neonatal screening programs [148]. The
ongoing development of enzyme replacement therapy and
other treatments for several LSDs, includingMPSs combined
with the growing evidence that early commencement of
therapy improves outcomes, has increased the pressure for
the introduction of newborn screening programs, and a
number of pilot studies are ongoing [148–152]. This is only
possible thanks to the significant advances that were made in
last decade since dried blood spot technology was introduced
for enzymatic assays and lysosomal protein profile was
developed.
Overall, there are encouraging results, with some ther-
apeutic approaches already approved and others under
development. Either way, it is important to stress that the
management of MPS requires lifelong attention to the mul-
tisystemic involvement by a team of specialists experienced
in dealing with these diseases, since none of the therapeutic
options currently available result in complete resolution of
morbidity.
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Lysosomal hydrolases are synthesized in the rough endoplasmic reticulum and speciﬁcally transported
through the Golgi apparatus to the trans-Golgi network, from which transport vesicles bud to deliver them
to the endosomal/lysosomal compartment.
The explanation of how are the lysosomal enzymes accurately recognized and selected overmany other proteins
in the trans-Golgi network relies on being taggedwith a uniquemarker: themannose-6-phosphate (M6P) group,
which is added exclusively to theN-linkedoligosaccharides of lysosomal soluble hydrolases, as theypass through
the cis-Golgi network. Generation of the M6P recognition marker depends on a reaction involving two different
enzymes: UDP-N-acetylglucosamine 1-phosphotransferase andα-N-acetylglucosamine-1-phosphodiesterα-N-
acetylglucosaminidase.
The M6P groups are then recognized by two independent transmembrane M6P receptors, present in the trans-
Golgi network: the cation-independent M6P receptor and/or the cation-dependent M6P receptor. These pro-
teins bind to lysosomal hydrolases on the lumenal side of the membrane and to adaptins in assembling clathrin
coats on the cytosolic side. In this way, the M6P receptors help package the hydrolases into vesicles that bud
from the trans-Golgi network to deliver their contents to endosomes that ultimately will develop into mature
lysosomes, where recently-delivered hydrolases may start digesting the endocyted material.
The above described process is known as the M6P-dependent pathway and is responsible for transporting most
lysosomal enzymes.
This review synthesizes the current knowledge on each of the major proteins involved in the M6P-dependent
pathway. Impairments in this pathway will also be addressed, highlighting the lysosomal storage disorders as-
sociated to GlcNAc-1-phosphotransferase loss of function: mucolipidosis type II and III.
© 2011 Elsevier Inc. All rights reserved.
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 543
2. The mannose-6-phosphate pathway: From amoebas to humans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 544
3. Functional components of the mannose-6-phosphate pathway. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 544
3.1. GlcNAc-1-phosphotransferase. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 544
3.2. The uncovering enzyme: N-acetylglucosamine-1-phosphodiester α-N-acetyl-glucosaminidase . . . . . . . . . . . . . . . . . . . . 545
3.3. Mannose-6-phosphate receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 545
4. Impairments in the mannose-6-phosphate pathway and disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 546
4.1. Defective GlcNAc-1-phosphotransferase causing mucolipidosis II and III . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 546
4.2. Mutations in the lysosomal enzyme-targeting pathway causing stuttering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 547
4.3. Secondary impaired uptake of lysosomal enzymes: A ‘symptom’ instead of a ‘cause’ . . . . . . . . . . . . . . . . . . . . . . . . . 547
4.4. Inﬂuence of expression levels of M6P pathway functional components on the efﬁcacy of some therapeutic approaches . . . . . . . . . 547
Molecular Genetics and Metabolism 105 (2012) 542–550
Abbreviations:M6P, Mannose-6-phosphate; (LSD), Lysosomal storage disorders; (UCE), N-acetylglucosamine-1-phosphodiester α-N-acetylglucosaminidase; (MPRs), Mannose-
6-phosphate receptors; (CI-MPR), Cation-independent mannose-6-phosphate receptor; (CD-MPR), Cation-dependent mannose-6-phosphate receptor; (ERT), Enzyme replacement
therapies; (ML II), Mucolipidosis II; (ML III), Mucolipidosis III.
⁎ Corresponding author at: Medical Genetics Center Jacinto Magalhães, INSA, Praça Pedro Nunes, 88, 4099-028 Porto, Portugal. Fax: +351 226070399.
E-mail addresses: francisca_coutinho@yahoo.com, francisca.coutinho@insa.min-saude.pt (M.F. Coutinho).
1096-7192/$ – see front matter © 2011 Elsevier Inc. All rights reserved.
doi:10.1016/j.ymgme.2011.12.012
Contents lists available at SciVerse ScienceDirect
Molecular Genetics and Metabolism
j ourna l homepage: www.e lsev ie r .com/ locate /ymgme
Author's personal copy
5. Conclusion and future perspectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 548
Acknowledgments. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 548
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 548
1. Introduction
Lysosomes are membrane delimited organelles with a characteris-
tic acidic pH that are responsible for the degradation of many differ-
ent substrates in the cell. This catabolic process is carried out by
over 60 soluble enzymes that are contained inside the organelle.
The majority of soluble acid hydrolases are modiﬁed with mannose-
6-phosphate (M6P) residues, allowing their recognition by M6P re-
ceptors in the Golgi complex and ensuring their transport to the
endosomal/lysosomal system [1].
Like several other proteins, lysosomal hydrolases are synthesized in
the endoplasmic reticulumand cotranslationally glycosylated on select-
ed asparagine residues. When moving to the secretory pathway, these
proteins are selectively recognized by a phosphotransferase, UDP-N-
acetylglucosamine 1-phosphotransferase (GlcNAc-1-phosphotransfer-
ase), which initiates the two-step reaction that results in the generation
of the M6P marker on speciﬁc N-linked oligosaccharides. The enzyme
catalyzes the transfer of a GlcNAc-1-phosphate residue from UDP-
GlcNAc to C6 positions of selectedmannoses in high-manose type oligo-
saccharides of the hydrolases. The second step involves the removal of
the terminal GlcNAc by an N-acetylglucosamine-1-phosphodiester α-
N-acetyl-glucosaminidase, also known as “uncovering enzyme” (UCE),
exposing the M6P recognition signal. Next, the modiﬁed proteins are
recognized by two independent receptors that bind the M6P residue
of the newly synthesized lysosomal hydrolases in the trans-Golgi net-
work. Finally, the ligand-receptor complex is packaged into clathrin-
coated transport vesicles for delivery to endosomes and lysosomes
(Fig. 1) [1].
The sequential action of these proteins, which is triggered upon
arrival in the Golgi apparatus of soluble lysosomal enzymes allowing
their subsequent transport to the endosomal/lysosomal compart-
ment, constitutes the M6P-dependent targeting pathway. The impor-
tance of providing lysosomes with an entire repertoire of degradative
enzymes for normal cellular processes is illustrated by the existence
of over 50 different monogenic human lysosomal storage diseases
that are caused by a deﬁciency of a catabolic enzyme [2] that as a
whole are estimated to affect 1 in 5000 live births [3].
This review aims to synthesize the current knowledge on each of
these proteins and their cellular function, passing through lysosomal
storage disorders (LSD) associated to the loss of function of some of
them. Recent studies on secondary impaired uptake of lysosomal en-
zymes and mutations in the lysosomal enzyme targeting pathway
Fig. 1. Transport of newly synthesized lysosomal hydrolases to lysosomes.Lysosomal hydrolases are synthesized in the endoplasmic reticulum and move to the cis Golgi network,
were they are covalently modiﬁed by the addition of mannose-6-phosphate (M6P) groups. The formation of this marker depends on the sequential effect of two lysosomal en-
zymes: UDP-N-acetylglucosamine 1-phosphotransferase (GlcNac-phosphotransferase) and N-acetylglucosamine-1-phosphodiester α-N-acetyl-glucosaminidase (uncovering en-
zyme). GlcNac-phosphotransferase catalyzes the transfer of a GlcNAc-1-phosphate residue from UDP-GlcNAc to C6 positions of selected mannoses in high-manose type
oligosaccharides of the hydrolases. Then, the uncovering enzyme removes the terminal GlcNAc, exposing the M6P recognition signal. At the trans Golgi network, the M6P signal
allows the segregation of lysosomal hydrolases from all other types of proteins through selective binding to the M6P receptors. The clathrin-coated vesicles produced bud off
from the trans-Golgi network and fuse with late endosomes. At the low pH of the late endosome, the hydrolases dissociate from the M6P receptors and the empty receptors are
recycled to the Golgi apparatus for further rounds of transport.
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causing stuttering, will also be addressed, together with the variable
efﬁcacy of the some therapeutic approaches depending on the ex-
pression levels of the M6P pathway functional components.
2. The mannose-6-phosphate pathway: From amoebas to humans
The mannose-6-phosphate dependent mechanism for lysosomal
enzyme routing was ﬁrst described in mammalian cells as involving
the sequential action of the above referred proteins: GlcNAc-1-
phosphotransferase, N-acetylglucosamine-1-phosphodiester α-N-acetyl-
glucosaminidase and the twomannose-6-phosphate receptors. An identi-
calmechanismwas then found to occur in avian (chicken) and amphibian
(Xenopus) cells [4], suggesting that the mannose-6-phoshate pathway
was likely shared by all vertebrates. In 1994, a UDP-GlcNAc: lysosomal
enzyme GlcNAc-1-phosphotransferase was detected in the fruit ﬂy
Ceratitis capitata with speciﬁcity and catalytic properties resembling
those found in mammalian cells [5]. The question of whether a homolo-
gous mannose-6-phosphate-dependent mechanism for lysosomal
enzyme targeting was also present in invertebrates, was only answered
two years later when Alvarez and collaborators ﬁrstly reported the
mechanism in the crab Chasmagnatus granulata [6]. These authors
puriﬁed an acid hydrolase with M6P residues, demonstrated the
existence of a GlcNAc-1-phosphodiester α-N-acetyl-glucosaminidase in
microsomal membranes of the crab's hepatopancreas and proved that
two mannose-6-phosphate receptors (see information about mannose-
6-phosphate receptors in Section 3.3 of this review), recognized by
speciﬁc antisera raised against each bovine receptor, were also present
in the microsomes of the crab [6].
Although GlcNAc-1-phosphotransferases have been described in
lower eukaryotes, Lang et al. [7] have demonstrated that both the soil
amoeba Acanthamoeba castellanii and the vegetative amoeba of the
cellular slime mold Dictyostelium discoideum contain an enzyme
that transfers GlcNAc-P from UDP-GlcNAc to mannose residues on high
mannose oligosaccharides. The enzyme of A. castellani is similar to
the mammalian enzyme in that it is able to recognize the common
protein determinant of lysosomal mammalian enzymes. By contrast, the
N-acetylglucosaminylphosphotransferase ofD. discoideum lacks this capa-
bility demonstrating that functional differences exist between GlcNAc-1-
phosphotransferases in lower eukaryotes and the mammalian ones. Re-
cently, Qian and colleagues [8] identiﬁed the gene (gpt1) that encodes
the D. discoideum GlcNAc-1-phosphotransferase. This enzyme presents
sequence similarity to thehumanGlcNAc-1-phosphotransferase, differing
from this one in by the lack of a DMAP binding domain on the αsubunit
and by the absence of the γ subunit. Nevertheless, the lysosomal hydro-
lases of wild type D. discoideum are well phosphorylated and, so, the γ
subunit seems to be dispensable in this species. [8].
Also in the unicellular organism A. castellanii referred above,
despite the presence of an enzyme with homology, in terms of
speciﬁcity, to mammalian GlcNAc-1-phosphotransferases, the addi-
tional components of the mammalian routing mechanism, such as
GlcNAc-1-phosphodiester α-N-acetyl-glucosaminidase or mannose-
6-phosphate receptors, were not detected, suggesting that in this
ameboid microorganism lysosomal targeting is not mediated by
M6P markers [9].
3. Functional components of the mannose-6-phosphate pathway
3.1. GlcNAc-1-phosphotransferase
GlcNac-phosphotransferase is a Golgi-resident 540-kDa hexame-
ric transmembrane enzyme composed by three subunits, α2β2γ2,
which catalyzes the ﬁrst step in the formation of the M6P recognition
marker on lysosomal enzymes (Fig. 1). This enzyme is coded by two
different genes: GNPTAB and GNPTG, encoding for the α/β subunits
and the α subunit, respectively. The GNPTAB gene contains 21 exons
and spans 85 kb on chromosome 12q23.3. It encodes a protein of
1256 amino acids with a predicted molecular mass of 144 kDa (α/β
precursor). Hydrophobicity analysis showed two transmembrane do-
mains and 19 potential N-glycosylation sites (17 in the α subunit and
3 in the β subunit) [10].
Proteolytic processing of the α/β precursor between Lys928 and
Asp929 generates the individual α and β subunits and is a prerequi-
site for the enzymatic activity of the GlcNAc-1-phosphotransferase
complex [10]. Recently Marschner et al. [11] provided evidence that
theα/β-subunit precursor of GlcNAc-1-phosphotransferase is cleaved
by the site-1 protease (S1P; also known as subtilisin kexin isoen-
zyme–1, SKI-1). This enzyme is encoded by the MBTPS1 gene and is
a membrane bound serine protease. The prototypical membrane-
bound S1P substrates are the sterol regulatory element-binding pro-
teins SREBP1 and 2, which play a major role in lipid metabolism and
cholesterol homeostasis [referred in 11]. These authors veriﬁed that
S1P-deﬁcient cells failed to activate the α/β-subunit precursor and
exhibited a mucolipidosis II-like phenotype. This implies that these
ﬁndings may also have consequences in terms of diagnosis, since mu-
tations in the gene that codes for this protease may be present in in-
dividuals with genetically undeﬁned mucolipidosis II-like phenotypes
such as Pacman dysplasia.
The GNPTG gene, spanning 11 exons on chromosome 16p13.3, en-
codes the γ subunit, which is a soluble glycoprotein of 305 amino
acids, with a molecular weight of 97 kDa capable to form disulﬁde-
linked dimers [12]. The initial 305 aminoacid polypeptide is pro-
cessed into a mature form by proteolytic cleavage of a signal peptide
with 24 amino acids; then the mature protein can form disulﬁde
bonds [13]. The γ subunit contains two potential N-glycosylation
sites at N88 and N115 [14].
Functionally, the α/β subunits constitute the catalytic portion of
the enzyme and carry the substrate binding sites for UDP-GlcNAc
and high mannose-type lysosomal enzymes [15,16]. In the α subunit
are located the UDP-GlcNAc binding site and homology region to the
bacterial capsular polymerases [10,15,17]. Nevertheless, the β
subunit also appears to be necessary, as demonstrated by the
failure of transfection of the α subunit alone to generate GlcNAc-1-
phosphotransferase activity [18] plus the genetic evidence that trun-
cation of the β subunit results in GlcNAc-1-phosphotransferase deﬁ-
ciency [13,18,19]. Moreover, the transmembrane domains on the α
and β subunits are required for natural processing of the GlcNAc-1-
phosphotransferase precursor [18].
Analysis of a library of cathepsin D/pepsinogen chimeric
proteins along with mutant cathepsin L has shown that GlcNAc-1-
phosphotransferase recognizes common conformation-dependent
protein structures of lysosomal enzymes in which lysine residues
are the major determinants [20–23], as was also proven through an-
tibody inhibition experiments with arylsulfatase A [24]. In addition,
the interaction of both subunits with the protein determinant of
acid hydrolases stimulates the catalytic function of the transferase
[23].
In 2007, Gelfman and colleagues [25] generated a mouse model
for GNPTAB deﬁciencies by microinjection of embryonic stem (ES)
cell clones GNPTAB−/− into host blastocysts. Homozygous mice lack-
ing α/β subunits of GlcNAc-1-phosphotransferase presented with
growth retardation, retinal degeneration and secretory cell lesions
that do not exactly mimic the human disease. Nevertheless, the less
severe phenotype of the GNPTAB-knockout mouse enables studies
designed to understand alternative molecular mechanisms involved
in the trafﬁcking of lysosomal enzymes to lysosomes and provides a
valuable tool for probing the role of proper lysosome function in the
maintenance of the retina and the secretory cells of exocrine glands
[25]. The role of the γ subunits of the GlcNAc-1-phosphotransferase
remained elusive [10,18] up to recently, when studies become to
appear demonstrating that the γ chains are important to facilitate
the proper folding of the full set of subunits in the GlcNAc-1-
phosphotransferase and to maintain them in the right conformation,
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turning the enzyme competent for substrate recognition and binding.
The γ chains are also necessary to regulate the activity and expression
of the α/β subunits [16,23,26,27]. Pohl and colleagues [26], after hav-
ing identiﬁed, in a boy with MLIII γ a novel homozygous mutation in
the GNPTG gene resulting in a truncated but stable γ subunit protein,
performed in vitro and in vivo experiments to characterize the muta-
tion, obtained compelling support that the γ subunit was involved in
the regulation of the GlcNAc-1-phosphotransferase activity. Latter,
the same group [27] showed that in human macrophages the proteo-
lytic cleavage of the γ subunit of the GlcNAc-1-phosphotransferase
leads to the formation of unique oligomers that fail to associate
with the other GlcNAs-1-phosphotransferase subunits in higher
molecular mass complexes, which might explain why almost all pro-
teins in human macrophages lack M6P residues. The limited proteol-
ysis of the γ subunits seems to be the regulator mechanism that
controls the GlcNAc-1-phosphotransferase activity and subsequent
sorting efﬁciency of lysosomal enzymes. In mice lacking the γ subu-
nit, the extent of acid hydrolases phosphorylation relative to wild-
type animals was investigated revealing that the γ subunit increases
the activity of the α/β subunits toward protein acceptors to variable
extents [23]. The same study afforded evidence that the γ subunit
serves at least two roles. One is to interact with the high mannose
oligosaccharides of the acceptor hydrolase facilitating the addiction
of the second GlcNAc-P to the molecule. This GlcNAc-P is trans-
ferred to a speciﬁc mannose residue on the 3′ arm of the high man-
nose unit, whereas the ﬁrst GlcNAc-P almost always is added to a
mannose on the 6′ arm of the glycan. In addition, the authors also
postulate that a speciﬁc domain of the gamma subunit, the man-
nose 6-phosphate receptor homology (MRH) domain binds the
high mannose oligosaccharide in such a way that the transfer of
the second GlcNAc-P is enhanced being the other role of the γ sub-
unit to enhance the overall phosphorylation in a subset of the acid
hydrolases [23]. This role is in line with previous data from Lee et
al. [16], who having analyzed brain tissue of knock-out mice for
the γ gene, observed that, for example, α-mannosidase and β-
glucuronidase are similarly phosphorylated as in the wild-type
brain, whereas β-hexosaminidase and β-galactosidase are not or
are weakly phosphorylated [16].
3.2. The uncovering enzyme: N-acetylglucosamine-1-phosphodiester
α-N-acetyl-glucosaminidase
N-acetylglucosamine-1-phosphodiester α-N-acetylglucosaminidase,
also known as the uncovering enzyme (UCE) excises the covering
GlcNAc from the GlcNAc-P-Man diesters, to form the M6P monoester
recognition signal on lysosomal acid hydrolases (Fig. 1). UCE is a type I
transmembrane glycoprotein of 515 amino acids which exists as a tetra-
mer that cycles between the trans-Golgi network and the plasma mem-
brane [28–30]. This enzyme is coded by theNAGPA gene, that contains 10
exons and is located on chromosome 16 [29]. UCE presents six potential
N-glycosylation sites [29], being synthesized as an inactive precursor
that is activated upon proteolytic cleavage of a 24-aminoacid propiece
by the endoprotease furin. As furin is localized in the trans-Golgi net-
work, newly synthesized UCE is inactive until reaching the terminal
Golgi compartment [31].
To date no pathological conditions have been associated with the
loss of UCE activity. Speculation on the existence or inexistence of
such pathologies was maintained over years, with some authors argu-
ing that alternative mechanism of conversion of the M6P diesters to
monoesters should exist able to correct malformation of the recogni-
tion signal induced by UCE deﬁciency, while others argued that inac-
tivating mutations in the UCE gene should be so rare events that
could explain the non-observation of UCE related phenotypes. How-
ever, a few years ago, Chavez and collaborators [32], shed some
light on why UCE loss of function might not be associated with
overt pathological condition. They demonstrated that the ﬁfth repeat
domain, of a total of 15 that constitute the cation-independent
mannose-6-phosphate receptor (CI-MPR), is able to bind GlcNAc-P-
Man diesters. This binding occurred with much lower afﬁnity than
the binding to M6P monoesters, which take place in domains 1–3
and 9 of the same receptor. Probably, then, in the absence of UCE ac-
tivity, acid hydrolases bearing M6P diesters might be able to bind
sufﬁciently to the CI-MPR, enabling trafﬁcking to lysosome enough
to prevent the clinical manifestations seen when GlcNAc-1-
phosphotransferase activity is absent/deﬁcient [32]. These ﬁrst evi-
dences came from in vitro studies but next were corroborated by in
vivo experiments with mice lacking UCE, created through insertional
mutagenesis in the gene that codes for UCE [33]. Despite UCE−/−
mice were viable, grew normally and lacked detectable histological
abnormalities, the plasma levels of six monitored lysosomal hydro-
lases were 1.6 to 5.4-fold elevated over wild type levels. The secreted
hydrolases contained GlcNAc-P-Man diesters, exhibited a decreased
afﬁnity for the CI-MPR receptor and no afﬁnity at all to the CD-MPR.
On the grounds of these results, Boonen and colleagues [33] proposed
that, in the absence of UCE, the weak binding of the lysosomal hydro-
lases to the CI-MPR allows enough sorting to lysosomes to prevent
the tissue abnormalities seen in GlcNAc-1-phosphotransferase deﬁ-
ciency. The ability of the CI-MPR to recognize the product of
GlcNAc-1-phosphotransferase implies that deﬁciencies in the unco-
vering enzyme probably will not be lethal [33]. Furthermore, it allows
delivery to the lysosome of those acid hydrolases that may be poor
substrates for the uncovering enzyme in quantities sufﬁcient to pre-
vent the severe phenotypes usually associated with lysosomal storage
diseases [34].
3.3. Mannose-6-phosphate receptors
Once anchored in the N-linked oligosaccharides of newly synthe-
sized hydrolases, the M6P recognition marker has to be recognized
by speciﬁc receptors, so that the labeled hydrolases are correctly
transported to the lysosome (Fig. 1) [reviewed in 35]. This role is car-
ried out by the mannose-6-phosphate receptors (MPRs), which are
type I transmembrane glycoproteins that bind their speciﬁc oligosac-
charide at pH 6,5-6,7, in the trans-Golgi network and release it at pH
6, the typical pH inside late endosomes. Inside these compartments,
lysosomal hydrolases dissociate from the MPRs, and when the pH
drops further, during endosomal maturation, and reaches 5 — the
typical acidic pH of lysosomes which is maintained by a membrane
ATP-driven H+ pump, hydrolases begin to digest the endocytosed
material delivered from early endosomes [reviewed in 36].
Sorting of MPRs at the TGN was long thought to predominantly
depend on binding to the heterotetrameric adaptor-protein complex
(AP)-1, which also mediates the recruitment of clathrin. The discov-
ery of the Golgi localized, γ-ear-containing, Arf-binding family of pro-
teins (GGA) as clathrin adaptors changed this view. GGAs are
monomeric proteins and three different forms are known in mam-
mals: GGA1, GGA2 and GGA3. Presently, GGAs and AP-1 are thought
to function in parallel to generate distinct MPR-containing vesicles
at the TGN, thereby allowing delivery to different endosomal com-
partments. Alternatively, or additionally, GGAs may facilitate entry
of MPR into clathrin-coated vesicles by interacting with AP-1. More-
over, it is possible that different adaptor proteins can also act sepa-
rately to a certain extent providing a means to establish the distinct
pathways [reviewed in 37].
A multiprotein complex known as retromer has been shown to
mediate retrieval of MPR to the TGN. It is likely that MPR retrieval
to the TGN involves retromer in the early part and Rab9-TIP47 in
the late part of the pathway. Retromer has been localized to mem-
brane tubules that extend from the vacuolar part of endosomes and
may participate in retrograde transport to the TGN. In contrast,
Rab9 is associated with vesicular intermediates that bud from late
endosomes and merge with the TGN. The existence of these two
545M.F. Coutinho et al. / Molecular Genetics and Metabolism 105 (2012) 542–550
Author's personal copy
retrieval mechanisms likely ensures efﬁcient recycling of MPR during
endosomal maturation. In addition, retrieval from endosomes to the
TGN also depends on speciﬁc signals in the cytosolic tails of the
MPR [reviewed in 1].
There are two different M6P receptors, both of them extensively
characterized over the last decades [38,39 reviewed in 40]. The ﬁrst
is the cation-independent M6P receptor (CI-MPR or MPR300), a
transmembrane glycoprotein of approximately 300-kDa that also
binds with high afﬁnity other ligands such as the insulin-like growth
factor II (IGF II) that is involved in early grow and development. This
is why the CI-MPR is also called the insulin-like growth factor II re-
ceptor. The extracytoplasmic domain of this receptor contains ﬁfteen
homologous repeating units of around 150 amino acids [41,42]. The
third and the ninth of them provide two M6P binding sites, whereas
the eleventh element provides a binding site to IGF II [43–45]. Addi-
tionally, CI-MPR also contains one phosphodiester (Man6P-GlcNAc)
binding site [46,47]. The other receptor is the cation-dependent
M6P receptor (CD-MPR or MPR46). The extracytoplasmic domain of
this 46-kDa transmembrane glycoprotein is homologous to each of
the ﬁfteen repeats found in the extracytoplasmic domain of CI-MPR
[48] and contains one M6P binding site [49]. The detergent-
solubilized CD-MPR is a homodimer which may form tetramers in
Golgi membranes [50,51].
Although related to one another, and even having similar do-
mains, both MPRs are essential and non-synonymous components
of the M6P-dependent targeting system. This was proven by gene dis-
ruption experiments in mice. Animals with disrupted CI-MPRs or CD-
MPRs genes were partially impaired in intracellular lysosomal en-
zyme sorting [52,53]. Mutant mice lacking the CD-MPR are viable,
while mice lacking the CI-MPR accumulate high levels of IGF-II and
usually die perinatally, whereas mice that lack both IGF-II and CI-
MPR are viable [54]. A partial missorting of phosphorylated lysosomal
enzymes was also observed in embryonic ﬁbroblasts derived from
mouse embryos lacking either the CI-MPR or the CD-MPR [55]. Fur-
ther experiments enlightened the fact that each mutant cell line se-
cretes, in a large part, different phosphorylated ligands and that
high levels of one MPR do not fully compensate for the absence of
the other, demonstrating that the two MPRs have complementary
targeting functions. One possible explanation is that each MPR recog-
nizes different features of the lysosomal enzymes [55]. Furthermore,
primary ﬁbroblasts from embryos lacking both MPRs are almost totally
impaired in lysosomal enzyme sorting. As a consequence, cells accumu-
late undigested material in their endosomes/lysosomes [56] presenting
a phenotype quite similar to the one characteristic of I-cell diseaseﬁbro-
blasts, which have a lack of synthesis of theM6P signal due to defects in
GlcNAc-1-phosphotransferase.
The functional mechanism through which MPRs work in vivo to
ensure hydrolases transport to lysosomes has largely remained
unclear. However, from the studies of receptor deﬁcient ﬁbroblasts,
three different subgroups of M6P containing proteins could be distin-
guished: (i) those which are preferentially secreted in the absence of
the CD-MPR and, therefore, do not interact well with the remaining
CI-MPR; (ii) those that are preferentially secreted in the absence of
the CI-MPR and, therefore, do not interact well with CD-MPR and, ﬁ-
nally, (iii) those which are only secreted in the absence of both MPRs,
thus interacting equally well with either MPR [55]. This reinforces the
idea that the MPRs are complementary in function.
In terms of localization, the MPRs are distributed over several in-
tracellular compartments including the trans-Golgi network, the plas-
ma membrane and the endosomes. At steady level, the majority of
MPRs reside in the endosomes [35].
When located in the trans-Golgi network, theMPRs divert the newly
synthesized lysosomal hydrolases from the secretory pathway to the
endocytic pathway, after which they unload their bound ligands.
However, not all the hydrolases that are tagged for delivery to the
endosome/lysosome compartment arrive to their proper destination.
Actually, some escape binding to MPR in the trans-Golgi network
being directed, by default, to the cell surface, where they are secreted
to the extracellular ﬂuid. When this happens some MPRs can take a
detour back to the plasma membrane, where they recapture the es-
caped lysosomal enzymes returning them to lysosomes by receptor-
mediated endocytosis via early and late endosomes [in 36]. The CI-
MPR localized at the plasma membrane may also contribute to the
partial rescue of those hydrolases [45,47]. Notwithstanding, as the
majority of lysosomal hydrolases require an acidic milieu to work,
they can do not any harm in the extracellular ﬂuid where the pH is
usually neutral.
The additional presence of mannose-6-phosphate receptors
(CI-MPR) in the plasma membrane allows internalization of glyco-
proteins containing the M6P recognition mark, which can bind to
the cell surface and then be targeted to the lysosome. Taking advan-
tage of this possibility, quite successful enzyme replacement thera-
pies (ERT) were designed for several lysosomal storage disorders.
Before administration in patients, the exogenous missing enzyme
must be modiﬁed with sufﬁcient M6P to bind to the receptor with
the appropriate afﬁnity. There are now available licensed products
to replacement therapy for Fabry disease, mucopolysacharidosis I, II
and VI and Pompe disease. Nevertheless, these approaches still
present some limitations since many manifestations of established
disease do not respond do ERT and, in some cases (e.g. renal impair-
ment in Fabry disease), disease progression continues despite thera-
py. Furthermore, such therapeutic options are only suitable for
lysosomal storage disorders without neurological manifestations or
with low neurological involvement, because recombinant enzymes
are not capable of crossing the blood–brain barrier, which would be
necessary to neutralize the neurological manifestations of the dis-
eases [reviewed in 57].
4. Impairments in the mannose-6-phosphate pathway and disease
4.1. Defective GlcNAc-1-phosphotransferase causing mucolipidosis II and III
Defective GlcNAc-1-phosphotransferase causes two distinct
human lysosomal storage diseases, Mucolipidosis II (ML II) and
Mucolipidosis III (ML III), which are among the few lysosomal storage
disorders related to defects in non-lysosomal proteins. ML II, also
known as I-cell disease, is characterized by a total loss of GlcNAc-1-
phosphotransferase activity whether ML III, often referred to as
pseudo-Hurler polydystrophy, manifests when enzymatic activity is
reduced [58,59]. In both ML II and ML III patients, newly synthesized
lysosomal enzymes fail to be correctly sorted to the endosome/lyso-
some compartment due to the absence or weak equipment in M6P
residues. As a consequence, lysosomal dysfunction develops leading
to accumulation of non-degraded material, the hallmark of this
group of diseases. Unlike the majority of lysosomal storage disorders,
which involve single enzymes acting in a catabolic pathway, MLII and
III results from impaired sorting of multiple enzymes to lysosomes
that instead are over-secreted from cells. The excessive accumulation
of non-degraded substrates results in the subsequent formation of
large inclusion bodies.
While ML II and ML III share similar clinical features, including
skeletal abnormalities, ML II is the more severe in terms of phenotype
[58]. In this pathology the skeletal system is severely affected, with
abnormalities in both cartilage and bone. Linear growth decelerates
during the ﬁrst year of life almost stopping during the second year
and death usually occurs between 5 and 8 years of age.
ML III is a much milder disorder, being characterized by latter
onset of clinical symptoms and slower progressive course, which
may allow the survival into the eighth decade. Usual clinical ﬁndings
in ML III patients include restricted joint mobility, short stature and
mild Hurler-like dysmorphism, among other less severe features
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[59,60]. Only 50% of the patients present with mental retardation
[60].
Once GlcNAc-1-phosphotransferase is an hexameric complex
whose protein subunits are encoded by two genes, depending on
which of them harbors the causal mutation(s) and simultaneously
on the severity/clinical course of the disease, the associated patholo-
gies are classiﬁed as ML II α/β (OMIM: 252500) and ML III α/β
(OMIM: 252600) if mutations are present in the GNPTAB gene, or
ML III γ (OMIM: 252605) if mutations occur in the GNPTG gene
[10,12].
To date, more than 100 different GNPTAB mutations have been
reported, causing either ML II α/β or ML III α/β, including 30 mis-
sense, 20 nonsense, 32 small deletions, 25 small insertions, 2 small
indels and 14 splice site mutations [61 and references therein,
reviewed in 62]. Large genomic rearrangements appear to be rare
(1.6%) although two gross insertions [63,64] and one large deletion
have already been detected [65]. Most of these mutations are private
or rare. Uncommonly, however, the microdeletion c.3503_3504delTC,
presents a remarkably wide geographical distribution, having been
detected among Israeli and Palestinian Arab-Muslim, Turkish, Irish
traveler [66], Italian [67], Portuguese [68] and U.S. patients [69].
That deletion was found to be a frequent mutation in a French Cana-
dian founder population [70] and, later, haplotypic analysis per-
formed on the majority of c.3503_3504delTC chromosomes up to
now detected, clearly pointed to the common origin of all of them, in-
dicating that the mutation is ancient enough to explain its present-
day broad geographical distribution [71].
Concerning the GNPTG gene, the mutations until now reported as-
sociated to Mucolipidosis type III include 4 missense, 2 nonsense, 5
small deletions, 4 small insertions, 4 splice site mutations and 2
gross deletions [61 and references therein, reviewed in 62].
4.2. Mutations in the lysosomal enzyme-targeting pathway causing
stuttering
Recently, genomewide scans have unveiled a curious and unex-
pected relation between mutations in the lysosomal enzyme-
targeting pathway and persistent stuttering.
This innovative technology is becoming widely applied when com-
plex, multifactorial and heterogeneous diseases are under investigation
since it may yield suggestive evidence of linkage at several chromosom-
al sites that inﬂuence phenotypes. Stuttering, is a disorder in which
speech ﬂuency can be severely compromised, but its primary causes,
the high rates of spontaneous recovery and the etiological differences
between persistent and resolved forms have resisted explanation. In
the last years, genomewide scans provided signals of linkage atmultiple
chromosomal sites with stuttering, [72–75] but the stronger evidence
was with a locus on chromosome 12q, which was found in a study of
stuttering in 46 consanguineous families from Pakistan [73]. After-
wards, when Kang and colleagues [76], focusing on the largest of
those families, carried out a search for mutations across the chromo-
somal interval showing the strongest linkage, ended up identifying a
single nucleotide change in the GNPTAB gene (G3598A), coding for
both α and β subunits of GlcNAc-1-phosphotransferase. Then, the au-
thorswent on to sequenceGNPTG, aswell asNAGPA, inwhichmutations
causing changes at highly conserved amino acid residues were also
identiﬁed, as occurred in GNPTAB. A strong association was established
between persistent stuttering and four mutations in the GNPTAB gene
(S321G, A455S, F624L and E1200K); three mutations in the GNPTG
gene (L5_R7dup; A25E and L230V) and three mutations in the NAGPA
gene (H84Q; R328C and F523SfsX113).
This elegant study unveiled an unsuspected culprit to explain stut-
tering in some cases, due to the nature of the implicated biologic
pathway whose impairment had been essentially connected to lyso-
somal storage diseases. Yet, the affected subjects studied by Kang et
al. [76] stuttered but were otherwise normal, without presenting
any of the typical symptoms of lysosomal malfunction, even being ho-
mozygous for some of the identiﬁed mutations on the GNPTAB and
GNPTG genes. Eventually, this can be explained admitting that the ef-
ﬁciency of lysosomal targeting was only partially reduced in the pres-
ence of the detected mutations. However, the effect of the mutations
on the function of the GlcNAc-1-phosphotransferase or UCE was not
examined, leaving open the possibility that the mutations were not
detrimental. Recently, Lee et al. performed a biochemical evaluation
of the effect of the three NAGPA mutations which were associated
with persistent stuttering and found that each mutation leads to
lower cellular UCE activity [77].
The most interesting ﬁnding was the strong connection between
stuttering and three enzymes that generate the mannose 6 phosphate
signal. Expression levels of the encoding genes in human brain re-
main largely unknown, but in the mouse GNPTG has the most local-
ized expression in the brain, with high levels of expression in the
hippocampus, hippocampal formation and cerebellum (according to
the Allen Brain Atlas and as postulated in [76]), well-known struc-
tures associated with emotion and motor function. Taking this into
account, it seems plausible that mutations in such gene may led to
stuttering since a person's emotional state can be a major conditioner
of the severity of stuttering. Furthermore, stuttering does not affect
the ability to conceptualize words and/or sentences, but only the ﬂu-
ency of speech, which is in accordance with a disruption of the motor
functions required for speech [76].
Further studies in this area may contribute to a better understand-
ing of the neural structures and functions within the brain that gener-
ate human speech, which are still poorly elucidated and to a better
comprehension on the role of the mannose-6-phosphate-dependent
pathway for lysosomal enzyme routing in this area.
4.3. Secondary impaired uptake of lysosomal enzymes: A ‘symptom’
instead of a ‘cause’
Up to this point, we have only addressed primary impairments in
the mannose-6-phosphate pathway, which are damages caused by
mutations in genes coding for the functional components of the
mannose-6-phosphate-dependent pathway that lead to speciﬁc clin-
ical phenotypes. However, recent studies revealed that expression
levels of these functional components may also be secondarily affect-
ed by other disease conditions.
Secondary impairments include, for example, increased levels of
the cation-independent mannose-6-phosphate receptor (CI-MPR) lo-
calized at the plasma membrane in cells from patients suffering from
metachromatic leukodystrophy, a lysosomal storage disorder, caused
by the deﬁciency of arylsulfatase A (ARSA) with consequent storage
of the sphingolipid 3-O-sulfogalactosylceramide. This compound ac-
cumulates in several cell types, such as renal tubular cells. It was
demonstrated that in sulfatide-storing kidney cells the uptake of lyso-
somal enzymes is more than two-fold increased. Uptake rates were
inferred trough analysis of CI-MPR expression levels (1.5-fold in-
creased) and internalization rate (1.5-fold increased), with the two
alterations accounting for the global 2.2-fold increase in M6P-
dependent endocytosis of recombinant ARSA in sulfatide-storing
cells. Recycling of CI-MPR was also found to be decreased. Similarly,
altered expression levels were observed at the transferrin receptor,
indicating that ARSA deﬁcient cells present a general alteration of
the endocytotic pathway [78].
4.4. Inﬂuence of expression levels of M6P pathway functional
components on the efﬁcacy of some therapeutic approaches
Evidence is emerging that the expression levels of several
mannose-6-phosphate pathway functional components may affect
the efﬁcacy of different therapeutic approaches in LSDs.
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In a recent study, Sun and colleagues [78] have evaluated the efﬁ-
cacy of gene replacement therapy in Pompe disease under different
conditions. They used acid α-glucosidase (GAA) knockout mice, im-
mune tolerant GAA KO mice and mannose-6-phophate deﬁcient
GAA-KOmice, in order to assess the impact of the following three fac-
tors in muscle-targeted gene therapy: antibody formation, age and
mannose-6-phosphate receptor availability. Overall, antibody forma-
tion had a subtle effect upon biochemical efﬁcacy from GAA expres-
sion, whereas the absence of mannose-6-phosphate receptors
markedly impaired muscle-targeted gene therapy in murine Pompe
disease. These results indicate that reduced mannose-6-phosphate
receptor availability in type II myoﬁbers represents an obstacle to a
therapeutic strategy in Pompe disease that otherwise could be advan-
tageous [79].
5. Conclusion and future perspectives
Over the last decades, much was learned about the mannose-6-
phosphate-dependent pathway, the main cellular passageway for
transporting soluble hydrolases to lysosomes. Its major functional
components are now quite well characterized both at biochemical
and genetic levels. Nevertheless, several important questions remain
unanswered. Although the key enzymes necessary to the formation
of the mannose-6-phosphate recognition signal have been identiﬁed,
the protease that cleaves and thereby activates the α/β subunit pre-
cursor of GlcNAc-1-phosphotransferase is still unknown. Further
studies on the β and γ subunits of GlcNAc-1-phosphotransferase are
also needed, in order to elucidate better the role of β subunit and
what is the functional relevance of γ subunit.
Secondary impairments of the mannose-6-phosphate pathway
were only very recently brought to light, as well were signals of
how expression levels of its functional components might affect ther-
apeutic approaches in LSDs. The next few years, certainly will bring
new data allowing for a better understanding of the biological impact
of this pathway, which will be pivotal to design more efﬁcient thera-
peutic strategies to overcome M6P related disruptions of enzyme
lysosomal sorting.
Another issue that importantly needs additional insights concerns
alternative mechanisms to the M6P pathway for enzyme lysosomal
targeting that mammalian cells possess. Some years ago, studies
with cells from patients with I-cell disease demonstrated that in
some cell types, such as hepatocytes, nearly normal levels of lysosom-
al enzymes were present, despite the absence of M6P signals due to
GlcNac-1-phosphotransferase deﬁciency. This ﬁnding clearly pointed
to the existence of M6P-independent pathway(s) for lysosomal sort-
ing and trafﬁcking that could be used in some cell types but not in
others. Accordingly, two alternative receptors have been discovered:
LIMP-2 and sortilin. LIMP-2 was shown to be implicated in the deliv-
ery of β-glucocerebrosidase to the lysosomes [80–82], while sortilin
was acknowledged to be a multifunctional receptor capable of bind-
ing several ligands including neurotensin, RAP (receptor-associated
protein) and to ensure the lysosomal trafﬁcking of several proteins,
both hydrolytic or non-hydrolytic such as the sphingolipid activator
proteins prosaposin and GM2 activator protein, acid sphingomyeli-
nase and cathepsins D and H [83–88]. But there is still much to be
learnt on these and other alternative pathways, as well on how
M6P-dependent and independent routes possibly cooperates target-
ing to lysosomes the full set of enzymes necessary to accomplish
the organelle function.
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Action myoclonus-renal failure syndrome
(AMRF)Lysosomal hydrolases have long been known to be responsible for the degradation of different substrates in the
cell. These acid hydrolases are synthesized in the rough endoplasmic reticulum and transported through the
Golgi apparatus to the trans-Golgi network (TGN). From there, they are delivered to endosomal/lysosomal
compartments,where theyﬁnally become active due to the acidic pH characteristic of the lysosomal compartment.
The majority of the enzymes leave the TGN after modiﬁcation with mannose-6-phosphate (M6P) residues, which
are speciﬁcally recognized byM6P receptors (MPRs), ensuring their transport to the endosomal/lysosomal system.
AlthoughM6P receptors play amajor role in the intracellular transport of newly synthesized lysosomal enzymes
in mammalian cells, several lines of evidence suggest the existence of alternative processes of lysosomal
targeting. Among them, the two that are mediated by the M6P alternative receptors, lysosomal integral
membrane protein (LIMP-2) and sortilin, have gained unequivocal support. LIMP-2 was shown to be implicated
in the delivery of beta-glucocerebrosidase (GCase) to the lysosomes, whereas sortilin has been suggested to be a
multifunctional receptor capable of binding several different ligands, including neurotensin and receptor-
associated protein (RAP), and of targeting several proteins to the lysosome, including sphingolipid activator pro-
teins (prosaposin and GM2 activator protein), acid sphingomyelinase and cathepsins D and H.
Here, we review the current knowledge on these two proteins: their discovery, study, structural features and
cellular function, with special attention to their role as alternative receptors to lysosomal trafﬁcking. Recent
studies associating both LIMP2 and sortilin to disease are also extensively reviewed.
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Lysosomes have long been known to be responsible for the degrada-
tion of different substrates in the cell, a crucial process only possible be-
cause of the existence of soluble enzymes inside the acidic organelle.
Most of those acid hydrolases require previous modiﬁcation with
mannose-6-phosphate (M6P) residues, which allow their recognition
by speciﬁcM6P receptors present in the trans-Golgi network (TGN), en-
suring the transport to the endosomal/lysosomal system [1].
Although M6P receptors play a major role in the intracellular trans-
port of newly synthesized lysosomal enzymes in mammalian cells,
there are several lines of evidence suggesting the existence of an alterna-
tive mechanism of lysosomal targeting [2], the most relevant of which
have come from studies with cells from patients with I-cell disease. Be-
cause these individuals harbor mutations in the gene encoding for the
phosphotransferase that adds M6P residues to hydrolases, they were
expected to present reduced or null levels of hydrolases inside the lyso-
some. Nevertheless, in some types of cells such as hepatocytes, Kupffer
cells and lymphocytes, the cellular levels of lysosomal enzymes can be
normal [3–5] despite the inability to add mannose-6-phosphate to
newly synthesized hydrolases [5]. These ﬁndings pivotally suggested
the existence of M6P-independent pathways for lysosomal sorting and
trafﬁcking.
Other experimental approaches have proven that there are soluble
enzymes aswell as non-enzymatic proteins that are transported to lyso-
somes in a M6P-independent manner, speciﬁcally by means of two al-
ternative receptors: the lysosomal integral membrane protein
(LIMP-2) and sortilin. LIMP-2 was implicated in the delivery of GCase
(the defective enzyme in patients with Gaucher disease) to the lyso-
somes [6]. Sortilin is a multifunctional receptor capable of binding dif-
ferent ligands, including neurotensin and receptor-associated protein
(RAP), and has been suggested to mediate Golgi-to-lysosome transport
of the sphingolipid activator proteins (SAPs) prosaposin (PSAP) and
GM2 activator protein (GM2AP), acid sphingomyelinase (ASM) and ca-
thepsins D and H [2,7–11].
Herein, we review the current knowledge on these two proteins,
their discovery, study, structural features and cellular function, with
special attention to their role as alternative receptors to lysosomal traf-
ﬁcking.Wewill also review the recently discovered disease associations:
the causal role of LIMP-2mutations in a severe autosomal recessive lyso-
somal storage disorder (action myoclonus-renal failure syndrome,
AMRF) and their roles as modiﬁers of Gaucher disease (GD) and sortilin
expression levels as regulators of hepatic lipoprotein export, associated
to increased risk of myocardial infarction (MI) in humans.
2. LIMP2
2.1. Historical perspective
The lysosomal integral membrane protein, LIMP-2, was recently
shown to be implicated in the delivery of GCase (the enzyme defective
in patients with Gaucher disease) to the lysosomes [6].
LIMP-2wasﬁrst described in 1995 [12], but its role as a sorting recep-
torwas only unveiled several years laterwhenReczek and colleagues un-
expectedly identiﬁed LIMP-2 as a speciﬁc receptor for GCase [6]. In the
following year, Berkovic et al. [13], aiming to map a severe genetic dis-
ease of unknown etiology characterized by action myoclonus associated
with renal failure (AMRF), found that SCARB2, the gene that codes for
LIMP-2, was responsible for the condition. In this study, the disorder
wasﬁrstmapped in 4q13-q21, and usingmicroarray expression analysis,
it was possible to identify the gene encoding a lysosomal membrane
protein as the most likely candidate found in the critical region of chro-
mosome 4. Then, the screening of the SCARB2 gene led to the identiﬁca-
tion of mutations associated with lack of the LIMP2 protein in the 3
families diagnosed with AMRF included in the study. Subsequent
reanalysis of a pre-existing Limp2 knockout mouse showed intracellularinclusions in the cerebral and cerebellar cortex, as well as subtle glomer-
ular changes in the kidneys. Notably, in 2003, Gamp et al. [14] had al-
ready reported on Limp2-deﬁcient mice with increased postnatal
mortality associated with uni- or bilateral hydronephrosis caused by
ureteropelvic junction obstruction. Additionally, those mice showed an
accumulation of lysosomes in epithelial cells of the ureter aswell as a dis-
turbed apical expression of uroplakin, further suggesting an impairment
of membrane transport processes. Limp2-deﬁcient mice suffered from a
massive decline of spiral ganglia in the cochlea concomitant with that of
the inner and outer hair cells. However, these pathologic changes were
thought to be secondary to degeneration of the stria vascularis.
Limp2-deﬁcient mice were also characterized by peripheral demyelinat-
ing neuropathy, associated with massive loss of peripheral myelin pro-
teins and increased activity and expression of lysosomal proteins.
2.2. A speciﬁc lysosomal receptor
LIMP-2 was shown to be a speciﬁc lysosomal receptor involved in
the transport of GCase (GBA) from the TGN to the endosomal/lysosomal
compartment. GCase has no membrane-spanning domain [15]; it is
glycosylated after synthesis, becoming membrane-associated [3].
Only in 2007 was the machinery required for its transport to the
endosomal/lysosomal compartment unveiled. It was discovered that
LIMP-2 binds GCase in a pH-dependent fashion, enabling its association
in the ER and transport to the lysosome, where the complex likely dis-
sociates due to the acidic pH [6]. In fact, during the passage through
the various organelles of the secretory pathway, the receptor-ligand
complex experiences a gradient of decreasing pH: the nearly neutral
milieu of the ER allows GCase to associate with LIMP2, whereas the
low pH of the endosomes/lysosomes leads to the dissociation of GCase
from LIMP2 [16]. Additional studies from Blanz et al. [17] demonstrated
that, through disruption of either the helical arrangement or the
amphiphatic nature of the LIMP2 coiled-coil domain (residues 152 to
167), GCase binding was abolished. Furthermore, a synthetic peptide
comprising the coiled-coil domain of LIMP2 was shown to display
pH-selective multimerization properties. In contrast to the reduced
binding properties of nonsense mutations affecting residues 145 to
288, the H363N mutation led to increased binding of GBA, indicating
that the highly conserved His363 residue may modify the afﬁnity of
LIMP2 to its ligand. All these data led to the conclusion that both disrup-
tion of the coiled-coil structure and AMRF disease-causing mutations
abolish GBA binding, indicating the importance of an intact coiled-coil
structure for the interaction of LIMP2 and GCase. In addition, Blanz et
al. [17] investigated the biochemical function of several SCARB2 muta-
tions in transfected cells, having observed that all three nonsensemuta-
tions under study led to the retention of the mutant protein in the
endoplasmic reticulum (ER) but affected the binding to GCase in differ-
entways: in the presence of the Q288Xmutation, LIMP2was still able to
bind to GBA as efﬁciently as the wild-type protein, whereas the
W146SfsX16 and W178X mutant proteins lost their GBA-binding ca-
pacity almost completely.
Further analysis of the pH dependency of LIMP-2 and GCase binding
by perturbing the intra-lysosomal pH in cultured cells revealed that lu-
menal acidiﬁcation mediated by the vacuolar (H+)-ATPase triggers the
dissociation of LIMP-2 and GC in late endosomal/lysosomal compart-
ments [16].Moreover, the same authors identiﬁed a single histidine res-
idue in LIMP2 (H171) that likely serves as the critical pH sensor.
Interestingly, that particular residue is in close proximity to the previ-
ously described coiled-coil motif in the luminal domain of LIMP2,
which is necessary for GCase binding. Interestingly, that residue is not
conserved in chicken or Xenopus; instead, an arginine residue is present
at the corresponding position,whichwould favor the dissociation of the
receptor and its ligand. In addition, the protein sequences of these spe-
cies are also devoid of the proposed coiled-coil domain, which is also an
important GCase binding factor. This led the authors to suggest that it is
unlikely that non-mammalian LIMP2 proteins are able to bind GCase
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decipher additional roles of LIMP2 other than transporting GCase to
lysosomes [16].
2.3. LIMP2 and disease: action myoclonus-renal failure syndrome
As mentioned in Section 2.1, mutations in the gene coding for this
receptor prevent GCase from reaching the lysosome and from as-
suming its function inside the lysosome. Not surprisingly, SCARB2
mutations underlie a serious autosomal-recessive disorder present-
ly known as action myoclonus-renal failure syndrome (AMRF;
OMIM#254900) [13,18]. This disease combines progressive myoclo-
nus epilepsy (PME), associated with storage material in the brain,
and focal glomerulosclerosis, frequently with glomerular collapse.
At the biochemical level, this condition was shown to be character-
ized by pathological levels of GCase activity in ﬁbroblasts, normal or
slightly reduced levels in leukocytes, increased levels in plasma and the
absence of other markers of Gaucher disease (GD), such as elevated
chitotriosidase activity [19].
Recently, Hopfner and colleagues [20], by screening a German AMRF
family with these features associated with renal failure, provided data
indicating that demyelinating polineuropathy and dilated cardiomyop-
athy are part of the AMRF syndrome. The ﬁndings were conﬁrmed al-
most simultaneously by Dibbens et al. [21], who reported on a patient
with progressive myoclonus epilepsy and demyelinating peripheral
neuropathy, also carrying a SCARB2 mutation that could explain the
phenotype. This particular case had previously been published in the
Archives of Neurology and presented with PME, preserved intellect and
a nonprogressive generalized demyelination neuropathy [22]. By that
time, failure to establish the cause of the phenotype, despite the exten-
sive evaluation, led the authors to describe a novel PME syndrome, but
due to the absence of renal failure, they withdrew the initial AMRF
diagnosis.
Currently, the presentation of PME without renal impairment [23]
prompts screening of the SCARB2 gene for causative mutations, and
new ﬁndings exemplify the study of Rubboli et al. [24], which reports
on SCARB2 mutations in ﬁve non-related Italian patients who
presented with PME of unknown origin of adolescent or adult onset.
So far, no SCARB2 genotype–phenotype correlations have been
established. From the inspection of the SCARB2 mutations found to
date, no clear distinction emerges between the class (e.g., missense or
nonsense) or position of the mutation and the patient phenotype. The
phenotypic heterogeneity encompasses a wide range of tissues, but it
is still unclear why some patients with SCARB2 mutations develop
PME with or without renal failure, or why others develop mild hearing
impairment or peripheral neuropathy [24].
Other symptoms may also occur, as suggested by the clinical mani-
festations observed in LIMP2-deﬁcient mice [14], which presented in-
creased postnatal mortality and uni- or bilateral hydronephrosis
caused by an obstruction of the ureteropelvic junction. The obstruction
was associated with metaplasia of the uretetic urothelium into simple
columnar epithelium and hypertrophy of the smooth muscle layer. In
addition, LIMP2-deﬁcient mice suffered from a peripheral demyelinat-
ing neuropathy. Demyelination was found to be associated with a loss
of peripheral myelin proteins. Serious hearing impairments were also
observed and were associated with massive spiral ganglion neuron
losses, concomitant with loss of the inner and outer hair cells and a
strongly impaired capacity to generate endocochlear potential [14]. In
a subsequent study, those mice were also shown to display progressive
high-frequency hearing loss and otoacoustic emissions. In fact, more in
depth studies on that model revealed that the potassium channel
KCNQ1 and its beta-subunit KCNE1 were almost completely lost in the
luminal part ofmarginal cells in the stria vascularis, affectingﬁrst higher
and then lower frequency processing cochlear turns. The study of this
mouse model and of its deafness was particularly important because it
suggests an important and previously unsuspected role for LIMP2 incontrolling the localization and the level of apically expressed mem-
brane proteins such as KCNQ1, KCNE2 and megalin in the stria
vascularis [25]. Extrapolation ofmouse studies to humans is still prema-
ture, but it is tempting to hypothesize that LIMP2may assume addition-
al roles in the endocytic pathway. Nevertheless, because for the
moment only a few clinical and neurophysiologic descriptions of
AMRF syndrome have been reported [13,18,26–30], there is still much
to learn about the clinical presentation and molecular basis of this dis-
ease. Future research exploring the function of SCARB2 gene and its
role in cerebral and renal function is warranted [24]. Further insights
into its function in the endocytic pathway and its unidentiﬁed
interacting partners [25] are also needed.
2.4. LIMP2 and disease: SCARB2 mutations as modiﬁers of Gaucher
disease
Recently, SCARB2 mutations have also been demonstrated to act as
modiﬁers in Gaucher disease. Considering that LIMP-2 is the only
known receptor for the enzyme that is deﬁcient in Gaucher disease,
Velayati and co-workers hypothesized that SCARB2mutations could im-
pact the Gaucher phenotype. In order to test that hypothesis, they
re-evaluated a previously reported case of two siblings with GD with
very disparate phenotypes [31,32]. One sibling had been followed
closely for over a decade with progressive myoclonic epilepsy (PME)
and dementia, while the second was subsequently diagnosed through
family screenings, having only a few disease manifestations throughout
his life, with no neurologic involvement. Both shared three GBA
alterations: the maternally inherited c.535G>C (p.Asp140His) and
c.10936G>A (p.Glu326Lys) and the paternally inherited c.586A>C
(p.Lys157Gln) [31]. Extensive analyses, including studies of endoplas-
mic reticulum-associated degradation (ERAD), have previously been
performed on ﬁbroblasts from both siblings, demonstrating that the
one withmyoclonic epilepsy had increased ERAD of GCase and elevated
intracellular cholesterol [32]. Velayati et al. screened this sib-pair
for mutations in SCARB2 and found one novel, heterozygous,
maternally-inherited mutation, c.1412A>G (p.Glu471Gly), in the
brotherwith GD andmyoclonic epilepsy, whichwas absent in his sibling
and controls. This ﬁnding demonstrated that LIMP-2 could serve as a
modiﬁer in GD. Although myoclonic epilepsy had previously been
reported in heterozygotes with SCARB2 mutations [6], only in this case
was it possible to demonstrate that the SCARB2 mutation alone was
not responsible for the development of such a phenotype, as it was
also present in the sib's mother, who had a normal clinical phenotype
[33]. In the severely affected brother, however, the deﬁcient GBA activ-
ity, accompanied by a mutation in the transporter, resulted in
mistrafﬁcking of the enzyme and contributed to the observed
phenotype.
3. Sortilin
3.1. Historical perspective: from a neurotensin alternative receptor to an
essential sorting receptor
Sortilin was ﬁrst discovered in 1997, when Petersen and colleagues
[7] performed receptor-associated protein afﬁnity chromatography and
isolated, identiﬁed and puriﬁed a previously unknown membrane gly-
coprotein of approximately 95 kDa. This protein was numbered gp95
and later coined as sortilin. After cloning of the encoding gene by
cDNA library screening, it was possible to verify that it has a type I
receptor structure and striking sequence homologies with yeast
Vps10p and the CD-MRP and CI-MPR receptors [7]. Transfection analy-
sis of this novel receptor demonstrated that it is able to bind
receptor-associated binding protein (RAP), which had previously only
been described for LDL receptors, and also showed that its cytoplasmic
tail provides localization to the Golgi and CI-MRP vesicles. Yet, the cell
functions of sortilin were far from being totally unveiled. In the next
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sortilin could be a candidate sorting receptor, targeted for transport by
ligands in the synthetic pathway as well as on the surface membrane.
First, as demonstrated byMazella et al. [8] and Nielsen et al. [9], sortilin
binds a variety of unrelated ligands in mammals, including lipoprotein
lipase and neurotensin. These ligands have in common the ability to
bind to other receptor(s) and candidates for regulated transport
[34–36]. Therefore, even though sortilin appeared to contribute to en-
docytosis and perhaps even signaling as evidenced by different works,
its main role seems plausibly related to functions not covered by other
receptors (e.g., regulated transport). Secondly, sortilin has striking
structural similarities to known receptors involved in intracellular
sorting and transport. Indeed, the C-terminal segment in sortilin's cyto-
plasmic tail is closely related to the corresponding and functionally im-
portant segment in Vps10p, the sorting receptor for carboxypeptidase Y
(CPY) in yeast [37–39]. Moreover, the sortilin cytoplasmic domain con-
tains several potential signal sequences that conform to established
consensus motifs known to be involved in adaptor protein binding, en-
docytosis, basolateral targeting andGolgi-endosome sorting [40]. Third-
ly, sortilin predominates in certain intracellular compartments; only a
minor fraction of the protein is expressed on the cell surface, whereas
asmuch as 90% of the receptor pool is found in the Golgi and its derived
vesicles, showing extensive co-localization with CI-MPR.
This prompted the next steps to examine the nature of sortilin as a
sorting receptor. In 2001, when examining the cellular trafﬁcking of
chimeric receptors containing constructs of the sortilin tail, Nielsen
et al. [34] demonstrated that CI-MPR-sortilin chimeras expressed in
CI-MPR knockout cells were almost as efﬁcient as the MPR itself in
the transport of newly synthesized beta-hexosaminidase and beta-
glucoronidase to lysosomes. It then became established that the
sortilin tail contains potent signals for Golgi-endosome sorting,
while the entire receptor had potential to convey transport from the
synthetic pathway to lysosomes. Later, direct binding was shown be-
tween this luminal receptor and a member of the GGA family of cyto-
solic proteins (multidomain protein family involved in protein
trafﬁcking between Golgi and endosomes), suggesting that GGA2 par-
ticipates in sortilin sorting. After this study, a number of works
reinforced the ability of sortilin to mediate lysosomal trafﬁcking of
several enzymes and non-enzymatic proteins such as prosaposin,
GM2AP [10], acid sphingomyelinase [2] and cathepsins D and H [11]
(see Section 3.3).
3.2. Structural features: insights into sortilin function and evolution
Sortilin is one of ﬁve members of a Vps10p domain receptor family,
often found in the trans-Golgi network and early endosomes: sortilin,
SorLA, SorCS1, SorCS2 and SorCS3 [41]. The Vps10 domain is a
10-bladed beta-propeller consisting of three structural domains: the
N-terminal domain (residues 45–576), which was the ﬁrst example of
a 10-bladed beta-propeller structure, followed by two smaller domains
named 10CC-a (residues 577–633) and 10CC-b (residues 634–716).
The 10CC domains have low secondary structure content and both in-
teract extensively with the beta-propeller [41]. Being the protein with
the largest number of blades at the Vps10 domain (10), sortilin has an
increased potential to accommodate larger ligands when compared to
similar proteins. With several highly conserved regions in the inner
rim of the tunnel that correspond to different binding sites, sortilin
has a unique structural organization that allows it to bind a series of dif-
ferent ligands. Furthermore, it is translated as an inactive propeptide,
which is only activated after furine cleavage. In fact, it has been proven
that newly synthesized sortilin (and SorLA) cannot bind ligands to their
Vps10p domain until they have been cleaved by furin in the TGN [42].
This simple structural organization seems to be a key element of protein
regulation because the sortilin propeptide blocks premature binding of
any ligand, preventing simultaneous binding of ligands with conﬂicting
functions [reviewed in 41]. Over the next years, evidence startedgathering that both sortilin and SorLA shuttle between the TGN and
late endosomes [34,43]. This type of trafﬁcking was shown to involve
interactions between the cytoplasmic domain of the receptors and var-
ious adaptors, including adaptor-protein-1 (AP1), Golgi-localized, γ
ear-containing, ARF-binding proteins (GGA1, GGA2 and GGA3) and
the retromer complex [43]. Other structural features exist, giving
more insights into this protein's function and evolution. The cytosolic
tail of sortilin closely resembles the one of the mannose-6-phosphate
receptors (MPRs), containingmotifs known to be involved in trafﬁcking
from the Golgi to the endosome and vice versa: FLV, YSVL and an
acidic-cluster dileucinemotif, all interactingwith the same adaptor pro-
teins (GGAs and AP-1) responsible for the forward transport of the
MPRs. In addition, the retrograde recycling of sortilin also involves an
interaction with the retromer complex through a YXXф site in the cyto-
solic tail [reviewed in 44]. There are also four particular amino acids in
the cytoplasmic domain shared by both sortilin and SorLA (the MVIA
motif), which are crucial for binding to the cytosolic adaptors GGA1, 2
and 3 [45].
There are some clues suggesting that the sortilin sorting pathway
may represent an evolutionary older mechanism for lysosomal trans-
port than the MPR pathway. Actually, even though the MPR is usually
described as analogous to the yeast Vps10p receptor, sortilin shares
more similarities with Vps10p than the MPR because both sortilin
and Vps10p contain the Vps10 domain, which is not present in the
MPR [46], and sortilin and Vps10p both interact with their ligands
through proteinaceous interactions, while the MPR recognizes its li-
gands through an oligosaccharide side-chain, the M6P tag [37,47,48,
reviewed in 44].
It appears, therefore, that the MPR pathway emerged as a very
speciﬁc mechanism for sorting soluble lysosomal hydrolases. Never-
theless, it did not completely substitute the mechanism mediated by
sortilin, which retained the ability to translocate different cargo pro-
teins (see Section 3.3).
3.3. A multiligand lysosomal receptor?
In 2003, the accumulated evidence of a possible role of sortilin as
an alternative sorting receptor in the M6P-independent transport of
newly synthesized hydrolases lead Lefrancois and colleagues [10] to
investigate whether sortilin could be involved in the sorting of SAPs.
Their attention was drawn to these activator proteins because earlier
reports ﬁrmly demonstrated that SAPs (prosaposin and GM2AP)
could reach the lysosomes in an M6P-independent manner.
A few years earlier, a carbohydrate-independent pathway of native
GM2AP had been characterized [49]. Formerly, immunocytochemical
analysis of tunicamycin-treated cells had shown that non-glycosylated
prosaposin could be targeted more efﬁciently to lysosomes, whereas
biochemical analysis revealed that prosaposin was associated with
Golgi membrane fractions in an association not disrupted by free
mannose-6-phosphate [50].
When Lefrancois et al. performed the ﬁrst study, they applied three
approaches: a dominant-negative competition experiment, siRNA and
Co-IP assays, which as a whole suggested that the SAPs (prosaposin
and GM2AP) constituted a class of proteins whose lysosomal sorting
and trafﬁcking were mediated by sortilin. The dominant-negative con-
struct was a truncated sortilin lacking the acidic cluster dileucine signal
(Δcytosolic), which is implicated in the binding of GGAs [34]. That con-
struct was retained in the Golgi apparatus and localized to the same
compartment as the Golgi marker. Full-length sortilin, in contrast, was
not restricted to the perinuclear region but extended into punctuate
structures. A C-terminal myc-tag was added to the construct, to dis-
criminate between truncate and endogenous sortilin. The over-
expression of such a construct abolished the punctuate staining seen
in non-transfected COS-7 cells with anti-GM2AP antibody, suggesting
that the truncated sortilin competed for the binding of prosaposin and
abolished its transport to the lysosomal compartment. Through siRNA
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of prosaposin into the culture media. Finally, co-immunoprecipitation
assays showed that sortilin interacts with both SAPs [10].
Then in 2006, using the same dominant-negative sortilin construct
(essential to recruit adaptor proteins and clathrin), Ni and colleagues
[2] demonstrated that sortilin was also involved in the lysosomal
targeting of acid sphingomyelinase (ASM). Confocal microscopy re-
vealed that truncated sortilin partially inhibited the lysosomal trafﬁck-
ing of ASM in COS-7 cells and abolished the lysosomal targeting of
ASM in I-cells. Pulse-chase experiments corroborated that sortilin was
involved in normal sorting of newly synthesized ASM. Furthermore,
over-expression of truncated sortilin accelerated and enhanced the se-
cretion of ASM fromCOS-7 cells and I-cells. Co-immunoprecipitation as-
says conﬁrmed the interaction between sortilin and ASM [2].
Two years later, sortilin was also implicated in the lysosomal
targeting of cathepsins D and H [11] in a study that was also based
on Co-IP assays but that used cathepsin B as a negative control and
prosaposin as a positive control. Interestingly, when analyzing the
cathepsins' interaction with the CI-MPR, the authors observed that,
unlike cathepsin H, which bound exclusively to sortilin, cathepsin
D was also able to bind to the CI-MPR. In the same study, COS7 cells
were transfected with a myc-tagged truncated sortilin construct,
and its effect on the transport of the lysosomal proteins was analyzed
by confocal immuno-microscopy. Untransfected cells labeled with
anti-cathepsin D or anti-cathepsin H antibodies revealed the pres-
ence of cathepsins D and H in punctate lysosomal structures that
overlapped with LAMP-1. However, anti-cathepsin D and anti-
cathepsin H antibodies did not yield granular staining in cells ex-
pressing truncated sortilin but did label the perinuclear region,
suggesting that truncated sortilin binds and retains cathepsins D
and H within the Golgi apparatus. This ﬁnding further showed that
truncated sortilin-myc competed not only with endogenous sortilin,
but also with the mannose-6-phosphate receptor to abrogate sorting
of cathepsin D. Canuel et al. [11] also addressed the effect of sortilin
inactivation on the transport of cathepsins D and H through sortilin
siRNA transfection and confocal microscopy analysis after staining
with anti-cathepsin D or H antibodies. The granular labeling and
perinuclear labeling of prosaposin and cathepsin H in untransfected
cells were absent in cells transfected with sortilin siRNA, but the
granular cytoplasmic staining of both anti-cathepsin B and D anti-
bodies was unaffected by the absence of sortilin. Thus the effect of
sortilin ablation on cathepsin D differed from the dominant-
negative experiment. To better understand the role of sortilin and
the M6PR in the trafﬁcking of cathepsins D and H, cells with both
the sortilin and the M6P pathways blocked were examined, demon-
strating that the transport of cathepsin D to the lysosomes occurs
through both sorting pathways. In conclusion, sortilin appears to
be the sole receptor necessary for lysosomal translocation of cathep-
sin H. Alternatively, the efﬁcient transport of cathepsin D requires
both the M6P receptor and sortilin.
Other soluble proteases that are known to be transported in a
M6P-independent fashion exist, but this transport is not mediated by
sortilin. This is the case with cathepsins K and L, where evidence of
MPR-independent transport are well established. When the M6P tag
was added to CHO cells expressing cathepsin K, its subcellular localiza-
tion remained unaltered, showing no competition between cathepsin K
and exogenousM6P [51]. For cathepsin L, low afﬁnity levels for theMPR
were registered [52], and mutagenic analysis of vacuolar sorting deter-
minants suggested a proteinaceous nature for its vacuolar sorting
signal, in contrast with the oligosaccharide nature of the M6P signal
expected for MPR-dependent transport [43,53]. Nevertheless, when
both cathepsins were studied using an approach similar to that applied
to cathepsins D and H, it was observed that neither cathepsins K nor L
interacted and immunoprecipitatedwith theMPR, nor did they interact
with sortilin. Their subcellular localization remained unaltered in cells
transfected with truncated sortilin when compared to untransfectedcells, clearly implying that cathepsins K and L do not require sortilin
for transport to the lysosomes [44].
Based on their assumption that sortilin was the sorting and trafﬁck-
ing receptor for at least ﬁve soluble lysosomal proteins, Carlos Morales'
group tested the hypothesis that inactivation of the sortilin gene results
in lysosomal storage disorders. To their surprise, none of the sortilin
nullizygous mice exhibited clinical signs of lysosomal pathologies.
Based on that observation, the authors decided to quantify the con-
centration of prosaposin in the lysosomes of nonciliated epithelial
cells lining the efferent ducts of sortilin−\− and sortilin+\+ mice.
Nonciliated cells are able to target both exogenous and endogenous
prosaposin to the lysosomes and are an excellent in vivo system with
which to analyze the effect of sortilin gene inactivation in cells with or
without luminal prosaposin. The authors observed that inactivation of
sortilin resulted in a signiﬁcant decrease in the level of prosaposin in
endosomes and lysosomes. Nevertheless, that inhibition was only
partial. In summary, the creation, characterization and analysis of a
sortilin knockout mouse, while supporting the idea that sortilin trans-
ports prosaposin, also suggests the existence of an alternative mecha-
nism of sorting and transport of the sortilin receptor [54]. On the
frontline of the most probable alternative receptors stands SorLA, the
only other known Vps10p family member containing motifs that have
been shown to be involved in trafﬁcking from the Golgi to the endo-
some and vice versa. Nevertheless, no studies to evaluate its function
in the M6P-independent transport of lysosomal hydrolases have yet
been conducted.
Some points concerning sortilin's function as an alternative receptor
for lysosomal transport remain unclear, however. Additional experi-
ments with non-tagged sortilin constructs and speciﬁc anti-sortilin
antibodies instead of myc-tagged ones would help to clarify sortilin's
subcellular location and interaction with its putative ligands by
preventing any disruption of the normal activation process of the pro-
tein by furin cleavage.
In general, there is still much to learn about the possible role of
Vps10p family receptors on the M6P-independent trafﬁcking path-
way. Further studies are needed on both sortilin and SorLA. A compel-
ling experiment would be the generation of a double knockout for
both proteins. In fact, the gene for SorLA has also been inactivated
in a previous study, and the knockout mice did not exhibit abnormal
phenotypes, which also suggests the existence of a complementary
receptor [55]. Finally, it would also be desirable to seek out rare
human patients with a large-effect mutation in SORT1 (e.g., a loss of
function mutation) and to carefully deﬁne the phenotype [56].
3.4. A multifunctional protein
Even though sortilin is an ancient lysosomal sorting receptor, dur-
ing the evolutionary process it has developed additional and novel
functions [Table 1 and references therein] that are gradually being
discovered. Several lines of evidence exist showing that in various
pathways sortilin plays key roles, which can range from important
functions in normal biological processes, such as glucose metabolism
[60,68] and neuronal cell proliferation and death [41,57], to inﬂuenc-
ing pathological processes like those underlying Alzheimer's disease
[69]. Sortilin is also acknowledged to play a part in lipoprotein metab-
olism by interacting with RAP [7,46] and binding lipoprotein lipase
(LPL) [9] and apolipoprotein (apo) A-V [63].
Since its early description, it has been known that sortilin is highly
expressed in several tissues, especially in the brain [7], which may be
easily explained by its role as a receptor of neuromediators [8] and
growth factors and also by its involvement in the fronto-temporal
lobar degeneration pathway. Indeed, sortilin may form part of a signal-
ing complex that regulates cell survival as evidenced by Teng and col-
leagues after performing coexpression assays of sortilin and p75
neurotrophin receptor (p75NTR) in sympathetic neurons [70]. The au-
thors found that the effects of proBDNF, an apoptotic ligand that induces
Table 1
Pleiotropic activities of sortilin in various biological pathways.
Adapted from Dubé et al. [56].
Pathway Sortilin mediated role
Lysosomal transport Mediates Golgi-to-lysosome transport of sphingolipid activator proteins (prosaposin and GM2 activator protein)
[10]
Mediates Golgi-to-lysosme transport of acid sphingomyelinase [2]
Mediates Golgi-to-lysosme transport of cathepsins D and H [11]
Neurotrophic signaling Binds proNGF forming an apoptotic signaling complex with p75NTR facilitating neuronal cell death [57]
Transports TrkA, TrkB and TrkC to nerve synapse terminals enhancing their interaction with neurotrophins;
facilitates neuronal differentiation, survival and plasticity [58]
Fronto-temporal lobar degeneration Modulates extracellular PGRN levels via binding and endocytosis; pathogenesis via decreased extracellular
PGRN levels through haploinsufﬁciency [59]
Carbohydrate metabolism Binds and translocates Glut4 to the plasma membrane from Glut4 storage vesicles in response to insulin
signaling [60]
Osteoblast differentiation Limits LPL-mediated suppression of mineralization activity in differentiating hMSC [61]
Identiﬁed as a marker of late osteogenesis [62]
Lipoprotein metabolism Binds LDL RAP [46]
Surface-expression mediates binding to LPL and subsequent degradation by endocytosis [9]
In vitro binding and endocytosis of apo A-V; facilitates lysosomal degradation of apo A-V [63]
Robust association between SORT1 variation (chromosome 1p13) and LDL-C concentrations [64]
Expression assays show regulatory effects on plasma LDL-C concentrations [65–67]
Implicated in apo B-100 metabolism and VLDL secretion [67]
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coexpression of both p75NTR and sortilin because neurons deﬁcient in
p75NTR are resistant to proBDNF-induced apoptosis, and competitive
antagonists of sortilin block sympathetic neuron death [70]. In addition,
sortilin facilitates neuronal differentiation, survival and plasticity by
transporting TrkA, TrkB and TrkC receptors to nerve synapse terminals,
enhancing their interaction with neurotrophins, as shown in the study
of Vaegter et al. [58], who demonstrated that sortilin is a positive
modulator of neurotrophin-induced neuronal survival. Neuronal
survival, differentiation and synaptic plasticity depend on the binding
of target-derived neurotrophins to Trk receptors at nerve terminals.
Nevertheless, the distance between the soma and the nerve terminal
is large enough to make efﬁcient anterograde Trk transport a critical
step for Trk synaptic translocation and signaling. Vaegter and colleagues
also observed that sortilin interacted with TrkA, TrkB and TrkC recep-
tors to enable their anterograde axonal transport, consequently con-
cluding that it enhanced neurotrophin signaling. Finding that sortilin
was frequently coexpressed with Trk and p75NTR in tissues that are
not destined for apoptosis (e.g., adult dorsal root ganglia (DRG)), the
authors hypothesized that sortilin might affect trafﬁcking and subcellu-
lar distribution of Trk receptors. In order to test that hypothesis, they
cultured DRG neurons lacking sortilin having veriﬁed that those cells
presented blunted MAP kinase signaling and reduced neurite out-
growth upon stimulationwith nerve growth factor (NGF). These results
were also supported by in vivo experiments in double knockout mice
(Sort1−/−; Ngfr−/−-knockout for the p75NTR coding gene), which
presented an aggravated phenotype when compared to the typical Trk
phenotypes observed in Ngfr−/−mice. Moreover, when sortilin knock-
outs (Sort1−/−) were crossed with mice heterozygous for a mutant
TrkA allele (Ntrk1+/−), an embryonic lethality and increased sympa-
thetic neuropathy with smaller superior cervical ganglion (SCG) were
observed [58].
Very recently, new evidence emerged indicating that sortilin also
has a role during phagosome maturation. Wähe and colleagues [71],
using a latex-bead phagosome (LBP) model, showed that in macro-
phages, sortilin is mainly localized in the Golgi and transported to
phagosomes. Through live-cell imaging and electron microscopy,
the authors observed that the delivery of sortilin to LBP was depen-
dent on its cytoplasmic tail and that sortilin participates in the direct
delivery of acid sphingomyelinase (ASM) and prosaposin (PS) to the
phagosome, bypassing fusion with lysosomal compartments. Further-
more, an analysis of primary macrophages isolated from Sort1−/−
mice indicated that the delivery of ASM and PS to LBP was severely
impaired, but the transport of pro-cathepsin D remained normal.Considering these results, the authors proposed a sortilin-mediated
pathway by which selected lysosomal proteins are transported to
the phagosome along a Golgi-dependent route during phagosomal
maturation.
In summary, additional roles of sortilin are still being unveiled,
suggesting that its function is far from being fully understood.3.5. Sortilin and disease: the cardiovascular risk association
Over the last few years, novel technological advances such as
next-generation sequencing catapulted genome wide association
studies (GWAS) of population-based cohorts into the limelight.
GWAS are reasonably successful in the identiﬁcation of single nucle-
otide polymorphisms (SNPs) within or near genes associated with var-
iations in plasma lipid and lipoprotein levels. More than 100 loci were
reported to account for a signiﬁcant part of the genetic variation in tri-
glyceride, low-density lipoprotein (LDL) and high-density lipoprotein
cholesterol levels. In coronary artery disease or MI, GWAS have identi-
ﬁed a smaller number of genetic loci, some of which are also associated
with changes in traditional lipoprotein risk factors. Notably, within a
widely replicated chromosome 1p13 locus associated with both MI
and LDL cholesterol levels [66,72–74], the relevant SNPs are located in
a gene cluster containing four genes, one of them SORT1, the gene cod-
ing for human sortilin. It has a key role contributing to the effects of the
chromosome 1p13q locus on LDL cholesterol and coronary artery
disease, which was described by three major studies. The ﬁrst was de-
veloped by Linsel–Nitschke and colleagues who, from their observa-
tions, proposed that the overexpression of sortilin increases the
internalization of LDL, with a consequent decrease of its plasma levels
[65]. Soon after, through studies in human cohorts, hepatocytes and
mice, Musunuru et al. reported an inverse relationship between sortilin
expression and circulating LDL-C levels and proposed an explanatory
mechanism through transcriptional regulation (liver-speciﬁc) of the
SORT1 gene by the transcription factor C/EBPα [66]. Conversely, Kjolby
and his team observed a direct relationship between the expression of
Sort1 and the concentration of circulating LDL, suggesting that it could
result from increased VLDL secretion [67].
Several explanations have been presented to justify the discrepan-
cy between these results and the answer seems to lie in sortilin itself,
which appears to be a multifaceted protein that may assume different
functions depending on the circumstances.
Overall however, the three studies presented strong evidence
demonstrating that SORT1 is a regulatory element of plasma LDL-C
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ignored until very recently.
3.6. Sortilin and disease: molecular basis for familial amyotrophic lateral
sclerosis?
Recently, Belzil and co-workers [75] hypothesized that, by reducing
progranulin levels and promoting neurodegeneration, SORT1mutations
or SORT1 aberrant splicing could cause amyotrophic lateral sclerosis
(ALS).
That hypothesis was based on independent assumptions. First, caus-
ative mutations had just been reported in the TARDBP and FUS genes,
encoding respectively for TAR DNA binding protein TDP-43 and RNA
binding protein FUS (both involved in the regulation of transcription
and RNA splicing) [76–79], in both amyotrophic lateral sclerosis (ALS)
and frontotemporal lobar degeneration (FTLD) [80,81]. The latter is a
condition commonly seen in comorbidity with ALS. It had also been
found that depletion of TDP-43 in the mouse adult brain modiﬁes the
expression levels of FUS and GRN (gene encoding progranulin) and al-
ters the splicing of SORT1 [82]. Finally, sortilin had also recently been
identiﬁed as a receptor that mediates progranulin uptake [59]. Thus,
the authors speculated that TARDBP, GRN, and SORT1 act in a common
pathological pathway and that mutations in any of those genes would
result in a similar phenotype.
To test this notion, they screened the SORT1 coding sequence
for mutations in a cohort of 112 unrelated individuals with familial
ALS and tested for aberrant splicing by RT-PCR using RNA samples
from cell lines expressing six different ALS-associated TARDBP muta-
tions [75]. They identiﬁed one unique missense and two unique silent
mutations; none of them were predicted to have functional effects.
No aberrant SORT1 splicing events were observed. SORT1 mutations
are not a common cause of familial ALS, and the inﬂuence of
TARDBP mutations on SORT1 splicing still requires clariﬁcation.
4. Conclusion
Although theM6P pathway is the primary sortingmechanism impli-
cated in lysosomal targeting, it is becoming clear that alternative recep-
tors are also involved in the lysosomal sorting of some soluble proteins.
Initial evidence for the existence of additional receptors came from
studies of immortalized cell lines of patients suffering from I-cell
disease, a lysosomal storage disorder in which the M6P sorting path-
way is disabled due to mutations in the genes that code for UDP-N-
acetylglucosamine-1-phosphotransferase. As a result of the loss of
enzyme function, lysosomal hydrolases are not modiﬁed withM6P res-
idues, and consequently, their trafﬁc to the endosomal–lysosomal com-
partment is impaired. Despite that, under this serious condition, some
soluble hydrolases such as SAPs and/or soluble hydrolases can still be
delivered to the lysosomes, implying that their transport is necessarily
conducted in a M6P-independent fashion [3,83]. Presently, there are
two potential alternative receptors: LIMP2 and possibly sortilin. LIMP2
transports GCase (the enzyme defective in patients with Gaucher
disease) to the lysosomes. Recently, mutations in its encoding gene,Table 2
Lysosomal storage disorders associated to deﬁciencies of alternative lysosomal receptors an
Lysosomal receptor Transported proteins
Sortilin
GM2AP
Saposin B
Saposin C
Cathepsin D
Acid sphingomyelinase
LIMP-2
Beta-glucocerebrosidaseSCRAB2, were shown to cause a severe autosomal recessive disorder
characterized by PME and nephrotic syndrome — AMRF. Sortilin is a
multifunctional protein that, apart from its role as a multiligand recep-
tor, was proposed to be responsible for the lysosomal transport of SAPs
(prosaposin and GM2AP), acid sphingomyelinase and cathepsins D and
H [2,10,11]. Like MPRs, sortilin is thought to be an ancient receptor in-
volved in a conserved trafﬁcking mechanism, but evolutionarily, the
sortilin sorting receptor has developed new functions essential in em-
bryonic development, neural function and apoptosis [44,11,84,85]. Fur-
ther understanding this network topology will permit better insights
into why certain lysosomal enzymes travel to the lysosomes in a
M6P-independent fashion while others do not, eventually leading to
the understanding of the mechanism underlying lysosomal storage dis-
orders of unknown origin [Table 2 and references therein].
The disruption of mechanisms involved in the trafﬁcking of lyso-
somal enzymes might have dramatic pathological consequences. Until
recently, attention was focused on lysosomal diseases resulting from
mutations in the gene that codes GlcNAc-phosphotransferase, which
plays a crucial role in lysosomal transport in a M6P-dependentmanner,
because the enzyme is responsible for addingM6P residues to enzymes
transported to the endosomal/lysosomal system. Total or near-total de-
ﬁciency of GlcNAc-phosphotransferase results in the nearly complete
absence of lysosomal targeting in many cell types and tissues, together
with the secretion of most lysosomal enzymes. This defect is clinically
recognized as mucolipidosis II (ML II or I-cell disease; MIM# 252500),
an autosomal recessive disease often resulting in death in the 1st de-
cade of life [92]. Another type of mucolipidosis, mucolipidosis III (ML
III or pseudo-Hurler polydystrophy; MIM# 252600), is a milder disease
inwhichGlcNAc-phosphotransferase activity is reduced rather than ab-
sent [93]. Both these pathologies belong to a group of rare genetic dis-
eases known as lysosomal storage diseases (LSD).
Now is the time to delve deeper to gain insights into the alterna-
tive trafﬁcking pathways to the lysosome. Strong evidence is accumu-
lating indicating that there is a series of proteins whose lysosomal
transport is done neither by the MPRs nor by any of the known alter-
native receptors. Cathepsins K and L, for example, have long been
known to reach the lysosomes through a M6P-independent pathway
[43,51,53] and were recently proven not to be transported by any of
the known alternative receptors [44]. Other hydrolases exist, though,
that do not acquire M6P residues and consequently travel to the lyso-
some in a MPR-independent fashion. Such is the case of lysosomal
acid phosphatase, for example. This lysosomal hydrolase is a type I
transmembrane protein that follows the constitutive secretory path-
way to the plasma membrane and reaches the lysosome via endocy-
tosis. In lysosomes, the transmembrane precursor is processed into
a soluble form [94]. It contains the tyrosine-based motif YRHV in its
cytosolic domain, which is required for endocytosis but does not me-
diate direct Golgi-to-endosome targeting [95–97]. It is clear that there
is still much to learn about Golgi-to-lysosome transport of lysosomal
hydrolases.
A proper understanding of these trafﬁcking pathways is essential
to gain a better understanding of lysosomal transport mechanisms
and may also unveil the molecular defects underlying LSD phenotypesd/or of their cargos.
Associated lysosomal storage disorder Reference
No known associated LSD
AB-variant of GM2 gangliosidosis [86]
Variant of metachromatic leukodystrophy [87]
Variant of Gaucher's [88]
Neuronal ceroid lipofuscinoses (CNCL) [89]
Niemann–Pick types A and B [90]
Action myoclonus-renal failure [13]
Gaucher [91]
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ical proﬁles do not ﬁt the characteristics of any known disorder.
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Resumo 
O nível plasmático de c-LDL constitui um determinante chave para o risco de doença 
cardiovascular, razão pela qual muitos estudos têm procurado elucidar as vias que regulam o 
seu metabolismo. As novas técnicas de sequenciação de última geração permitiram identificar 
um forte sinal de associação entre o locus 1p13 e o risco de doença cardiovascular causada 
por alteração dos níveis de LDL no plasma. Como seria de esperar para um fenótipo 
complexo, os efeitos da variação nesse locus são apenas moderados, mas ainda assim, o 
conhecimento da associação foi de grande importância uma vez conduziu à descoberta de 
uma nova via metabólica reguladora dos níveis de colesterol no plasma. Para tal, foram 
fundamentais os trabalhos efetuados por três equipas independentes, que ao procurarem 
esclarecer as bases biológicas da associação em causa, conseguiram provar que o gene SORT1, 
codificador da sortilina, era o gene do locus 1p13 implicado no metabolismo do LDL. SORT1 
foi o primeiro dos genes identificados como determinantes dos níveis plasmáticos de LDL a ser 
alvo de avaliação mecanística, e embora cada uma das equipas recorresse a metodologias 
experimentais diferentes, mas igualmente apropriadas face à questão em investigação, os 
resultados que obtiveram foram contraditórios em alguns aspetos. Neste trabalho, revemos o 
caminho percorrido até descoberta da nova via que relaciona a sortilina com os níveis 
plasmáticos de LDL e com o risco de enfarte do miocárdio. Ainda por esclarecer permanece o 
mecanismo regulador dessa ligação, mas a sua descoberta sugere novos alvos terapêuticos até 
há bem pouco tempo desconhecidos. 
 
Abstract 
Plasma LDL levels are a key determinant for the risk of cardiovascular disease. This is the 
major reason why many studies have attempted to elucidate the pathways that regulate its 
metabolism. The novel next-generation sequencing techniques allowed the identification of a 
strong association between the 1p13 locus and the risk of cardiovascular disease caused by 
changes in the levels of LDL in plasma. As expected for a complex phenotype, effects of 
variation in that locus are only moderate. Still, knowledge of that association was of major 
importance since it unveiled a new metabolic pathway regulating plasma cholesterol levels. 
Crucial for this discovery were the works performed by three independent teams who seek to 
clarify the biological basis of such association and managed to prove that SORT1, encoding 
sortilin, was the gene in the 1p13 locus involved in the metabolism of LDL. SORT1 was the 
first gene identified as determinant of plasma LDL levels to be mechanistically evaluated and, 
although each of the three teams used different, even though valuable, experimental 
methodologies, their results were somehow contradictory. Here we review all experiments 
that led to the identification of the new pathway connecting sortilin with plasma LDL levels 
and risk of myocardial infarction. The regulatory mechanism underlying such association 
remains unclear but its discovery has paved the way for considering previously unsuspected 
therapeutic targets and/or approaches. 
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Abreviaturas 
apo – apolipoproteína apo – apolipoprotein 
C/EBP - CCAAT-enhancer binding protein 
CT- colesterol total  TC – total cholesterol 
DAC – doença das artérias coronárias CAD – coronary artery disease 
DALYs – disability-adjusted life years 
DCI – doença cardíaca isquémica IHD – ischaemic heart disease 
DCV – doença cerebrovascular CVC – cerebrovascular disease 
EAM – enfarte agudo do miocárdio  MI – myocardial infarction 
GLUT4 – glucose transport isoform 4 
GM2AP – GM2 activator protein 
GWAS – Genome-wide association studies 
LDL – Low-density lipoproteins 
HDL – High-density lipoproteins 
LPL – lipoproteina lípase LPL – lipoprotein lípase 
RAP - receptor associated protein 
SAP – sphingolipid activator protein 
SNP – single nucleotide polymorphism 
 
 
 
Introdução 
As doenças cardiovasculares constituem a maior causa de mortalidade nos países 
desenvolvidos (1), sendo responsáveis por 32% das mortes em Portugal, segundo dados do 
Instituto Nacional de Estatística (2). A Doença Arterial Coronária (DAC), em particular, 
representa um enorme problema clínico, provocando uma em cada cerca de cinco mortes nos 
Estados Unidos (3,4). Se para o desenvolvimento de DAC contribuem múltiplos fatores, está 
bem estabelecido que um dos determinantes chave de risco são os níveis de colesterol LDL no 
plasma. Segundo estimativa da OMS, cerca de 9 milhões de mortes/ano e mais de 75 milhões 
de anos de vida perdidos/ano podem ser atribuíveis a hipertensão ou Hipercolesterolemia (5). 
Globalmente a hipercolesterolemia é responsável por 18% da doença cerebrovascular (DCV), 
maioritariamente eventos não fatais, e por 56% da doença cardíaca isquémica (DCI) (5). Os 
dados disponíveis relativamente à Europa indicam que a hipercolesterolemia possa ser 
responsável por até 12 % dos anos de vida perdidos ajustados à incapacidade (DALYs – 
Disability-Adjusted Life Years) (5). Face à ordem de grandeza destes números, muitas têm sido 
as tentativas no sentido de esclarecer as vias que regulam o metabolismo do colesterol 
associado às lipoproteínas de baixa densidade (c-LDL). Atualmente sabe-se que em subgrupos 
minoritários de indivíduos o colesterol elevado pode ser de origem genética simples, 
resultando em doenças mendelianas como a Hipercolesterolemia Familiar (6) A maioria dos 
doentes com esta patologia apresenta mutações patogénicas no gene que codifica o recetor 
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das LDL (LDLR), mas tem-se verificado que defeitos no gene que codifica a apolipoproteína B 
(APOB) ou, mais raramente, no que codifica a proproteína convertase subtilisina quexina tipo 
9 (PCSK9) também estão associados ao mesmo fenótipo clínico (6, 7) As mutações encontradas 
em qualquer um destes genes provocam perda (no caso do LDLR e APOB) ou ganho de função 
(no caso do PCSK9) da proteína que codificam, alterando significativamente a sua função, 
sendo consideradas fator de elevado risco para o desenvolvimento de DCV. 
Todavia, poucos são os casos em que se pode relacionar DCV com os efeitos drásticos de uma 
mutação num dado gene. Na patogénese da maioria das formas estão envolvidos fatores 
comportamentais, ambientais e genéticos, sabendo-se ainda que a componente genética é 
por si complexa podendo implicar a interação entre múltiplos determinantes genéticos (8). 
Conhecem-se já uma série de polimorfismos nos genes referidos ou outros envolvidos no 
metabolismo lipídico que podem contribuir significativamente para o risco de DCV (revisto em 6), 
embora o efeito individual de cada variação seja pequeno. 
Com o advento das novas tecnologias de sequenciação, ganhou-se novo fôlego o esforço para 
alcançar uma compreensão mais profunda dos fatores genéticos subjacentes ao 
desenvolvimento de doenças complexas. Assistiu-se assim a um aumento substancial dos 
estudos de epidemiologia molecular e a avanços importantes no entendimento da etiologia de 
muitas dessas doenças, o que em última análise é fundamental para desenhar novas 
estratégias de prevenção e tratamento (9).  
Recentemente, através de estudos de associação envolvendo rastreios genómicos de grande 
escala (GWAS, Genome Wide Association Studies) foi possível identificar uma série nova de 
variantes de DNA que influenciam os níveis de LDL no plasma. Uma das associações mais 
consistentes foi inicialmente observada numa região do cromossoma 1p13, onde acabaria por 
se identificar uma variação genética comum fortemente associada ao c-LDL e enfarte de 
miocárdio. A importância clínica desta descoberta está patente na diferença de 40% no risco 
de enfarte do miocárdio verificada em indivíduos homozigóticos para os alelos maioritário 
(mais comum) e minoritário (menos comum) dessa variação. O efeito é comparável ao das 
variantes comuns dos já mencionados LDLR e PCSK9 e maior do que descrito para as variantes 
mais comuns de HMGCR (gene que codifica a 3-hidroxi-3-methilglutaril-CoA reductase) (10), o 
gene que codifica o alvo terapêutico das estatinas, os fármacos mais usados no tratamento 
das hiperlipidemias. No locus 1p13, está localizado SORT1, o gene que codifica a sortilina, 
uma proteína multifuncional cuja relevância a nível biológico tem vindo a ser cada vez mais 
valorizada à medida que lhe vão sendo decifradas novas funcionalidades. Embora já fossem 
conhecidas as suas funções como recetor de vários ligandos, começaram a aparecer indícios 
claros de que a sortilina pode influenciar os níveis plasmáticos de c-LDL e, 
consequentemente, o risco de DAC. Se inicialmente, diferentes GWAS foram fundamentais 
para chegar a SORT1 como provável gene de risco para a associação c-LDL/DAC, em 2010 
surgiram quase em simultâneo 3 estudos desenvolvidos por equipas independentes (10-12) que 
procuraram explorar o mecanismo biológico que poderia relacionar a sortilina com os níveis 
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de c-LDL. Para tal, utilizaram abordagens mecanicistas diferentes tendo, curiosamente, 
chegado a conclusões também diferentes. Neste artigo, resumimos cada uma dessas 
abordagens e suas principais conclusões, avançando ainda com as razões que têm sido 
invocadas para conciliar os resultados aparentemente discrepantes.  
 
Em busca de uma agulha num palheiro: os GWAS 
Ao longo dos últimos anos, os avanços ao nível das técnicas da Biologia Molecular, em grande 
parte proporcionados pelo aparecimento e generalização do uso da terceira geração de 
sequenciadores, catapultaram os GWAS para a linha da frente dos estudos populacionais, com 
enfoque na identificação de moduladores genéticos de doenças, em especial de doenças 
complexas. Os GWAS baseiam-se na premissa de que em muitas dessas doenças as variantes 
hereditárias que concorrem para explicar o desenvolvimento do processo patogénico podem 
ser relativamente comuns, com frequência do alelo minoritário (minor allele frequency, MAF) 
superior a 5%, o que torna possível identificar associações entre doenças e variações 
genómicas através de grandes rastreios populacionais. Essas variações não são 
necessariamente codificantes, e de facto, através de GWAS têm sido identificadas associações 
com uma série de variantes genéticas localizadas em zonas não codificantes do genoma. A 
interpretação do significado destas associações depende, em grande parte, do conhecimento 
fino sobre as regiões em que se encontram as variantes. No fundo, questiona-se se uma 
variante para a qual se detetou um sinal positivo de associação não influenciará a expressão 
de um gene, ou se o sinal não será consequência da ocorrência de desequilíbrio de ligação 
com outras variações em genes localizados nessa mesma região genómica. Procura-se, então, 
identificar os genes com potencial para explicar a associação detetada, seguindo-se um outro 
desafio, que é compreender a base biológica dos sinais revelados pelos GWAS. Embora as 
expectativas nem sempre sejam alcançadas, este tipo de estudos tem desvendado 
importantes fatores genéticos que estão por detrás de uma série de doenças complexas. Um 
dos casos de maior sucesso, é ilustrado pela identificação de SNPs (SNP, single nucleotide 
polimorphism) relevantes em doenças cujos quadros patogénicos dependem dos níveis de 
lípidos e de lipoproteínas no plasma, como são exemplo a dislipidemia ou o enfarte agudo do 
miocárdio (EAM). Ao longo dos últimos anos, foram já descritos mais de 100 loci associados a 
variação dos níveis de triglicerídeos, c-LDL e colesterol HDL (13-20). Relativamente a DAC ou 
EAM, os GWAS levaram à identificação de um menor número de loci, alguns dos quais 
igualmente associados a alterações nos fatores de risco tradicionais. Um balanço conjunto dos 
vários GWAS que resultaram na anotação de loci associados a DAC (14, 17, 21-23), entre os quais se 
incluíam os estudos do “Welcome Trust Case Control Consortium” e do “German MI Family 
Study”, saldou-se no registo de indícios de associação com 7 loci cromossómicos (14), 
nomeadamente localizados em 1p13.3 (compreendendo os genes SARS, CELSR2, PSRC1, 
MYBPHL, SORT1, PSMA5 e SYPL2), 1q41 (gene MIA3), 2q36.3 (região intergénica), 6q25.1 
(gene MTHFD1L), 9p21.3 (genes CDKN2A e CDKN2B), 10q11.21 (região intergénica) e 15q22.33 
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(gene SMAD3). A questão imediata que se colocou foi a de saber se estes novos loci afetavam 
os fatores de risco cardiovascular já conhecidos. Para a esclarecer, Samani e colaboradores 
(15) investigaram a relação destes sete loci com uma série de parâmetros mensuráveis de 
reconhecida relevância em termos de doença cardiovascular, tendo demonstrado que apenas 
o locus de risco de DAC no cromossoma 1p13 estava significativamente associado a níveis 
elevados de c-LDL, sendo na região intergénica localizada entre os genes PSRC1 e CELSR2 que 
detetaram o sinal de associação mais forte. Os genes PSRC1 e CELSR2 codificam 
respetivamente as proteínas proline/serine-rich coiled-coil 1 e caderina EGF, cuja função 
permanece desconhecida, e estão muito próximos do gene codificador da sortilina, SORT1. 
Nenhum destes 3 genes ou dos outros contidos no locus 1p13 tinha sido conotado com alguma 
das doenças mendelianas conhecidas que afetam os níveis de colesterol LDL (10, 13, 20).  
 
Os suspeitos do costume e um suspeito inesperado: LDL e sortilina 
Face à grande robustez estatística da associação detetada entre o locus 1p13 e os níveis 
plasmáticos de c-LDL, a busca do mecanismo biológico capaz de explicar a observação tornou-
se o foco de pesquisa de diversas equipas. 
Em primeiro lugar, importava conseguir uma melhor aproximação à causa genética da 
associação, impossível de obter através dos GWAS devido aos efeitos de linkage 
disequilibrium (relação não aleatória) entre vários SNPs do locus 1p13. 
Para alcançar o fim em vista, seria necessário proceder à re-sequenciação fina da região 
contendo os genes SORT1, PSRC1, CELSR2, e efetuar diversos estudos in silico, in vitro e in 
vivo. À medida que os resultados foram surgindo, um gene começou a destacar-se de entre os 
candidatos que compõem este locus de risco de DAC: SORT1, o gene que codifica a sortilina 
(10-12). 
A sortilina pertence à família de recetores de domínio Vps10p, constituída por cinco membros 
atualmente conhecidos. É sintetizada sob a forma de uma proproteína e clivada no Golgi por 
convertases de proproteínas, processo após o qual assume a forma matura que lhe permite a 
correta ligação aos ligandos. Em termos funcionais, é um recetor de múltiplos ligandos, 
incluindo a lipoproteína lípase (LPL) (24), as apolipoproteínas A-V (apo A-V) (25), a neurotensina 
(26) e a proteína RAP (receptor-associated protein) (27). É ainda responsável por mediar o 
transporte do Golgi para o lisossoma de uma série de proteínas, enzimáticas ou não: proteínas 
ativadoras dos esfingolípidos (SAPs, sphingolipid activator proteins: prosaposina e, GM2AP, 
GM2 activator protein), esfingomielinase ácida, catepsina D e catepsina H (24, 28-30). 
Demonstrou-se ainda que a sortilina está envolvida numa série de processos de grande 
relevância biológica de que é exemplo a formação de vesículas de armazenamento de GLUT-4 
(glucose transport isoform 4) na resposta à insulina durante a diferenciação dos adipócitos 
(31). No cérebro, faz parte de um complexo de sinalização que regula a sobrevivência da célula 
(32). 
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A relevância in vivo destas propriedades multifacetadas ainda permanece por esclarecer, mas 
cada vez mais se tem reforçado a noção de que se trata de uma proteína com importantes 
papéis a nível biológico e cuja desregulação parece passível de causar efeitos indesejáveis, 
podendo ir muito além do possível transtorno dos níveis de colesterol LDL no plasma. 
 
Uma abordagem exemplar: análise mecanística 
Em 2010, três equipas independentes publicaram resultados de trabalhos pioneiros na 
tentativa de esclarecer o mecanismo biológico que poderia explicar a associação do locus 
1p13 aos níveis de colesterol LDL no plasma (10-12). Recorrendo a sólidas abordagens 
experimentais mas distintas entre si, os 3 estudos apontaram para o gene SORT1 como sendo 
o responsável pelo aumento do risco de DAC e/ou EAM. Pese embora esta unanimidade, 
curioso é o facto de os 3 estudos terem chegado não apenas a conclusões diferentes mas até 
opostas em alguns aspetos quanto ao papel da sortilina na secreção de colesterol das 
lipoproteínas de muito baixa densidade (VLDL) (revisto em 33, 34).  
As primeiras evidências in vitro da interação entre a sortilina e partículas de c-LDL foram 
apresentadas por Linsel-Nitschke e colaboradores. Através do mapeamento fino do locus 
1p13, os autores começaram por procurar a variação com sinais mais fortes de associação, 
chegando ao SNP rs599839 e verificando que o alelo G era o que se associava a redução dos 
níveis plasmáticos de LDL e diminuição do risco de doença cardiovascular. Demostraram 
depois que os indivíduos homozigóticos para o mesmo alelo apresentavam expressão 
aumentada dos genes SORT1, CELSR2 e PSRC1 em glóbulos brancos do sangue periférico, 
sendo, no entanto, nos níveis de mRNA SORT1 que observaram o efeito mais acentuado. Estes 
resultados foram confirmados em células embrionárias de fígado humano (HEK293) induzidas 
a sobre-expressar SORT1, em que verificaram um aumento da internalização de partículas c-
LDL, com consequente diminuição dos respetivos níveis plasmáticos (11). 
No mesmo ano, Musunuru et al. apostaram numa abordagem multifacetada, vista como um 
autêntico “tour de force” exemplar para dar sentido aos resultados obtidos com os GWAS (35). 
Baseando-se no conhecimento prévio de que os SNPs rs646776, rs599839, rs12740374, e 
rs629301 do locus 1p13 eram os mais altamente associados ao c-LDL no plasma, e partindo do 
princípio que variantes de DNA não codificantes, como o caso das 4 em que se centraram, 
podem alterar a expressão génica, Musunuru e seus colaboradores começaram por analisar os 
seus efeitos nos níveis de mRNA dos seis genes localizados no locus 1p13: SARS, CELSR2, 
PSRC1, MYBPHL, SORT1 e SYP2. Verificaram, então, que no fígado humano o alelo minoritário 
de rs646776 estava associado a um aumento da expressão de 3 genes, SORT1, CELSR2 e PSRC1 
(36), tendo verificado maior alteração de expressão ao nível de SORT1, traduzida no aumento 
da quantidade do seu produto proteico, a sortilina. O mapeamento fino da região genómica 
em estudo, permitiu-lhes identificar os haplótipos definidos pelos SNPs presentes numa região 
de 6.1 kilobases localizada entre os genes CELSR2 e PSRC1, e chegar ao SNP rs12740374 como 
sendo afinal o responsável pela associação evidenciada pelos GWAS. Os indícios começaram 
Coutinho et al., in press 
9 
 
por surgir na sequência da análise bioinformática, indicando que ao alterar a sequência 
GGTGCTCAAT para GTTGCTCAAT, o alelo minoritário deste SNP criava um novo local de 
ligação de fator de transcrição, especificamente para a proteína C/EBP (CCAAT-enhancer 
binding protein) α, capaz de aumentar a atividade do promotor e o nível de expressão de 
SORT1. O efeito previsto in silico foi depois confirmado in vitro. Refira-se que este resultado 
era consistente com o reportado pelo grupo de Linsel-Nitschke et al. (11) relativamente aos 
níveis de mRNA expressos no fígado. Finalmente, Musunuru et al. (10) efetuaram estudos em 
células de fígado de ratinhos mutantes, em que o gene que codifica a sortilina tinha sido 
inativado ou sobrexpresso, demonstrando que o nível de expressão da sortilina era capaz de 
modular a secreção hepática das VLDL. O ratinho transgénico escolhido por esta equipa, com 
o gene Apobec1 (que efetua a correção das transições C>U nos mRNAs da apo B, entre outros) 
suprimido, Apobec1-/-, era um ratinho “humanizado”, apresentando um perfil lipídico 
diferente do que é normal naquela espécie e mais próximo do que se observa em humanos, 
em que o c-LDL é o transportador de colesterol predominante na circulação. Quando 
Musunuru et al. (10) sobre-expressaram o gene Sort1 nas células hepáticas desses ratinhos, 
observaram uma redução 70% nas concentrações de colesterol total (CT) e de colesterol LDL. 
Pelo contrário, quando procederam à inativação do gene Sort1 por siRNA, registaram um 
aumento de 46% dos níveis de CT e de 125% dos níveis de LDL.  
De um modo geral, os dados apresentados por estas duas equipas vinham reforçar, e também 
dar sentido, às conclusões extraídas dos GWAS, na medida em que ao demostrarem a 
existência de uma correlação negativa entre os níveis de mRNA SORT1 e a concentração de c-
LDL no plasma, sustentavam um mecanismo biológico explicativo de como variações genéticas 
no locus 1p13 podiam influenciar os níveis plasmáticos de LDL e, portanto, alterar o risco de 
DAC/EAM.  
No entanto, ainda no mesmo ano, foi publicado um terceiro estudo mecanístico abordando a 
mesma questão, cujos resultados nem se conciliavam tão facilmente com os dois anteriores 
nem com as evidências inferidas através dos GWAS.  
Referimo-nos ao trabalho de Kjolby e sua equipa (12), que utilizaram como modelo um ratinho 
knockout duplo, Sort1-/-,Ldlr-/-, tendo observado que os seus hepatócitos apresentavam 
reduções de 30% nos níveis de CT, de ~50% nos níveis de proteínas contendo apo B100 (VLDL e 
LDL) e de ~60% na área das placas arteroscleróticas, quando comparados com o ratinho 
knockout simples, Ldlr-/-. De seguida, induziram sobre-expressão do gene Sort1 ao nível do 
fígado dos ratinhos, verificando, resumidamente, que enquanto a deficiência de sortilina 
levava a uma redução de 50% na secreção de lipoproteínas, a sua sobre-expressão se traduzia 
num aumento de 50% na secreção das mesmas proteínas. No conjunto, os resultados 
apontavam para uma correlação positiva entre a expressão Sort1 e a concentração de c-LDL, 
ou seja, de sentido oposto ao observado por Musunuru et al (10). 
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Descubra as diferenças: análise dos resultados 
A discrepância entre os resultados destes três estudos tem vindo a ser discutida entre a 
comunidade científica, como ilustram as publicações surgidas em 2011 de Dubé ou de Tall e 
Ai (33, 34). Nos seus comentários, estes autores chamam a atenção para as diferenças 
experimentais entre os trabalhos de Linsel-Nitschke et al. (11), Kjolby et al. (12) e Musunuru et 
al. (10), e para como tais diferenças podem ter condicionado algum desacordo nos resultados 
obtidos. Tendo em vista esclarecer o mecanismo através do qual o locus 1p13 afetava os 
níveis de LDL e risco de DAC, as 3 equipas optaram por modelos diferentes, e embora cada 
uma delas tivesse recorrido a abordagens experimentais bem desenhadas e delas extraído 
ilações apropriadas, as diferentes conclusões podem não ser estritamente comparáveis entre 
si. 
Primeiro, devido à diferença de background metabólico dos modelos animais usados nas 
experiências efetuadas. Linsel-Nitschke et al. (11) conduziram as suas investigações apenas em 
humanos, ao contrário das equipas de Musunuru (10) e Kjolby (12) que apostaram na análise de 
modelos animais não-humanos, especificamente em modelos de ratinho mas, mesmo assim, os 
ratinhos que escolheram tinham diferentes perfis metabólicos: Musunuru et al. (10) 
trabalharam com células hepáticas de um ratinho “humanizado”, Apobec-/-; Kjolby et al. 
estudaram um knockout duplo para a sortilina e para o recetor das LDL (Sort1-/-,Ldlr-/-). 
Enquanto o modelo de Musunuru (10) sobre-produzia e secretava quantidades anormalmente 
elevadas de lipoproteínas de modo a mimetizar o perfil lipídico humano, o que pode ter 
alterado artificialmente as vias secretórias e a disponibilidade de sortilina, o de Kjolby (12) 
tinha um catabolismo deficiente em lipoproteínas, criado pela repressão da expressão no 
interior dos hepatócitos e acentuado pela dieta “high fat western”. Outro ponto a ter em 
linha de conta, são as diferenças na regulação génica entre as duas espécies, homem e 
ratinho, como ficou demonstrado, por exemplo, pela inexistência do local C/EBP α no ratinho 
(10; 37). No que se refere à sortilina, isto significa que as conclusões retiradas de observações 
no ratinho não podem ser linearmente extrapoladas para o homem, nem vice-versa (34).   
Em conjunto, as observações in vivo dos estudos em ratinhos parecem demonstrar que a 
sortilina pode assumir funções hepáticas complementares dependentes do meio metabólico, 
que em última análise regulam a secreção das VLDL. É de admitir que a sortilina possa regular 
a secreção e o tráfego das VLDL para o lisossoma quando os níveis intracelulares de apo B-100 
são extremamente elevados. Pelo contrário, em condições de menor expressão da apo B-100, 
a sortilina poderá regular a formação e secreção das VLDL (33, 34).  
Porém, esta possível função da sortilina na formação e secreção das VLDL não se harmoniza 
facilmente com os resultados obtidos com os GWAS que demonstravam uma associação 
específica com o c-LDL e não com os triglicerídeos, que são o componente principal das 
partículas das VLDL (34). Fica assim em aberto a possibilidade de a sortilina ter um papel 
noutras vias de regulação dos níveis lipídicos no plasma que não impliquem as VLDL. 
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Se os 3 estudos em apreço forneceram pistas que em parte são contraditórias, apresentaram 
também provas da existência de uma nova via regulatória para o metabolismo das 
lipoproteínas e da possibilidade da modulação desta via alterar o risco de DCV em humanos, 
não obstante haver ainda muito a percorrer para obter uma visão clara de como se processa e 
dos fatores que a modulam.  
 
Conclusão 
Como os GWAS envolvem a genotipagem de variantes comuns em termos populacionais, têm a 
limitação de só terem capacidade para identificar alelos cujo efeito num fenótipo associado a 
um quadro patogénico é mínimo, senão negligenciável (38). Ou seja, permitem identificar 
alelos relativamente comuns mas que explicam apenas uma pequena porção da variação 
genética associada a um fenótipo (39). Assim, mesmo depois de todos os esforços de 
investimento em GWAS, uma parte significativa da hereditariedade das doenças complexas, 
como é o caso das doenças cardiovasculares e das DAC em particular, permanece 
desconhecida. Esta porção da hereditariedade foi denominada “a hereditariedade perdida” ou 
“a matéria negra da hereditariedade” (35). Os grandes defensores dos GWAS argumentam que 
aumentando o tamanho das amostras e reforçando substancialmente a densidade dos SNPs a 
estudar, será possível ir desvendando a porção da hereditariedade que se mantém 
desconhecida (35). Porém, há quem defenda uma estratégia diferente que consiste na 
sequenciação direta de todo o genoma tendo em vista a identificação de alelos raros que 
exerçam grandes efeitos no fenótipo (40). As portas para o recurso generalizado a esta 
estratégia começam agora a abrir-se com o aparecimento e aperfeiçoamento de novas 
plataformas de sequenciação de terceira geração que permitem a sequenciação do genoma 
completo a um custo cada vez mais acessível. Estima-se que o genoma de cada indivíduo 
contenha aproximadamente 10000 variantes não sinónimas entre cerca de 3.5 milhões de 
SNPs. Tendo em mente a ordem de grandeza destes valores é compreensível que este tipo de 
sequenciação venha a dominar os estudos genéticos nos próximos anos, tendência que já hoje 
se verifica (41-45).  
Mas a descoberta de novas variantes genéticas associadas a doenças complexas pode não ser 
suficiente para descodificar a “matéria negra da hereditariedade”, dado que esta pode ser o 
produto de interações complexas entre fatores genéticos, genómicos e epigenéticos (39, 46). E a 
um outro nível, também o fenótipo pode ser consequência de interações não lineares entre 
diversos fatores de natureza genética e ambiental.  
Apesar disso, é muito importante ir enriquecendo o catálogo das variantes genéticas 
associadas a um determinado fenótipo complexo, até porque a descoberta de novas variantes 
pode abrir caminho para chegar a via moleculares até então insuspeitas de influenciar a 
doença, como aconteceu com o exemplo que temos vindo a referir.  
Os três reports aqui revistos representam abordagens exemplares e paradigmáticas de como 
se pode partir de uma associação estatística “cega” fornecida pelos GWAS, até encontrar uma 
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explicação mecanística, mais ou menos esclarecida, do modo como uma variação genética 
pode modular um certo fenótipo. Neste caso, os GWAS orientaram para um ponto de partida 
particular, o locus 1p13 (14, 21-23), que acabaria por despertar a atenção de três equipas 
independentes, levando-as a enveredar por diferentes abordagens experimentais para 
compreender em que se fundamentava a associação estatística, mas todas apostando no gene 
SORT1 como o modulador chave dos níveis de c-LDL e risco de EAM. Se os resultados foram 
concordantes na indicação de que SORT1 tinha um papel importante na regulação do 
metabolismo lipoproteíco, já foram menos consonantes as interpretações sobre a direção do 
efeito da expressão do gene nos níveis plasmáticos do c-LDL bem como sobre o mecanismo 
subjacente (10-12).  
Face às suas observações, Linsel-Nitschke (11) e colaboradores propuseram que a sobre-
expressão da sortilina aumentava a internalização de LDL, com consequente diminuição dos 
respectivos níveis plasmáticos (11). Pouco depois, Musunuru et al. (10) reportaram uma relação 
inversa entre a expressão da sortilina e a concentração de LDL circulante, avançando com um 
mecanismo explicativo que passava pela regulação transcricional, específica ao nível do 
fígado, do gene SORT1 por fatores de transcrição C/EBP α, em que  a sobre-expressão da 
SORT1 reduziria a produção/secreção de VLDL (10). Mas pelo contrário, Kjolby e a sua equipa 
(12) observaram uma relação direta entre a expressão da Sort1 e a concentração de LDL 
circulante, sugerindo que tal poderia resultar de secreção aumentada das VLDL (11).  
Entre as várias explicações que foram já apresentadas para justificar a discrepância entre 
resultados, a resposta parece em parte residir na própria sortilina, que emerge cada vez mais 
como uma proteína multifacetada podendo assumir diferentes funções consoante as 
circunstâncias.  
Em síntese, os estudos aqui revistos proporcionaram uma série de provas consistentes de que 
SORT1 é um elemento regulador dos níveis de c-LDL no plasma, o que veio acrescentar ao 
gene que codifica a sortilina uma importante função de que não se desconfiava até há bem 
pouco tempo. De momento, é ainda controversa a via celular que relaciona a sortilina com o 
metabolismo lipídico, mas certamente que nos próximos anos a questão vai continuar a ser 
explorada, sendo fundamental para avaliar se a sortilina pode representar um alvo potencial 
para abordagens terapêuticas direcionadas para hipercolesterolemia ou DCV (revisto em 33-35).  
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Introduction
Cardiovascular disease is the leading cause of death in developed countries (1), being 
responsible for 32% of deaths registered in Portugal, according to our National Institute of 
Statistics (2). Coronary artery disease (CAD), in particular, represents a major clinical 
problem, accounting for one in every five deaths in the U.S. (3, 4). For the development of CAD 
multiple factors contribute but it is well established that one of its key determinants are the 
plasma LDL levels. According to the WHO estimate, about 9 million deaths/year and more 
than 75 million years of life lost/year are due to hypertension or hypercholesterolemia (5). 
Overall, hypercholesterolemia is responsible for 18% of registered events of cerebrovascular 
disease (CVD), mostly non-fatal events, and 56% of ischaemic heart disease (IHD) (5). The data 
available for Europe suggest that hypercholesterolemia may be responsible for up to 12% of 
disability-adjusted life years (DALYs) (5). Given the magnitude of these numbers, many 
attempts have been made to elucidate the pathways that regulate LDL metabolism. 
Presently, it is known that, for minor groups of individuals, high cholesterol levels may be of 
genetic origin. There is even a Mendelian disease associated to it: familial 
hypercholesterolemia (6). Most patients suffering from this pathology present pathogenic 
mutations in the gene that codes for the LDL receptor (LDLR), but it has been reported that 
also defects in the the apolipoprotein B gene (APOB), or less commonly, in the proprotein 
convertase subtilisin/kexin type 9 (PCSK9) gene, may also be associated to that clinical 
phenotype (6, 7). Mutations in any of these genes lead to either loss (LDLR and APOB) or gain 
(PCSK9) of function of its associated protein and high cardiovascular risk.  
However, there are few cases in which it is possible to relate the presence of a specific gene 
mutation with CVD. The pathogenesis of the major forms of CVD involves behavioral, 
environmental and genetic factors and it is known that the genetic component is very 
complex resulting from the interaction of multiple genetic determinants (8). There are, 
however, several polymorphisms in these or other genes involved in lipid metabolism that, 
even though presenting a smaller effect in the protein which they code, may play a 
significant part in CVD risk (reviewed in 6). 
With the advent of new sequencing technologies, the search for a deeper understanding of 
these mechanisms, as well as the genetic basis of other risk factors had a new incentive. It 
became possible to screen large populations for the genetic basis for complex diseases. 
Ultimately, such epidemiological studies may lead to better and deeper understanding of 
etiological pathways and contribute to the development of new strategies for prevention and 
treatment (9). 
Recently, through association studies involving large-scale genome screenings (genome-wide 
association studies, GWAS) it was possible to identify a novel set of DNA variants that 
influence plasma LDL-c levels. The most consistent of these associations was observed in a 
cluster of genes on chromosome 1p13. The clinical relevance of this novel pathway is defined 
by the 40% difference in risk of myocardial infarction (MI) verified between individuals 
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homozygous for the minor (less common) and major (more common) alleles of the p13 locus 
on chromosome 1. The effect is comparable to the one attributed to common variants of LDLR 
and PCSK9 and greater than that described for the most common variants in HMGCR (gene 
that codes for 3-hydroxy-3-methylglutaryl-CoA reductase) (10) the gene that encodes the 
therapeutic target of statins, which is the class of drugs more commonly used in the 
treatment of hyperlipidemias. In the 1p13 cluster is located the SORT1 gene. This gene 
encodes for sortilin, a multifunctional protein whose biological relevance is becoming greater 
as novel and unexpected functions are being unveiled for it. Even though its functions as a 
receptor for various ligands were already known, given the clear association reported by 
different GWAS, three independent teams (10-12) tried to understand the biological mechanism 
relating sortilin to LDL cholesterol (LDL-c) levels and, ultimately, to risk of CAD. To this end, 
they used different mechanistic approaches and, interestingly, they also came to different 
conclusions. Here we summarize each of those approaches and their main conclusions, trying 
to reconcile the apparently discrepant results. 
 
Looking for a needle in a haystack: GWAS 
Over the past few years, advances in sequencing and genotyping, with the emergence and 
spread of third-generation sequencers, catapulted GWAS to the forefront of population 
studies, with special focus on the relationship between genotype and common disease. These 
studies are based on the premise that, for a large number of such diseases, the underlying 
hereditary variations have a minor allele frequency (MAF) higher than 5%. It is, then, possible 
through the analysis of large populations samples, to identify associations of certain diseases 
to certain regions of the genome, both coding and non-coding. In fact, several genetic 
variants identified through GWAS are located in non-coding regions of the genome. The 
interpretation of the effects of the identified variants depends largely on the knowledge 
available for those regions. It is then estimated the potential of genes located in the target 
region being responsible for the detected association, without excluding the possibility that it 
may result from long-range genetic interactions or from other unknown reasons. The 
challenge is to understand the biological basis of the signs revealed in GWAS. And, although 
this is may be a difficult task, GWAS have already uncovered important genetic factors 
underlying a number of complex diseases. One of the most successful cases in terms of 
identification of SNPs (single nucleotide polymorphisms) which are relevant to the 
pathogenesis of a complex disease is precisely the annotation of genes correlated with plasma 
lipid and lipoprotein levels, factors which are long known to have great importance in 
pathological conditions such as dyslipidemia and/or myocardial infarction (MI). Over the last 
few years more than 100 loci have been described as associated with the genetic variation of 
triglycerides, LDL cholesterol and HDL cholesterol levels (13-20). In cases of CAD or MI, GWAS 
identified a smaller number of genetic loci, some of which were also associated with changes 
in traditional risk factors. A comprehensive analysis of several GWAS identified and annotated 
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CAD-associated loci (14, 17, 21-23), by combining the data revealed in the studies of "Welcome 
Trust Case Control Consortium" and "German MI Family Study". It presented evidences of 
associations between 7 chromosomal loci and CAD risk (14): 1p13 (SARS, CELSR2, PSRC1, 
MYBPHL, SORT1, PSMA5 and SYPL2 genes), 1q41 (MIA3 gene), 2q36 (intergenic region), 6q25.1 
(MTHFD1L gene), 9p21 (CDKN2A and CDKN2B genes), 10q11 (intergenic region) and 15q22.33 
(SMAD3 gene). The immediate question that arose was whether these new loci affected 
already known cardiovascular risk factors. To clarify it, Samani et al. (15) investigated the 
association of these 7 loci with a number of quantitative traits of known relevance to 
cardiovascular disease, showing that only the risk locus on chromosome 1p13 was significantly 
associated with higher levels of LDL cholesterol. The strongest association was located in the 
intergenic region comprehending the PSRC1 and CELSR2 genes. PSRC1 and CELSR2 genes code 
for the protein proline/serine-rich coiled-coil 1 and for cadherin EGF, respectively. The 
function of these proteins remains unknown and its coding genes are very closely located to 
the one that codes for sortilin, SORT1. None of these 3 genes nor any of the others present in 
the 1p13 locus have ever been associated to a known Mendelian disease affecting LDL-c levels 
(10, 13, 20). 
 
Usual and unusual suspects: LDL-cholesterol and sortilin 
Given such a statistically significant association between the 1p13 locus and plasma LDL-c 
levels, the search for its explanatory mechanism became the research focus of various teams. 
Firstly, it was important to clarify which was the particular genomic variant that was causing 
this association. Due to the linkage desequilibrium (extensive and non-random relationship) 
between multiple SNPs at the 1p13 locus (comprising the genes SORT1, PSRC1 and CELSR2), it 
was impossible to identify solely through GWAS, the causal variant. To clarify this point, as 
well as the mechanisms behind this association in silico, in vitro and in vivo studies would be 
required. And, as those studies have been carried out, a gene began to detach itself from all 
the others comprising this CAD risk locus: the SORT1 gene that codes for sortilin (10-12). 
Sortilin belongs to the Vps10p domain receptor family, which consists of five known members. 
It is synthesized as a propeptide, cleaved in the Golgi by proprotein convertases, after which 
the process takes the mature form, which allows the proper ligand binding. Functionally, 
sortilin is a receptor of multiple ligands, including lipoprotein lipase (LPL; 24), the A-V 
apolipoproteins (apo A-V) (25), neurotensin (26) and receptor associated protein (RAP; 27). It is 
also responsible for mediating Golgi-to-lysosome transport of a number of lysosomal proteins, 
enzymatic or not: sphingolipid activator proteins (SAPs: prosaposin and GM2AP), acid 
sphingomyelinase, cathepsin H and cathepsin D (24, 28-30). In recent years, it has been 
demonstrated that sortilin is involved in a number of highly relevant biological processes such 
as the formation of GLUT-4 (glucose transport isoform 4) storage vesicles in response to 
insulin during adipocyte differentiation (31). In the brain, is part of a signaling complex that 
regulates cell survival (32). 
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The in vivo relevance of these multifaceted properties still remains unclear but reinforces the 
notion that sortilin is a protein with an important biological role, and whose deregulation 
seems likely to cause severe side effects that may go beyond its effect on the levels of 
plasma LDL-c levels.  
 
An exemplary approach: mechanistic analysis 
In 2010, three independent teams published results from pioneer studies, trying to clarify the 
biological mechanism underlying the association between the 1p13 locus and plasma LDL 
levels (10-12). Based on solid, even though different, experimental approaches, all three studies 
indicate the SORT1 gene as the one responsible for the increased risk of CAD and/or MI. 
Curiously, different studies have reached conclusions that were not only different but, in 
some cases, even opposite about the role of sortilin on the secretion of very low density 
cholesterol (VLDL-c) (reviewed in 33, 34). 
The first in vitro evidences of the interaction between sortilin and LDL particles were given 
by Linsel-Nitschke et al. (11) Through a fine mapping of the 1p13 locus, the authors started by 
searching the variant with stronger signs for that association and reached to the rs599839 
SNP, verifying that the G allele was the one associated to reduced LDL-c plasma levels and 
lower cardiovascular disease risk. The authors demonstrated that homozygous individuals for 
the G allele showed increased expression of the SORT1, CELSR2 and PSRC1 genes in peripheral 
white blood cells. The strongest and most consistent association, however, was seen for 
SORT1 mRNA levels. These results were confirmed in human embryonic kidney cells (HEK293) 
over-expressing SORT1 that showed increased internalization of LDL-c particles, with 
consequent reduction of its plasma levels (11). 
In the same year, Musunuru et al. (2010) presented a multifaceted approach, an exemplar 
"tour de force" for the follow-up of GWAS (35). Based on the previous recognition that the 
rs646776, rs599839, rs12740374 and rs629301 SNPs from the 1p13 locus were the most 
strongly associated to LDL-c plasma levels and on the assumption that non-coding DNA 
variants may alter gene expression, Musunuru et al. (10) started by analysing the effects if 
these 4 variants on the mRNA levels of the 6 genes located in that locus: SARS, CELSR2, 
PSRC1, MYBPHL, SYP2 and SORT1. The authors verified that in human liver the minor allele 
for the rs646776 SNP was associated to increased expression of the SORT1, CELSR2 and PSRC1 
genes (36), with the strongest association observed for SORT1 mRNA levels and its 
corresponding protein: sortilin. The fine mapping of the interest region led to the definition 
of the haplotypes defined by the SNPs present in 6.1 kilobases located between the CELSR2 
and the PSRC1 genes, and to the identification of the SNP rs12740374 as the ultimate 
responsible for the association observed in GWAS. Bioinformatic analysis showed that, by 
altering the wild-type sequence from GGTGCTCAAT to GTTGCTCAAT, the minor allele of this 
variant created a binding site for the C/EBP (CCAAT-enhancer binding protein) α protein 
increasing promoter activity and SORT1 expression level. This was later confirmed in vitro. It 
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should be noted that these results are in full agreement with the analyses published by Linsel-
Nitsche's group (11), concerning the mRNA expression levels in the liver. Finally, through 
studies on liver cells from mutant mice in which the gene coding for sortilin was over-
expressed or inactivated, Musunuru et al. (10) demonstrated that sortilin expression levels 
modulate the hepatic secretion of VLDL. The transgenic mouse chosen by this team was 
Apobec1-/- (having suppressed the gene that encodes the C->U-editing enzyme APOBEC-1) , a 
"humanized" mouse, with a lipid profile closer to that seen in humans, where LDL is the 
predominant cholesterol transporter in circulation, rather than typical of mice. When 
Musunuru et al. (10) over-expressed the Sort1 gene in Apobec1-/- liver cells, a 70% reduction in 
plasma total cholesterol (TC) and LDL-c was observed. Similarly, Sort1 inactivation by siRNA, 
led to increases of 46% in TC and 125% in LDL. 
In general, the data presented by these two teams supports GWAS’ findings and reinforces the 
idea of a negative correlation between SORT1 mRNA levels and plasma LDL-c concentration. 
However, in the same year a third mechanistic study addressing this association was published 
and in this latter case, the results were not so easily reconciled neither with the results from 
the previous studies, nor with the previous assumptions inferred through GWAS. 
We are referring to the results presented by Kjolby et al. (12) that were published almost 
simultaneously. These authors used as a model a double knockout mouse, Sort1-/-,Ldlr-/- 
having observed that its’ hepatocytes presented reductions of 30% of the TC levels, of ~50% of 
proteins containing apo B100 (VLDL and LDL) and of ~60% in atherosclerotic plaque area 
compared to Ldlr-/- single KO mice. Next, they performed liver-specific Sort1 over-expression. 
Briefly, they found that sortilin deficiency led to a 50% reduction in the secretion of 
lipoproteins, whereas its over-expression resulted in a 50% increase in the secretion of those 
proteins. Together, these results indicate a positive correlation between Sort1 expression and 
LDL-c levels, opposite to the one observed by Musunuru et al (10). 
 
Discover the differences: results’ analysis 
The question of the discrepancy between the results of these three studies has been 
discussed by various experts, as illustrated by the publications of Dubé (34) and Tall and Ai (33), 
from 2011. In their comments, these authors drew attention to the differences between the 
experimental works by Linsel-Nitschke et al. (11), Musunuru et al. (10) and Kjolby et al. (12) and 
the consequences that those differences may have had in their results. The three teams that 
tried to clarify the mechanism by which the 1p13 locus affects the LDL levels and the risk of 
CAD, have opted for different experimental models which seem to have influenced the final 
results. This implies that, even though their conclusions are consistent and have resulted 
from well designed and consistent experiments, may not be comparable. 
The first important point to focus is the metabolic background in which each of the 
experiments was carried out. Linsel-Nitschke, and his team (11) conduced their investigation 
only in humans, unlike Musunuru (10) and Kjolby (12) who, together with their collaborators 
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analysed non-human animal models. Nevertheless, these latter teams chose mice models with 
different metabolic profiles: Musunuru et al. (10) worked with liver cells from a "humanized" 
mouse, Apobec-/-; Kjolby et al. studied a double knockout for sortilin and LDL receptor (Sort1-
/-, Ldlr-/-). Musunuru’s mouse produced and secreted abnormally high amounts of lipoproteins 
in order to mimic the human lipid profile. This may have artificially modified sortilin’s 
secretory pathways and availability; Kjolby’s (12) mouse had a deficient lipoprotein catabolism, 
created by the repression of Sort1 expression within hepatocytes and marked by "high fat 
western diet". Finally, it is also known that there are differences in gene regulation between 
the two species, man and mouse, as demonstrated by the absence of the C/EBP α binding site 
in mice (10, 37). This may hinder extrapolation of mouse studies to human when referring to 
sortilin (34). 
It should be highlighted that, altogether, the in vivo observations from studies in mouse 
models showed that sortilin assumes complementary liver functions, depending on the 
metabolic milieu in which it operates and, ultimately, regulates VLDL secretion. The different 
results here reviewed seem to suggest that sortilin can regulate VLDL secretion and traffic to 
the lysosome when the intracellular levels of apo B-100 are extremely high. Conversely, at 
low apo B-100 expression levels, sortilin can regulate the formation and secretion of VLDL (33, 
34). 
Nevertheless, this putative role of sortilin in the formation and secretion of VLDL hardly 
reconciles with the GWAS' results that pointed to a specific association with LDL-c and not to 
triglycerides, which are the major components of VLDL particles (34). 
Taken together, even though these studies provide evidences which are somehow contrary, 
they also give strong evidence of the existence of a novel regulatory pathway for lipoprotein 
metabolism and the possibility that its modulation alters the risk of cardiovascular disease in 
humans. Nevertheless, there's still a long way to walk in order to get a clear vision of the 
whole process and its modulator factors. 
 
Conclusion
By genotyping alleles whose frequency is higher, GWAS are limited to the identification of 
alleles which exert minimal, if not negligible, effects on the phenotype (38). Furthermore, 
these most common alleles seem to explain only a small portion of the phenotype (39). Thus, a 
significant fraction of the inheritance of complex phenotypes such as cardiovascular diseases 
(CAD in particular) remains unknown, even after all efforts have been directed to this area 
through numerous GWAS. This portion of heredity is often called "the missing heritability" or 
"the dark matter of heritability" (35). GWAS’ supporters argue that, by increasing the size of 
the studied samples and the SNP density, it will be possible to detect alleles with very small 
effect sizes, revealing the portion of inheritance which remains unknown (35). Nevertheless, 
some authors support an alternative strategy based on whole genome direct sequencing as a 
way of identifying rare alleles carrying large effects on the phenotype (40). Crucial to this are 
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the recent advances in DNA sequencing technology, with the onset and development of new 
platforms for third-generation sequencing. These platforms allow low cost whole genome 
sequencing, with consequent identification of rare and/or new variants. It is believed that 
each genome has approximately 10000 non-synonymous variants, among approximately 3,5 
millions of SNPs. Having in mind the magnitude of these values it is expectable that this kind 
of sequencing dominates genetic studies in the coming years, a trend that is already seen 
nowadays (41, 42, 43, 44, 45).  
It seems, however, correct to state that the “dark matter of heritability” is the product of 
complex interactions between factors of different nature: genetic, genomic and epigenetic 
(39, 46). Similarly, also the phenotype is the result of nonlinear and stochastic interactions 
between different genetic and non-genetic factors.  
Nevertheless, the discovery and systematization of new genetic variants associated with a 
particular complex phenotype is very important, particularly for the case here reported, in 
which this variant has pioneered the discovery of a previously unknown molecular pathway.  
The three reports here reviewed are exemplary and paradigmatic approaches of how to get 
from a “blind” statistical association given by GWAS to a mechanistic explanation of how a 
certain genetic variation may modulate a particular phenotype. In this case, GWAS' results 
pointed to a particular starting point, the 1p13 locus (14, 21-23), which would end up catching 
the attention of three independent teams who relied on different experimental approaches to 
unveil the basis of the statistical association, all of them highlighting the SORT1 gene as the 
modulator of LDL-c levels and MI risk. But, if their results were in accordance concerning the 
relevance of SORT1's role on the lipoprotein metabolism regulation, their interpretations on 
the direction of the effect of its expression over plasma LDL-c levels and its underlying 
mechanism are far from concordant (10-12). 
Linsel-Nitschke and colleagues (11) have proposed, due to their observations, that the 
overexpression of sortilin increases the internalization of LDL, with a consequent decrease of 
its plasma levels (11). Soon after, through studies in human cohorts, hepatocytes and mice, 
Musunuru et al. (10) reported an inverse relationship between the sortilin expression and 
circulating LDL-c levels and proposed an explanatory mechanism through transcriptional 
regulation (liver-specific) of the SORT1 gene by transcription factor C/EBPα (10). On the 
contrary, Kjolby and his team (12) observed a direct relationship between the expression of 
Sort1 and the concentration of circulating LDL, suggesting it could result from increased VLDL 
secretion (12). 
Several explanations have been presented to justify the discrepancy between these results 
and the answer seems to depend on sortilin itself, which appears to be a multifaceted protein 
that may assume different functions depending on the circumstances. 
In summary, the studies here revised, presented a number of strong evidence demonstrating 
that SORT1 is a regulatory element of plasma LDL-c levels, adding a significant role to the 
sortilin-coding gene, until very recently ignored. Presently, the cellular pathway relating 
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sortilin to lipid metabolism is still controversial but it is surely an issue that will be further 
explored. A full understanding of this pathway will be crucial to evaluate if sortilin may 
represent a potential target for therapeutic interventions for hypercolesteronemia or CAD 
(reviewed in 33-35). 
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N-acetylglucosamine-1-phosphate transferase, gamma
subunit; N-acetylglucosamine-1- (GNPTG, GNPTAB)
Introduction
GlcNAc-1-phosphotransferase catalyses the transfer of a GlcNAc-1-phosphate residue from UDP-GlcNAc to C6 positions
of selected mannoses in high-mannose type oligosaccharides of the hydrolases (Goldberg and Kornfeld, 1981; Natowicz 
. At a biological level this reaction is followed by the removal of the terminal GlcNAc., 1982; Varki and Kornfeld, 1983)et al
by an -acetylglucosamine-1-phosphodiester α- -acetyl-glucosaminidase, usually referred to as ‘uncovering enzyme’N N
(UCE; ). Sequential action of these two enzymes results in the formation of thesee Chapter 78; Article ID: 332135
mannose-6-phosphate (Man-6-P) marker, a specific tag acquired by lysosomal hydrolases that ensures recognition by
M6P receptors and delivery to the endosomal/lysosomal system (Braulke and Bonifacino, 2009).
GlcNAc-1-phosphotransferase was purified from bovine  and proposed to exist as an hexamericmammary glands
complex with a molecular mass of 540  composed of two α-, two β- and two γ-subunits (Bao ., 1996).kDa et al
Two independent genes code for GlcNAc-1-phosphotransferase: , which codes for the α/β-subunit precursorGNPTAB
(Raas-Rothschild ., 2000) and  that codes for the γ-subunit (Kudo ., 2005; Tiede ., 2005).et al GNPTG et al et al
Absence or deficient activity of GlcNAc-1-phosphotransferase leads to lysosomal storage disorder, underlying
Mucolipidosis type II or III, respectively.
Databanks
IUBMB enzyme nomenclature: EC 2.7.8.17
 
Species Gene Symbol GeneBank accession number Uniprot ID PDB accession number
Homo sapiens        
α/β-subunit precursor
GNPTAB
(alternatively ; )GNPTA KIAA1208
NP_077288 Q3T906 N/A
γ-subunit
GNPTG
(alternatively ; )GNPTAG C16orf27
NP_115909 Q9UJJ9 N/A
Mus musculus        
-subunit precursorα/β
Gnptab
(alternatively ; )Gnpta Kiaa1208
NM_001004164.2 Q69ZN6 N/A
γ-subunit
Gnptg
(alternatively ; )Gnptag C16orf27
BC055872.1 Q6S5C2 N/A
 
Name and History
GlcNAc-1-phosphotransferase was first demonstrated in the membrane fraction of rat liver, skin fibroblasts and CHO cells
(Reitman and Kornfeld, 1981a; Hasilik ., 1981).et al
Early reports on GlcNAc-1-phosphotransferase activity have shown that it phosphorylates acid hydrolases at least
100-fold more than nonlysosomal glycoproteins containing identical oligosaccharide units (Reitman and Kornfeld, 1981b;
Lang ., 1984; Ketcham and Kornfeld, 1992). Additionally, heat-denaturated acid hydrolases as well aset al
high-mannose-type oligosaccharides and glycopeptides were shown to be extremely poor substrates, while
deglycosylated lysosomal enzymes acted as potent inhibitors of the phosphorylation of intact lysosomal enzymes (Lang et
., 1984). Altogether, these data suggested that GlcNAc-1-phosphotransferase recognizes a conformation-dependental
protein domain that is common to all acid hydrolases but absent in non-lysosomal glycoproteins (Lang ., 1984).et al
It is this specific ability to recognize lysosomal hydrolases that allows for the critical role GlcNAc-1-phosphotransferase
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plays in the cell: to selectively target those enzymes to their final destination, the endosomal/lysosomal compartment, by
catalyzing the first of two steps that result in the biosynthesis of the Man-6-P recognition signal (Fig. 1). The modified
proteins are then recognized by two independent receptors that bind the Man-6-P residue of the newly synthesized
lysosomal hydrolases in the  and finally, the ligand-receptor complex is packaged intotrans-Golgi network (TGN)
clathrin-coated transport vesicles for delivery to endosomes and lysosomes (Braulke and Bonifacino, 2009).
Numerous researchers tried to purify and clone this enzyme. In 1981, rat GlcNAc-1-phosphotransferase was partially
purified (Reitman and Kornfeld, 1981b) but the complete enzyme was only accessed in 1996, when the group of Canfield
succeeded in purifying it from bovine  and demonstrated that GlcNAc-1-phosphotransferase is, indeed, amammary glands
540-kDa complex composed of three different subunits: two α, two β and two γ (Bao ., 1996a). Latter, threeet al
independent teams have identified and/or cloned the genes that code for those subunits: , which codes forGNPTAB
the  α/β-subunits (Raas-Rothschild ., 2000) and , which codes for the γ-subunit (Kudo ., 2005; Tiede et al GNPTG et al et al
., 2005). The  gene contains 21 exons and spans 85 kb on chromosome 12q23.3 (Tiede ., 2005), whilst the GNPTAB et al
 gene spans 11 exons on chromosome 16p13.3 (Raas-Rothschild ., 2000).GNPTG et al
UDP-N-acetylglucosamine (UDP-GlcNAc): lysosomal enzyme N-acetylglucosamine-1-phosphotransferase may also be
referred to as stealth protein GNPTAB or UDP-N-acetylglucosamine-1-phosphotransferase, and is usually abbreviated as
GlcNAc-1-phosphotransferase.
 
 Phosphorylation of mannose residues of lysosomal enzyme oligosaccharides. mannose;  GlcNAc.Figure 1: Circles, Squares,
 
Structure
GlcNAc-1-phosphotransferase is a Golgi-resident 540-kDa hexameric transmembrane enzyme composed by three
subunits, α β γ .2 2 2
The α/β-subunit precursor is synthesized as an -glycosylated 190-kDa type III membrane protein. Proteolytic cleavageN
of the α/β-precursor between Lys928 and Asp929 by site-1 protease (S1P; also known as  kexin isoenzyme–1,subtilisin
SKI-1) generates the individual α- and β- subunits with molecular masses of 145  and 45 kDa, respectively (Tiede kDa et
., 2005; Marschner  2011). The mature human α-subunit is a type II membrane protein with an N-terminal tail of 19al et al.,
amino acids, a  consisting of 22 amino acids and a subsequent luminal domain comprising 886transmembrane domain
residues (Kudo ., 2005; Tiede ., 2005). The luminal domain of the α-subunit contains 17 potential -glycosylationet al et al N
sites and exhibits a conserved modular structure composed of at least six domains with homologies to bacterial synthesis
proteins plus two repeats of the Notch receptor and a binding domain for the transcriptional  DMAP1 (Fig. 2).co-repressor
Additionally, a potential conserved coiled-coil domain comprising amino acids 80 to 120 is also present (Kudo ., 2005;et al
Tiede ., 2005; reviewed in Kollmann ., 2010).et al et al
The mature β- subunit is a type I membrane protein with three potential -glycosylation sites, and contains cytoplasmic,N
transmembrane and luminal domains of 21, 23 and 284 amino acids, respectively.
The human γ-subunit, on the other hand, is not a transmembranar but a soluble glycoprotein of 305 amino acids with a
predicted  of 24 amino acids and can form disulfide-linked dimmers (Raas-Rothschild ., 2000). Itsignal sequence et al
contains two in vivo used -glycosylation sites at positions 88 and 115, equipped with high mannose-typeN
oligosaccharides (Encarnação ., 2010).et al
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 Schematic presentation of the modular structure of the type III membrane protein α/β-subunit precursor ofFigure 2:
GlcNAc-1-phosphotransferase. The α/β-subunit precursor is cleaved by site-1-protease into the mature type II α-subunit and the
mature type I β-subunit membrane protein (adapted from Kollmann ., 2010).et al
 
Enzyme Activity Assay and Substrate Specificity
GlcNac-1-phosphotransferase catalyzes the first step in the two-step reaction sequence shown in Fig. 1 by selectively
recognizing and phosphorylating lysosomal enzymes (Reitman and Kornfeld, 1981; Waheed ., 1982):et al
UDP-N-acetyl-D-glucosamine + lysosomal-enzyme D-mannose =
UMP + lysosomal-enzyme N-acetyl-D-glucosaminyl-phospho-D-mannose
GlcNac-1-phosphotransferase activity assays are carried out with a radioactively-labeled sugar donor: [b- P]32
UDP-GlcNAc. Even though not being commercially available, [β- P] UDP-GlcNAc is the most suitable substrate for32
determining this enzyme's activity and may be easily prepared from [γ- P] ATP using commercially available enzymes32
(Lang and Kornfeld, 1984) and α-methylmannoside.The transfer of P-labeled GlcNAc-1-phosphate from [β- P]32 32
UDP-GlcNAc to various acceptor substrates is quantified by one of two methods. In the first method, α-methylmannoside
is the acceptor. Ion-exchange chromatography is used to separate the  product, which has only onephosphodiester
negative charge at neutral pH, from free phosphate, phosphomonoesters, and nucleotide sugars. The second method is
used to measure GlcNAc-1-phosphate transfer to glycoprotein and glycopeptide acceptors. After incubation, the acceptor
glycoproteins are digested with , producing glycopeptides that are then subjected to affinity chromatography onPronase
concanavalin A (Con A)-Sepharose. The P radioactivity bound to the Con A-Sepharose is the product (Reitman ,32 et al.
1984).
The enzyme activity is dependent on a divalent cation, Mg  or Mn  (Reitman and Kornfeld, 1981a). The  of bovine2+ 2+ Km
GlcNAc-1-phosphotransferase for UDP-GlcNAc is 30 μM and that for the lysosomal enzyme cathepsin D is 18 μM. On the
other hand, the  for the nonlysosomal enzyme  B is 1,2 mM and that for a-methylmannoside is 64 mM (Bao Km RNase et
., 1996b).al
The recognition site of GlcNAc-1-phosphotransferase is separate from its catalytic domain (Reitman and Kornfeld, 1981b;
Waheed ., 1982). The recognition site binds to a signal patch that is present in lysosomal hydrolases but absent inet al
most secretory glycoproteins. Early reports by the Kornfeld’s lab demonstrated that lysine 203 and amino acids 265-292
of cathepsin D were the minimum number of amino acids on the signal patch for recognition by
GlcNAc-1-phosphotransferase (Baranski ., 1990; Baranski ., 1991; Cantor ., 1992). Latter, antibody inhibitionet al et al et al
experiments with  were also used to show that GlcNAc-1-phosphotransferase recognizes commonarylsulfatase A
conformation-dependent protein structures of lysosomal enzymes in which lysine residues are the major determinants
(Sommerlade  1994). In addition, the interaction of both subunits with the protein determinant of acid hydrolaseset al.
stimulates the catalytic function of GlcNAc-1-phosphotransferase (Qian  2010).et al.
GlcNAc-1-phosphate is transferred to selected mannose residues on high mannose type -glycans at the  ofN catalytic site
GlcNAc-1-phosphotransferase. The first mannose to be phosphorylated is generally the terminal mannose on the α1,6
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branch linked to the core mannose, while phosphorylated oligosaccharides formed subsequently contain one or two
Man-6-P residues, located at different positions on the oligosaccharide (Goldberg and Kornfeld, 1981; Natowicz .,et al
1982; Varki and Kornfeld, 1983).
 
Preparation
GlcNAc-1-phosphotransferase activity has been demonstrated in membranes of a multitude of tissues and cells, including
rat liver, skin fibroblasts, , bovine pancreas,  and COS1-cells (Waheed ., 1981; Hasilik ., 1981;placenta CHO cells et al et al
Reitman and Kornfeld, 1981a,b; Reitman ., 1984; Zhao ., 1992; Nishikawa ., 1997; ).et al et al et al Kudo ., 2006et al
Rat GlcNAc-1-phosphotransferase was partially purified through diethylaminoethanol-cellulose chromatography (Reitman
and Kornfeld, 1981b). The bovine form of the same enzyme was purified at approximately 490.000-fold from mammary
 using monoclonal antibody immunoaffinity chromatography (Bao ., 1996a).glands et al
 
Biological Aspects
The α β γ  heterohexamericcomplex that constitutes the active GlcNAc-1-phosphotransferase is encoded by two2 2 2
different genes,  and , which code for the synthesized    α/β- and the γ-subunits, respectively. TheGNPTAB GNPTG
α/β-subunit precursor is synthesized as an inactive 190-kD precursor protein in a  orientation that containshairpin
cytosolic N and C termini and a complex modular structure. Subsequent cleavage of the α/β-precursor by the S1P gives
origin to the mature α- and β-subunits, which are catalytically active (Tiede ., 2005; Kudo ., 2005; Marschner et al et al et
 2011).al.,
The γ-subunit, on the other hand, is synthesized as a soluble glycoprotein of 305 amino acids that forms disulfide-linked
homodimers (Raas-Rothschild ., 2000). Its function is still unclear even though recent studies have suggested thatet al
the γ-subunit is important to facilitate the proper folding of the subunits that constitute GlcNAc-1-phosphotransferase and
to maintain them in a conformation competent for substrate recognition and binding or to regulate the activity/expression
of the α/β-subunits (Lee , 1981; Pohl , 2009; Pohl ., 2010).  γ-subunit et al. et al. et al Furthermore, the was proposed to
facilitate the addition of the second GlcNAc-P to high mannose oligosaccharides of protein substrates (Qian  2010).et al.
It is now known that the assembly of the GlcNAc-1-phosphotransferase complex takes place in the ER and depends on a
proper  of the γ-subunits (Encarnação , 2010). Then, thanks to a combinatorial sorting motif that isdimerization et al.
present in the α/β-subunit precursor protein, the oligomeric type III GlcNAc-1-phosphotransferase is exported from the ER
to the Golgi in a COPII-dependent fashion (Franke , 2013). Once in the Golgi, the α/β-subunit precursors of theet al.
complex may finally be cleaved by the S1P, thus becoming active (Marschner , 2011).et al.
GlcNAc-1-phosphotransferase activity is essential to a proper delivery of acid hydrolases to the endosomal/lysosomal
compartment. The interaction of GlcNAc-1-phosphotransferase with those hydrolases results in the transfer of
GlcNAc-1-phosphate to mannose residues on the asparagines-linked high-mannose oligosaccharides of the acid
hydrolases. GlcNAc residues are subsequently removed by the sequential action of a second enzyme, N
-acetylglucosamine-1-phosphodiester α- -acetyl-glucosaminidase ( ) that exposes the Man-6-PN see Chapter 78
recognition signal which is then recognized by specific receptors at the  the cation-independent M6P receptor and/orTGN:
the cation-dependent M6P receptor. Ligand-receptor complexes are packed intoclathrin-coated that bud from the TGN
and, ultimately, fuse with late endosomes. At the low pH of the late , the hydrolases dissociate from theendosome
Man-6-P receptors and the empty receptors are recycled to the  for further rounds of transport (BraulkeGolgi apparatus
and Bonifacino, 2009). Ultimately, the biological relevance of GlcNAc-1-phosphotransferase and of the targeting pathway
in which it is involved, may be demonstrated by the severity of pathology triggered by GlcNAc-1-phosphotransferase
impaired function or, in extreme, by its complete absence.
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Knockout Mouse and Transgenic mice
through The first mouse model for  deficiencies was generated in 2007 by Gelfman and colleagues,GNPTAB
 of  clones  into host blastocysts. Homozygous mice lacking αmicroinjection embryonic stem (ES) cell GNPTAB-/- /β-
subunits of GlcNAc-1-phosphotransferase presented with growth retardation, retinal degeneration and secretory cell
lesions that do not exactly mimic the human disease (Gelfman ., 2007)et al . Latter, a second mouse model was
generated, to prevent compensatory mechanisms in the complete absence of GlcNAc-1-phosphotransferase. This
‘knock-in’ mouse model, generated by Kollmann and collaborators, has a single  inserted (c.3082insC), whichcytosine
disrupts the  causing a premature  in the C-terminal open reading frame translational termination conserved region
(p.G1049R X16) (fs Kollmann ., 2012)et al . This insertion  a human pathogenic mutation (p.G1049R X16) alreadymimics fs
.  ‘knock-in’ mice are severely affected and show all of thereported and extensively analysed (Tiede ., 2005)et al The
clinical and biological symptoms and features of the human ML II disease thus being the ideal model to further investigate
pathology (Kollmann ., 2012)et al .
Finally, the only mouse model for ML III gamma reported so far was generated by direct  targeting, leading to aGnptg
. -deficient mice presented with normal growth andtruncated γ-subunit with only 59 amino acids (Lee ., 2007)et al Gnptg
no cartilage defects or retinal degeneration, even though the serum levels of numerous enzymes were elevated (Vogel et
.., 2009)al
With the exception of the knock-in' mouse generated in the Braulke lab (Gnptab ' Kollmann ., 2012)et al , mice lacking
 or γeither α/β- -subunits displayed clinical and pathologic features that differed substantially from those reported in
humans having mutations in orthologous genes (Vogel ., 2009)et al .
Human Disease
Defective GlcNAc-1-phosphotransferase causes two distinct human ,  (ML II)lysosomal storage diseases Mucolipidosis II
and  (ML III), which are among the few lysosomal storage disorders related to defects in non-lysosomalMucolipidosis III
proteins. ML II, often referred to as , is characterized by a total loss of GlcNAc-1-phosphotransferase activityI-cell disease
whether ML III,   also known as , manifests when enzymatic activity is reduced (Leroy andpseudo-Hurler polydystrophy
Spranger, 1970; Spranger and Wiedemann, 1970). In both ML II and ML III patients, newly synthesized lysosomal
enzymes fail to be correctly sorted to the endosome/lysosome compartment due to the absence or weak equipment in
M6P residues. As a consequence, lysosomal dysfunction develops leading to accumulation of non-degraded material, the
hallmark of this group of diseases. Unlike the majority of lysosomal storage disorders, which involve single enzymes
acting in a , MLII and III results from impaired sorting of multiple enzymes to lysosomes that instead arecatabolic pathway
over-secreted from cells. The excessive accumulation of non-degraded substrates results in the subsequent formation of
large inclusion bodies.
While ML II and ML III share similar clinical features, including skeletal abnormalities, ML II is the more severe in terms of
phenotype (Leroy and Spranger, 1970). In this pathology the skeletal system is severely affected, with abnormalities in
both , cardiomegaly and developmental delay. Linear growth decelerates during the first year of lifecartilage and bone
almost stopping during the second year and death usually occurs between 5 and 8 years of age (Kornfeld and Sly in
Scriver, 2001).
ML III is a much milder disorder, being characterized by latter onset of clinical symptoms and slower, progressive course,
which may allow the survival into the eighth decade. Usual clinical findings in ML III patients include restricted joint
mobility, short stature and mild Hurler-like dysmorphism, among other less severe features (Spranger and Wiedemann,
1970; Umehara ., 1997). Only 50% of the patients present with mental retardation (Umehara ., 1997).et al et al
Once GlcNAc-1-phosphotransferase is an hexameric complex whose protein subunits are encoded by two genes,
depending on which of them harbors the causal mutation(s) and simultaneously on the severity/clinical course of the
disease, the associated pathologies are classified as ML II alpha/beta (OMIM: 252500) and ML III alpha/beta  (OMIM:
252600) if mutations are present in the  gene, or ML III gamma (OMIM: 252605) if mutations occur in the GNPTAB
 gene (Cathey ., 2008).GNPTG et al
To date, more than 100 different  mutations have been reported, causing either ML II alpha/beta or ML IIIGNPTAB
alpha/beta, including missense, nonsense, small deletions, small insertions, small indels and splice site mutations (HGMD
and references therein). Large genomic rearrangements appear to be rare although two gross insertions (Otomo .,et al
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2009; Tapino ., 2008) and one large deletion have already been detected (Coutinho ., 2011a). Most of theseet al et al
mutations are private or rare. One exception does exist, however:  the  c.3503_3504delTC. Being the mostmicrodeletion
common ML II alpha/beta-causing allele, c.3503_3504delTC presents a remarkably wide geographical distribution, having
been detected among Israeli and Palestinian Arab-Muslim, Turkish, Irish  (Bargal ., 2006), Portuguesetraveler et al
(Encarnação ., 2009), Italian (Tapino ., 2009) and U.S. patients (Kudo ., 2006). This pathogenic mutationet al et al et al
was due to an ancient and unique founder molecular lesion that arose, most probably, in a peri-Mediterranean region
(Coutinho ., 2011b).et al
Concerning the  gene, the mutations until now reported associated to Mucolipidosis type III gamma includeGNPTG
4 missense, 2 nonsense, 5 small deletions, 4 small insertions, 4 splice site mutations and 2 gross deletions [HGMDand
references therein].
Recently, genomewide scans have unveiled a curious and unexpected relation between mutations in the Man-6-P
dependent lysosomal enzyme-targeting pathway and persistent . While studying individuals with persistentstuttering
stuttering, Kang and colleagues (2010)    found mutations in all the three genes which encode the two enzymes that
generate the Man-6-P recognition marker:     and  Ten different mutations were found in total,GNPTAB, GNPTG NAGPA.
including four mutations in the  gene and three mutations in the . Yet, the affected subjects studied byGNPTAB GNPTG
Kang  (2010) stuttered but were otherwise normal, without presenting any of the typical symptoms of lysosomalet al.
malfunction, even when being homozygous for some of the identified mutations on the  and  genes.GNPTAB GNPTG
Eventually, this can be explained admitting that the efficiency of lysosomal targeting was only partially reduced in the
presence of the detected mutations.
 
Future Perspectives
Over the last two decades many important progresses were made with the purification of the bovine
GlcNAc-1-phosphotransferase and the subsequent identification of the genes encoding its α/β-precursor and γ-subunit.
All these achievements allowed improved pre- and postnatal diagnosis of ML II and III patients with immediate
consequences for affected families.
Nevertheless, several questions remain unanswered and important issues remain to be solved concerning
GlcNAc-1-phosphotransferase itself. Detailed analysis of the modular structure of the α/β-precursor for the binding of
lysosomal enzymes, high-mannose-type oligosaccharides, and UDP-GlcNAc is still missing. Knowledge of the
GlcNAc-1-phosphotransferase crystallographic structure and subunit  is also missing (Kollmann .,oligomerization et al
2010).
Only a deeper understanding of this enzyme, the travelling pathway in which it is involved and the alternative mechanisms
of M6P-independent lysosomal enzyme transport may allow establishment and improvement of therapeutic approaches
not only for ML II and III but also for other lysosomal storage disorders.
Finally, also the remarkable finding that mutations in the  and  may be associated with persistentGNPTAB GNPTG
stuttering in individuals who are otherwise normal, deserves further attention. Additional studies in this area may
contribute to a better understanding of the neural structures and functions within the brain that generate human speech,
which are still poorly elucidated.
Cross Reference
N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase (NAGPA)
Further Reading
Bao ., 1996  and : purification of bovine GlcNAc-1-phosphotransferase and insights into its heterohexamericet al a b
structure, enzymatic activity and catalytic subunit.
Raas-Rothschild ., 2000; Kudo ., 2005 and Tiede ., 2005: cloning of the two genes that code foret al et al et al
GlcNAc-1-phosphotransferase and their involvement in disease.
Braulke and Bonifacino, 2008 and Coutinho ., 2012: comprehensive revisions on the newly synthesized lysosomalet al
enzymes’ travelling routes to the , particularly of the Man-6-P-dependent pathway in whichlysosome
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GlcNAc-1-phosphotransferase plays a key role.
Kollmann ., 2010: complete, easy-to-follow review on the involvement of mannose-phosphorylation in human disease.et al
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